================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
----------
WASHINGTON, D.C. 20549
FORM 20-F(MARK ONE)
[ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES
EXCHANGE ACT OF 1934
OR
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE FISCAL YEAR ENDED December 31, 2005
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________
OR
[ ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
DATE OF EVENT REQUIRING THIS SHELL COMPANY REPORT _____________
COMMISSION FILE NUMBER 0-28996
----------
ELBIT MEDICAL IMAGING LTD.
(Exact Name of Registrant as specified in its charter)
ISRAEL
(Jurisdiction of incorporation or organization)
13 MOZES STREET, TEL-AVIV 67442, ISRAEL
(Address of principal executive offices)
Securities registered or to be registered pursuant to Section 12(b) of
the Act:
NAME OF EACH EXCHANGE ON WHICH
TITLE OF EACH CLASS: REGISTERED:
- -------------------- ------------------------------
NONE NONE
----------
Securities registered or to be registered pursuant to Section 12(g) of
the Act:
ORDINARY SHARES, NIS 1.0 PAR VALUE PER SHARE
----------
Securities for which there is a reporting obligation pursuant to Section 15(d)
of the Act: NONE
----------
Indicate the number of outstanding shares of each of the issuer's classes of
capital or common stock as of the close of the period covered by the annual
report: 25,426,298 ordinary shares, NIS 1.0 par value per share
Indicate by check mark if the registrant is a well known seasoned issuer, as
defined in Rule 405 of the Securities Act. YES [ ] NO [X]
If this report is an annual or transition report, indicate by check mark if the
registrant is not required to file reports pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934. YES [ ] NO [X]
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days: YES [X] NO [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 in the Exchange Act. (Check
one).
Large Accelerated Filer [ ] Accelerated Filer [X] Non-Accelerated Filer [ ]
Indicate by check mark which financial statement item the registrant has elected
to follow: ITEM 17 [ ] ITEM 18 [X]
If this is an annual report indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act YES [ ] NO [X]
================================================================================
1
TABLE OF CONTENTS
Page
----
ITEM 1. Identity of Directors, Senior Management and Advisors 3
ITEM 2. Offer Statistics and Expected Timetable 3
ITEM 3. Key Information 3
ITEM 4. Information on the Company 21
ITEM 4A. Unresolved Staff Comments 52
ITEM 5. Operating and Financial Review and Prospects 52
ITEM 6. Directors, Senior Management and Employees 86
ITEM 7. Major Shareholders and Related Party Transactions 94
ITEM 8. Financial Information 98
ITEM 9. Offer and Listing 101
ITEM 10. Additional Information 103
ITEM 11. Quantitative and Qualitative Disclosure About Market Risks 116
ITEM 12. Description of Securities Other than Equity Securities 122
ITEM 13. Defaults, Dividend Arrearages and Delinquencies 122
ITEM 14. Material Modifications to the Rights of Security Holders and
Use of Proceeds 122
ITEM 15. Controls and Procedures 122
ITEM 16A. Audit Committee Financial Expert 123
ITEM 16B. Code of Ethics 123
ITEM 16C. Principal Accountant Fees and Services 123
ITEM 16D. Exemptions From Listing Standards for Audit Committees 124
ITEM 16E. Purchases of Equity Securities by the Company and Affiliated
Purchasers 124
ITEM 17. Financial Statements 124
ITEM 18. Financial Statements 124
ITEM 19. Exhibits 125
2
CURRENCY TRANSLATION
For the reader's convenience, financial information for 2005 has been
translated from various foreign currencies to the U.S. dollar ("$" or U.S.
dollar), as of December 31, 2005 in accordance with the following exchange
rates:
DECEMBER 31, 2005
CURRENCY $
- -------- -----------------
1 EURO 1.18
1 GBP 1.73
1 HUF 0.04
1 RAND 0.11
1 PLN 0.31
The dollar amounts reflected in these convenience translations should not
be construed as representing amounts that actually can be received or paid in
dollars or convertible into dollars (unless otherwise indicated), nor do such
convenience translations mean that the NIS amounts (i) actually represent the
corresponding dollar amounts stated, or (ii) could be converted into dollars at
the assumed rate. The Federal Reserve Bank of New York does not certify for
customs purposes a buying rate for cable transfers in NIS. Therefore all
information about exchange rates is based on the Bank of Israel rates.
PART I
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS
Not Applicable.
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
Not Applicable.
ITEM 3. KEY INFORMATION
A. SELECTED FINANCIAL DATA
The following selected consolidated financial data of Elbit Medical Imaging
Ltd. and its subsidiaries (together, "EMI," the "Company," "our Company," "we"
or "us") are derived from our 2005 consolidated financial statements and are set
forth below in table format. Our 2005 consolidated financial statements and
notes included elsewhere in this report were prepared in accordance with Israeli
generally accepted accounting principles ("GAAP"), and audited by Brightman
Almagor & Co., a firm of certified public accountants in Israel and a member of
Deloitte Touche Tohmatsu, except for certain subsidiaries and an associate which
were audited by other auditors. Our selected consolidated financial data are
presented in NIS. A convenience translation to U.S. dollars is presented for
2005 only.
Our consolidated financial statements have been prepared in accordance with
Israeli GAAP, which differs in significant respects from U.S. GAAP. We have
summarized principal differences relevant to us between Israeli GAAP and U.S.
GAAP in Note 25 to our consolidated financial statements included in Item 18 of
this Annual Report. You should read the information in the following tables in
conjunction with "Operating and Financial Review and Prospects" and the
consolidated financial statements and Notes to the consolidated financial
statements included in Item 18 of this Annual Report.
Through December 31, 2003, our financial statements were prepared in
adjusted values (in NIS of constant purchase power), on the basis of changes in
the consumer price index ("Inflation" and "CPI"), in accordance with Israeli
GAAP. On January 1, 2004, Accounting Standard No. 12 of the Israel Accounting
Standards Board ("IASB") came into force and effect ("Standard 12"). In
accordance with the provisions of Standard 12, adjustment of financial
statements to inflation shall cease commencing January 1, 2004, with
adjusted amounts of non-monetary items which were included in the balance sheet
as of December 31, 2003, used as basis for the nominal financial reporting as
and from January 1, 2004. Amounts presented in the financial statements for
periods commencing January 1, 2004 were, therefore, included in values to be
hereinafter referred to as "Reported amounts".
3
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
FOR THE YEAR ENDED DECEMBER 31
------------------------------------------------------------------
2005
Reported
Convenience 2005 2004 2003 2002 2001
Translation Reported Reported Adjusted Adjusted Adjusted
----------- -------- -------- -------- -------- --------
$'000 (In Thousand NIS)
REVENUES
Sale of real estate assets and
investments, net 61,191 281,661 131,921 -- -- --
Commercial centers operations 31,057 142,957 311,893 347,056 279,776 132,212
Hotels operations and management 58,670 270,057 218,365 189,205 206,679 139,226
Sale of medical systems 16,449 75,713 44,049 -- -- --
Realization of investments 425 1,958 16,415 45,129 24,710 --
Other operational income 9,648 44,409 13,238 13,495 1,509 10,030
Other income -- -- -- -- 30,760 54,394
------- ------- ------- -------- ------- --------
177,440 816,755 735,881 594,885 543,434 335,862
------- ------- ------- -------- ------- --------
COSTS OF EXPENSES
Commercial centers operations 34,248 157,640 271,392 257,913 218,673 85,786
Hotels operations and management 56,331 259,293 207,152 188,672 205,635 133,652
Cost and expenses of medical systems
operation 10,771 49,577 26,039 8,720 8,015 7,023
Other operational expenses 10,166 46,793 3,655 3,510 1,392 7,311
Research and development expenses, net 12,796 58,899 38,158 43,719 28,454 24,198
General and administrative expenses 8,025 36,939 43,627 42,144 44,070 42,839
Share in losses of associated
companies, net 2,613 12,028 15,968 20,951 2,906 9,712
Financial expenses (income), net 26,574 122,321 53,569 211,821 5,440 (101,559)
Other expenses 12,406 57,106 51,428 10,477 45,965 20,317
------- ------- ------- -------- ------- --------
173,930 800,596 710,988 787,927 560,551 229,279
------- ------- ------- -------- ------- --------
PROFIT (LOSS) BEFORE INCOME TAXES 3,511 16,159 24,893 (193,042) (17,117) 106,583
Income taxes (tax benefits) 1,694 7,798 15,804 (20,217) 21,711 13,596
------- ------- ------- -------- ------- --------
PROFIT (LOSS) AFTER INCOME TAXES 1,816 8,361 9,089 (172,825) (38,828) 92,987
Minority-interest in results of
subsidiaries, Net 15,922 73,287 27,448 48,671 24,490 (5,915)
PROFIT (LOSS) FROM CONTINUING
OPERATIONS 17,738 81,648 36,537 (124,154) (14,338) 87,072
Profit from discontinued operations,
net 1,285 5,917 6,810 12,073 54,752 18,759
Cumulative effect of accounting change
at the beginning of the year (135) (622) -- -- -- --
------- ------- ------- -------- ------- --------
NET INCOME (LOSS) 18,888 86,943 43,347 (112,081) 40,414 105,831
======= ======= ======= ======== ======= ========
(In NIS)
------------------------------------------------------------------
EARNINGS (LOSS) PER SHARE
From continuing operations 0.80 3.66 1.59 (5.56) (0.64) 3.92
From discontinued operations 0.06 0.27 0.30 0.54 2.45 0.84
Cumulative effect of accounting change
at the beginning of the year (0.01) (0.03) -- -- -- --
------- ------- ------- -------- ------- --------
Basic earnings (loss) per share 0.85 3.90 1.89 (5.02) 1.81 4.76
======= ======= ======= ======== ======= ========
Dividend declared per share 2.69 12.39* -- -- -- --
======= ======= ======= ======== ======= ========
* We declared distribution of dividends twice during 2005, see "Item 4.
Information on the Company - A. History and Development of the Company -
Recent Developments" below.
4
INCOME STATEMENT DATA
AS PER U.S. GAAP (*):
YEAR ENDED DECEMBER 31
------------------------------------------------------------------
Convenience 2005 2004 2003 2002 2001
Translation Reported Reported Adjusted Adjusted Adjusted
----------- -------- -------- -------- -------- --------
$'000 (In Thousand NIS)
A) NET INCOME (LOSS) AND COMPREHENSIVE
INCOME:
Net income (loss) according to U.S.
GAAP 21,800 103,344 (92,446) (19,251) (27,747) (21,112)
Total comprehensive income (loss)
according to U.S. GAAP 26,816 123,429 (149,915) 35,545 143,360 16,373
Basic earning (loss) per ordinary
share as per U.S. GAAP (NIS) 0.98 4.53 (4.02) (0.86) (1.24) (0.94)
Diluted earning (loss) per ordinary
share as per U.S. GAAP (NIS) 0.98 4.53 (4.02) (0.86) (1.35) (0.96)
Weighted average of number of shares
and share equivalents under U.S.
GAAP (thousands) 22,154 22,154 23,025 22,337 22,337 22,224
(*) For further information as to the differences between Israeli and U.S.
GAAP, as applicable to the Company's financial statements, see Note 25 to
our consolidated financial statements, included in Item 18 below.
SELECTED BALANCE SHEET DATA
(INCLUDING AS PER U.S. GAAP)
DECEMBER 31
-----------------------------------------------------------------------
2005
Reported
Convenience 2005 2004 2003 2002 2001
Translation Reported Reported Adjusted Adjusted Adjusted
----------- --------- --------- --------- --------- ---------
$'000 (In Thousand NIS)
Current Assets 188,058 865,632 736,339 577,687 1,006,237 1,132,194
Long term investments and
receivables 25,839 118,937 185,393 218,407 453,839 477,052
Hotels, commercial centers and
other fixed assets 599,275 2,758,465 3,527,988 4,629,675 4,090,936 2,858,129
Other assets and deferred expenses 6,621 30,476 55,859 85,798 73,024 60,596
Assets related to discontinued
operations 2,739 12,607 14,700 16,228 111,984 199,360
Total 822,532 3,786,117 4,520,279 5,527,795 5,736,020 4,727,331
Current Liabilities 150,397 692,278 794,741 1,178,415 1,901,506 1,612,532
Long-term liabilities 413,294 1,902,391 2,418,897 2,841,326 2,176,301 1,446,923
Liabilities related to
discontinued operations 13,563 62,430 71,986 82,802 110,007 253,854
Convertible debentures 13,514 62,159 -- -- -- --
Minority interest 2,487 11,449 430,687 471,606 486,670 497,257
Shareholders' equity 229,287 1,055,410 803,968 953,646 1,061,536 916,765
Total 822,532 3,786,117 4,520,279 5,527,795 5,736,020 4,727,331
Total assets according to U.S. GAAP 835,635 3,846,427 4,676,008 5,917,917 6,007,937 4,772,914
Total liabilities according to
U.S. GAAP 608,633 2,801,532 3,905,673 4,891,985 5,040,903 3,955,945
Total shareholders equity
according to U.S. GAAP 227,002 1,044,894 770,335 1,025,932 967,034 816,969
EXCHANGE RATES
The exchange rate between the NIS and U.S. dollar published by the Bank of
Israel was NIS 4.518 to the dollar on May 31, 2006. The exchange rate has
fluctuated during the six months period beginning December 2005 through May 2006
from a high of NIS 4.725 to the dollar to a low of NIS 4.428 to the dollar. The
monthly high and low exchange rates between
5
the NIS and the U.S. dollar during the six months period beginning December 2005
through May 2006, as published by the Bank of Israel, were as follows:
HIGH LOW
MONTH 1 U.S. dollar = 1 U.S. dollar =
----- --------------- ---------------
December 2005 4.662 NIS 4.579 NIS
January 2006 4.658 NIS 4.577 NIS
February 2006 4.725 NIS 4.664 NIS
March 2006 4.717 NIS 4.658 NIS
April 2006 4.671 NIS 4.503 NIS
May 2006 4.522 NIS 4.428 NIS
The average exchange rate between the NIS and U.S. dollar, using the
average of the exchange rates on the last day of each month during the period,
for each of the five most recent fiscal years was as follows:
PERIOD EXCHANGE RATE
------ -------------
January 1, 2001 - December 31, 2001 4.219 NIS/$1
January 1, 2002 - December 31, 2002 4.738 NIS/$1
January 1, 2003 - December 31, 2003 4.544 NIS/$1
January 1, 2004 - December 31, 2004 4.483 NIS/$1
January 1, 2005 - December 31, 2005 4.488 NIS/$1
FORWARD LOOKING STATEMENTS
This annual report on Form 20-F contains "forward-looking statements,
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the "1934 Act")
(collectively, the "Safe Harbor Provisions"). Forward-looking statements are
typically identified by the words "believe," "expect," "intend," "estimate" and
similar expressions. Such statements appear in this annual report and include
statements regarding the intent, belief or current expectation of EMI or its
directors or officers. Actual results may differ materially from those
projected, expressed or implied in the forward-looking statements as a result of
various factors including, without limitation, the factors set forth below under
the caption "Risk Factors" (we refer to these factors as "Cautionary
Statements"). Any forward-looking statements contained in this annual report
speak only as of the date hereof, and we caution potential investors not to
place undue reliance on such statements. We undertake no obligation to update or
revise any forward-looking statements. All subsequent written or oral
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by the Cautionary Statements.
B. CAPITALIZATION AND INDEBTEDNESS
Not Applicable.
C. REASONS FOR THE OFFER AND USE OF PROCEEDS
Not Applicable.
D. RISK FACTORS
We have made some statements in this annual report about our future
activities that may or may not come true. Factors, over which we have no or
limited control, may affect our actual performance and results of operations and
may cause them to be different from what we present to you in this Annual
Report.
Our statements in this annual report are accurate to the best of our
knowledge and belief as of the date of this document is filed with the SEC. We
take no responsibility to publicly update or revise such statements.
During 2005, our activities were divided into five principal fields: (i)
initiation, construction, operation, management and sale of shopping and
entertainment centers in Israel and in Central and Eastern Europe; (ii)
ownership, operation, management, and sale of hotels in major European cities;
(iii) long term lease of real estate property, (iv) investments in the research
and development, production and marketing of magnetic resonance imaging guided
focused ultrasound treatment equipment, through InSightec Ltd. ("InSightec");
and (v) other activities which consist of the distribution and marketing of
women's fashion and accessories through our wholly-owned Israeli subsidiary,
Mango Israel Clothing and Footwear Ltd. ("Mango") and venture-capital
investments. In December 2005 we sold all of our holdings in the company holding
one of our hotels in London (referred to in clause (iii) above) which is subject
to a long term lease agreement.
The following is a list of the material risk factors that affect our
business and our results of operation. We cannot
6
predict nor can we asses the impact, if any, of such risk factors on our
business or the extent which any factor, or a combination of factors, may cause
actual results to differ materially from those projected in any forward looking
statement.
RISKS RELATING TO THE SHOPPING AND ENTERTAINMENT CENTERS BUSINESS
SUITABLE LOCATIONS ARE CRITICAL TO THE SUCCESS OF A SHOPPING AND ENTERTAINMENT
CENTER.
The choice of suitable locations for the development of shopping and
entertainment center projects is an important factor in the success of the
individual projects. Ideally, these sites should be located: (i) within the city
center, with well-developed transportation infrastructure (road and rail)
located in close proximity to facilitate customer access; and (ii) within local
areas with sufficient population to support the centers. If we are not able to
find sites in the target cities which meet these criteria, either at all or at
viable prices, this may materially adversely affect our business and results of
operation.
Historically, most of the centers developed by us have been in Budapest and
other locations in Hungary. We do not currently believe that there are
additional suitable locations for the development of shopping and entertainment
centers in Hungary beyond those currently under development that satisfy our
investment criteria. Therefore, our future success will depend in large part on
our ability to identify locations and develop centers in other countries where
we may have less experience and less market knowledge than in Hungary. As a
result, we may not be as successful in the identification and development of
future projects as we have been historically in Hungary.
ZONING RESTRICTION AND LOCAL OPPOSITION CAN DELAY OR PRECLUDE CONSTRUCTION OF A
CENTER.
Sites which meet our criteria must be zoned for commercial activities of
the type contained in shopping and entertainment centers. In instances where the
existing zoning is not suitable or in which the zoning has yet to be determined,
we will apply for the required zoning classifications. This procedure may be
protracted, particularly in countries where the bureaucracy is cumbersome and
inefficient, and we cannot be certain that the process of obtaining proper
zoning will be completed with sufficient speed to enable the centers to open
ahead of the competition or at all. Opposition by local residents to zoning
and/or building permit applications may also cause considerable delays. Certain
of our site acquisitions are conditioned upon the grant of a building permit. In
addition, arbitrary changes to applicable zoning may jeopardize projects that
have already commenced. For example, a ministerial decision was issued in Greece
which changed the land use of certain property owned by our Greek subsidiary and
as a result thereof a shopping and entertainment center may not be built on such
land. See "Item 4. Information on the Company - B. Business Overview - Shopping
and Entertainment Centers - Other Real Estate Properties" below. Therefore, if
we cannot receive zoning approvals or if the procedures for the receipt of such
zoning approvals are delayed, our cost will increase which will have an adverse
affect on our business.
WE DEPEND ON CONTRACTORS AND SUBCONTRACTORS TO CONSTRUCT OUR CENTERS.
We rely on subcontractors for all of our construction and development
activities. If we cannot enter into subcontracting arrangements on terms
acceptable to us or at all, we will incur additional costs which will have an
adverse affect on our business. The competition for the services of quality
contractors and subcontractors may cause delays in construction, thus exposing
us to a loss of our competitive advantage. Subcontracting arrangements may be on
less favorable terms than would otherwise be available, which may result in
increased development and construction costs. By relying on subcontractors, we
become subject to a number of risks relating to these entities, such as quality
of performance, varied work ethics, performance delays, construction defects and
the financial stability of the subcontractors. A shortage of workers would have
a detrimental effect on us and our subcontractors and, as a result, on our
ability to conclude the construction phase on time and within budget. We
generally require our subcontractors to provide bank guarantees in our favor to
financially secure their performance. In the event the subcontractor fails to
perform, the bank guarantees provide for a monetary payment to us. The
guarantees do not, however, obligate the subcontractors to complete the project
and may not adequately cover our costs of completing the project or our lost
profits during the period while alternative means of completing the project are
sought.
DELAYS IN THE COMPLETION OF CONSTRUCTION PROJECTS COULD AFFECT OUR SUCCESS.
An important element in the success of our shopping and entertainment
center projects is the short construction time (generally 12 to 18 months from
the receipt of building permits, depending on the size of the project), and our
ability to open the centers ahead of our competition, particularly in cities
which do not have shopping and entertainment centers of the type constructed by
us.
This makes us subject to a number of risks relating to these activities,
including:
- delays in obtaining zoning and other approvals;
- the unavailability of materials and labor;
- the abilities of sub-contractors to complete work competently and
on schedule;
- the surface and subsurface condition of the land underlying the
project;
- environmental uncertainties;
7
- extraordinary circumstances or "acts of god"; and
- ordinary risks of construction that may hinder or delay the
successful completion of a particular project.
In addition, under our development contracts with local municipalities, we
have deadlines for most of our projects (subject to limited exceptions). If
construction of a project does not proceed in accordance with our schedule, we
may in some instances be required to pay penalties to the vendor (usually local
municipalities) based on the extent of the delay and in isolated instances to
forfeit rights in the land. The failure to complete a particular project on
schedule or on budget may have a material adverse effect on our business,
prospects, results of operations or financial condition.
WE ARE DEPENDENT ON ATTRACTING THIRD PARTIES TO ENTER INTO LEASE AGREEMENTS.
We are dependent on our ability to enter into new leases on favorable terms
in order to receive a profitable price for each shopping and entertainment
center. We may find it more difficult to engage third parties enter into leases
during periods when market rents are increasing, or when general consumer
activity is decreasing. We seek agreements in principle with anchor tenants
(such as the operators of cinemas, supermarkets, department stores and
electrical appliances stores), either generally or on a property-by property
basis, prior to entering into a formal lease. The termination of a lease by any
anchor tenant may adversely affect the relevant specific shopping and
entertainment center and the price obtainable for it. The failure of an anchor
tenant to abide by these agreements may cause delays, or result in a decline in
rental income (temporary or long term), the effect of which we may not be able
to offset due to difficulties in finding a suitable replacement tenant.
OUR RESULTS OF OPERATIONS MAY BE AFFECTED BY RETAIL CLIMATES AND TENANT
BANKRUPTCIES.
Bankruptcy filings by retailers are normal in the course of our operations.
We are continually re-leasing vacant spaces arising out of tenant terminations.
Pressures that affect consumer confidence, job growth, energy costs and income
gains can affect retail sales growth, and a continuing soft economic cycle may
impact our ability to find new tenants for property vacancies that result from
store closings or bankruptcies.
GENERAL ECONOMIC CONDITIONS IN A REGION WILL AFFECT OUR TENANTS.
If an economic recession occurs, the demand and rents for neighborhood and
community shopping and entertainment centers could decline and adversely affect
our financial condition and results of operations. Our financial condition and
results of operations could also be adversely affected if our tenants are unable
to make lease payments or fail to renew their leases as a result of declining
consumer spending.
WE ARE DEPENDENT ON THE PRESENCE OF ANCHOR TENANTS.
We rely on the presence of "anchor" tenants in our entertainment and
commercial centers. Anchor stores in entertainment and commercial centers play
an important part in generating customer traffic and making a center a desirable
location for other tenants. The failure of an anchor store to renew its lease,
the termination of an anchor store's lease, or the bankruptcy or economic
decline of an anchor tenant can have a material adverse effect on the economic
performance of the centers. There can be no assurance that if the anchor stores
were to close or fail to renew their leases, we would be able to replace such
anchor stores in a timely manner or that we could do so without incurring
material additional costs and adverse economic effects. The expiration of an
anchor lease at an entertainment and commercial center may make refinancing of
such center difficult.
COMPETITION IS BECOMING MORE RAPID IN THE CERTAIN EASTERN EUROPEAN COUNTRIES.
The shopping and entertainment centers business in Eastern Europe is
rapidly becoming more competitive, with a number of developers (particularly
from Germany and France) becoming active in our target areas. The shopping and
entertainment centers concept we promote is gaining increasing popularity due to
its potentially high yields. Developers compete not only for patrons, but also
for desirable properties, financing, raw materials, qualified contractors,
experienced system consultants, expert marketing agents and skilled labor. The
public bidding process (the process through which we often acquire new
properties) is subject to intense competition and some of our competitors have
longer operating histories and greater resources than us, all of which may limit
our ability to obtain such projects. There can be no assurance that we will be
successful in winning projects that we bid for or which are awarded pursuant to
fixed price tenders or that we will otherwise continue to be successful in
competing in Eastern Europe.
RISKS RELATING TO THE HOTEL BUSINESS
THE HOTELS INDUSTRY MAY BE AFFECTED BY ECONOMIC CONDITIONS, OVERSUPPLY, TRAVEL
PATTERNS, WEATHER AND OTHER CONDITIONS BEYOND OUR CONTROL WHICH MAY ADVERSELY
AFFECT OUR BUSINESS AND RESULTS OF OPERATIONS.
The hotels industry may be adversely affected by changes in national or
local economic conditions and other local
8
market conditions. Our hotels generally, and in particular, in London, Amsterdam
and Budapest, may be subject to the risk of oversupply of hotel rooms. Other
general risks that may affect our hotels business are changes in travel
patterns, extreme weather conditions, changes in governmental regulations which
influence or determine wages, workers' union activities, increases in land
acquisition prices or construction costs, changes in interest rates, the
availability of financing for operating or capital needs, and changes in real
estate tax rates and other current operating expenses. Unforeseen events, such
as terrorist attacks, outbreaks of epidemics and economic recessions have had
and may continue to have an adverse effect on local and international travel
patterns and, as a result, on occupancy rates and prices in our hotels.
Downturns or prolonged adverse conditions in the real estate or capital markets
or in national or local economies and difficulties in securing financing for the
development of hotels could have a material adverse effect on our business,
results of operations, ability to develop new projects and the attainment of our
strategic goals.
COMPETITION IN THE HOTELS INDUSTRY COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR
BUSINESS AND RESULTS OF OPERATIONS.
The hotels business is highly competitive. This is particularly the case in
those areas where there is an over supply of rooms, such as in London, Amsterdam
and Budapest. Competitive factors within the industry include:
- - convenience of location and accessibility to business centers;
- - room rates;
- - quality of accommodations;
- - name recognition;
- - quality and nature of service and guest facilities provided;
- - reputation;
- - convenience and ease of reservation systems; and
- - the supply and availability of alternative lodging.
We operate, and intend to develop or acquire, most of our hotels in
geographic locations where other hotels are or may be located. We expect to
compete for guests and development sites with national chains, large franchisees
and independent operators. Many of these competitors have greater financial
resources and better brand name recognition than we do, and may have more
established relationships with prospective franchisers, representatives in the
construction industry and other parties engaged in the lodging industry. The
number of competitive lodging facilities in a particular area could have a
material adverse effect on our hotel occupancy and rates and, therefore,
revenues of our hotels. We believe that competition within the lodging market
may increase in the foreseeable future in particular in our hotels located in
Eastern Europe.New or existing competitors may significantly reduce their rates
or offer greater convenience, services or amenities or significantly expand or
improve hotels in the markets in which we currently or may subsequently compete,
thereby materially adversely affecting our business and results of operations.
ACQUIRING, DEVELOPING AND RENOVATING HOTELS INVOLVES SUBSTANTIAL RISKS, AND WE
CANNOT BE CERTAIN OF THE SUCCESS OF ANY FUTURE PROJECTS.
Part of our strategy is to develop new hotels and to acquire and redevelop
old or under-performing hotels. Acquiring, developing and renovating hotels
involves substantial risks, including:
- - costs exceeding budget or amounts agreed to with contractors, because of
several factors, including delays in completion of construction;
- - competition for acquisition of suitable development sites from competitors,
who may have greater financial resources;
- - the failure to obtain zoning and construction permits;
- - unavailability of financing on favorable terms, if at all;
- - the failure of hotels to earn profits sufficient to service debt incurred
in construction or renovation, or at all;
- - the failure to comply with labor and workers' union legal requirements;
- - relationships with and quality and timely performance by contractors; and
- - compliance with changes in governmental rules, regulations, planning and
interpretations.
As of May 31, 2006, we were involved in the following construction hotel
projects: (i) we commenced the renovation and the refurbishment of the Bucuresti
Hotel in Bucharest, Romania; and (ii) we commenced the internal renovation of
the Ballet Institute Building in Budapest, Hungary. We cannot be certain that
present or future development or renovation will be successful. If we are not
successful in future projects, it will have a material adverse affect on our
business. For successful growth, we must be able to develop or acquire hotels on
attractive terms and integrate the new or acquired hotels into our existing
operations. For acquired hotels, we must consolidate management, operations,
systems, personnel and procedures, which may not be immediately possible due to
collective labor agreements or other legal or operational obstacles. Any
substantial delays or unexpected costs in this integration process could
materially affect our business, financial condition or results of operations. We
cannot be certain that our newly acquired hotels will perform as we expect or
that we will be able to realize projected cost savings.
9
CONTINUOUS DELAYS WITH RESPECT TO RENOVATIONS OF THE PHYSICAL ENVIRONMENT
APPROXIMATE TO THE ASTRID PARK PLAZA HOTEL IN BELGIUM MAY CONTINUE TO HAVE AN
ADVERSE EFFECT ON ITS OPERATIONS.
The Municipality of Antwerp is engaged in extensive construction in the
Astridplein, located directly opposite the Astrid Park Plaza Hotel since 2000.
The construction is intended to prepare the square to accommodate the increased
traffic which will result once the TGV services to the railway station located
adjacent to the square become operational. The completion of this construction
has been delayed several times, and has caused and continues to cause
obstructions to access to the hotel. In the past, this had an adverse effect on
the occupancy rate at our hotel and on the performance of the Aquatopia
attraction located within the hotel. The continuation of the construction, the
permanent changes to the traffic flow around the hotel and the less convenient
access for the hotel's patrons may have an adverse effect on our results of
operations.
WE DEPEND ON PARTNERS IN OUR JOINT VENTURES AND COLLABORATIVE ARRANGEMENTS.
We own interests in seven operational hotels and are developing two
additional hotels, in partnership with other entities, including in particular,
the Red Sea Group of companies ("Red Sea") (for information regarding our
partnership with Red Sea, see "Item 4. Information on the Company - B. Business
Overview - Hotels" below). Red Sea is engaged in the initiation and development
of residential and commercial real estate projects in Israel and in the
operation of chain of hotels and income producing real estate abroad. We may in
the future enter into joint ventures or other collaborative arrangements. Our
investments in these joint ventures, including in particular our numerous
partnerships with Red Sea, may, under certain circumstances, be subject to (i)
the risk that one of our partners may become bankrupt or insolvent, which may
cause us to be unable to fulfill our financial obligations, may trigger a
default under our bank financing agreements or, in the event of a liquidation,
may prevent us from managing or administering our business; (ii) the risk that
one of our partners may have economic or other interests or goals that are
inconsistent with our interests and goals, and that such partner may be in a
position to veto actions which may be in our best interests; and (iii) the
possibility that disputes may arise regarding the continued operational
requirements of our hotels that are jointly owned.
WE RELY ON MANAGEMENT AGREEMENTS WITH PARK PLAZA WHICH MAY NOT PROVIDE THE
INTENDED BENEFITS, AND MAY BE TERMINATED.
All of the operating hotels in which we have an interest (other than the
Centreville Apartment hotel in Bucharest) are either directly or indirectly
operated under long-term management agreements with Park Plaza Hotels Europe
Ltd. ("Park Plaza"). Park Plaza is the franchisee for certain territories under
territorial license and franchise agreements with Golden Wall Investment Ltd.,
which entitles Park Plaza to use the "Park Plaza" tradename. Any significant
decline in the reputation of Park Plaza or in its ability to ensure the
performance of our hotels at anticipated levels could adversely affect our
results of operations. If for any reason Park Plaza loses its principal
franchise, we will automatically lose our ability to use the Park Plaza name and
other benefits, in which case we may suffer in the areas of brand name
recognition, marketing, and centralized reservations systems provided by Park
Plaza, which, in turn, could materially affect our operations. If our agreement
with Park Plaza is terminated, we would not be certain that we would be able to
obtain alternative management services of the same standard on similar or better
terms.
OUR AGREEMENTS WITH PARK PLAZA AND THE REZIDOR GROUP IMPOSE OBLIGATIONS ON US
THAT MAY FORCE US TO INCUR SIGNIFICANT COSTS.
Our agreements with Park Plaza (for the management of the operational
hotels) and the Rezidor group (for the future management of two hotels, which
are currently under construction and/or renovation: the National Ballet Building
in Hungary, which is intended to be operated under the "Regent" brand name, and
the Bucuresti hotel in Bucharest, which is intended to be operated under the
brand name "Radisson SAS") contain specific standards for, and restrictions and
limitations on, hotel operation and maintenance. These standards, restrictions
and limitations may conflict with our priorities, and impose capital demands
upon us. In addition, Park Plaza and the Rezidor group may alter their standards
or hinder our ability to improve or modify our hotels. In order to comply with
their requirements, or alternatively, to change a franchise affiliation for a
particular hotel and disassociate ourselves from any of the "Park Plaza",
"Regent" or "Radisson" tradenames, we may be forced to incur significant costs
or make capital improvements.
THE VALUE OF OUR INVESTMENT IN OUR HOTEL PROPERTIES IS SUBJECT TO VARIOUS RISKS
RELATED TO OWNERSHIP AND OPERATION OF REAL PROPERTY.
Our investment in hotel properties is subject to varying degrees of risk
related to the ownership and operation of real property. The intrinsic value of
our hotels and income from the hotels may be materially adversely affected by:
- changes in global and national economic conditions, including global
or national recession;
- a general or local slowdown in the real property, market which may
make it difficult to sell a property;
- political events that may have a material adverse effect on the hotel
industry;
- competition from other lodging facilities, and oversupply of hotel
rooms in a specific location;
10
- material changes in operating expenses, including as a result of
changes in real property tax systems or rates;
- changes in the availability, cost and terms of financing;
- the effect of present or future environmental laws;
- our ongoing need for capital improvements and refurbishments; and
- material changes in governmental rules and policies.
OUR OWNERSHIP RIGHTS IN THE BUCURESTI HOTEL HAVE BEEN CHALLENGED.
Since we acquired a controlling interest in the Bucuresti Hotel complex in
Bucharest, Romania (which includes the Bucuresti Hotel and the Centerville
apartment hotel), we have encountered a number of attempts to challenge both the
validity of the acquisition of the complex and our control over the company
owning the rights to the hotel. To date, two claims have been filed challenging
our ownership in the Bucuresti Hotel Complex both of which are currently pending
in the Bucuresti court of appeal (See "Item 8. Financial Information - Legal
Proceedings" below). In addition, another appeal to the Romanian Supreme Court
was filed requesting to nullify the public tender for the sale of Bucuresti
shares, the privatization contract and the transfer of the Bucuresti shares to
our Company, Domino. We anticipate, based on our legal counsel's advice, that
the appeal will be rejected by the Supreme Court. Nevertheless, if any of the
above appeals will be accepted, our results of operation will be materially
adversely affected
RISKS RELATING TO BOTH THE SHOPPING AND ENTERTAINMENT CENTERS BUSINESS AND TO
THE HOTEL BUSINESS
THE FAILURE TO COMPLY WITH GOVERNMENT REGULATION MAY ADVERSELY AFFECT OUR
BUSINESS AND RESULTS OF OPERATIONS
Both the shopping and entertainment centers business and the hotel industry
are subject to numerous national and local government regulations, including
those relating to building and zoning requirements and fire safety control. In
addition, we are subject to laws governing our relationships with employees,
including minimum wage requirements, overtime, working conditions, and work
permit requirements, and in some localities to collective labor agreements. A
determination that we are not in compliance with these regulations could result
in the imposition of fines, an award of damages to private litigants and
significant expenses in bringing our shopping and entertainment centers and
hotels into compliance with the regulations. In addition, our ability to dismiss
unneeded staff may be hampered by local labor laws and courts which
traditionally favor employees in disputes with former employers, particularly in
countries with strong socialist histories such as those in Eastern Europe.
WE MAY BE HELD LIABLE FOR DESIGN OR CONSTRUCTION DEFECTS OF THIRD-PARTY
CONTRACTORS.
We rely on the quality and timely performance of construction activities by
third-party contractors. Claims may be asserted against us by local government
and zoning authorities or by third parties for personal injury and design or
construction defects. These claims may not be covered by the professional
liability insurance of the contractors or of the architects and consultants.
These claims may give rise to significant liabilities.
WE MAY BE AFFECTED BY SHORTAGES IN RAW MATERIALS AND EMPLOYEES.
The building industry may from time to time experience fluctuating prices
and shortages in the supply of raw materials as well as shortages of labor and
other materials. The inability to obtain sufficient amounts of raw materials and
to retain efficient employees on terms acceptable to us may result in delay in
the construction of the project and increase in the budget of the project and,
consequently may have a material adverse effect on the results of our
operations.
WE MAY EXPERIENCE FLUCTUATIONS IN OUR ANNUAL AND QUARTERLY RESULTS AS A RESULT
OF OUR OPENING NEW CENTERS, ENTERING INTO NEW BUSINESSES AND DISPOSING OF OTHER
CENTERS, HOTELS OR OTHER BUSINESSES.
We periodically review our business to identify properties or other assets
that we believe either no longer complement our business, or could be sold at
significant premiums. We are focused on restructuring and enhancing real estate
returns and monetizing investments and from time to time, attempt to sell these
identified properties and assets. There can be no assurance, however, that we
will be able to complete dispositions on commercially reasonable terms or at
all. We also periodically review our business to identify opportunities for the
acquisition or development of new centers and/or hotels. There can be no
assurance that we will be able to develop or acquire centers and/or hotels that
will become successful. As a result of our disposition and acquisition or
development of centers, we may experience significant fluctuations in our annual
and quarterly results. As a result, we believe that period-to-period comparisons
of our historical results of operations may not necessarily be meaningful and
that investors should not rely on them as an indication for future performance.
11
FACTORS THAT AFFECT THE VALUE OF OUR REAL-ESTATE ASSETS AND OUR INVESTMENTS MAY
ADVERSELY CHANGE AND THEREFORE WE WILL NEED TO CHARGE AN IMPAIRMENT LOSS NOT
PREVIOUSLY RECORDED.
Certain specific circumstances may affect the fair value of our real estate
assets (operating or under construction) and investments. An impairment loss not
previously recorded may be required and/or depreciation may be accelerated, upon
the occurrence of one or more of the following circumstances:
(i) Absence of or modifications to permits or approvals. A construction
permit may be revoked as a result of unauthorized delays in commencing
construction; a construction permit may be cancelled altogether under
certain circumstances, such as where the use of land does not
correspond to the permitted usage; a need for a revised construction
permit arises by reasons of governmental or other instructions to
carry out modifications to our original architectural plans so as to
comply, among other things, with environmental and traffic impact plan
or obtain archeological clearance; new laws and regulations are
enacted which limit the use of our land for structures other than
centers or hotels; voluntary modifications to original plans where we
encounter opportunities to substantially upgrade our project by
acquisitions of adjacent land plots or expansion of original project
or otherwise, may trigger the need for a revision to or modification
of the issued construction permit if the permit becomes inapplicable;
a revised construction permit may be required where changes occur to
zoning plans which indirectly affect our proposed commercial center; a
new, revised permit, when required, may nevertheless be denied for
reasons beyond our control or following our failure to fulfill
preconditions or otherwise;
(ii) Strategy in respect of long term lease commitments. In commercial
centers, where a significant part of the rental areas is subject to
long term leases with a small group of retailers which is
distinguished (from other lessees) by a direct correlation between the
rental fees paid by such retailer and the revenues from their
respective rental areas, we may be exposed to a risk of rental fees
rates being significantly lower than originally anticipated. A
material decline in the long run in the business operations of such
retailers may therefore, have an adverse affect on the results of
operations of these commercial centers as well as on their recoverable
amount. Other commercial centers, the rental areas of which have not
been fully rented or which we have designated for an interim period as
free of charge public areas, may be required to alter their original
designation of use so as to serve, in the best optimal manner, our
strategy for the center. Should these areas remain vacant or public,
for a period longer than originally anticipated, our long-term cash
flows may be negatively impacted and, as a result, it may decrease the
value of the center;
(iii) External Interruptions. Circumstances having significant impact on
our real estate may include extensive and continuous infrastructure
works carried out by municipalities or other legal authorities. Delays
in completion of such works, beyond the anticipated target, may cause
harm and damages to the results of operations of the real estate; and
(iv) Legal Issues and Other Uncertainties. Lawsuits that are pending,
whether or not we are a party thereto, may have a significant impact
on our real estate assets and/or on certain of our shareholding rights
in the companies owning such assets. Certain laws and regulations,
applicable to our business in certain countries where the legislation
process undergoes constant changes, may be subject to frequent and
substantially different interpretations; agreements which may be
interpreted by governmental authorities so as to shorten term of use
of real estate, and which may be accompanied with a demand to demolish
the construction thereon erected, be that with or without
compensation, may significantly affect the value of such real estate
asset.
Since market conditions and other parameters (such as macroeconomic
environment trends, and others), which affect the fair value of our real-estate
and investment, vary from time to time, the fair value may not be adequate on a
date other than the date the measurement was executed (immediately prior to the
balance sheet date). In the event the projected forecasts regarding the future
cash flows generated by those assets are not met, we may have to record an
additional impairment loss not previously recorded.
12
RISKS RELATING TO THE IMAGE GUIDED TREATMENT BUSINESS
INSIGHTEC IS CURRENTLY DEPENDENT ON SALES OF THE EXABLATE 2000 FOR THE TREATMENT
OF UTERINE FIBROIDS FOR VIRTUALLY ALL OF ITS REVENUE.
The ExAblate 2000 is in an early stage of commercialization. InSightec
received FDA approval in October 2004 to market the ExAblate 2000 in the United
States only for the treatment of uterine fibroids. InSightec expects sales of
the ExAblate 2000 for this application to account for virtually all of its
revenues for the foreseeable future, depending upon the timing of regulatory
approval of additional applications for the ExAblate 2000. As a result, factors
adversely affecting InSightec's ability to sell, or pricing of or demand for,
InSightec's product for this application would have a material adverse effect on
its financial condition and results of operations, which would in turn adversely
affect the Company's results of operations.
IF THE EXABLATE 2000 DOES NOT ACHIEVE BROAD MARKET ACCEPTANCE FOR THE TREATMENT
OF UTERINE FIBROIDS, INSIGHTEC WILL NOT BE ABLE TO GENERATE SUFFICIENT SALES TO
SUPPORT ITS BUSINESS.
InSightec must achieve broad market acceptance of the ExAblate 2000 for the
treatment of uterine fibroids among physicians, patients and third party payors
in order to generate a sufficient amount of sales to support its business.
Physicians will not recommend the use of the ExAblate 2000 unless InSightec can
demonstrate that it produces results comparable or superior to existing
treatments for uterine fibroids. If long-term patient studies do not support
InSightec's existing clinical results, or if they indicate that the use of the
ExAblate 2000 has negative side effects on patients, physicians may not adopt or
continue to use the ExAblate 2000. Even if InSightec demonstrates the
effectiveness of the ExAblate 2000, physicians may still not use the system for
a number of other reasons. Physicians may continue to recommend traditional
uterine fibroid treatment options simply because those methods are already
widely accepted and are based on established technologies. Patients may also be
reluctant to undergo new, less established treatments for uterine fibroids. If,
due to any of these factors, the ExAblate 2000 does not receive broad market
acceptance among physicians or patients, InSightec will not generate significant
sales. In this event, InSightec's business, financial condition and results of
operations would be seriously harmed, and InSightec's ability to develop
additional treatment applications for the ExAblate 2000 would be adversely
affected.
IF PHYSICIANS, HOSPITALS AND OTHER HEALTHCARE PROVIDERS ARE UNABLE TO OBTAIN
COVERAGE AND SUFFICIENT REIMBURSEMENT FROM THIRD PARTY HEALTHCARE PAYORS FOR
TREATMENT PROCEDURES USING THE EXABLATE 2000, INSIGHTEC MAY BE UNABLE TO
GENERATE SUFFICIENT SALES TO SUPPORT ITS BUSINESS.
Demand for the ExAblate 2000 is likely to depend substantially on the
extent to which sufficient reimbursement for treatment procedures using
InSightec's system will be available from third party payors such as private
health insurance plans and health maintenance organizations and, to a lesser
degree, government payor programs such as Medicare and Medicaid. In the United
States, the assignment of a Current Procedural Terminology, or CPT, code is
generally necessary to facilitate claims for reimbursement. In July 2004, two
CPT III codes were implemented allowing to track the use of the ExAblate 2000
system to treat uterine fibroids. However, the assignment of these codes does
not require third party payors to provide reimbursement for procedures performed
with the ExAblate 2000. InSightec believes that third party payors will not
provide reimbursement on a national basis for treatments using the ExAblate 2000
unless InSightec can generate a sufficient amount of data through long-term
patient studies to demonstrate that such treatments produce favorable results in
a cost-effective manner relative to other treatments. Furthermore, InSightec
could be adversely affected by changes in reimbursement policies of private
healthcare or governmental payors to the extent any such changes affect
reimbursement for treatment procedures using the ExAblate 2000. If physicians,
hospitals and other healthcare providers are unable to obtain sufficient
coverage and reimbursement from third-party payors for treatment procedures
using the ExAblate 2000, InSightec may be unable to generate sufficient sales to
support its business.
InSightec's success in non-U.S. markets also depends on treatment
procedures using the ExAblate 2000 being eligible for reimbursement through
government-sponsored healthcare payment systems, private third-party payors and
labor unions. Reimbursement practices vary significantly from country to country
and within some countries, by region. Many non-U.S. markets have
government-managed healthcare systems that control reimbursement for new
products and procedures. Other non-U.S. markets have private insurance systems,
labor union-sponsored programs and government-managed systems that control
reimbursement for new products and procedures. To date, only one third party
payor, a health maintenance organization in Israel, has approved reimbursement
coverage for treatments using the ExAblate 2000. We cannot assure you that such
coverage will be approved by additional payors in other markets in a timely
manner, if at all, thereby materially adversely affecting InSightec's results
our operation. In the event that InSightec is unable to timely obtain acceptable
levels of reimbursement coverage in its targeted markets outside of the United
States, InSightec's ability to generate sales may be adversely affected.
INSIGHTEC'S FUTURE GROWTH SUBSTANTIALLY DEPENDS ON ITS ABILITY TO DEVELOP AND
OBTAIN REGULATORY CLEARANCE FOR ADDITIONAL TREATMENT APPLICATIONS FOR THE
EXABLATE 2000.
Currently, InSightec has received regulatory approvals to market the
ExAblate 2000 in the United States, Israel,
13
Russia, Taiwan, Australia, Singapore and the European Union Economic Area, or
EEA, which is comprised of the member nations of the European Union and certain
additional European nations, solely for the treatment of uterine fibroids.
InSightec's objective is to expand the use of the ExAblate 2000 by developing
and introducing new treatment applications. InSightec is currently in various
stages of product development and clinical studies for a number of new treatment
applications for the ExAblate 2000. It will be required to obtain FDA approval
in the United States and other regulatory approvals outside of the United States
before marketing the ExAblate 2000 for these additional treatment applications.
Furthermore, InSightec cannot guarantee that InSightec's product development
activities for these other applications will be successful and in such event,
InSightec's future growth will be harmed. In particular, InSightec's future
oncology treatment applications are subject to significant risks since these
applications must be able to demonstrate complete ablation of malignant tumors.
If InSightec is unable to demonstrate this degree of efficacy, its future
oncology treatment applications may not prove to be successful. In addition,
assuming product development is successful, the regulatory processes can be
lengthy, lasting many years in some cases, and expensive. We cannot assure you
that FDA approval or other regulatory approvals will be granted.
In order to obtain FDA clearance and other regulatory approvals, and to
obtain reimbursement coverage for use of the ExAblate 2000 treatment for
additional applications, InSightec is required to conduct clinical studies to
demonstrate the therapeutic benefits and cost-effectiveness of these new
treatment applications and products. Clinical trials are expensive and may take
several years to complete. If future clinical trials indicate that the ExAblate
2000 is not as beneficial or cost-effective as existing treatment methods, or
that such products cause unexpected complications or other unforeseen adverse
events, InSightec may not obtain regulatory clearance to market and sell the
ExAblate 2000 for these additional treatment applications or obtain
reimbursement coverage, and InSightec's long-term growth would be seriously
harmed.
The product development and regulatory approval process for each of
InSightec's future applications is subject to a number of application-specific
risks and uncertainties. For example, the life expectancy from existing surgical
treatment options for breast cancer is long and the survival rate is relatively
high. As a result, InSightec will have to conduct extensive clinical trials
which may include several thousand participants and extend over several years of
follow-up. This may delay the commercial introduction of InSightec's
applications by several years. In addition, InSightec is still in the process of
developing and improving clinical prototypes for its liver, bone metastatic
tumors, prostate and brain treatment applications. If it is unable to surmount
these challenges, as well as the challenges relating to its other future
applications, its business and results of operations may be adversely affected.
INSIGHTEC IS DEPENDENT ON GENERAL ELECTRIC.
The ExAblate 2000 is compatible only with certain of GE Healthcare, a
division of the General Electric Company ("GE") Healthcare's Magnetic Resonance
Imaging (MRI) systems, which may limit InSightec's potential market. A
significant portion of the MRI systems in use in the United States and elsewhere
are not GE MRI systems. InSightec estimates that there are over 2,400 GE MRI
systems in the United States that are compatible with the ExAblate 2000 and
InSightec estimates that there are a similar number of such GE MRI systems
outside of the United States. InSightec has no current plans to develop a system
that would be compatible with MRI systems manufactured by companies other than
GE and is, therefore, limited in its target market to potential customers who
already own or otherwise have access to a compatible GE MRI system, or are
willing to purchase such a system in order to use the ExAblate 2000. In
addition, in the event that GE is unable to effectively market its MRI systems,
InSightec's ability to generate additional sales of the ExAblate 2000 may be
adversely affected.
InSightec depends on its collaboration with GE to ensure the compatibility
of the ExAblate 2000 with new models of GE MRI systems and upgrades to existing
GE MRI systems. GE regularly develops new models of its MRI systems, as well as
new capabilities for its existing MRI systems, which could affect their
compatibility with the ExAblate 2000. If InSightec is unable to receive
information regarding new models of the GE MRI systems or upgrades to existing
GE MRI systems, and coordinate corresponding upgrades to the ExAblate 2000 to
ensure continued compatibility with new and existing GE MRI systems, its ability
to generate sales of its system will be adversely affected. In addition, If
InSightec is unable to coordinate new applications or upgrades with GE's
research and development team, it may be unable to develop such applications or
upgrades in a timely manner and its future revenue growth may be seriously
harmed.
In addition, InSightec entered into a five year exclusive worldwide
(excluding Japan and Russia) sales and marketing agreement with GE with respect
to the ExAblate 2000. Although the agreement does not prohibit InSightec from
marketing and selling the ExAblate 2000 directly, InSightec expects that a
substantial portion of its sales of the ExAblate 2000 will be developed through
this agreement with GE. Since InSightec has no direct control over GE's sales
and marketing personnel, InSightec must rely on incentives provided by GE to its
personnel to encourage effective marketing of the ExAblate 2000, as well as
contractual provisions contained in the agreement. In addition, GE has a right
of first negotiation with respect to the distribution, financing and servicing
of our focused ultrasound products, and the design and supply of imaging devices
to be used in connection with our current and future MRgFUS products. These
rights continue until five years after the sale by GE of all of our ordinary
shares that it holds or, with respect to any distribution agreement, until the
earlier of three years after such sale of our ordinary shares or the date on
which GE fails to meet minimum thresholds provided in such distribution
agreement. We cannot assure you that GE will be successful in efforts to
generate sales of the ExAblate 2000 or any other products developed by us as to
which it obtains distribution rights. In such event InSightec's results of
operation may be materially adversely affected.
14
The sales and marketing agreement does not prohibit GE from marketing or
manufacturing other focused ultrasound-based products that may compete with the
ExAblate 2000. In addition, GE retained the right to use certain focused
ultrasound-related patents which it assigned to InSightec at the time of its
formation and InSightec has granted to GE a non-exclusive license to certain of
our patents derived from technology and patent rights licensed to InSightec by
GE. GE may use such patents to develop its own focused ultrasound based products
without InSightec's consent. In the event that GE chooses to distribute or
manufacture medical devices that may compete with the ExAblate 2000 or other
products based on the Magnetic Resonance Guided Focused Ultrasound (MRgFUS)
technology, InSightec's sales may be adversely affected.
IF INSIGHTEC IS UNABLE TO PROTECT ITS INTELLECTUAL PROPERTY RIGHTS, ITS
COMPETITIVE POSITION COULD BE HARMED. THIRD-PARTY CLAIMS OF INFRINGEMENT COULD
REQUIRE INSIGHTEC TO REDESIGN ITS PRODUCTS, SEEK LICENSES, OR ENGAGE IN FUTURE
COSTLY INTELLECTUAL PROPERTY LITIGATION, WHICH COULD IMPACT INSIGHTEC'S FUTURE
BUSINESS AND FINANCIAL PERFORMANCE.
InSightec's success and ability to compete depend in large part upon its
ability to protect its proprietary technology. InSightec relies on a combination
of patent, copyright, trademark and trade secret laws, and on confidentiality
and invention assignment agreements, in order to protect its intellectual
property rights. A few of InSightec's patents were transferred to InSightec from
GE at the time of its formation, and GE retains a non-exclusive license to make,
use and sell products covered under these patents in the imaging field only
without InSightec's permission. Prior to the transfer, GE had entered into
cross-license agreements with respect to these patents with a number of
companies, including some that may be potential competitors of InSightec. As a
result of these cross license agreements, InSightec may not be able to enforce
these patents against one or more of these companies.
The process of seeking patent protection can be long and expensive, and
there can be no assurance that InSightec's existing or future patent
applications will result in patents being issued, or that InSightec's existing
patents, or any patents which may be issued as a result of existing or future
applications, will provide meaningful protection or commercial advantage to
InSightec. Any issued patents may be challenged, invalidated or legally
circumvented by third parties. InSightec cannot be certain that its patents will
be upheld as valid, proven enforceable, or prevent the development of
competitive products. Consequently, competitors could develop, manufacture and
sell products that directly compete with InSightec's product, which could
decrease its sales and diminish its ability to compete.
Claims by competitors and other third parties that InSightec products
allegedly infringe the patent rights of others could have a material adverse
effect on InSightec's business. The medical device industry is characterized by
frequent and substantial intellectual property litigation. Intellectual property
litigation is complex and expensive, and the outcome of this type of litigation
is difficult to predict. Any future litigation, regardless of outcome, could
result in substantial expense and significant diversion of the efforts of
InSightec's technical and management personnel. An adverse determination in any
such proceeding could subject InSightec to significant liabilities or require
InSightec to seek licenses from third parties or pay royalties that may be
substantial.
RISKS RELATING TO OUR OTHER ACTIVITIES
OUR MANGO BUSINESS IS DEPENDENT ON A SINGLE FRANCHISE AND SUPPLIER WHICH COULD
CAUSE DELAYS OR DISRUPTIONS IN THE DELIVERY OF OUR MANGO PRODUCTS, WHICH COULD
HARM OUR BUSINESS AND RESULTS OF OPERATIONS.
Mango, an apparel company which we acquired in May 2005, depends on its
franchise with and supply of products from Punto Fa, S.L., a contemporary
women's apparel company, and its international brand name MANGO-MNG(TM) (which
supplier we refer to collectively herein as Mango International). If Mango
International ends its relationship with Mango or enters into liquidation,
Mango's business in Israel will be terminated. In addition, Mango relies on the
supply of its products from Mango International and may face a shortage of
inventory if there is a worldwide excess demand for Mango International's
products. If either of these events occurs, our results of operations may be
materially adversely affected.
A RISE IN WAGE LEVELS IN ISRAEL COULD ADVERSELY AFFECT MANGO'S FINANCIAL
RESULTS.
Mango relies mainly on minimum wage employees. The Israeli government
increased the applicable minimum wage effective as of July 2006. If wage levels
generally, and particularly the minimum wage in Israel, increase, Mango's
results of operations could be harmed.
THE APPAREL INDUSTRY IS SUBJECT TO CHANGES IN FASHION PREFERENCES. IF THE
MANUFACTURER OF MANGO PRODUCTS MISJUDGES FASHION TRENDS, OR IF WE FAIL TO CHOOSE
FROM THE MANGO INTERNATIONAL INVENTORY DESIGN PRODUCTS THAT APPEAL TO OUR
CUSTOMERS, OUR SALES COULD DECLINE AND OUR RESULTS OF OPERATIONS COULD BE
ADVERSELY AFFECTED.
Neither the manufacturer of Mango products nor Mango may be successful in
anticipating and responding to fashion trends in the future. Customer tastes and
fashion trends change rapidly. Our success depends in part on Mango
International's ability to effectively anticipate and respond to changing
fashion tastes and consumer demands and to translate market trends into
appropriate, saleable product offerings far in advance. If Mango International
is unable to successfully anticipate, identify or react to changing styles or
trends and misjudges the market for its products or any new product lines, or if
we fail to choose
15
from the Mango International inventory design products that appeal to our
customers' changing fashion preferences, Mango's sales will be lower and we may
be faced with a significant amount of unsold finished goods inventory. As a
result, we may be forced to increase our marketing promotions or price
markdowns, which could have a material adverse effect on our business. Our Mango
brand image may also suffer if customers believe merchandise misjudgments
indicate that Mango no longer offers the latest fashions.
A CHANGE IN CUSTOMS RATES AND CUSTOM AND HARBOR STRIKES COULD ADVERSELY AFFECT
MANGO'S FINANCIAL RESULTS.
Mango is subject to Israeli customs since all of its products are imported.
An increase in customs rates on Mango's products could adversely affect Mango's
ability to compete against local manufacturers or with products from countries
which enjoy more favorable customs rates in Israel. On the other hand, a
reduction in customs rates may encourage entrance penetration of new competitors
to the market. In addition, since most of Mango's products are imported, custom
and harbor strikes and delays could adversely affect Mango's ability to meet
customer demands and adversely affect Mango's financial results.
MANGO MAY BE UNABLE TO COMPETE FAVORABLY IN THE HIGHLY COMPETITIVE WOMEN'S
APPAREL INDUSTRY, AND MANGO'S COMPETITORS MAY HAVE GREATER FINANCIAL, GEOGRAPHIC
AND OTHER RESOURCES.
The sale of fashionable women's apparel is highly competitive. Mango
competes directly with a number of Israeli and international brands (such as
Zara, Castro, Honigman, Renuar and Dan Casidi, some of which have longer
operating histories and enjoy greater financial and marketing resources than
Mango, for example, Mango's competitors may have the ability to obtain better
geographic locations for their stores in commercial centers, with better traffic
flow and access to customers, which would have a positive impact on their sales.
Increased competition could result in pricing pressure, increased marketing
expenditures or loss of market share to Mango and adversely affect Mango's
revenues and profitability. There can be no assurance that Mango will be able to
compete successfully against existing or new competitors.
MANGO HAS NO CONTROL OVER FLUCTUATIONS IN THE COST OF THE RAW MATERIALS IT USES
AND A RISE IN COSTS COULD HARM MANGO'S PROFITABILITY.
Mango buys its entire inventory from Mango International, which is
responsible for the design and manufacturing of all of Mango's products. The
prices of the inventory that Mango purchases from Mango International are
dependent on the manufacturing costs of Mango International. Mango
International's manufacturing costs are substantially dependent on the prices of
raw materials and level of wages in the countries where its products are
manufactured. Therefore, an increase in the manufacturing costs of Mango
International will cause an increase in Mango's cost of goods sold and Mango may
not be able to pass on the increased costs to its customers. Such increased
costs would likely adversely affect Mango's profitability, operational results
and its financial condition.
A DEVALUATION OF THE NIS AGAINST THE EURO COULD HARM MANGO'S PROFITABILITY.
Mango buys its entire inventory from Mango International. The price of this
inventory is denominated in Euros. Therefore, a devaluation of the NIS against
the Euro will cause an increase in Mango's cost of goods sold expressed in NIS,
and Mango may not be able to pass the increased costs to its customers. This
would likely adversely affect Mango's profitability, operational results and its
financial conditions.
OUR VENTURE CAPITAL INVESTMENTS ARE MADE IN DEVELOPMENT STAGE COMPANIES AND
INVOLVE HIGH RISKS.
Investments in biotechnology development stage companies involve high
risks. These companies are subject to various risks generally encountered by new
enterprises, including costly, delayed or protracted research and development
programs, the need for acceptance of their products in the market place, and the
need for additional financing which might not be available. We cannot be certain
that the assessments we made at the time of investment in our venture capital
investments, as to the quality of the concept or the prototype, will prove
correct, or that there will be an adequate return on investment, if at all. If
our assessment of the venture capital investments are incorrect, our results of
operations may be adversely affected.
OUR VENTURE CAPITAL INVESTMENTS ARE SPECULATIVE IN NATURE AND WE MAY NEVER
REALIZE ANY REVENUES OR PROFITS FROM THESE INVESTMENTS.
We cannot be certain that our venture capital investments will result in
revenues or profits. Economic, governmental, regulatory and industry factors
outside our control affect our venture capital investments. If our venture
capital investments will not successfully implement its business plan we will
not be able to realize any profits from it. Our ability to realize profits from
these investments will be dependent upon the management of these companies, the
success of its research and development activities, the timing of the marketing
of its products and numerous other factors beyond our control.
16
RISKS RELATING TO ISRAEL
SECURITY AND ECONOMIC CONDITIONS IN ISRAEL MAY AFFECT OUR OPERATIONS.
We are incorporated under Israeli law and our principal offices are located
in Israel. In addition, the Arena shopping and entertainment center is located
in Herzliya, Israel as well as our operations in our other activities segments,
such as Mango and other venture capital investments operating in Israel.
Political, economic and security conditions in Israel directly affect our
operations. Since the establishment of the State of Israel in 1948, various
armed conflicts have taken place between Israel and its Arab neighbors and a
state of hostility, varying in degree and intensity, has led to security and
economic problems for Israel. Israel signed a peace treaty with Egypt in 1979
and a peace treaty with Jordan in 1994. As of the date of this annual report,
Israel has not entered into any peace agreement with Syria or Lebanon. Since
1993, several agreements have been signed between Israel and the Palestinians,
but a final agreement has not been achieved. Since October 2000, there has been
a marked increase in hostilities between Israel and the Palestinians,
characterized by terrorist attacks on civilian targets, suicide bombings and
military incursions into areas under the control of the Palestinian Authority.
These developments have adversely affected the peace process, placed the Israeli
economy under significant stress, and have negatively influenced Israel's
relationship with several Arab countries. In January 2006, Hamas, an Islamic
movement responsible for many attacks against Israelis, won the majority of the
seats in the Parliament of the Palestinian Authority. The election of a majority
of Hamas-supported candidates is expected to be a major obstacle to relations
between Israel and the Palestinian Authority, as well as to the stability in the
Middle East as a whole. In addition, some neighboring countries, as well as
certain companies and organizations, continue to participate in a boycott of
Israeli firms and others doing business with Israel or with Israeli companies.
Restrictive laws, policies or practices directed towards Israel or Israeli
businesses could have an adverse impact on the expansion of our business. In
addition, we could be adversely affected by the interruption or curtailment of
trade between Israel and its trading partners, a significant increase in the
rate of inflation, or a significant downturn in the economic or financial
condition of Israel.
MANY OF OUR DIRECTORS, OFFICERS AND EMPLOYEES ARE OBLIGATED TO PERFORM ANNUAL
MILITARY RESERVE DUTY IN ISRAEL. WE CANNOT ASSESS THE POTENTIAL IMPACT OF THESE
OBLIGATIONS ON OUR BUSINESS.
Our directors, officers and employees who are male adult citizens and
permanent residents of Israel under the age of 45 are, unless exempt, obligated
to perform annual military reserve duty and are subject to being called to
active duty at any time under emergency circumstances. The deteriorating
security situation in the Middle East has caused, and will continue to cause, a
sharp increase in the army reserve obligations of our directors, officers and
employees who are subject to such reserve duty obligations. Although we have
operated effectively under these requirements in the past, including during
recent hostilities with the Palestinians and the war in Iraq, we cannot assess
the full impact of these requirements on our workforce or business if conditions
should change, and we cannot predict the effect of any increase or reduction of
these requirements on us.
AN INCOME TAX REFORM IN ISRAEL MAY ADVERSELY AFFECT US.
Effective as of January 2003, the Israeli Parliament has enacted a
wide-ranging reform of the Israeli income tax system. These tax reforms have
resulted in significant changes to the Israeli tax system. The main effect of
this new tax reform on us is that we might be subject to additional tax arising
from profits from our foreign companies which would be defined as "Controlled
Foreign Companies" (CFC) in accordance with the provisions of the law. See "Item
10. Additional Information - E. Taxation - Taxation in Israel - Tax Reform in
Israel" below. This may have adverse tax consequences for us.
ISRAELI COURTS MIGHT NOT ENFORCE JUDGMENTS RENDERED OUTSIDE OF ISRAEL, WHICH MAY
MAKE IT DIFFICULT TO COLLECT ON JUDGMENTS RENDERED AGAINST US.
We are incorporated in Israel. Some of our directors and officers are not
residents of the United States and some of their assets and our assets are
located outside the United States. Service of process upon our non-U.S. resident
directors and officers and enforcement of judgments obtained in the United
States against us, and our directors and executive officers may be difficult to
obtain within the United States.
We have been informed by our Israeli legal counsel, that there is doubt as
to the enforceability of civil liabilities under U.S. securities laws in
original actions instituted in Israel. However, subject to certain time
limitations, an Israeli court may declare a foreign civil judgment enforceable
if it finds that all of the following terms are met: (i) the judgment was
rendered by a court which was, according to the laws of the state of the court,
competent to render the judgment; (ii) the judgment can longer be appealed;
(iii) the obligation imposed by the judgment is enforceable according to the
rules relating to the enforceability of judgments in Israel and the substance of
the judgment is not contrary to public policy; and (iv) the judgment is
executory in the state in which it was rendered or issued.
Even if the above conditions are satisfied, an Israeli court will not
enforce a foreign judgment if it was given in a state whose laws do not provide
for the enforcement of judgments of Israeli courts (subject to exceptional
cases) or if its enforcement is likely to prejudice the sovereignty or security
of the State of Israel. An Israeli court will also not declare a foreign
judgment enforceable in the occurrence of any of the following: (i) the judgment
was obtained by fraud; (ii) there was
17
no due process; (iii) the judgment was rendered by a court not competent to
render it according to the laws of private international law in Israel; (iv) the
judgment is at variance with another judgment that was given in the same matter
between the same parties and which is still valid; or (v) at the time the action
was brought in the foreign court a suit in the same matter and between the same
parties was pending before a court or tribunal in Israel.
ANTI-TAKEOVER PROVISIONS COULD NEGATIVELY IMPACT OUR SHAREHOLDERS.
The Israeli Companies Law of 1999 (the "Companies Law") provides that an
acquisition of shares in a public company must be made by means of a special
tender offer if as a result of such acquisition the purchaser becomes a holder
of 25% or more of the voting rights in the company. This rule does not apply if
there already is another holder of 25% or more of the voting rights in the
company. Similarly, the Companies Law provides that an acquisition of shares in
a public company must be made by means of a special tender offer, if as a result
of the acquisition the purchaser becomes a holder of more than 45% of the voting
rights in the company. This rule does not apply if another party already holds
more than 45% of the voting rights in the company.
Furthermore, under the Companies Law, a person is not permitted to acquire
shares of a public company or a class of shares of a public company, if
following such acquisition such person holds 90% or more of the company's shares
or class of shares, unless such person conducts a tender offer for all of the
company's shares or class of shares (a "Full Tender Offer"). In the event that
holders of less than 5% of the company's issued share capital or of the issued
class of shares did not respond to the tender offer, then such offer will be
accepted and all of the company's shares or class of shares with respect to
which the offer was made will be transferred to the offeror, including all of
the company's shares or class of shares held by such non-responsive shareholders
that will be transferred to the offeror by way of a compulsory sale of shares.
In the event that holders of 5% or more of the issued shares did not respond to
the tender offer, the offeror may not purchase more than 90% of the shares or
class of shares of such company.
At the request of an offeree of a Full Tender Offer which was accepted, the
court may determine that the consideration for the shares purchased under the
tender offer, was lower than their fair value and compel the offeror to pay to
the offerees the fair value of the shares. Such application to the court may be
filed as a class action.
The Companies Law provides that for as long as a shareholder in a publicly
held company holds more than 90% of the company's shares or of a class of
shares, such shareholder shall be precluded from purchasing any additional
shares.
THE VIOLATION OF CERTAIN CONDITIONS UNDER THE ISRAELI TAX ORDINANCE AND/OR THE
PRE-RULING ISSUED BY THE ISRAELI TAX AUTHORITIES IN CONNECTION WITH THE MERGER
BY WAY OF EXCHANGE OF SHARES BETWEEN EMI AND ITS SUBSIDIARY, ELSCINT, MAY RESULT
IN THE MERGER NOT BEING TREATED AS TAX EXEMPT BY THE ISRAELI TAX AUTHORITIES AND
THE IMPOSITION OF CAPITAL GAINS TAX ON THE EXCHANGE OF SHARES.
In November 2005, a merger between Elscint Limited ("Elscint"), our
subsidiary, and EMI was consummated pursuant to which EMI purchased the entire
outstanding share capital of Elscint not already owned by EMI and by or for the
benefit of Elscint, in consideration for 0.53 ordinary shares of EMI for each 1
ordinary share of Elscint. If any requirement or condition of the merger under
the Israeli Tax Ordinance [New Version] of 1961, the regulations promulgated
thereunder or the pre-ruling issued by the Israeli tax authorities in connection
with the merger is breached and/or is not met, the merger will not be treated as
tax exempt for Israeli tax purposes. As part of the final pre-ruling issued by
the Israeli tax authorities, EMI, Elscint and their controlling shareholders
were subject to certain restrictions and conditions. In that event, the Israeli
tax authorities may impose, in accordance with the Ordinance, Israeli capital
gains tax on EMI and on the former Elscint shareholders in respect of the
exchange of shares under the merger.
RISKS RELATING TO OPERATIONS IN EASTERN EUROPE
WE ARE SUBJECT TO VARIOUS RISKS RELATED TO OUR OPERATIONS IN EASTERN EUROPE,
INCLUDING ECONOMIC AND POLITICAL INSTABILITY, POLITICAL AND CRIMINAL CORRUPTION.
Many of the Eastern European countries in which we operate are countries
that until the last decade were allied with the former Soviet Union under a
communist economic system, and they are still subject to various risks. Certain
Eastern European countries, in particular those countries that are not expected
to join the European Union in the near future, are still economically and
politically unstable and suffer from political and criminal corruption, lack of
commercial experience, and unpredictability of the civil justice system. Certain
Eastern European countries also continue to suffer from high unemployment, low
wages and low literacy rates. These risks could be harmful to us and are very
difficult to quantify or predict. Although many governments of the Eastern
European countries have liberalized policies on international trade, foreign
ownership and development, investment, and currency repatriation to increase
both international trade and investment, such policies might change
unexpectedly. We will be affected by the rules and regulations regarding foreign
ownership of real and personal property. Such rules may change quickly and
dramatically and thus may have an adverse impact on ownership and may result in
a loss without recourse of our property or assets. Domestic and international
laws and regulations, whether existing today or in the future, could adversely
affect our ability to market and sell our products and could impair our
18
profitability.
Certain Eastern European countries may regulate or require governmental
approval for the repatriation of investment income, capital or the proceeds of
sales of securities by foreign investors. In addition, if there is deterioration
in a country's balance of payments or for other reasons, a country may impose
temporary restrictions on foreign capital remittances abroad. Any such
restrictions may adversely affect our ability to repatriate investment loans or
to remit dividends. Many emerging countries have experienced substantial, and in
some periods extremely high, rates of inflation for many years. Inflation and
rapid fluctuations in inflation rates have had and may continue to have negative
effects on the economies and securities markets of certain emerging countries.
In addition, in an attempt to control inflation, price controls at our hotels
have been imposed at times in certain countries, which may affect our ability to
increase our room rates.
ENVIRONMENTAL ISSUES ARE BECOMING OF INCREASING SIGNIFICANCE IN EASTERN EUROPE
WHICH MAY RESULT IN DELAYS IN CONSTRUCTION AND INCREASED COSTS.
There is increasing awareness of environmental issues in Eastern Europe.
This may be of critical importance in areas previously occupied by the Soviet
Army, where soil pollution may be prevalent. We generally insist upon receiving
an environmental report as a condition for purchase, or alternatively, conduct
environmental tests during our due diligence investigations. Also, some
countries such as Poland and the Czech Republic require that a developer carry
out an environmental report on the land before building permit applications are
considered. Nevertheless, we cannot be certain that all sites acquired will be
free of environmental pollution. If a property that we acquire turns out to be
polluted, such a finding will adversely affect our ability to construct, develop
and operate a shopping and entertainment center on such property, and may cause
us to suffer expenses incurred in cleaning up the polluted site which may be
significant. We have found sub-terranean oil storage tanks in our property in
Rybnik, Poland, which caused a delay of eight months in the construction works
of this center and an increase in construction costs.
WE ARE SUBJECT TO VARIOUS RISKS RELATED TO OUR OPERATIONS IN ROMANIA INCLUDING
THE UNPREDICTABILITY OF THE CIVIL JUSTICE SYSTEM.
Our Bucuresti Hotel is generally affected by risks of doing business in
Romania. Any foreign company or litigant may encounter difficulty in prevailing
in any dispute with, or enforcing any judgment against, the Romanian government
or any officers or directors under the Romanian legal system. If our ownership
rights in the company that owns the Bucuresti Hotel Complex are successfully
challenged, this may affect our ability to obtain compensation for our original
investment. We have faced several challenges to our acquisition under the
privatization contract. In addition, the privatization process itself has been
challenged as illegal. All of these claims have been dismissed (See "Item 3. Key
Information - D. Risk Factors - Risks Relating to the Hotel Business" above and
"Item 8. Financial Information - Legal Proceedings" below).
GENERAL
IF WE ARE CHARACTERIZED AS A PASSIVE FOREIGN INVESTMENT COMPANY FOR U.S. FEDERAL
INCOME TAX PURPOSE, HOLDERS OF ORDINARY SHARES MAY SUFFER ADVERSE TAX
CONSEQUENCES.
Generally, if for any taxable year 75% or more of our gross income is
passive income, or at least 50% of the our assets are held for the production
of, or produce, passive income, we will be characterized as a passive foreign
investment company ("PFIC"), for U.S. federal income tax purposes. A
determination that we are a PFIC could cause our U.S. shareholders to suffer
adverse tax consequences, including having gains realized on the sale of our
shares taxed at ordinary income rates, rather than capital gains rates and could
have an adverse effect on the price and marketability of our shares. See "Item
10. Additional Information - E. Taxation- Tax consequences if we are a Passive
Foreign Investment Company" below.
WE ARE SUBJECT TO VARIOUS LEGAL PROCEEDINGS THAT MAY HAVE A MATERIAL ADVERSE
EFFECT ON OUR RESULTS OF OPERATIONS.
Certain legal proceedings have been initiated against us, including
litigation in connection with the change of control of EMI and our subsidiary
Elscint Ltd. in May 1999 and the acquisition of the hotel businesses by Elscint
in September 1999, including motions to certify such claims as class actions.
See also "Item 8. Financial Information - Legal Proceedings" below. A claim has
also been made by an individual that a percentage of EMI and certain of our
subsidiaries belongs to him. We cannot estimate the results of these
proceedings. A determination against us in some or all of these proceedings may
materially adversely affect our results of operations.
WE HAVE SIGNIFICANT CAPITAL NEEDS AND ADDITIONAL FINANCING MAY NOT BE AVAILABLE.
The sectors in which we compete are capital intensive. We require
substantial up-front expenditures for land acquisition, development and
construction costs as well as certain investments in research and development.
In addition, following construction capital expenditures are necessary to
maintain the centers in good condition. As part of our growth strategy, we
intend to acquire, renovate and redevelop additional hotels and to develop new
hotels. In addition, in order for our hotels to remain competitive, they must be
maintained and refurbished on an ongoing basis. Accordingly, we require
19
substantial amounts of cash and construction financing from banks for our
operations and require financing for the development, renovation and maintenance
of our hotels. We cannot be certain that such external financing would be
available on favorable terms or on a timely basis or at all. In addition,
construction loan agreements generally permit the draw down of the loan funds
against the achievement of pre-determined construction and space leasing
milestones. If we fail to achieve these milestones, the availability of the loan
funds may be delayed, thereby causing a further delay in the construction
schedule. If we are not successful in obtaining financing to fund our planned
projects and other expenditures, our ability to undertake additional development
projects may be limited and our future profits and results of operations could
be materially adversely affected. Our inability to obtain financing may affect
our ability to construct or acquire additional centers and hotels, and we may
experience delays in planned renovation or maintenance of our hotels that could
have a material adverse affect on our results of operations.
OUR HIGH LEVERAGE COULD ADVERSELY AFFECT OUR ABILITY TO OPERATE OUR BUSINESS.
We are highly leveraged and have significant debt service obligations. As
of December 31, 2005, we had total debts to banks and other financial
institutions in the aggregate amount of NIS 2,258 million (approximately $491
million). In addition, we and our subsidiaries may incur additional debt from
time to time to finance acquisitions or capital expenditures or for other
purposes. We will have substantial debt service obligations, consisting of
required cash payments of principal and interest, for the foreseeable future.
Our lenders require us to maintain and comply with certain financial and
operational covenants. Our ability to comply with these covenants may be
affected by events beyond our control. A breach of any of the covenants in our
debt instruments or our inability to comply with the required covenants could
result in an event of default, which, if not cured or waived, could have a
material adverse effect on us. In the event of any default under the loan
agreements, the lenders thereunder could elect to declare all borrowings
outstanding immediately due together with accrued and unpaid interest and other
fees. Furthermore, in the event of any default under the loan agreements, such
loans could be reclassified as short-term debt. Such classification in our
financial statements may improperly reflect our working capital ratio as well as
other financial indicators since the assets which were financed by these loans
are classified as non-current assets. As a result of our substantial
indebtedness:
- - we could be more vulnerable to general adverse economic and industry
conditions;
- - we may find it more difficult to obtain additional financing to fund future
working capital, capital expenditures and other general corporate
requirements;
- - we will be required to dedicate a substantial portion of our cash flow from
operations to the payment of principal and interest on our debt, reducing
the available cash flow to fund other projects;
- - we may have limited flexibility in planning for, or reacting to, changes in
our business and in the industry; and
- - we may have a competitive disadvantage relative to other companies in our
business segments with less debt.
We cannot guarantee that we will be able to generate enough cash flow from
operations or that we will be able to obtain enough capital to service our debt
or fund our planned capital expenditures. In addition, we may need to refinance
some or all of our indebtedness on or before maturity. We cannot guarantee that
we will be able to refinance our indebtedness on commercially reasonable terms
or at all. We have the ability under our debt instruments to incur substantial
additional indebtedness and any additional indebtedness we incur could
exacerbate the risks described above.
RESULTS OF OPERATIONS FOR US FLUCTUATE DUE TO THE SEASONALITY OF OUR VARIOUS
BUSINESSES.
The annual revenues and earnings of our shopping and entertainment centers
business, hotels business and Mango, are substantially dependent upon general
business activity, vacation and holiday seasons and the influence of weather
conditions. As a result, changes in any of the above have a disproportionate
effect on the annual results of operations of our shopping and entertainment
centers, hotels and Mango businesses.
ONE OF OUR SHAREHOLDERS BENEFICIALLY OWNS A SUBSTANTIAL AMOUNT OF OUR ORDINARY
SHARES AND, THEREFORE, EFFECTIVELY CONTROLS OUR AFFAIRS.
As of May 31, 2006, Mordechay Zisser, the Executive Chairman of our board
of directors, held, directly or indirectly, approximately 48.73% of our issued
share capital. As a result of such holdings he has the ability, in effect, to
elect the members of our board of directors and to effectively control our
business.
A LOSS OF THE SERVICES OF MEMBERS OF THE SENIOR MANAGEMENT OF EMI, INCLUDING IN
PARTICULAR THAT OF MR. MORDECHAY ZISSER, COULD MATERIALLY ADVERSELY AFFECT OUR
BUSINESS AND RESULTS OF OPERATIONS
We depend on the continued services of the members of our senior management
team, including in particular that of Mr. Mordechay Zisser, our Executive
Chairman of the board of directors. Any loss of the services of Mr. Mordechay
Zisser or other member of our senior management team could result in the loss of
expertise necessary for us to succeed, which could cause our revenues to decline
and impair our ability to meet our objectives.
20
OUR ANNUAL AND QUARTERLY RESULTS MAY VARY WHICH MAY CAUSE THE MARKET PRICE OF
OUR ORDINARY SHARES TO DECLINE.
We have experienced at times in the past, and may in the future experience,
significant fluctuations in our quarterly and annual operating results which may
cause the market price of our ordinary shares to decline. These fluctuations may
be caused by various factors, particularly due to significant sales of our
properties and the frequency of such transactions. During 2005, we changed our
business strategy to the entrepreneurship and development of shopping and
entertainment centers supported by short term management and operation
activities with the principal objective of founding and stabilizing the centers
in order to sell them during their construction or as closely as possible to
their completion. Our decision to sell properties is based on various factors,
including market conditions, and we cannot predict when such sales will actually
occur. Accordingly, investors should not rely on the results of any past periods
as an indication of our future performance. It is likely that in some future
periods, our operating results may be below expectations of public market
analysts or investors. If this occurs, our share price may drop.
ITEM 4. INFORMATION ON THE COMPANY
A. HISTORY AND DEVELOPMENT OF THE COMPANY
Elbit Medical Imaging Ltd. was incorporated in 1996. EMI is a company
incorporated under the laws of the State of Israel and is subject to the Israeli
Companies Law 1999 - 5759 and the Israeli Securities Law 1968 - 5728 and any
regulations published under these laws. Our shares are listed on the NASDAQ
National Market (ticker symbol: EMITF) and on the Tel Aviv Stock Exchange. Our
executive offices are located at 13 Mozes Street, Tel-Aviv 67442, Israel. You
may reach us by telephone at (972-3) 608-6010 or by fax at (972-3) 695-3080. Our
U.S. agent is CSC Corporation Service Company 2711 Centerville Road, Suite 400
Wilmington, DE 19808.
The following is a summary of the principal fields of our businesses during
2005:
- Initiation, construction, operation, management and sale of shopping
and entertainment centers in Israel and in Central and Eastern Europe.
- Hotels ownership, primarily in major European cities, as well as
operation, management and sale of same.
- Long-term lease of real estate property.
- Investments in the research and development, production and marketing
of magnetic resonance imaging guided focused ultrasound treatment
equipment, through InSightec.
- Other activities consisting of the distribution and marketing of
women's fashion and accessories through our wholly-owned Israeli
subsidiary, Mango, and venture-capital investments.
In December 2005 we sold all of our holdings in the company holding one of
our hotels in London (referred to in clause (iii) above) which is subject to a
long term lease agreement.
The following are the highlights of our main business activities and
investments during 2005 and through the date of this filing by order of
occurrence:
- - PRIVATE ISSUANCE OF UNSECURED NON-CONVERTIBLE DEBENTURES
Between February and June 2006 we have issued two series of unsecured
non-convertible debentures to investors in Israel in the aggregate principal
amount of approximately NIS 527 million (approximately $114 million). For
additional information on the terms of this private issuance, including certain
undertaking we have taken towards our investors. See "Item 5. Operating and
Financial Review and Prospects - B. - Liquidity and Capital Resources -
Liquidity" below.
- - APPROVAL OF THE TOWN PLAN ("KSZT") OF THE DREAM ISLAND PROJECT ON THE OBUDA
ISLAND IN THE DANUBE RIVER AND SIGNING OF A FRAMEWORK CITY REGULATION
AGREEMENT WITH THE BUDAPEST CAPITAL 3RD DISTRICT AND BUDAPEST CAPITAL
MUNICIPALITY
On May 25, 2006, a Framework City Regulation Agreement was signed with the
Budapest Capital 3rd district and the Budapest Capital Municipality for the
development and infrastructure of the Dream Island project in the Danube River,
Budapest, in accordance with the city regulation plans and in the KSZT. Formal
regulatory approvals of the KSZT modification contained in the Budapest General
Assembly resolution are currently pending. The proposed plan of the Dream Island
project is to construct on approximately 3.2 million square feet of land located
on the Obuda Island in the Danube River, a tourist and entertainment area in
central Budapest which includes designations for offices, commercial space,
tourism, entertainment and leisure and hotels. See "- B. Business Overview -
Shopping and Entertainment Centers - Other Real Estate Properties" below.
21
- - REFINANCING OF THREE HOTELS IN THE UNITED KINGDOM
On March 2, 2006, we (through our three jointly-controlled subsidiary
companies) refinanced our three hotels in London (the Riverbank Park Plaza
Hotel, the Victoria Park Plaza Hotel and the Sherlock Holmes Park Plaza Hotel)
for a non-recourse refinancing loan in the amount of L195 million (in which our
share amounted to approximately L97.5 million (approximately $168 million)). See
"Item 5. Operating and Financial Results and Prospects. - B. Liquidity and
Capital Resources - Loans" below.
- - DIVIDEND DECLARED AND PAID
On December 22, 2005, we declared a dividend in an aggregate amount of
approximately NIS 130 million (approximately $28.2 million). The dividend was
paid on January 17, 2006 to shareholders of record as of January 4, 2006.
- - SALE OF ONE OF OUR HOTELS IN LONDON
In December 2005, we, together with the remaining holders of Shaw Hotel
Holding B.V, sold all of our holdings (in which we were a 30% shareholder) in
Shaw Hotel Holding B.V., the owner of one of our hotels in London, to an
unrelated third party at an asset value of L74.8 million (approximately $129
million). The net consideration received by us (after deduction of bank loans
and other working capital items) was approximately L4 million (approximately
$6.9 million). The hotel is located in London, the United Kingdom, and is
subject to a long-term lease agreement executed in 2003 for a period of 25
years. See "- B. Business Overview - Long Term Lease of Real Estate Property"
below.
- - PURCHASE OF A LAND IN KEREPESI STREET IN BUDAPEST, HUNGARY
In November 2005, we (through our subsidiary) purchased a large area of
land measuring approximately 1.32 million square feet situated on Kerepesi
Street in central Budapest, the former site of the Hypodrome. . The acquisition
was carried out by the purchase of the entire equity rights of four companies
holding all the freehold ownership and usage rights to the site. The purchase
price of the entire equity rights represents a site value of approximately E21
million (approximately $24 million), out of which E3.9 million is the quota
(similar to shares) purchase price and the remaining are assumed liabilities.
- - CONSUMMATION OF A MERGER BY WAY OF EXCHANGE OF SHARES WITH ELSCINT
On August 21, 2005, EMI and Elscint signed an Agreement and Plan of Merger
pursuant to which each ordinary share of Elscint (other than Elscint ordinary
shares held by EMI and by or for the benefit of Elscint) was converted into 0.53
ordinary share of EMI. The merger was completed on November 23, 2005 and as of
such date, Elscint ordinary shares have ceased to trade on the New York Stock
Exchange and Elscint became a wholly-owned subsidiary of EMI. See "Item 10.
Additional Information - Material Contracts - General" below.
- - SALE OF FOUR OPERATIONAL SHOPPING AND ENTERTAINMENT CENTERS IN POLAND AND
ENTERING INTO AGREEMENTS FOR THE SALE OF ADDITIONAL FOUR CENTERS UNDER
DEVELOPMENT IN POLAND AND THE CZECH REPUBLIC
In July 2005, our indirect wholly-owned subsidiary, Plaza Centers (Europe)
B.V. ("PC") sold to the Klepierre Group of France ("Klepierre"), one of the
leading owners and operators of shopping centers in Europe, four operational
shopping and entertainment centers in Poland as well as PC's management company
in Poland at an aggregate asset value of approximately E204 million
(approximately $241 million). The aggregate net consideration was approximately
E73.8 million (approximately $88.7 million) which is subject to post closing
adjustments. In addition, Klepierre has also undertaken, subject to the
fulfillment of certain conditions, to acquire four additional shopping and
entertainment centers in Poland and in the Czech Republic which are currently
under construction, at a price calculated on the basis of the gross rentals on
the date of delivery, capitalized at agreed yields. Klepierre was also awarded
an option to acquire an additional shopping center presently under development
in Poland, upon the fulfillment of certain conditions. For additional
information regarding the agreement including its material terms, see "Item 10.
Additional Information - C. Material Contracts - Shopping and Entertainment
Centers" below.
- - ACQUISITION OF MANGO
In May 2005, Elscint completed the acquisition of the entire equity and
voting rights of Mango Israel Clothing and Footwear Ltd. ("Mango"), the Israeli
distributor and retailer of the international retail brand name MANGO-MNG(TM) in
consideration for approximately E2.6 million ($3.1 million) and additional
consideration paid for inventories and other working capital items. Concurrently
with the above agreement, Mango executed a distribution agreement with the
owners of the MANGO-MNG(TM) brand name for a 10-year period.
22
- - SALE OF FOUR OPERATIONAL SHOPPING AND ENTERTAINMENT CENTERS IN HUNGARY
On April 21, 2005, PC sold four shopping centers in Hungary to a subsidiary
of the Dawnay Day Group ("Dawnay Day"), a leading financial and property group
in the United Kingdom, at an aggregate asset value of approximately E54.4
million (approximately $64.3 million) determined as of the closing date. The
aggregate net consideration (after deduction of bank loans and other working
capital items) was approximately E17.2 million (approximately $20.7 million).
See "Item 10. Additional Information - Material Contracts - Shopping and
Entertainment Centers" below.
- - DIVIDEND DECLARED AND PAID
On February 7, 2005, we declared a dividend in an aggregate amount of $37
million. The dividend was paid on March 17, 2005 to shareholders of record as of
March 2, 2005.
PRINCIPAL CAPITAL EXPENDITURES AND DIVESTITURES
The following is a description of our capital expenditures and divestitures
during the years 2003, 2004 and 2005 and capital expenditures and divestitures
in progress (our share in each expenditure and divestment is 100% unless
otherwise indicated):
FISCAL YEAR 2003
THE SHOPPING AND ENTERTAINMENT CENTERS BUSINESS
- Continuing investments in shopping and entertainment centers projects
- Throughout 2003, we continued the construction of shopping and
entertainment centers (mainly in the "Arena" center Herzliya and
Poznan project) for a total investment of approximately $62.7 million.
We financed the construction of the centers through long term bank
facilities and shareholder loans provided to the subsidiary.
THE HOTEL BUSINESS
- Riverbank Park Plaza Hotel - The total additional amount invested by
our jointly controlled subsidiary in the Riverbank Park Plaza Hotel
during 2003 was L22.6 million of which our share is 50%. These amounts
were expended principally on construction. We financed the
construction of the hotel through long term bank facilities and our
available funds.
- Aquatopia project - The total cost of the construction of the
Aquatopia within the Astrid Park Plaza Hotel facility was
approximately E12.5 million. During 2003 our subsidiary invested E11.1
million in this project. Elscint financed these costs mainly through
shareholder loans.
- Centerville Apartment Hotel - The total amount invested by our
subsidiary in the renovation of the Centreville Apartment Hotel in the
Bucuresti complex during 2003 was E3.1 million.
FISCAL YEAR 2004
- Klepierre transaction - Acquisition from PC by Klepierre of 12
shopping and entertainment malls owned and operated by PC in Hungary.
The net consideration received by PC amounted to E94.1 million. See
Item 10. Additional Information - Material Contracts - Shopping and
Entertainment Center" below. Such investments were financed mainly by
bank loans and shareholder loans.
- Continuing investments in shopping and entertainment centers projects
- During 2004, we were in the process of constructing, through
subsidiaries, ten shopping and entertainment centers (Poznan, Rybnik,
Sosnoweic, Bestes, Pilsen, Lublin, Riga, Lodz, Helios and Arena) as
well as an extension to another center (Duna extension). The total
additional amount invested in these projects was approximately $36
million. These amounts were expended principally on construction. We
financed the construction of the centers through long term bank
facilities and shareholder loans provided to the subsidiary.
THE HOTEL BUSINESS
- Riverbank Park Plaza Hotel - The total additional amount invested by
our jointly controlled subsidiary in this project during 2004 was L34
million of which our share is 50%. These amounts were expended
principally on construction. We financed the construction of the hotel
through long term bank facilities and shareholder loans provided to
the subsidiary.
23
- Apartment Hotel Bucuresti Complex (Centerville)-The total amount
invested by our subsidiary in the renovation of the hotel apartment in
the Bucuresti complex during 2004 was E2 million. We financed these
costs through short-term facility and available free cash flow from
the operations of the Centreville apartment hotel.
THE IMAGE GUIDED TREATMENT BUSINESS
In 2004, InSightec signed an agreement for an internal round of financing
totaling $21 million from its existing shareholders in which our share totaled
$7.5 million. The convertible notes may be converted in whole or in part at any
time into ordinary shares of InSightec at a conversion rate of $7.30 per share.
FISCAL YEAR 2005
THE SHOPPING AND ENTERTAINMENT CENTERS BUSINESS
- Klepierre transaction - In July 2005 PC sold to Klepierre a portfolio
that includes our four operational shopping and entertainment centers
in Poland. The net consideration received by PC for the sale of these
centers amount to E73.8 million ($87.1 million). In addition, PC and
Klepierre have entered into an agreement for the future sale of an
additional four centers under development in Poland and the Czech
Republic. Klepierre also has an option to acquire a fifth shopping
center under development in Poland, subject to the attainment of
certain conditions.
- Dawnay Day Transaction -In April 2005, PC sold four shopping and
entertainment centers in Hungary to the Dawnay Day Group ("Dawnay
Day"), in the aggregate net consideration (after deduction of bank
loans and other working capital items) of approximately E17.2 million
($20.7 million).
- Continuing investments in shopping and entertainment centers projects
- During 2005, we were in the process of constructing, through
subsidiaries, ten shopping and entertainment centers (Poznan, Rybnik,
Sosnoweic, Bestes, Pilsen, Lublin, Riga, Lodz Kerepesi and Helios).
The total additional amount invested in these projects was
approximately $63 million. These amounts were expended principally on
construction. We financed the construction of the centers through long
term bank facilities and shareholder loans provided to the subsidiary.
- Kerepesi Budapest project - In November 2005, we purchased a large
area of land situated on Kerepesi Street in central Budapest, the
former site of the Hypodrome. The purchase price of the entire equity
rights represents a site value of E21 million (approximately $24
million), out of which E3.9 million is the quota purchase price and
the remaining are assumed liabilities.
- Acquisition of the Remaining 50% of Sadyba Best-Mall - In May 2005 PC
completed the acquisition of the 50% not owned by it in the Sadyba
commercial and entertainment center in Warsaw, Poland, for a purchase
price of approximately $19.5 million.
THE HOTEL BUSINESS
- Sale of Shaw hotel - In December 2005, we sold all of our holdings (in
which we were a 30% shareholder) in Shaw Hotel Holding B.V., the owner
of one of our hotels in London, to an unrelated third party for a net
consideration of L4.0 million ($6.9 million).
- Construction and renovation of the Centerville apartment hotels - The
total amount invested in this project during 2005 was E7.0 million
($8.3 million). Such investments are in connection with the renovation
of an additional 60 apartments as well as other facilities in the
hotel. We financed this project through a bank facility and cash
resulted from operational activities.
- Riverbank hotel - The total amount invested by our subsidiary in this
project was L18.6 million ($32.4 million) in which our share is 50%.
We financed this project through a bank loan and shareholder loans to
the subsidiary.
- Aquotopia project - During 2005 we invested an amount of E3.0 million
($3.5 million) in the refurbishment of the Aquotopia project within
the Astrid Plaza facility. We financed this project through
shareholder loans to the subsidiary.
OTHER ACTIVITIES
In May 2005, we completed the acquisition of the entire equity and voting
rights of Mango in consideration for approximately E2.6 million ($3.1
million) as well as working capital adjustments.
24
PRINCIPAL CAPITAL EXPENDITURES AND DIVESTITURES CURRENTLY IN PROGRESS
Currently, we are either in the process of making or are planning to make
additional capital expenditures, as follows:
SHOPPING AND ENTERTAINMENT CENTERS BUSINESS
- The additional estimated costs expected to be invested in our projects
which are currently under construction (Rybnik, Sosnoweic, Pilsen,
Lublin, Riga, Lodz, Kerepesi and Helios) is E353 million. We
expect to finance these projects by long term bank loans and
shareholder loans. We expect to complete the construction of these
projects in 2007 - 2009.
- Dream Island project - In May 2006, the Budapest General Assembly
approved the amendment to the local town-planning scheme (KSZT), which
approves the construction plans for this site. Formal regulatory
approvals of the KSZT modification contained in the Budapest General
Assembly resolution are currently pending. We plan to commence the
construction of this Project in 2007 and we expect to complete it
within six years. The total estimated costs expected to be invested in
this project is E1,100 million.
HOTEL BUSINESS
Bucuresti Hotel Complex, Bucharest, Romania - In January 2006 we commenced
the renovation of the Bucuresti Hotel in order to enable compliance with the
international standards required for a four star business hotel. The additional
estimated costs expected to be invested in this project is E33 million. We
expect to complete the construction of this project in late 2007. Such
investment will be financed by bank loans.
B. BUSINESS OVERVIEW
During 2005, our activities were divided into five principal fields: (i)
initiation, construction, operation, management and sale of shopping and
entertainment centers in Israel and in Central and Eastern Europe; (ii)
ownership, operation, management, and sale of hotels in major European cities;
(iii) long term lease of real estate property, (iv) investments in the research
and development, production and marketing of magnetic resonance imaging guided
focused ultrasound treatment equipment, through InSightec Ltd. ("InSightec");
(v) other activities consisting of the distribution and marketing of women's
fashion and accessories through our wholly-owned Israeli subsidiary, Mango
Israel Clothing and Footwear Ltd.; and venture-capital investments. In December
2005, we sold all of our holdings in the company holding one of our hotels in
London, which was the subject of the long term lease agreement referred to in
clause (iii) above.
Below is a description of our five principal fields of activity since 2005:
SHOPPING AND ENTERTAINMENT CENTERS
The shopping and entertainment centers business includes our operational
shopping and entertainment centers and other shopping and entertainment centers
which are currently under construction and/or development. In addition, this
business includes the Dream Island project, a tourist and entertainment area in
central Budapest which includes designations for commercial space, tourism,
entertainment and leisure hotels and apartments hotel, which is currently in
preliminary stages of development as well as other income producing real estate
properties and other properties.
SHOPPING AND ENTERTAINMENT CENTERS - GENERAL
We presently have one operating shopping and entertainment center in the
Czech Republic (which is expected to be sold to Klepierre effective as of June
30, 2006, see "- material transactions in the shopping and entertainment
centers" below), one in Israel and seven other projects in various stages of
planning and development in Poland, Hungary, the Czech Republic and Latvia. The
operations of each of our shopping and entertainment center projects are
conducted through a special purpose project corporation.
Generally, approximately 75% of the total constructed area of each shopping
and entertainment center is set aside to be leased. The focus of our centers is
on two principal elements: shopping and entertainment. The anchor tenants form
the core of these elements, around which the smaller businesses and activities
are introduced, and provide a wide range and choice of activities to patrons.
The entertainment facilities generally include a cinema complex of between 8-12
screens, a video and gaming arcade, bowling alleys, billiard halls, fitness
centers, bars, discotheques, children's playgrounds and, in some projects, an
IMAX three-dimensional cinema screen. The food court consists of a range of
restaurants, offering a variety of culinary opportunities from fast food to
gourmet foods. Unless otherwise indicated in the tables below, we own 100% of
each identified center.
25
The commercial activities focus on supermarket and department store anchor
tenants, and are carefully monitored to allow an optimal mix of stores and
services to cater for all requirements and to offer the maximum range of
commodities to patrons.
Our shopping and entertainment centers business currently consists of the
following projects:
26
Operational Centers
APPROXIMATE
APPROXIMATE CONSTRUCTED APPROXIMATE APPROXIMATE
NAME OF COMMENCEMENT LAND AREA AREA LEASEABLE OCCUPANCY AT PARKING
CENTER OF OPERATION TITLE (SQ.FT.) (SQ.FT.) AREA (SQ. FT.) 03/31/06 SPACES ENCUMBRANCES MISCELLANEOUS
------- ------------ --------- ----------- ----------- --------------- ------------ ------- ------------- --------------
NOVO PLAZA March 2006 Freehold 355,500 591,800 Retail: 243,000 Retail: 92% 900 First ranking Sub lease
Prague, Offices & Office & mortgage on rights for 25
Czech Leasehold 86,080 Storage: 35,000 Storage: 40% the land and years until
Rep (1) on the 2024 with an
center. Two option to
second extend the
ranking lease for
mortgages are additional 25
currently years which
being carried expires in
out on the 2049.
land and on a
new building
that is being
constructed.
ARENA June 2003 Leasehold 269,000 830,000 Retail: 274,000 Retail: 95% 1,250 First ranking Capitalized
Herzliya, Offices & Offices & mortgage on lease rights
Israel Storage: 45,000 Storage: 56% the land and for 49 years
on the until 2037
center. with an option
to extend the
lease for
additional 49
years which
expires in
2086. Lease
may be
terminated if
Arena does not
meet the terms
of the lease.
(1) This center is the subject of a sale agreement with Klepierre. Delivery is
expected on June 30, 2006. See below.
27
Centers under Development
LEASEABLE
APPROXIMATE AREA PARKING
SCHEDULED LAND AREA (SQ.FT.) SPACES
NAME OF PROJECT OPENING TITLE (SQ.FT.) (1) (1) ENCUMBRANCES PERMITS MISCELLANEOUS
- --------------- ---------- --------- ------------ --------- -------- --------------- ------------ -----------------------
LUBLIN PLAZA 2007 Perpetual 182,812 277,000 690 First ranking All required The property is subject
Lublin, Poland Usufruct mortgage on permits were to a joint venture
(2)(3) the building. issued with agreement, see below.
respect to
Certain the first Perpetual usufruct for
easements were stage 99 years until 2097.
granted to (congress The perpetual usufruct
owners of and may be terminated if
adjacent commercial the use of the land
plots. areas). does not correspond to
No permits the approved usage, or
were issued in the occurrence of
with respect unauthorized delays. We
to the undertook to complete
second stage the first stage of the
(hotel and project by August 31,
office 2006 and to commence
building). the second stage by
We are September 30, 2009 and
currently ending it by the end of
not 2011. Failure to meet
considering these dates requires
the the payment of a
development penalty in the amount
of the of $0.8 million. If the
second perpetual usufruct is
stage. terminated, we will be
entitled to
reimbursement of our
investment in the
construction of the
complex until the date
of termination.
We have the right to
acquire the land upon
completion of
construction in
consideration for up to
approximately $2.6
million. If we choose
not to conduct the
second stage of the
transaction we are
required to pay a
penalty of
approximately PLN 2.5
million (approximately
$0.8 million)
RYBNIK PLAZA 2007 Freehold 198,823 195,000 470 First ranking All required
Rybnik, Poland mortgage on the permits were
(4) land. issued.
SOSNOWIEC PLAZA 2007 Freehold 127,600 139,000 400 -- All required Perpetual usufruct
Sosnowiec, permits were right until December
Poland (4) Perpetual 16,170 issued. 17, 2092. The perpetual
Usufruct usufruct may be
terminated before the
lapse of the specified
time if the pereptual
usufructee uses the
land in a manner
self-evidently
inconsistent with its
designation in the
agreement, in
particular if he has
not erected the
buildings or facilities
specified in the
agreement. If the
perpetual usufruct is
terminated, we will be
entitled to claim the
reimbursement of our
investment in the
construction of the
complex.
PILZEN PLAZA 2007 Leasehold 370,600 + 220,000 600 -- Building Leasehold rights for 99
Pilzen, Czech 561,000 as a permits years (and 97 years for
Republic (4) park pending. a land area of
approximately 89,523
square leased for the
construction of a
parking building) until
2102.
28
LEASEABLE
APPROXIMATE AREA PARKING
SCHEDULED LAND AREA (SQ.FT.) SPACES
NAME OF PROJECT OPENING TITLE (SQ.FT.) (1) (1) ENCUMBRANCES PERMITS MISCELLANEOUS
- --------------- ---------- --------- ------------ --------- -------- --------------- ------------ -----------------------
RIGA PLAZA 2007 Freehold 856,000 479,000 1,500 Undertaking to City The property is subject
Riga, Latvia encumber the approval for to a joint venture
(2) land upon the plans agreement, see below.
drawdown from was received
the facility in May 2006.
agreement.
LODZ PLAZA Not yet Freehold 44,589 -- -- First ranking Demolition Perpetual usufruct
Lodz, Poland determined mortgage on permits were right until December 5,
(4) Perpetual 311,964 land. issued. 2089.
Usufruct
Tenancy for 30 years
tenancy 2,636 until August 29, 2031,
with two options to
extend for additional
30 years which expires
in 2061 and for 20
years which expires in
2081.
This project is in the
preliminary planning
and development stage
as a shopping center
integrated with a
public market. Due to
strong competition, we
are currently assessing
the scope and nature of
this project.
ARENA PLAZA 2007 Freehold 1.32 million 713,000 2,600 First ranking All required
(KEREPESI) mortgage on the permits were
Budapest, land issued.
Hungary
(2) Details provided in these items are presented according to the plans and
designs of each respective center and may subsequently differ.
(3) PC has 50% interest in this project.
(4) This center is the subject of a purchase option awarded to Klepierre, see
below.
(5) This center is the subject of a sale agreement with Klepierre, see below.
The expected future costs for the completion of each of the above shopping
and entertainment centers are detailed in "Item 4. Information on the Company -
A. Business and Development of the Company - Recent Developments - Principal
Capital Expenditures and Divestitures" above.
29
Set forth below is additional information with respect to our ownership of
certain of the above real estate properties:
LUBLIN PLAZA
In May 2002, PC entered into a joint venture agreement with an unrelated
third party for the purchase of 50% of the ownership of Movement Poland S.A.
("MPSA"), a company registered in Lublin, Poland, for a consideration of
approximately $1.5 million.
Under the joint venture agreement each party was granted a right of first
offer and a tag along right in the event the other party wishes to sell its
rights in MPSA. The agreement further provides for a buy-out mechanism in the
event of certain deadlocks. Financing of the project is to be made by both
parties in equal share, except for an initial $4 million investment to be
provided by PC. PC and the other party are currently in dispute regarding the
shareholders loan required to be invested by the other party. The other party
alleges that the increase in the project budget in comparison with the original
one was caused by the acts or omissions of PC and, accordingly, that PC alone
should bear all additional equity loans. PC disputes this allegation and has
demanded the fulfillment of the agreement in accordance with its terms. PC
decided, without waiving its right towards the other party, to provide MPSA with
an additional financing by way of equity loans. Through December 31, 2005, PC
invested indirectly in MPSA a total amount of approximately $10.5 million.
RIGA PLAZA
In February 2004, PC and Development Capital Corporation (Lativa) ("DCC")
entered into a joint venture agreement pursuant to which PC purchased from DCC
in consideration for approximately $2.7 million, 50% of the outstanding share
capital of SIA Diskna ("SIA"), a Latvian corporation wholly owned by DCC. The
agreement provides for a buy-out mechanism in the event of certain deadlocks. In
addition, the joint venture agreement provides for certain limitations on the
sale of each party's holdings in SIA, including a right of first offer and a tag
along right to all of each party's shares. Future financing of the project will
be provided by the parties as shareholder loans. In the event of failure by any
party to provide such shareholder loans, the other party may elect to provide
SIA with such shareholder loans at an increased interest rate or to invest the
required amounts, while diluting the defaulting party's holdings in SIA.
Material Transactions in the Shopping and Entertainment Centers business
during 2005
In April 2005, PC sold its entire equity and voting rights in the companies
owning four shopping and entertainment centers in Hungary (Pecs Plaza,
Szombathely Plaza, Veszprem Plaza and Sopron Plaza) to a subsidiary of Dawnay
Day. The aggregate net cash consideration paid to PC totaled approximately E17.2
million (approximately $20.7 million).
During July 2005, PC entered into definitive agreements with Klepierre
which consisted of a two-stage transaction. Within the framework of first stage
of the transaction, consummated on July 29, 2005, Klepierre acquired the entire
equity and voting rights in the companies owning four operational shopping
centers in Poland (Sadyba Best Center, Krakow Plaza, Ruda Slaska Plaza and
Poznan Plaza) as well as the management company in Poland. The aggregate net
consideration paid for the purchase of the above companies was approximately
E73.8 million (approximately $88.7 million) which is subject to post closing
adjustments. Under the second stage of the transaction, Klepierre has undertaken
to acquire the entire equity and voting rights in the companies presently
developing two shopping centers in Poland (Rybnik Plaza and Sosnowiec Plaza) and
two companies developing shopping centers in the Czech Republic (Novo Plaza and
Pilsen Plaza). Upon the completion and delivery of the shopping centers,
Klepierre will pay a purchase price calculated on the basis of the gross rentals
on the date of delivery, capitalized at agreed yields. In addition, PC granted
to Klepierre an option to acquire an additional shopping center presently under
development in Poland (Lublin Plaza), upon the fulfillment of certain
conditions.
On the same day, PC entered into an additional agreement with Klepierre
pursuant to which Klepierre purchased the remaining 50% of the equity and voting
rights in our Hungarian management company (in addition to the 50% of the equity
and voting rights already purchased by Klepierre from PC in 2004), in
consideration for E0.9 million ($1.1 million).
For additional information on all of the above agreements, including price
adjustments and guarantees, see "Item 10. Additional Information - C. Material
Contracts - Shopping and Entertainment Centers" below.
Project Management and Supervision
During the planning and construction of our shopping and entertainment
centers, we enter into transactions with various contractors and subcontractors
for the planning, design and construction of each shopping and entertainment
centers. The supervision over the construction project is usually conducted by
Control Centers Ltd. ("Control Centers"), our indirect parent, which provides us
services of coordination, planning, execution and supervision over construction
projects of shopping and entertainment centers and other real estate projects
initiated by us. See "Item 7. Major Shareholders and Related Party Transactions
- - B. Related Party Transactions - Agreements for the Purchase of Coordination
Planning and Supervision Services over Construction Projects" below. Immediately
following the completion and opening of each shopping and entertainment center,
the subsidiary that constructed the center enters into a management agreement
with one of our
30
subsidiaries which renders services relating to the ongoing administration,
maintenance and operation of the shopping and entertainment center, and receives
service fees which are paid by the tenants of the center.
Business Concept and Strategy
The business concept and strategy of the shopping and entertainment centers
business include the following elements:
Development. Develop modern western-style shopping and entertainment
centers in the capital and regional cities of selected countries, primarily in
Central and Eastern Europe and focusing in the medium term on Poland, the Czech
Republic and Romania. We are currently reviewing investments in various other
selected countries including in India.
Acquisitions. Acquire operating shopping centers that show significant
redevelopment potential (either as individual assets or as portfolios) for
refurbishment and subsequent re-sale.
Pre-sale. Pre-sell, where prevailing market and economic conditions are
favorable, the centers prior to, or shortly after, commencement of construction
or redevelopment.
Where the opportunity exists, extend in developments beyond shopping and
entertainment centers by leveraging our strengths and drawing upon our
experience and skills to participate in residential, hotel and other development
schemes where such development forms a part of integrated large scale business
and leisure developments, such as the Dream Island project.
We will also assess and consider specific development opportunities that
satisfy our development parameters and investment criteria in countries not
previously targeted by us.
While our current strategy is to dispose of a shopping and entertainment
center upon completion, if economic conditions, including property yields,
change such that retaining and operating a shopping and entertainment center on
completion is likely to be more profitable to us than disposing of it, we will
consider retaining and operating the completed shopping and entertainment center
until economic conditions warrant a profitable sale.
OTHER REAL ESTATE PROPERTIES
In addition to our engagement in the shopping and entertainment centers
business, we own several other real estate projects of various types, as
described below.
The Dream Island Project
Dream Island 2004 Real Property Development Ltd. ("Dream Island"), a
Hungarian company, owns approximately 3.5 million square feet of land located on
the Obuda Island in the Danube River, a leisure and entertainment area in
central Budapest. The construction rights on this area are for approximately
350,000 square (approximately 3.8 million square feet, with designations for
offices, commercial space, tourism, entertainment and leisure and hotels. The
buildings presently located on these properties, measuring approximately 600,000
square feet are leased out as offices, restaurants and entertainment outlets,
generating rental revenues of approximately E2.8 million (approximately $3.5
million) per year.
Approximately 67% of Dream Island was originally acquired by Ercorner, our
indirect subsidiary, in October 2003 through a privatization tender won by us.
The purchase of the our holdings in Dream Island was made in consideration for
approximately HUF 4.6 billion (approximately $21.5 million).
We have obtained financing for the purchase by Ercorner of Dream Island
through an arrangement between PC (Ercorner's parent) and MKB Bank Nyrt.,
pursuant to which MKB provided Ercorner with a loan in the amount of
approximately HUF 3.7 billion (approximately $17.3 million), constituting
approximately 80% of the purchase price for the acquisition of the interests in
Dream Island by Ercorner. The loan was provided for a two-year period and was
extended until March 2007. In addition, PC granted an option to MKB to acquire
50% of the equity interest in Ercorner, which MKB exercised in 2004 in
consideration for the same price per share paid by Ercorner to purchase the
holdings in Dream Island.
In April 2004, a shareholders agreement was signed between Ercorner, Obuda
Holdings Limited ("CPH"), an unrelated third party, which held at that time,
approximately 33% of Dream Island's quotas, ESI Associates Holdings Ltd.
("ESI"), the management company of Dream Island and Dream Island. Under the
agreement, the parties agreed on the equalization of voting rights in Dream
Island in consideration for which CPH paid Ercorner an aggregate amount of $1
million. Ercorner and CPH further agreed to grant ESI 10% of their respective
holdings in Dream Island in consideration for the same price per share paid by
Ercorner to purchase the holdings in Dream Island. 80% of the above
consideration was assigned to MKB decreasing the outstanding loan while CPH and
Ercorner provided ESI with a loan, in equal shares, with regard to the remaining
20%. As of today, PC, MKB, CPH and ESI hold approximately 30%, 30%, 27% and 10%
respectively directly or indirectly in Dream Island. A fourth unrelated company
- - Minesol Magyarorszag Vagyonkezelo Korlatolt Felelossegu, holds approximately
3% of Dream Island's shares.
31
Under the above shareholders agreement, CPH was also granted a put option,
exercisable during the 3-year period after the closing of the agreement (April
2005), to sell all its holdings in Dream Island to Ercorner at a price
reflecting the cost of acquisition of the quotas by Ercorner plus interest less
profits paid out by Ercorner until the date of sale. The parties have agreed to
make necessary contributions with regard to any additional financing pro-rata to
their holdings.
In the event of a change of control in one of the parties or in the event
of a defaulting party, as stipulated in the agreement, a "buy-out" option is
triggered for the benefit of the remaining parties pro rata to their holdings at
a price to be determined by the shareholders, or where the shareholder are
unable to reach an agreement-by specified experts. The parties undertook certain
restrictions on the transfer of quotas within Dream Island during a period of
two years from the closing of the transactions.
Dream Island has submitted applications to local planning authorities in
order to modify the permitted urban usage designations, so as to maximize the
development potential of the area owned by Dream Island. As security for
obtaining these permits, EMI has executed a corporate guarantee in favor of MKB.
In May 2006, the Budapest General Assembly approved the amendment to the local
town-planning scheme (KSZT), which approves the construction plans for this
site. Formal regulatory approvals of the KSZT modification contained in the
Budapest General Assembly resolution are currently pending. As part of the above
approval provided, Dream Island has undertaken to ensure the traffic connections
to, from and within the island and to develop detailed landscape works. The
additional investment required of Dream Island in consideration of the traffic
connections and the development of landscape is estimated in HUF 14.5 billion
(approximately $67.9 million).
Plaza House Building
Plaza House Kft., our indirect wholly owned subsidiary, owns an office
building located on the prestigious Andrassy Boulevard, in the center of
Budapest. The building is located on a property totaling approximately 6,600
square feet and consists of four floors, an atrium and a basement, with a total
constructed area of approximately 26,000 square feet. The site is located in an
exclusive area of the city in which several foreign embassies are located. Parts
of the building have been leased to subsidiaries of PC. The building is also
used as the headquarters of PC's management.
Duna Plaza Offices
Within the framework of the 2004 Klepierre sale agreement (as described
above), Klepierre has acquired from PC all of the equity rights in Duna Plaza.
Duna Plaza is the owner of the Duna Plaza complex, which is comprised of Duna
Plaza shopping and entertainment center and the Duna Plaza offices ("DPO"). The
DPO are located on the third, fourth and fifth floors of the building and having
approximately 120,000 square feet leasable area of offices and approximately
5,700 square feet leasable area of storage.
Since DPO was specifically excluded from the framework of the transaction,
Klepierre and PC have agreed to implement certain procedures to cause: (i) the
registration of the DPO as a separate condominium unit the rights of which will
be initially held by Duna Plaza; (ii) implementation of a de-merger of the Duna
Plaza complex in such manner that DPO will be owned by a newly incorporated
company; and (iii) the sale and transfer to PC of the of the new company that
will hold the DPO. The assets of the Duna Plaza complex will be divided in such
manner that Duna Plaza will retain ownership of the Duna Plaza shopping center,
while the DPO will be owned indirectly by PC. The liabilities of Duna Plaza
shall be divided in such a manner that Duna Plaza shall retain the liabilities
associated with the sold center, while DPO Owner shall assume the liabilities
associated with the DPO. PC shall indemnify Duna Plaza for the liabilities
assumed by DPO Owner. All costs, liabilities and expenses incurred or to be
incurred in connection with the de-merger procedures shall be at PC's sole cost.
During the interim period prior to the consummation of the de-merger
procedures, PC shall be entitled to all rental and other revenues (excluding
from the sale of utilities) which shall received by Duna Plaza from the DPO
tenants, after deducting the aggregate amount of: (i) all direct costs and
expenses and taxes which shall be incurred or paid by Duna Plaza which directly
relate to the ownership, operation and management of the DPO; and (ii) that
proportion of the general costs and expenses and taxes of the Duna Plaza
Complex, which may reasonably be attributed and apportioned to the DPO. During
the interim period, PC shall be responsible for and shall manage and operate the
DPO. Duna Plaza shall have a lien over DPO's funds, as security for payment of
the DPO costs. PC will indemnify Klepierre for and against any cost, debt,
actions, suits and liability, that may arise as a result of or in connection
with the ownership, possession, operation and transfer of the DPO.
As of the date of this annual report, the condominium was registered in
June 2006 and we expect the de-merger to be completed by the end of 2006.
The Praha Plaza Commercial Complex
Praha Plaza s.r.o., our indirect wholly-owned subsidiary, owns a commercial
complex comprised of a number of buildings located in the Third District of
Prague, the Czech Republic. The building' strategic location allows for
convenient transportation to the complex.
32
The buildings are located on property totaling approximately 500,000 square
feet and consist of a five floor main building and a basement, an office
building consisting of four floors and an office building of two floors. In
addition, there are a number of other buildings of one floor each. The total
leasable area of the buildings is approximately 477,000 square feet. The
property is currently operating as a commercial complex with a 45% occupancy
rate as at May 31, 2006.
We are currently considering the construction of residential apartments on
the land.
Helios Plaza
We own a plot of land measuring approximately 160,000 square feet located
adjacent to the Piraeus Avenue in Athens, Greece. The book value of the
investment in the land (including development and other costs) equaled on
December 31, 2005, approximately E22.5 million (approximately $26.6
million). Following the issue of a ministerial decision which changed the land
use along the Piraeus Avenue, the permitted land use applicable to this site are
presently unclear. We have filed in April 2005 a petition in the Constitutional
Court against this ministerial decision. We, together with our legal counsel and
professional advisers, are presently examining the ministerial decision and
assessing the development opportunities for this site.
In addition to the above, we own several other plots in Central and Eastern
Europe whose costs is not material to us.
33
The following table summarizes the principle characteristics of each of the
real estate properties described above.
APPROXIMATE
APPROXIMATE CONSTRUCTED LEASEABLE
NAME, LAND AREA AREA AREA OCCUPANCY
LOCATION TITLE (SQ.FT.) (SQ.FT.) (SQ.FT) RATE ENCUMBRANCES PERMITS MISCELLANEOUS
-------- -------- ----------- ----------- --------- --------- ---------------- -------------- -------------------------
DREAM ISLAND Freehold Estimated Estimated Estimated -- First ranking Amendment to Scheduled opening is
PROJECT at 3.5 at 3.5 as 3.8 mortgage on the the local town expected to be in 2002.
Budapest, million million million land and on the planning
Hungary buildings. scheme (KSZT)
was approved.
Formal
regulatory
approvals of
the KSZT
modification
contained in
the Budapest
General
Assembly
resolution are
currently
pending.
PLAZA HOUSE Freehold 6,600 26,400 19,874 100% First ranking --
BUILDING, mortgage on the
Budapest, land and the
Hungary building.
DUNA PLAZA Freehold part of 147,000 120,157 81% After de-merger -- The Duna Plaza offices
OFFICES the Duna the real estate are currently owned by
Budapest, Plaza will be Klepierre. Upon the
Hungary center mortgaged. completion of the
de-merger, Klepierre will
maintain ownership over
the Duna Plaza center and
we will own the Duna
Plaza Offices
THE PRAHA Freehold 538,000 505,720 484,000 45% First ranking --
PLAZA mortgage on land
COMMERCIAL and buildings.
COMPLEX,
Prague,
Czech
Republic
HELIOS Freehold 160,000 -- -- -- Prenotation of -- Due to changes in the
PLAZA, mortgage relevant zoning scheme
Athens Greece (similar to a applicable to the
mortgage) on the project, we are presently
land. re-assessing this
project.
34
HOTELS
The goal of our hotel business is to acquire and manage, via management
companies, four-star hotel properties which provide, at four star hotel prices,
the business and vacation traveler with five star quality accommodations that
are conveniently located near major transportation stations.
Our ownership percentage in our hotels varies, and the remaining interests
in those hotels that are not wholly-owned by us are owned by various unrelated
third parties, including subsidiaries of the Red Sea group of companies ("Red
Sea") which is our business partner in six of our eight operating hotels and in
one of the hotels which is currently under development. Red Sea is engaged in
the initiation and development of residential and commercial real estate
projects in Israel and in the operation of chain of hotels and income producing
real estate abroad. In certain hotels, Park Plaza received 5% or 10% of the
equity rights in the companies holding these hotels. See "- Management of
Hotels" below.
Set forth below is our percentage ownership and other certain information
relating to our hotels:
35
OPERATING HOTELS
AVERAGE
APPROXIMATE OCCUPANCY
CONSTRUCTED RATES
NAME AND RATE AREA TOTAL DURING
OF HOTEL TITLE (SQ. FT.) ROOMS 2005 OTHER INFORMATION ENCUMBRANCES
- -------------- --------- ----------- ---------- --------- -------------------- ---------------
VICTORIA Freehold 220,000 305 (27 93% - business center Mortgage on the
HOTEL, Suites) hotel.
Amsterdam, The - health center
Netherlands
Four Star
UTRECHT PARK Leasehold 55,880 120 (40 74% - 11 conference Pledge on long
PLAZA HOTEL, executive rooms term lease
Utrecht, the rooms) rights.
Netherlands
Four Star Mortgage on the
hotel.
ASTRID PARK Freehold 223,300 229 (19 74% - includes An undertaking
PLAZA HOTEL, business an oceanarium to mortgage the
Antwerp, suites) attraction hotel. The
Belgium (Aquatopia) mortgage has
Four Star not yet been
- 12 boardrooms registered.
- 18 conference
rooms
CENTERVILLE Freehold 409,000 230 89% - fully First ranking
HOTEL operational mortgage on the
APARTMENTS since May 2003. apartments
Bucaresti, hotel.
Romania
SHERLOCK Leasehold 67,460 119 (17 83% - fitness First ranking
HOLMES PARK executive center mortgage on the
PLAZA HOTEL, studios, land and the
London, the 3 split - main hotel.
United Kingdom level meeting room
Four Star "loft" for 600 people
suites)
- 6 board
rooms
36
APPROXIMATE
NAME AND RATE OF CONSTRUCTED AVERAGE OCCUPANCY
HOTEL TITLE AREA (SQ. FT.) TOTAL ROOMS RATES DURING 2005 OTHER INFORMATION ENCUMBRANCES
- ------------------ --------- -------------- ------------ ------------------ ------------------ -----------------------------
VICTORIA PARK Freehold 242,000 287 (22 87% - Executive lounge First ranking mortgage on the
PLAZA HOTEL, business - health center land and the hotel.
London, the United suite and 12 - main conference
Kingdom main suites) room for up to
Four Star Deluxe and 12 750 people
apartments - 13 additional
conference rooms
- underground
parking
facilities
RIVERBANK PARK Leasehold 337,100 396 and an soft opening - full leisure First ranking mortgage on the
PLAZA HOTEL, additional since April 2005 center land and the hotel
London, the United 66 apartment - two main
Kingdom Four Star hotel luxury conference
Deluxe suites rooms, each with
capacity of up
to 650 people
- 20 additional
conference rooms
SANDTON PARK PLAZA Freehold 99,000 138 (61 53% business center First priority mortgage on
HOTEL, (1) suites) the hotel
Johannesburg,
South Africa
Four Star
(1) Subject to a sale agreement, see below.
37
HOTELS UNDER DEVELOPMENT
APPROXIMATE APPROXIMATE
NAME AND RATE OF LAND CONSTRUCTED TOTAL
HOTEL TITLE AREA (SQ.FT.) AREA (SQ.FT.) ROOMS ENCUMBRANCES
- ------------------ -------- ------------- ------------- ----- -------------
BALLET BUILDING Freehold 29,000 180,500 199 --
PROJECT,
Budapest, Hungary
FIVE STAR
BUCURESTI HOTEL,
Bucharest, Romania Freehold 80,700 484,000 438 First ranking
Four Star mortgage on
the hotel.
38
During 2005, we opened the Riverbank Park Plaza Hotel located on the bank
of the River Thames in London, the United Kingdom. We also continued our plans
for the development of two additional hotel projects described in the table
above. In Hungary, we made progress on the project for the conversion of the
former National Ballet Institute Building, centrally located on Budapest's
prestigious Andrassy Boulevard, into a Western business oriented hotel. We
commenced the renovation and the refurbishment, and expect to be completed by
June 2008. However, we are currently re-assessing our development plans for the
project in the light of offers for the sale of the premises which are currently
under consideration. In addition, we commenced the renovation and refurbishment
of the Bucuresti Hotel in order to enable compliance with the international
standards required for a four star business hotel. We expect the renovation
works in the Bucuresti hotel to be completed during the fourth quarter of 2007.
On May 30, 2006, we, together with the other owners of the Sandton Hotel,
have entered into an agreement for the sale of the entire issued share capital
of Park Plaza Hotel Sandton (Pty) Ltd, the company owning the Sandton Hotel, and
assignment of all shareholder loans to an unrelated third party effective as of
June 30, 2006. This transaction reflects an asset value of the Sandton Hotel of
approximately Rand 52 million (approximately $8 million). The net consideration
to be received by us is estimated at $1.6 million. The execution of the
agreement is subject, inter alia, to the completion of a due diligence
investigation to the satisfaction of the Purchaser.
AGREEMENTS WITH RESPECT TO OWNERSHIP OF THE HOTELS
We are a party to a shareholder agreement with Red Sea dated February 15,
1993, as amended, with respect to our indirect ownership of the Victoria Park
Plaza hotel in Amsterdam. Under the agreement, in the event Control Centers or
Red Sea no longer controls the entities owning the Victoria Park Plaza hotel,
then the party who ceased to control such entity must offer its holdings in the
entities owning the Victoria Park Plaza hotel to the other party at value to be
agreed upon by the parties. We are also a party to a shareholder agreement with
all unrelated third parties that hold interests in the company owning the
Sandton Hotel, dated April 1, 1999, with regard to the Sandton Hotel. The
agreement includes right of first offer and tag along provisions applicable to
all parties. For the sale of the company holding the Sandton Hotel, see above.
With respect to all the other properties we have no written agreements
governing the operation of the hotels and the sale of our respective shares.
HOTELS UNDER DEVELOPMENT
We are a party to an agreement with Control Centers, our indirect parent,
for the receipt of services of coordination, planning, execution and supervision
over with respect to the renovation works of the Bucuresti Hotel complex, which
include the Bucuresti hotel and the Centerville hotel apartments. See "Item 7.
Major Shareholders and Related Party Transactions - B. Related Party
Transactions - Agreements for the Purchase of Coordination Planning and
Supervision Services over Construction Projects" below.
MANAGEMENT OF HOTELS
Management agreement with Park Plaza
Most of our operating hotels have appointed Park Plaza Europe B.V. ("Park
Plaza"), an unrelated third party management company, as their management
company. Park Plaza owns the franchise to the "Park Plaza" brand name in the
Benelux countries, the United Kingdom, various countries in Eastern Europe,
South Africa and a number of countries in the Middle East. Park Plaza is
responsible for the operation of the hotels, including the supervision of the
local management and staff. Local management is employed by the respective
company owning the hotel and not by Park Plaza, although Park Plaza does render
hiring services.
Each of our subsidiaries holding interests in the Victoria, Utrecht,
Astrid, Sherlock Holmes, Victoria London and Riverbank hotels has entered into a
restated management agreement with Park Plaza, the principal provisions of which
include:
- Payment to Park Plaza of an annual incentive fee of 7% of the gross
operating profit (as defined in the applicable agreement) of the hotel
("Incentive Fee").
- Payment to Park Plaza of an annual base fee of 2% of the gross hotel
room revenues ("Annual Base Fee")
- Reimbursement of reasonable out-of-pocket expenses, including
advertising expenses, office expenses (at a fixed amount) and other
expenses incurred by Park Plaza in carrying out its duties of up to 3%
of the aforementioned gross operating profit.
- In consideration for monthly royalties of up to 1.5% of the gross
hotel-room revenues ("Franchise Fee"), our hotels may use the brand
name "Park Plaza", certain Park Plaza trademarks, Park Plaza's
international marketing network and international booking center, Park
Plaza's marketing and advertising material, Park Plaza's
39
international hotel conferences, Park Plaza's assistance in planning,
developing and applying its methods with respect to the hotels,
training of staff and senior management of the hotels, and inclusion
in the list of Park Plaza hotels worldwide. We design and refurbish
our hotels in order to comply with Park Plaza's operational standards.
- Each management agreement is valid for an initial fifteen-year period,
and renewable automatically for an additional period of ten years,
subject to the right of either party to terminate the agreement by
giving twelve months advance notice (or six months advance notice in
the event that we decide on early termination of the management
agreement). If any of the hotel-owning companies should decide on
early termination of the management agreement, then it would be
required to pay to Park Plaza an amount equal to the Incentive Fee,
the Annual Base Fee and the Franchise Fee for the year immediately
preceding the date of that sale. In the event the company holding the
Victoria hotel (Amsterdam) sells the hotel or should the control of
the hotel be transferred to third party, we are also required to pay
2.5% of any gain derived from the sale of the hotel.
No formal agreement has been signed with Park Plaza in respect of the
management of the Sandton Hotel in South Africa, although Park Plaza manages the
hotel on a de-facto basis on the same terms and conditions as the remaining
operational hotels.
Park Plaza has been awarded 5% or 10% of the equity rights (excluding
voting rights) in the companies holding the Riverbank (10%), Sherlock Holmes
(10%) and Victoria London (5%) hotels.
Option to purchase Park Plaza's Operations
BEA Hotels N.V, our wholly owned indirect subsidiary, ("BEA"), was granted
an option in June 2001 from Park Plaza, exercisable until December 31, 2006, to
purchase from Park Plaza 33% of the ownership and controlling rights in a
company under its ownership, which was incorporated to acquire the business
(including tangible assets, hotel management agreements, management rights,
rights to use trade names, etc.) of the Park Plaza chain in Europe (the
"Acquired Company"). As part of the agreement, BEA granted Park Plaza two loans
in the aggregate amount of $5 million. The terms of the loans are as follows:
(i) a loan of $1.67 million linked to the U.S. Dollar, which bears annual
interest at the rate of Libor plus 1% and (ii) an additional loan of $3.33
million in exchange for an option to convert the principal of $3.33 million into
shares of the Acquired Company. As part of this agreement, if BEA decides not to
exercise the option, the additional loan of $3.33 million would have the same
terms of the $1.67 million loan described above. As security for the repayment
of the loans, we will hold back amounts payable to Park Plaza with respect to
Park Plaza's rights in our hotels, except for management fees of the hotels. In
addition, we have further agreed to provide the Acquired Company with an
additional loan of up to an additional $2.25 million, if and to the extent this
amount is required for the purchase of other assets by the Acquired Company. As
part of this agreement, in the event of exercise of the option by us, Park Plaza
has an option, exercisable at any time prior to December 31, 2006, in the event
of disagreement between the parties regarding Park Plaza's rights, to acquire
BEA's shares in the Acquired Company in consideration for the refund of the cost
of BEA's original investment.
Management Agreement with the Rezidor Group
On June 9, 2004, our indirect subsidiary, S.C. Bucuresti Turism S.A., the
owner of the Bucuresti hotel (the "Owner"), which is currently undergoing
renovation works, entered into an agreement with the Rezidor Group (through its
subsidiaries) (the "Management Company") regarding the future management of the
Bucuresti hotel to be operated under the "Radisson SAS" trade name.
Under the agreement the Owner undertook to pay the Management Company an
annual base fee of 3.5% of the total revenue and an annual management fee of 10%
of the gross operating profit. Both fees payable to the Management Company shall
be no less than certain agreed minimum amounts depending on the relevant year.
In addition, the Owner will pay the Management Company 2.5% of gross room
revenue for marketing and advertising services as well as an agreed fee per room
for reservations of rooms.
The Management Company guarantees the Owner that the adjusted gross
operating profit (the total revenue less expense, permitted deductions,
management fee and property insurance) for the hotel operation shall not be less
than fixed annual amounts.
On the same day, our indirect subsidiary, Andrassy 25 kft, the owner of the
"Ballet Institute" building in Budapest (the "Owner"), which is currently under
development, entered into an agreement with the Management Company regarding the
future management of the "Ballet Institute" to be operated under the "Regent"
trade name.
Under the agreement the Owner undertook to pay the Management Company an
annual base fee ranging from 3.5% to 4.25% of the total revenue depending on the
relevant year, and an annual management fee ranging from 10% to 13% of the gross
operating profit depending on the relevant year. Both fees payable to the
Management Company shall be no less than certain agreed minimum amounts
depending on the relevant year. In addition, the Owner will pay the Management
Company 2.5% of gross room revenue for marketing and advertising services as
well as an agreed fee per room for reservations of
40
rooms.
The Management Company guarantees the Owner that the adjusted gross
operating profit (the total revenue less expense, permitted deductions,
management fee and property insurance) for the hotel operation shall not be less
than fixed annual amounts.
BUSINESS CONCEPT AND STRATEGY
The business concept and strategy of the hotels include the following
elements:
Location. Our hotels are generally situated in close proximity to major
railway links into cities, such as the central railway station in Amsterdam
(situated across from our Victoria Hotel), the central railway station in
Antwerp (situated close to our Astrid Park Plaza hotel) and the Victoria railway
station in London (situated close to our Victoria Park Plaza hotel). The London
and Antwerp stations are scheduled to accommodate the services of the Train de
Grand Vitesse (the "TGV"), when such services become operational in those areas.
Service. Our hotels make considerable efforts to offer personal services at
a five-star level but at four-star level prices.
Customer base. Our hotels' principal target customer base is the business
traveler and the tourist industry, both individuals and groups.
Management. Our hotels focus on strategic cooperation and affiliation with
management companies with know-how and expertise in hotel management, which
enables optimal use of a centralized reservation system, and which provides the
advantage of a unified management system that promotes the efficiency of the
operation and control of hotels in diverse locations.
Strategy. Our strategy for the hotels business is increasing the number of
hotel rooms in both Western and Eastern Europe, with emphasis on those cities in
which a shortage of rooms exists, or where a shortage of quality rooms exists.
This strategy is being implemented both by the acquisition and renovation of
existing operational hotels and by the construction and development of new
hotels on land purchased or leased in optimal locations. Where appropriate, we
may draw on the experience and resources of our group affiliates to develop
integrated projects which will include hotels and shopping and entertainment
centers, subject to applicable restrictions. When opportunities arise, we also
seek to lease hotels or sell our interests in hotels.
LONG-TERM LEASE OF REAL ESTATE PROPERTY
In January 2003 one of our hotels in London, England owned by Shaw Hotel
Holding B.V (in which we are a 30% shareholder) was leased to a company engaged
in the hotels business for a period of 25 years in consideration for fixed
rental fees for each of the initial four years of the lease. Commencing the
fifth year and throughout the term of the lease period, rental fees are to
increase at an annual rate of 2.5%. Payment of the rental fees were guaranteed
by a deposit in the amount of approximately L2.5 million (approximately $4.3
million) (our part being approximately L0.75 million (approximately $1.3
million)). The lessee was granted on option to extend the lease period by two
consecutive periods of 15 years each.
In December 2005, we, together with the remaining holders of Shaw Hotel
Holding B.V, sold all of our holdings in Shaw Hotel Holding B.V., the owner of
the above hotel, to an unrelated third party at an asset value of L74.8 million
(approximately $129 million). The net consideration received (after deduction of
bank loans and other working capital items) was approximately L4 million
(approximately $6.9 million).
THE IMAGE GUIDED TREATMENT BUSINESS
All of our activities in the image guided treatment field are performed
through InSightec.
As of December 31, 2005, the principal shareholders of InSightec were EMI
(69.40% shareholder and 52.15% shareholder on a fully diluted basis), GE (25.25%
shareholder and 20.63% shareholder on a fully diluted basis) and MTA (3.87%
shareholder and 6.87% shareholder on a fully diluted basis). The remaining
holdings of InSightec are held by employees, directors and officers.
We are a party to an amended and restated shareholders agreement together
with GE and MTA dated September 27, 2004. For so long as we continue to
beneficially hold 50.01% or more of the outstanding share capital of InSightec
on a fully diluted basis, we are allowed to appoint three directors to serve on
InSightec's board of directors and no action shall be taken without the
affirmative vote of a majority of our designated directors present. GE was
granted veto rights over the execution of certain significant transactions or
activities not in the ordinary course of business of InSightec. The parties have
a right to participate in any new financing pro rata to their holdings.
41
The agreement further provides for certain limitations on the transfer of
each party's holdings in InSightec, including, transfer to a competing entity
and a right of first refusal granted to us and GE in the event of sale by either
of us of its holdings. In the event we sell our holdings, GE and MTA have a
right of co-sale. A change of control in us to a competing entity of GE in the
focused ultrasound therapy or medical imaging business while we control or own
30% of InSightec's outstanding shares on a fully diluted basis, grants GE and
MTA a right to sell their holdings in InSightec to us at fair value (in
accordance with a mechanism provided in the agreement) or acquire our holdings
in InSightec at fair value. Termination of the agreement by either us or GE
following a material breach of the other party grants the other party a right to
purchase the defaulting party's securities at 90% of their fair value. If GE
terminates the agreement as aforementioned, GE has a right to sell its holding
to us at 110% of their fair value. If the rights to purchase or sell the other
party's holdings in the event of termination, as described above, is exercised,
the terminating party who purchases the other party's holdings has an option to
include all of MTA's holdings in the transaction. MTA has a right to include its
holdings in such transaction under the same terms and conditions in the event a
purchase transaction is consummated (upon termination as described above)
without the exercise of the option.
Business description
InSightec has developed and markets the ExAblate 2000, the first
FDA-approved system for Magnetic Resonance guided Focused Ultrasound Surgery
("MRgFUS"). InSightec's objective is to transform the surgical environment for
the treatment of a limited number of forms of benign and malignant tumors by
replacing invasive and minimally invasive surgical procedures with an
incisionless surgical treatment solution. The system is designed to deliver safe
and effective non-invasive treatments while reducing the risk of morbidity and
potential complications, as well as the direct and indirect costs associated
with conventional surgery. In October 2004, InSightec received FDA approval to
market the ExAblate 2000 in the United States for the treatment of uterine
fibroids, a type of benign tumor of the uterus. Prior to that, in October 2002,
InSightec received authorization to affix the CE mark to the ExAblate 2000,
enabling it to market the system in the European Economic Area for the treatment
of uterine fibroids. InSightec also has regulatory approval for the ExAblate
2000 for uterine fibroids in Russia, Taiwan, Australia and Singapore. InSightec
is also in various stages of development and clinical research for the
application of its MRgFUS technology to the treatment of other types of benign
and malignant tumors. These additional applications are being developed to take
advantage of the modular design of the ExAblate 2000, which enables it to
function as a common platform for multiple MRgFUS-based surgical applications.
Currently, InSightec has an installed base of 36 units around the world in
academic hospitals, community hospitals, MRI clinics and physician-formed joint
ventures. The ExAblate 2000 is operable only with certain MRI systems
manufactured by GE. InSightec estimates that the ExAblate 2000 is compatible
with approximately 2,400, or 34%, of the estimated 7,000 MRI systems installed
in the United States. InSightec recently signed an exclusive worldwide (except
for Russia and Japan) sales and marketing agreement with GE with respect to the
ExAblate 2000. InSightec believes that its relationship with GE will enable us
to leverage GE's marketing and sales resources to accelerate its market
penetration.
InSightec's MRgFUS technology integrates the therapeutic effects of focused
ultrasound energy with the precision guidance and treatment outcome monitoring
provided by MRI systems. Ultrasound is a form of energy that can pass harmlessly
through skin, muscle, fat and other soft tissue, and is widely used in
diagnostic applications. The ExAblate 2000 uses a phased-array transducer that
generates a high intensity, focused beam of ultrasound energy, or a sonication,
aimed at a small volume of targeted tissue. The focused ultrasound energy
provides an incisionless therapeutic effect by raising the temperature of the
targeted tissue mass high enough to ablate, or destroy it, while minimizing the
risk of damage to overlaying and surrounding tissue.
Magnetic resonance imaging provides an effective guidance system for the
use of focused ultrasound energy in InSightec's therapeutic applications. Used
in conjunction with the ExAblate 2000, the MRI system precisely maps the
treatment area in three dimensions immediately prior to the treatment, providing
information on the location and shape of the targeted tissue mass. The
high-quality images produced by the MRI system enable the operating physician to
easily differentiate between the targeted tissue mass and the surrounding
tissue. Based upon this information, the operating physician delineates the
targeted tissue mass and our system calculates an optimal treatment plan which
is displayed to the operating physician. The operating physician is then able to
alter the pathway of the ultrasound beam by adjusting the position of the
transducer before initiating the sonication of the targeted tissue mass. At
three second intervals during the procedure, the MRI system provides "real-time"
imaging and other data that are used by the ExAblate 2000 to calculate and
display temperature maps of the treatment area in what is known as a "closed
loop process." This continuous stream of data enables the operating physician to
make adjustments during the treatment to achieve the desired outcome. At the end
of the procedure, the operating physician can initiate a MRI scan to immediately
assess the overall treatment outcome. InSightec believes that by combining the
non-invasive therapeutic effects of focused ultrasound energy and the precise
"real-time" data provided by the MRI system, it has developed an effective,
non-invasive treatment solution for uterine fibroids.
Concurrent with FDA approval for the use of the ExAblate 2000 to treat
uterine fibroids, the FDA issued a "Talk Paper" stating that the ExAblate 2000
provides significant advantages over existing uterine fibroid treatment options.
The FDA issues "Talk Papers" in situations where the FDA desires to increase
awareness of certain issues or developments, including significant new product
approvals. InSightec believes that its MRgFUS technology can be applied to the
treatment of other medical conditions, providing similar advantages by
presenting both physicians and patients with a safe and effective incisionless
surgical treatment option for several medical conditions, including a number of
indications for which there are
42
currently few effective treatment options.
The following table summarizes the current indications for which InSightec
has developed or is developing the ExAblate 2000:
PRODUCT DEVELOPMENT
TREATMENT APPLICATION STATUS CLINICAL STUDY STATUS
--------------------- ------------------- ---------------------
UTERINE FIBROIDS Complete FDA and CE mark approval received. Follow-up studies underway.
BREAST FIBROADENOMAS Final stages Feasibility study started in Japan.
BREAST CANCER Final stages Feasibility study finished outside the United States. Phase 2 study
to start in the United States soon.
METASTATIC BONE TUMORS Ongoing Feasibility study underway outside the United States.
(PALLIATIVE TREATMENT ONLY)
LIVER CANCER Ongoing Feasibility study underway outside the United States.
PROSTATE CANCER Prototype under Phase I study in the United States in planning stages.
development
BRAIN TUMORS Ongoing Feasibility study underway outside the United States; Phase I study
underway in the United States.
Distribution and Marketing
InSightec distributes and markets its products directly and through the
entering into distribution agreements with third parties.
In June 2005, InSightec entered into a worldwide distribution and sale
representation agreement with GE granting GE the exclusive worldwide
distribution rights to market and promote InSightec's product subject to the
achievement of a minimum sales targets, except in territories where InSightec
already has existing distributors and representatives (Russia and Japan as
described below). Subject to the terms of the agreement, in consideration of the
services rendered, InSightec shall pay GE a commission on the net sales invoiced
and actual payments received by InSightec for each order for the sale of
products from an end-user resulting from GE Healthcare's activities. InSightec
undertook not to enter into any new arrangements with third parties for so long
as GE maintains its exclusive rights as described herein. Nevertheless,
InSightec retains the right to promote, market and sell its products to
end-users directly, through its employees. In case GE desires to market or sell
any competing MRgFUS product in a territory, which InSightec holds all
authorizations required to market its product in, then GE will notify InSightec
of such intention. If despite InSightec's objection, GE chooses to market such
competing product, then its rights in such country, for InSightec's product will
automatically become non-exclusive. The agreement is for a five-year term ending
in June 2010, unless earlier terminated in accordance with the terms of the
agreement. Thereafter, the agreement will automatically renew, each time, for an
additional year, unless either party provides a written notice of its intent to
terminate the agreement.
InSightec retains an exclusive distributor in Russia and a non-exclusive
distributor in Japan. Each of these distributors undertook not to distribute any
other systems, which compete or may compete with InSightec's FUS system for
specific periods determined in the agreements.
In addition, since September 2002, InSightec has been a party to an
agreement with MTA, as amended, pursuant to which InSightect received advisory
and consultation activities as well as marketing activities from MTA in
consideration for a fixed monthly amount and a success fee commission of 2% of
the value of any signed purchase order, for which MTA was involved. The
agreement was terminated on April 1, 2006.
Business Concept and Strategy
InSightec's strategic objective in this area is to continue its follow-up
studies for uterine fibroids, as well as its product development efforts and
clinical studies for additional applications. If the results of its clinical
studies are positive, InSightec intends to pursue regulatory approval in the
United States and other targeted jurisdictions to market the ExAblate 2000 for
these additional treatment applications.
In addition, InSightec aims to become the market leader in MRgFUS systems,
and to achieve a significant improvement in the quality and efficacy of the
treatment while demonstrating cost effectiveness.
43
OTHER ACTIVITIES
MANGO
In May 2005, Elscint has purchased from Punto FA the entire equity and
voting rights in Mango Israel Clothing and Footwear Ltd., the Israeli
distributor and retailer of the internationally renowned retail brand name
MANGO-MNG(TM) in consideration for E2.85 million. Under the agreement, Elscint
has undertaken to develop at least two stores in Israel within five years and an
additional two stores during the five years thereafter. Under the agreement
Punto FA is allowed to continue operating an additional store in Eilat and to
sell the MANGO products in Israel via the Internet. Elscint was awarded an
option to purchase the store in Eilat by February 2007 in consideration for
E250,000 ($295,000).
Concurrently with the purchase agreement, Mango executed an exclusive
distribution agreement of Mango products in Israel for a ten-year period. Under
the agreement, Elscint has agreed to guarantee annual minimum purchases at rates
and subject to terms and conditions specified in the agreement. Mango Israel has
undertaken to pay Punto FA seasonal marketing, public relations, and
store-support fees as specified in the agreement.
Mango currently leases six stores in Israel: in Tel Aviv (Azrieli shopping
center), Kfar-Saba, the Kraiot (Kyrion shopping center), Haifa (Grand Canyon
shopping center), Petah-Tikva (The Grand Canyon), Herzliya (the Arena) and an
additional three outlet stores in Haifa, Natanya and Beer-Sheva.
The key elements of Mango's strategy are to:
- Increase sales to existing and new customers by adjusting our pricing
strategy and market behavior. Mango believes its customer service and
reliability as a franchisee of a leading international brand to
provide it with a competitive advantage.
- Localization and enhancing the Mango brand in Israel by improving its
marketing and branding strategy.
- Open new stores in strategic locations across Israel with emphasis on
opening smaller shops of 250-300 square meters rather than stores of
larger square meters, which are currently in operation, as well as by
reducing the size of the stores currently in operation.
- Reduce the percentage of outlet stores out of the total Mango stores
in Israel, and relocate the outlet stores to the suburbs.
VENTURE CAPITAL INVESTMENTS
In addition to our core operations, we hold interests in the following
companies. Our investments in these companies are not significant to our results
of operations.
Gamida Cell Ltd.
Since its establishment in early 2000, Elscint Bio-Medical Ltd. ("EBM"),
our indirect wholly owned subsidiary, has focused on investments in early stage
biotechnology companies. During 2001 and 2002, EBM expanded its investment in
Gamida, an Israeli company that engages in the expansion of hematopoietic
(blood) stem cells therapeutics in clinical development for cancer and
autoimmune diseases, as well as future regenerative cell-based medicines
including cardiac and pancreatic repair. Cord blood stem cells have the ability
to treat the same diseases as bone marrow with significantly less rejection. In
addition, stem cells could become the vehicle of choice for gene therapy and,
ultimately, be used for tissue regeneration.
Elscint is a party to an agreement pursuant to which mainly the existing
shareholders of Gamida invested during July 2005 an aggregate amount of $4
million (out of which our share was $1.36 million) in consideration for the
issuance of Gamida's securities which have the same rights as the securities
issued during Gamida's last equity financing round.
As of December 31, 2005, EBM holds approximately 33.46% of the outstanding
shares of Gamida (approximately 30.3% on a fully-diluted basis. EBM has the
right to appoint one quarter of the members of Gamida's board of directors. The
aggregate investment made by EBM in Gemida since Gemida's establishment is
approximately $9.2 million (out of which approximately $1.6 million was invested
in 2005).
In May 2003, Teva Pharmaceuticals Ltd. ("Teva") invested $3 million in
Gamida in exchange for approximately 9% (on a fully-diluted basis) of Gamida's
outstanding share capital.
On February 12, 2006, Gamida Cell Holding Ltd. ("Holding"), Gamida, Teva
and Holding signed a founders
44
agreement. The sole purpose of Holding shall be
commercialization of the products and obtaining all required registrations and
marketing approvals.
Teva shall make an equity investment in Holding of up to $25 million in
consideration for up to 50% of Holding shares. The funding shall be payable as
follows: as of the closing date, Teva will sign an irrevocable commitment for
payment of a total amount of $10 million payable in installments. The additional
funding totaling $15 million shall be paid quarterly based on the budget of
Holding. Teva shall be entitled to accelerate the funding payments schedule.
In the framework of the agreement Gamida and Holding shall sign a license
agreement according to which Gamida shall grant Holding a royalty free,
worldwide license to exploit the products and Gamida's IP necessary for
developing, manufacturing sale and distribution of the product and a royalty
free, illimitable, worldwide exclusive license to manufacture, develop, market,
offer for sale, distribute and sell the products and the right to sublicense.
The license agreement is subject to the approvals required from Office of the
Chief Scientist. Certain cancellation arrangements were determined between
Gamida and Teva.
EBM was bound in the past by agreements with a company controlled by its
former Chief Executive Officer ("CEO") entitling him to shares representing 2%
of EBM's issued and paid-up capital, in consideration for their nominal value.
The agreement also provided that EBM would invest 92% and the CEO's company
would invest 8% in venture capital investments. The CEO's company's investment
would be financed by a dollar-linked non-recourse loan bearing LIBOR+1% interest
from EBM. In the event of cancellation of this agreement (or another agreement
between the parties for the provision of consulting services), EBM would be
entitled, under certain conditions, to acquire all or any of the CEO's company's
holdings in the venture capital investments and in EBM at cost or at market
value, as relevant (depending on the purchase date).
In November 2002, the employment agreement between EBM and its CEO was
terminated. Pursuant to the termination agreement, EBM transferred to itself the
CEO's rights in EBM and its portfolio investee companies, in consideration for
the repayment of the loans provided by EBM to the CEO.
A dispute arose between the parties, with the CEO contending that EBM had
lost its right to acquire his holdings, claiming the deadline according to the
agreement for giving notice to acquire had expired. EBM's management disputes
this contention and is acting to realize its rights under the agreement. The
parties have yet to sign a full and final agreement for the waiver and/or
settlement of their mutual claims. EBM's management estimates that in any event,
it will not incur significant costs from the termination of the agreements.
Concurrently with the termination of the employment agreement of the CEO,
EBM's management postponed for the foreseeable future further investment
opportunities in biotechnology related companies, other than Gamida, pending its
re-assessment of the market situation.
Olive Software Inc.
Olive Software Inc. ("Olive"), a Delaware corporation, is engaged in the
development and marketing of products that enable a transparent link between the
newspapers' traditional printing systems and the world of e-publishing. These
products enable newspapers and magazines to automatically present their printed
edition on the Internet, while supporting the e-commerce applications,
personalization and interactive advertising. In addition, Olive develops and
markets digital archive services for newspapers and libraries. In January 2000,
the Dafnit fund invested $1.2 million in Olive in consideration for an 8.5%
interest in Olive (on a fully diluted basis), in March 2004, the Sequoia fund
invested $6 million in Olive in exchange for approximately 26% interest in Olive
(on a fully-diluted basis) and in August 2005, the Sequoia and Pitango funds
invested $9 million in Olive in exchange for 5% and 15% interest in Olive (on a
fully-diluted basis), respectively. Following the above issuances and as of May
31, 2006, our interest in Olive is 18.3% on a fully diluted basis.
Easyrun Ltd.
Easyrun Ltd. ("Easyrun"), an Israeli corporation, is engaged in the
development and marketing of "call centers" solutions, which support under one
platform, diversified infrastructure from historical telephony and up to
futuristic telecom equipment (IP switchboards) and modern e-commerce
applications (Web). We hold a total of 42% of the outstanding shares of Easyrun
and the right to appoint 40% of the directors of Easyrun. We also hold other
convertible instruments of Easyrun.
Within the framework of the rights offering executed by Easyrun in August
2004, we invested $0.4 million (out of a $0.65 million total funding) calculated
at $0.13 per share. In consideration for our investment, we were also granted
warrants exercisable into shares, at $0.13 per share, up to a total amount of
$0.8 million. In addition, we converted a $0.3 million loan into shares of
Easyrun. Assuming all loans are converted and warrants are exercised, our
interest in Easyrun would be increased to approximately 53% on a fully diluted
basis.
45
VCON Telecommunications Ltd.
VCON Telecommunications Ltd. ("Vcon"), an Israeli company is a developer
and manufacturer of software videoconferencing systems for ISDN and Internet
Protocol networks. Vcon offers comprehensive meeting solutions for desk top,
portable and group conferencing over ISDN, Transmission Control Protocol or
TCP/IP, ATM, Satellite, xDSL and other carriers. Vcon is publicly traded on the
Paris Stock Exchange (Nouveau Marche). In August 2005, Vcon reported that
following the failure in its previously announced fund raising negotiations, it
has determined that it can no longer independently pursue its current mode of
operations, and has entered into an agreement for the sale of its business,
activities and the majority of its assets, to Emblaze group in consideration of
$1.6 million. Emblaze has also agreed to establish a limited line of credit in
an amount, in NIS, equal to $250,000. Following this transaction, Vcon only
engages, under the given circumstances, in maximizing the payments and
satisfaction of its debts to its creditors and in its dissolution. Vcon
estimates that none of the consideration from the sale will be allocated to its
shareholders, accordingly, we recorded a provision for loss in our investment in
Vcon amounting to NIS 13.9 million ($3 million), which constitutes the entire
balance of our investment in Vcon.
REVENUES CLASSIFIED BY BUSINESS SEGMENTS AND BY GEOGRAPHICAL MARKETS
The following table sets forth our breakdown of revenues by each geographic
market in which we operate, for each of the last three years (in thousands of
NIS):
Convenience
Fiscal Year Translation
Ended December 31, in U.S.
--------------------------- Dollars
2005 2004 2003 For 2005
------- ------- ------- -----------
(in thousands of NIS)
Western Europe 304,731 203,615 181,668 66,203
Eastern and Central Europe 359,420 414,457 346,200 78,084
Israel 92,226 71,678 65,235 20,036
Others 60,378 46,131 1,782 13,117
Total Revenues 816,755 735,881 594,885 177,440
The breakdown of revenue by business segments for each of the last three
years is presented in the following table (in NIS thousands):
Convenience
Fiscal Year Translation
Ended December 31, in U.S.
--------------------------- Dollars
2005 2004 2003 For 2005
------- ------- ------- -----------
Shopping and Entertainment centers 366,237 443,814 347,056 79,565
Hotels 270,057 218,365 189,205 58,670
Image Guided Treatment 75,713 57,052 20,412 16,449
Lease of an Asset 71,000 15,425 13,495 15,425
Other Activities 33,748 3,412 24,717 7,331
Total Revenues 816,755 735,881 594,885 177,440
SEASONALITY
SHOPPING AND ENTERTAINMENT CENTERS
Each shopping and entertainment center may experience seasonal shifts in
retail activity. Generally speaking, during peak holiday seasons (such as
Christmas, Easter, Passover, the Jewish New Year and other national holidays
generally in the third and fourth quarter), there is generally an increase in
patron traffic, both for the purchase of holiday gifts and for utilizing the
entertainment facilities offered by the center. During the period immediately
following such periods, there is generally a decrease in the number of patrons
visiting the centers and a corresponding slow down in retail activity. However,
this slow down may be offset by the fact that the indoor facilities offer an
air-conditioned environment for shoppers and patrons, which is of particular
significance during the warm summer months in Israel (April/May to
October/November), particularly in July and August when schools are in recess
and it is customary in Israel to take summer vacations.
HOTELS
The business activities of the various hotels, especially in Western
Europe, are influenced by several factors that affect the revenues and gross
operating profit. These factors include (i) fluctuations in business activity in
certain seasons (which
46
affects the volume of traffic in the business community), (ii) holiday seasons
(such as Christmas and Easter), and (iii) weather conditions. In Western Europe,
these factors generally cause the first and third quarters to be weaker than the
second and fourth quarters. Similarly, in England, differences in the weather
and certain other factors cause the first and third quarters to be weaker than
the second and fourth quarters.
The first quarter, which is the period immediately following the Christmas
season and the height of the European winter, is traditionally characterized by
lower revenues and gross operating profit resulting from lower occupancy rates
and reduced room rates. During the third quarter, there is generally a decrease
in local business activities due to the summer holidays which, together with a
tendency for local tourist traffic to seek out resort destinations, also
generates slower results. This is offset somewhat by increase in international
tourism but the impact of this increase is, in turn, offset by lower room rates,
particularly for groups.
However, during the second quarter, there is generally a marked increase
due to more favorable weather conditions (spring to early summer), the Easter
holiday and the corresponding revival of both business and tourist activity. The
fourth quarter is usually the strongest period due to the Christmas and New
Year's holiday season and a significant year-end increase in business
activities.
For our South African hotel, generally the holiday seasons (Christmas and
Easter) show slightly stronger results, although the depressed economy and the
political uncertainty of the region have resulted in reduced occupancy rates to
the point that seasonal comparisons are largely irrelevant.
OTHER ACTIVITIES
Mango's business is influenced by seasonal shifts in the apparel market.
During the winter season (December - January) and summer season (June- July),
the apparel market, including Mango, commences discount sales to the public
which consequently increases Mango's revenues and causes a decrease in the gross
profit margin for such periods. In addition, Mango's revenues may fluctuate due
to seasonal purchasing by consumers especially in peak holiday seasons such as
Passover generally in the second quarter, the Jewish New Year and other Jewish
and national holidays generally in the third and fourth quarter.
PATENTS AND PROPRIETARY RIGHTS; LICENSES
Our parent Europe-Israel was registered by mistake as the owner of a
European Community Trademark "Plaza Centers+figures" in classes 35, 36, 37 and
42. Europe-Israel has signed an agreement for the assignment of such trademark
to Park Plaza. As of the date of this annual report, the assignment agreement
has not yet been registered with the European patent and trademark office.
Within the framework of our agreements with Park Plaza and the Rezidor
Group for the management of our hotels we were granted rights to use the trade
names "Park Plaza" "Regent" and "Radisson SAS". See "- Hotels - Management of
the Hotels" above.
In December 1998, InSightec's subsidiary acquired focused ultrasound
technology from GE Medical Systems, and all relevant intellectual property
including 14 United States patents, as well as 3 applications pending in other
countries of which two have subsequently been approved, at an aggregate purchase
price of $5 million and the minority interest in Texsonics Ltd.. As of May 31,
2006, InSightec has submitted 72 additional patent applications, out of which 21
have already been approved (19 in the United States and the other two in
Europe), with another 40 that remain pending and in process.
In addition, we use the MANGO-MNG(TM) brand name in accordance with our
distribution agreement with Punto FA. See "- Other Activities - Mango" above.
COMPETITION
SHOPPING AND ENTERTAINMENT CENTERS
There are a number of competitors in the Eastern and Central European
countries in which we operate or intend to operate in the shopping and
entertainment centers business, particularly in larger cities such as Budapest
and Warsaw. The following factors, however, should be noted: (a) shopping
centers which are not in close proximity and which do not draw their clientele
from the same catchment areas are not considered as being competitive; (b) we
believe that large retail centers (known as "power centers"), even if they
compete with our centers directly merely by virtue of their proximity to our
shopping and entertainment centers, are at a disadvantage because they do not
offer the entertainment facilities that are offered at our
47
shopping and entertainment centers, and which we consider to be a significant
element in the attraction of our patrons; and (c) in the regional cities of
Hungary, Poland, Lativa, Romania and the Czech Republic competitive activity is
more limited.
In addition to several ad hoc entrepreneurial projects, there are two
significant groups operating a number of shopping and entertainment centers in
the Eastern and Central Europe with whom we compete directly, namely the
Tri-Granit based in Hungary and the ECE chain based in Germany. We compete with
these chains in the pre-development stage (for acquisition of suitable sites),
in the development stage (obtaining suitably qualified architects, consultants
and contractors) and in the operational stage, if the centers compete for the
patronage of the same population. We also compete for quality "brand name"
tenants to occupy rental units. In locations where competing centers are being
constructed simultaneously, the first center to open generally enjoys an
advantage over its competitor, which is the reason behind our emphasis on the
expeditious completion of construction operations.
Our project in Lodz, Poland is in preliminary planning and development
stage as a shopping center integrated with a public market. Due to strong
competition, we are currently assessing the scope and nature of this project.
In most of the cities in Poland in which we operate or are developing
shopping and entertainment centers, our centers are the only ones of their type
in the city, and competition from other centers is minimal or non-existent. In
these cities, we compete with traditional shopping outlets. These outlets lack
the added benefit of the entertainment activities which our centers offer and,
accordingly, we believe that they have difficulty competing with us.
Our Arena shopping and entertainmet center in Herzliya, Israel competes
directly with a shopping center located in Herzliya and another center located
in northern Tel-Aviv, and is approximately 8 kilometers from the site. All these
centers compete vigorously for tenants and customers. We are attempting to
establish a competitive edge, based on the unique location of the Marina,
overlooking the Mediterranean Sea and the strong emphasis on the entertainment
facilities offered to its patrons.
HOTELS
The lodging industry in Europe has traditionally been classified on a
grading system, with five-star representing a luxury hotel and one-star a budget
hotel. All of our hotels (except for the Centerville hotel apartments) enjoy a
four-star grading, or qualify as four-star establishments, while some are
designated as "Four Star Deluxe" establishments.
Each of our hotels competes with other hotels in its geographic area for
clientele, including hotels associated with franchisers, which may have more
extensive reservation networks than those which may be available to us. We
compete with other facilities on various bases, including room prices, quality,
service, location and amenities customarily offered to the traveling public.
Levels of demand are dependent upon many factors including general and local
economic conditions and changes in levels of tourism and business-related
travel. Our hotels depend upon both business and tourist travelers for revenues.
Many of these other companies are larger than us. Our hotel in Utrecht, The
Netherlands competes directly with the NH Utrecht (which is located directly
opposite our hotel), the Mercure Hotel and the Carlton President Hotel. The
Victoria Hotel in Amsterdam is located in the city center and is in direct
competition with the Barbizon Palace, Swissotel, Golden Tulip Intell,
Krasnapolsky and the Crown Plaza. Our Astrid Park Plaza hotel in Antwerp,
Belgium competes directly with the Hilton, Holiday Inn, Crown Plaza and Park
Lane hotels. The Victoria Park Plaza Hotel in London is in direct competition
with a number of three-star plus and four-star rated hotels within relatively
close proximity to the Victoria railway station, including the Thistle Grosvenor
and the Victoria Holiday Inn hotels, both of which benefit from their close
proximity to Victoria station, as well as the Thistle Royal Westminster, Rubens,
Status Street, Jolly St Ermins, St. James's Court and Merchant Court hotels. In
addition, there is a considerable number of traditional budget hotels in the
proximity of the Victoria Hotel. The Sherlock Holmes Park Plaza Hotel in London
competes directly with a number of four-star rated hotels such as Dorst Square
Hotel, Myhotel Bloomsbury, Radisson SAS and the Radisson Edwardian. The New
Riverbank Park Plaza in London is in direct competition with a number of
four-star and five-star rated hotels in relative proximity to the River Thames,
including the City Inn Westminster, Crowne Plaza Hotel, County Hall Marriott,
Royal Lancaster and the Grosvenor House. The hotel we are planning to construct
in Budapest, Hungary will compete directly with the Kempinski, Marriott, Hilton,
Inter-Continental and Hyatt hotels. The Bucuresti Hotel in Bucharest competes
with the Hilton situated directly across the street, the Intercontinental, and
the Marriott Grand Palace hotel. We believe that the average room rate in our
hotels is competitive. In addition, we compete with other companies in the hotel
industry for opportunities to purchase or build new hotels.
THE IMAGE GUIDED TREATMENT BUSINESS
The competition in the MRgFUS products field can be divided into two main
categories: alternative Minimally Invasive Surgery methods (MIS) and competing
image guided high intensity focused ultrasound systems (HIFUS).
With respect to MIS methods, in general, there are already tissue ablation
methods in various MIS versions (e.g., radio frequency electromagnetic energy
inserted into the body by a special needle, laser and cryogenic, and
embolization), which are potential competitors with InSightec's application
market. InSightec is not presently aware of any approved non-invasive
48
method in the clinical applications of breast tumors, uterine fibroids or brain
tumors. Although these techniques might be somewhat less expensive, they are
invasive and may be less accurate and less effective.
InSightec faces competition from both traditional and minimally invasive
solutions for the treatment of uterine fibroids and the other medical conditions
that InSightec has targeted for its future applications. Traditional treatment
methods for uterine fibroids and other medical conditions that InSightec has
targeted for product development are more established and widely-accepted among
physicians. In addition, there are potential competitors developing alternative
treatment options for various medical indications, some of which may be relevant
for the treatment of uterine fibroids. However, we are not aware of any
MRI-guided treatments for uterine fibroids or other medical conditions that are
approved for commercial use or are in advanced stages of clinical trials. These
potentially competitive technologies include laser therapies, radio frequency
therapies, microwave therapies, cryogenic surgery, external beam radiation
therapy, brachytherapy and radiation surgery.
We are currently aware of two Chinese companies, one French company and one
U.S. company which offer ultrasound-guided focused ultrasound solutions, or
ULSgFUS, for a number of medical conditions. We believe that InSightec's
magnetic resonance guidance solution is superior to the products offered by
these competitors. In a non-MRI guided treatment, the operating physician cannot
see the effects of the treatment in real time and must complete the treatment,
follow up with diagnostic testing and then plan future treatment sessions. The
ExAblate 2000 allows the operating physician to complete all of these steps
within a single treatment session while also enabling the operating physician to
alter treatment parameters to optimize the treatment outcome. None of these
potential competitors have received FDA pre-market approval for the marketing of
their products in the United States.
At present, to our knowledge, the Chinese ULSgFUS companies have focused
their marketing efforts in Asia, and have not received any regulatory approvals
outside of Asia. One of the companies, China Medical (NASDAQ: CMED), has placed
a system in the United States and announced plans to initiate clinical trials in
the United States. The other company, HAIFU, has placed a system in the United
Kingdom and obtained a CE mark approval for treating liver and kidney cancer. In
addition, it has signed an agreement with Siemens AG to develop a MR-guided
version of its product. Philips Medical has also announced plans to introduce a
MR-guided FUS product based on collaboration it has with the University of
Bordeaux, France.
The French (EDAP) and U.S. (Focus Surgery) FUS companies focus on
ultrasound guided treatment of prostate cancer disease. To the extent InSightec
enters the U.S. or European markets for the treatment of prostate cancer or
other applications, it may face competition from both of these companies. These
competitors may have access to greater resources allowing them to offer their
products at lower prices and they may have other advantages. EDAP has now
started a phase II/III trial in the United States while Focus Surgery has
initiated a phase 1 trial, both for prostate cancer.
OTHER ACTIVITIES
Mango
Mango operates in a competitive market characterized by a large and
increasing number of international and local brand stores and independent stores
in Israel. Mango's direct competitors include brand stores such as Zara, Castro,
Honigman, Renuar and Dan Casidi which are located in the vast majority of the
shopping centers in Israel. Increased competition could result in pricing
pressure or loss of market share and adversely affect Mango's revenues and
profitability. Mango's competition strategy includes: attempting to be a fashion
trend leader, investing in branding, maintaining a compatible pricing strategy
and maintaining leadership in fashion trends.
Venture Capital Investments
Start up companies, including companies in the biotechnology field, tend to
operate in a highly competitive environment. In order to succeed, the products
or services require a unique "added value" factor, relatively brief concept to
market parameters, and aggressive marketing. Our venture capital companies face
competition from large international companies with access to financial
resources and with well-established research and development capabilities. The
biotechnology field, which is dominated by large multi-national conglomerates
and may be affected by global pressures on the investment market, is more
resilient to market trends than the more volatile high technology industry.
GOVERNMENTAL REGULATION
SHOPPING AND ENTERTAINMENT CENTERS
The development, construction and operation of shopping and entertainment
centers are subject to various regulatory controls, which vary according to the
country of activity. In addition, some countries such as Poland and the Czech
Republic require that a developer carry out an environmental report on the land
before building permit applications are considered.
In certain countries, acquisitions of shares of a local company or of a
foreign company that controls a local company in some instances require a permit
from the Anti-Monopoly Office.
49
In order to begin construction works in Poland an investor must obtain a
construction permit. A prerequisite for applying for a construction permit is
receipt of a decision stating the conditions for construction and development of
a site (a site permit). The site permit is issued for specific real property and
specifies the designated purpose of the real property, i.e,. what kind of
buildings and business activity may be carried out on the real property.
However, in the case of areas for which local zoning plans have been
established, an investor will be entitled to apply for a decision granting a
construction permit based directly on the purpose of the real estate as
determined in the local zoning plan. The following must be attached to the
application for a construction permit: (i) a final and legally valid site permit
- - if there is no local zoning plan; (ii) proof of the investor's right to use
the land for construction purposes; and (iii) the technical design along with
opinions, consents and permits required by detailed provisions of law.
In the Czech Republic a planning decision and the construction permit must
be obtained prior to beginning of construction. In the planning decision
proceedings the building office examines the planned construction from the
various perspectives (in co-operation with various other authorities, including
without limitation the environment protection authorities). The owners of
neighboring real estate property as well as organizations for environmental
protection may also be parties to the proceedings and submit their opinions as
to whether or not the building office should issue the planning decision in
favor of the proposed construction. In the event the planning decision is
issued, it is necessary to apply for the construction permit with the building
office within two years. In the construction permit proceedings the building
office examines the compliance of the contemplated construction with the
planning decision as well as various other aspects, including, without
limitation, the environmental aspects. Owners of the neighboring real estate
property as well as organizations for environmental protection may take part in
the proceedings. If the zoning plan was already approved for the location in
which the construction shall take place, the building office may join the
planning decision proceedings with construction permit proceedings.
In Hungary building permits are ordinarily issued in two stages. The first
stage determines the "building conditions", which addresses factors such as the
proposed area to be constructed and its distribution over the floors of the
building, the building "foot-print" within the plot, building lines, access
routes, and conceptual design. Once the building conditions have been approved
and have become lawful (see below), the application for the formal building
permit is submitted, which includes detailed architectural building plans,
sections, elevations etc. all of which must comply with the approved building
conditions. Following the issuance of both the "building conditions" approval
and the building permit approval, a period of time is allowed (which varies from
country to country) for third parties whose rights are allegedly affected by the
permits to file objections. Only in the event that this period passes without
objection, or in the event that objections raised are dismissed by the competent
authorities, do the permits become lawful, valid and available for execution.
The rule described above applies also to Poland, where construction works may be
commenced only once the construction permit becomes valid and binding. Such a
situation occurs when no party to the proceedings, (which may be an investor and
owners, perpetual usufructuaries or managers of the real properties situated
within the area that might be affected by the constructed building), appeals
against the construction permit within 14 days of issue or the competent
authority dismisses the objections raised by the appealing party. In the Czech
Republic the construction may begin once the construction permit becomes valid
and effective. The validity of construction permit is two years.
In Latvia, approval of a construction plan is ordinarily though not always
also divided into two stages, such stages generally being the approval of sketch
design stage and approval of technical design stage. However, for larger
projects it may be required that an interim approval from the local construction
authority be obtained before finalization of the sketch design. The number of
stages is set out in the architectural planning authorization. Sometimes it may
be necessary to work out a detailed plan of the intended development site. In
order to initiate the approval procedure of a construction plan in Latvia,
initially a construction application must be submitted to the local construction
authority, which reviews it and issues an architectural planning authorization.
Under some circumstances it may be required that public discussion be arranged
prior to the issue of such authorization. The resulting construction permit is
issued after the construction authority has approved the technical plan of the
building. Sometimes it is possible to get a fast track construction permit for
underground parts of the building only.
In some instances where the applicable local plan scheme does not permit
commercial activities of the type characterized by our centers, it is necessary
to apply for an amendment to the zoning scheme, which may be a protracted
process and may not necessarily be successful.
Apart from the building permits which are required for the construction of
the shopping and entertainment centers as mentioned above, the developers are
required to obtain operating permits from the municipal authorities before the
center can be opened to the public and commence operation. Such permits will
typically address issues such as fire fighting facilities, escape routes,
mechanical integrity of systems, public sanitation, and compliance with the
approved building conditions and building permits. In addition, the individual
tenants are required to obtain operating or business licenses in order to
commence business within the centers. This requirement is not applicable in
Poland, since no special operating or business licenses are needed to carry out
business activity within centers. In certain countries, video arcade operators
may be required to obtain gaming licenses. The developers are also required to
comply with local regulations governing the employment of its employees.
50
HOTELS
The development, construction and operation of hotels and leisure
facilities, including advertising tariffs and hotels, health safety issues,
activities conducted within the premises of the hotels (such as restaurants,
bars, shops, health clubs, and in particular the sale of alcohol, food and
beverage to the public), installations and systems operating within the hotel
(elevators, sprinkler systems, sanitation, fire department etc.), terms of
employing personnel, as well as methods of rating the hotels are all subject to
various regulatory controls, which vary according to the country of activity.
The lodging industry in Europe has traditionally been classified on a
grading system, with five-star representing a luxury hotel and one-star a budget
hotel. The rating of hotels is established based on, among other things, the
following criteria: size of rooms; suite-to-room ratio; number of restaurants
and other catering facilities; level of room service provided; level of room
amenities provided; air-conditioning; guest facilities; and the quality and
periods of food and beverage services provided. The rating of our hotels is
conducted by various organizations which are either established by law, operate
under the authorities and regulations of the tourism ministries in different
countries, or conducted by the ministry of tourism. In some countries hotels
that are not graded are prohibited from operating as a hotel. All of our hotels
have received a four-star rating.
In all the countries we operate, the operation of hotels requires licenses
for the operation of the building as a hotel and the obtaining of local
municipal and police approvals for the means of access to and egress from the
hotel for motor vehicles. In addition, in most countries we are required to
receive licenses for the sale of alcohol on the premises and the operation of a
restaurant and tourism services. Our hotels are also required to comply with
regulations regarding food, hygiene, the operation and maintenance of the
swimming pool, casino, elevators, health, sanitation, electricity and fire
hazards prevention.
In most of the countries we operate hotels we are required to comply with
various regulations in connection with employees, in particular working hours'
regulations. For example: the hotel and restaurant industry in the Netherlands
has a collective labor agreement which provides a grading system for employees
in the hotel and restaurant industry. For each grade there is a minimum wage
mandated. Among other things, the provisions of the collective labor agreement
obligate the employer to provide money for employees for a number of funds.
Also, the total obligations of companies that might arise from the termination
of employees cannot be predicted.
With regard to our hotel in Hungary which is currently under construction,
the hotel building (the Ballet Institute Building) has a historical landmark
status, under the protection of the Hungarian Historical Building Office (which
has authority for the administration and preservation of the building). This
status mandates that the planning consents and requisite permits for the
proposed renovation of the Ballet Institute Building and its conversion into a
hotel must be applied for and obtained from the Historical Building Office. In
order to obtain such consents and permits, it is necessary to ensure that the
renovation plans provide for the restoration of the building and the
preservation of its historical status. In addition, our hotel in Romania which
is being renovated required the receipt of building permits under local
applicable laws, in order to enable the re-opening of the hotel following
renovation.
THE IMAGE GUIDED TREATMENT BUSINESS
The testing, manufacture and sale of InSightec's products are subject to
regulation by numerous governmental authorities, principally the FDA, the
European Economic Community (the "EEC"), and corresponding state and foreign
regulatory agencies.
The U.S. Safe Medical Devices Act of 1990 (the "SMDA") includes various
provisions which are applicable to each of the existing products of InSightec
and may result in the pre-market approval process (a process whereby the FDA
approves a new system that has no predicate devices that have been approved in
the past) for such products becoming lengthier and more costly. Under the SMDA,
the FDA can impose new special controls on medical products. These include the
promulgation of performance standards, post-market surveillance requirements,
patient registries, and the development and dissemination of guidelines and
other actions as the FDA may deem necessary to provide a reasonable assurance of
safety and effectiveness.
In June 1993, directive 93/42/EEC for medical devices was adopted by the
EEC. In June 1998, this directive replaced the local regulations and ensured
free transfer of qualified medical equipment among member states. Medical
devices that meet the established standards receive certification represented by
the symbol "CE". There are two types of certifications that are granted: (i)
general certification of a company and (ii) certification for a specific
product. Instead of choosing to comply with directive 93/42/EEC InSightec
decided to comply with the then effective International Standard ISO 9001
(European Standard EN 29001) entitled "Model for Quality Assurance in Design,
Development, Production, Installation and Servicing" and its extension to
medical products EN 46001 which satisfies the medical device directive. On May
10, 2001, InSightec obtained a certification by the European Notified Body that
it complies with the requirements of ISO 9001 and EN 46001. ISO 9001 and EN
46001 have been replaced by International Standard ISO 13485 entitled: "Medical
Devices - Quality management systems -Requirements for regulatory purposes."
InSightec obtained certification of compliance with the new standard in March
2004 and is subject to annual audits by the European Notified Body to renew the
certification in accordance with all applicable updates of the standard.
51
OTHER ACTIVITIES
The principal regulatory requirements for the operation of Mango in Israel
include: (i) compliance with the Israeli consumer protection law, (ii)
maintaining various licenses and permits issued by governmental authorities
(including receiving applicable standards from the Israeli consumer standard
institute for certain imported accessories), and (iii) compliance with
employment regulations.
C. ORGANIZATIONAL STRUCTURE
EMI is a subsidiary of Europe-Israel (M.M.S.) Ltd. (approximately 48%
shareholder). Europe Israel is wholly owned by Control Centers Ltd., an Israeli
privately held company, controlled by Mr. Mordechay Zisser, who serves as EMI's
Executive Chairman of the Board. EMI's significant subsidiaries and companies in
which EMI has a significant interest as of December 31, 2005 are as follows:
EMI'S DIRECT/
INDIRECT OWNERSHIP
PERCENTAGE
COUNTRY OF ------------------
NAME OF COMPANY ABBREVIATED NAME ORGANIZATION EQUITY VOTING
- --------------- ------------------- --------------- ------ ------
Elscint Ltd. Elscint Israel 100% 100%
BEA Hotels NV BEA The Netherlands 100% 100%
S.L.S. Sails Ltd. SLS Israel 100% 100%
Elbit Ultrasound (Netherlands) BV EUBV The Netherlands 100% 100%
InSightec - Image Guided Treatment Ltd. InSightec Israel 52.2% 69.4%
Plaza Centers (Europe) BV PC or Plaza Centers The Netherlands 100% 100%
Mango Israel Clothing and Footwear Ltd. Mango Israel 100% 100%
(*) on a fully diluted basis.
D. PROPERTY, PLANTS AND EQUIPMENT
EMI leases approximately 8,607 square feet in Tel Aviv, Israel for
management and administration purposes, of which approximately 3,604 square feet
are leased from Control Centers. The lease agreement with Control Centers
expired on December 31, 2005, but EMI continues to lease the office space on the
same terms. The other lease expires on February 28, 2007. The aggregate rental
fees paid by EMI in 2005 with respect to such lease were approximately $125,720
out of which approximately $56,120 were paid to Control Centers. The leased
property is adequate for EMI's needs in the foreseeable future.
Elscint leases approximately 4,929 square feet of office space in Tel Aviv,
Israel for its management and administration activities of which approximately
4,218 square feet are leased from Control Centers. The lease agreements expired
in July-August 2005, however, Elscint continues to lease the office space on the
same terms. The aggregate rental fees paid by Elscint in 2005 with respect to
such lease were approximately $100,000 out of which approximately $65,000 were
paid to Control Centers. The leased property is adequate for Elscint's needs in
the foreseeable future.
InSightec leases its main office and research and development facilities,
located in Tirat Carmel, Israel, pursuant to a lease that expires in August
2010, with an option to renew the lease for up to five years. InSightec occupies
approximately 52,000 square feet in Tirat Hacarmel and Or-Yehuda, with an option
to lease another 13,520 square feet. Total annual rental expenses under these
leases are $700,000. The leased property is adequate for InSightec's needs in
the foreseeable future.
Mango leases from May 2005 approximately 2,700 square feet of office space
in Tel Aviv, Israel, from Europe-Israel. The aggregate rental fees paid to
Europe-Israel in 2005 were approximately $44,000 (approximately NIS 196,000).
ITEM 4A. UNRESOLVED STAFF COMMENTS.
Not applicable.
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS.
OVERVIEW
Our revenues from the sale of real estate assets are recognized upon
consummation of the sale of real estate and/or the investments (see also below
revenue recognition). Our revenues from shopping and entertainment centers
derive primarily from leasing assets and management fees, both recognized pro
rata over the respective term of the lease and/or the management services
provided. Our revenues derive also from ownership of hotels owned by Elscint,
which revenues are recognized upon performance of service. Operating lease fees,
gradually received over the period of the lease, are recognized as revenues by
the straight-line method throughout the period of the lease. In December 2005,
we sold all of our holdings in the company holding one of our hotels in London,
which was the subject of a long term lease agreement, and we are therefore no
longer party to the long term lease. Revenues from sale
52
of medical products are recognized provided the following factors are fulfilled:
there exists persuasive evidence of an arrangement; delivery has occurred or
services have been rendered; the price is fixed or determinable; and
collectibility is reasonably assured. As to arrangements with multiple
deliverables, revenue thereform will be recognized while consideration is
allocated by and between the various items of the agreement.
Our functional currency is NIS, and our financial statements are prepared
in accordance with Israeli GAAP. Israeli GAAP and U.S. GAAP differ in certain
respects, which are summarized in detail in Note 25 to our consolidated
financial statements included in Item 18 below.
Because our revenues and expenses are recorded in various currencies, our
results of operations are affected by several inter-related factors, including
the ratio between the value of the operational and functional currencies of the
Company and the timing and amount of the devaluation of the Israeli currency
compared to other functional currencies. For additional information relating to
the impact of fluctuation on currency exchange rates, see "- Critical Accounting
Policies and Estimates - Functional Currency of Investee Companies" below.
Financial data included in this discussion were derived from our
consolidated financial statements and analyses based on our general accounting
records and published statistical data. Such financial data have been rounded to
the nearest thousand. For convenience purposes, financial data 2005 presented
herein for the fiscal year ended December 31, 2005, have been translated into
dollars using the representative exchange rate on December 31, 2005 of NIS 4.603
= $1.00.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
GENERAL
The following discussion should be read in conjunction with our
consolidated financial statements included in Item 18 and the accompanying Notes
thereto ("Consolidated Financial Statements").
A "critical accounting policy", is one that (i) is important to the
portrayal of an entity's financial condition and results of operations and (ii)
requires management's most difficult, subjective or complex judgments, often as
a result of the need to make estimates about the effect of matters that are
inherently uncertain. We believe that our critical accounting policies,
estimates and assumptions, the impact of which are material to our financial
condition or operating performance, or the nature of which are material because
of the level of subjectivity and judgment necessary for highly uncertain
matters, are those described below.
The preparation of our consolidated financial statements in conformity with
accounting principles generally accepted in Israel ("Israeli GAAP") requires us
to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. We evaluate, on an on-going basis, our estimates, including,
but not limited to, those related to impairment of real estate assets and
investments, investments in non-marketable securities, allocation of the
consideration within a business combination, assessment of the probable outcome
of litigation matters in which we are involved and other contingent liabilities,
allowance for doubtful debts, determination of subsidiaries' functional
currency, revenue recognition, current and deferred taxes and capitalization of
costs. We base our estimates on past experience, on professional advice or on
various other assumptions that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments as to
the carrying values of assets and liabilities that are not readily apparent from
other sources. In preparing the consolidated financial statements and forming
our estimates and judgments with respect to certain amounts included therein, we
have utilized available information including, among other factors, our past
history as above mentioned, industry standards and the current economic
environment, while giving due consideration to materiality. It is possible that
the ultimate outcome, as anticipated by us in formulating our estimates inherent
in these consolidated financial statements, will either not materialize or prove
to be substantially different. Moreover, application of the critical accounting
policies described below involves the exercise of judgment and use of
assumptions as to future uncertainties and, as a result, the actual outcome
could differ from these estimates. Other companies may use different estimates,
which may have an impact on the comparability of our results of operations to
those of companies in similar businesses.
Issues regarding our consolidated financial statements, that (i) in
accordance with Israeli GAAP, are subject to considerable judgment; and (ii)
involve critical assumption and estimates, are in general similar to those under
U.S. GAAP, except for the accounting treatment regarding derivative financial
instruments embedded within non-derivative instruments, in accordance with SFAS
No. 133 and the accounting for stock - based compensation, in accordance with
APB 25 described below.
IMPAIRMENT AND DEPRECIATION OF REAL ESTATE PROPERTIES, DEVELOPMENT ASSETS
We evaluate the existence of any other-than-temporary decline, and hence,
the need for an impairment loss on our real estate assets (operating or under
construction), when indicators of impairment are present. Our evaluation is
based, on the higher of (i) our estimated selling price in the open market or
(ii) the estimated value-in-use, based on discounted operational
53
cash flows (before interest and income tax charges), expected to be generated by
those assets ("cash flows"; and collectively - "recoverable amounts").
Fair value estimates represent the best estimates based on industry trends,
market rates, prices and transactions. Our value-in-use estimation involves
estimating the future cash flows expected to be derived from continuing use of
the assets and from their ultimate disposal. Such value is based on reasonable
and supportable assumptions as well as on historical results adjusted to reflect
our best estimate of future market and economic conditions that we believe will
exist during the remaining useful life of the assets. The discount rate used in
measuring the value-in-use estimation reflects economic environment risks,
current market assessments regarding the time value of money, industry risks as
a whole and risks specific to the assets, and is the return that investors would
require if they were to choose an investment that would generate cash flows of
amounts, timing and risk profile equivalent to those that the enterprise expects
to derive from the assets. Such rate is generally estimated from the rate
implied in current market transactions for similar assets. When an
asset-specific-rate is not directly available in the market, we use a substitute
rate to estimate the discount rate, by evaluating, as much as possible, a market
assessment of: (a) the time value of money for the periods through the end of
the assets' useful life; and (b) the possible risk that future cash flows will
differ in amount or timing from estimates.
Based on our estimates of future cash flows, our real estate assets were
determined to be recoverable, with the exception of the provisions for
impairment made by us in previous and current years. As for the current and
accumulated provisions for impairment loss - see Notes 10A. 10C. and 19L. to our
Consolidated Financial Statements.
The recognition of an impairment to property and the potential impairment
calculation are subject to a considerable degree of judgment, the results of
which, when applied under different principles or different conditions or
assumptions, are likely to result in materially different amounts and could have
a material adverse impact on our consolidated financial statements. The
evaluation of future cash flows expected to be generated by each property is
subject to significant uncertainty in the estimation of future income and
expenses of each hotel's and/or each shopping and entertainment center's
operations, and the future capital expenditures. In preparing these projections,
we make a number of assumptions concerning market share of the asset, benchmark
operating figures such as occupancy rates, average room rate (in respect of
hotels), rental and management fees rates (in respect of the shopping and
entertainment centers), collection rates, market prospects, industry labor cost
prospects, operating efficiency of the management companies and the scope of
maintenance and other operating expenses. as well as the value of similar real
estate assets in the approximate area of our real estate assets having similar
zoning and planning status to our real estate assets.
Depreciation of real estate is based on the estimated useful life of the
property (50 years, in respect of shopping and entertainment centers and 67 or
95 years, as the case may be, in respect of hotels), using the straight-line
method. Changes in our estimates regarding the expected economic useful life of
our assets might significantly affect our depreciation expenses.
Under different assumptions or conditions, the asset impairment analysis or
the depreciation rates may yield a different outcome, which may alter the
impairment analysis on our assets, as well as the gain or loss on the eventual
disposition of the assets.
For information on the material differences between Israeli GAAP and US
GAAP relating to impairment of real estate assets and/or investments in investee
companies - see subsections A8. and A9. to Note 25 to our consolidated financial
statements. In accordance with U.S GAAP, we should also use critical estimates
by determining the useful life of each group of assets. An indication that an
asset may be impaired may sometimes indicate that the remaining useful life, the
depreciation rates or the residual value for the asset, needs to be reviewed and
adjusted under accounting standards applicable to the asset, even if no
impairment loss is to be recognized for the asset and vice versa.
EQUITY SECURITIES
We invest in non-marketable equity securities of private companies or
companies, whose securities are traded in low volume trading markets, ranging
from early-stage companies that are often still defining their strategic
direction.
Investments in non-marketable equity securities are inherently risky, and a
number of these companies are likely to fail. Their success (or lack thereof) is
dependent on product development, time-to-market factors, market acceptance,
operational efficiency and other key business success factors. In addition,
depending on their future prospects, these companies may not be able to raise
additional funds when needed or they may receive lower valuations, with less
favorable investment terms than in previous financings, and the investments are
then likely to become impaired. In the current equity market environment, while
the availability of additional funding from venture capital sources has
improved, the companies' ability to take advantage of liquidity events, such as
initial public offerings, mergers and private equity funding, nevertheless
remains limited.
We evaluate impairment on individual investments in our portfolio when an
investment has experienced a sustained decline in fair value below the carrying
amount as of the date of evaluation. Investments identified as having an
indicator of impairment are subject to further analysis to determine if the
investment is other-than-temporarily impaired, in which case we write the
investment down to its impaired value. However, for non-marketable equity
securities, the impairment analysis requires
54
significant judgment to identify events or circumstances that are likely to have
a significant adverse effect on the fair value of the investment. The indicators
that we use and factors we consider in order to identify those events or
circumstances include, but are not limited to the following: (a) the investee's
revenue and earnings relative to predefined milestones and overall business
prospects which may indicate a significant under-performance of historical or
projected operating results or under-achievement of business plan objectives and
milestones; (b) the technological feasibility of the investee's products and
technologies; (c) the general market conditions in the investee's industry or
geographical area, including adverse regulatory or economic changes or a
significant adverse industry or economic trend; (d) factors relating to the
investee's ability to remain in business, such as the investee's liquidity, debt
ratios, burn rate of the investee's cash and the general financial condition and
prospects of the investee, including obtaining funding at a valuation lower than
our carrying amount or which requires a new round of equity funding to stay in
operation when funding does not appear imminent; (e) the value of each ownership
interest in relation to the carrying amount and the length of time during which
that value has experienced a decline; (f) the volatility inherent in the
external markets for these investments; and (g) several other relevant factors
and indicators. In such case, we presume that the investment is
other-than-temporarily impaired, unless specific facts and circumstances
indicate otherwise. In cases where securities of an investee are traded in the
market, our evaluation is based principally on the shares' market price and the
trends thereof. These evaluations are subjective in nature. A permanent decline
in value results in a charge, reducing the carrying amount of the investment to
its fair value.
Since market conditions and other parameters, which affect the recoverable
amount, vary from time to time, the recoverable amount may not be adequate on a
date other than the date the measurement was done (which is close to the balance
sheet date). Future adverse changes in market conditions or poor operating
results of underlying investments could result in losses or an inability to
generate the anticipated cash flow from holding the investee company and recover
the carrying amount of the investments, thereby possibly requiring an impairment
charge in the future not previously recorded.
For the current and accumulated provisions for impairment loss - see Notes
9A.(1) c. (3) to our Consolidated Financial Statements.
BUSINESS COMBINATIONS
We allocate the purchase price of acquired companies and properties to the
tangible and intangible assets acquired and liabilities assumed, based on their
estimated fair values. In order to allocate the purchase price attributed to
each acquired company and/or asset (tangible and intangible; monetary and
non-monetary) and liabilities, we identify and estimate the fair value of each
of the main acquired tangible assets (land, building, improvement, other
equipment and other monetary and non-monetary items) and estimate any other
identifiable intangible assets. Such valuations require us to make significant
estimates and assumptions. We believe that our estimates used as the basis for
this allocation are reasonable under the circumstances. A different method of
allocation may cause (i) an increase or decrease (as the case may be) in our
depreciation costs; (ii) the need to provide an impairment loss for each of the
acquired companies' assets, or to amend it; and (iii) an increase or decrease
(as the case may be) in gain (loss) derived from the disposal of these assets.
LITIGATION, OTHER CONTINGENT LIABILITIES AND ALLOWANCE FOR DOUBTFUL DEBTS
A. We are currently involved in various litigation disputes in substantial
amounts. We make provision for contingent obligations (including those in
respect of discontinuing operation) when the obligations are probable and their
amounts can reasonably be estimated. We include in our consolidated financial
statements provisions which are based on, among other factors, legal
consultation and past experience, and which in our opinion are deemed adequate
to cover the costs and resources necessary to satisfy the potential liabilities
under these claims. The outcome of such contingent liabilities may differ
materially from our assessment. We periodically evaluate these assessments and
make appropriate adjustments to our consolidated financial statements. In
addition, as facts concerning contingencies become known, we reassess our
position and make appropriate adjustments to our consolidated financial
statements.
We are involved in litigation matters, the amount or outcome of which may
not be estimable (e.g., class actions). Due to the uncertainties related to the
possible outcome and/or the amounts and/or ranges of losses in these litigation
matters, neither our management nor our legal advisors are able to make a
reasonable estimate of the liability that could result from an unfavorable
outcome and accordingly no provision is provided for such claims in our
consolidated financial statements. As additional information becomes available,
we will re-assess the potential liability related to our pending litigation and
will revise our estimates accordingly. Such revisions in our estimates of the
potential liability could materially impact our results of operations and
financial position.
See also Note 17B, 17C. and 24A, B and D to our Consolidated Financial
Statements.
B. We examine, on an ongoing basis, the volume of credit extended to our
customers in the ordinary course of business (including long term loans to third
parties, in line with and regarding our business) and accordingly, record a
provision for doubtful debts based on those factors affecting credit risks,
based upon our best judgment. We periodically evaluate the quality and value of
loans granted by us to various third parties in the ordinary course of business,
taking into consideration the
55
security that was provided, the term of the loans and our past experience with
these third parties. If our estimate of collectibility differs from the cash
received, the timing and amount of our reported results of operations could be
adversely affected.
FUNCTIONAL CURRENCY OF INVESTEE COMPANIES
In preparing our consolidated financial statements, we are required to
evaluate the functional currency of certain subsidiaries operating outside of
Israel (especially in central Europe). In principle, the functional currency is
the currency which management believes, based on qualitative criteria, reflects
the economic nature of the events and circumstances relevant to the operating
subsidiary ("investee") or currency that is extensively used in or has a
significant effect on its activity. The functional currency is determined based
on management's judgment and involves consideration of all relevant economic
factors and circumstances affecting each subsidiary (e.g., the currency of the
financial environment that significantly influences management in determining,
inter alia, selling prices and payment conditions, or the currency used by
management for the purpose of decision making). Generally, the currency in which
each subsidiary executed (denominated and settled) the majority of its financing
and transactions, which include purchases, billings, collections and payments
(i.e., currency in which receivables and payments from current activity are
denominated and settled or in which they are retained following their
conversion) and the currency in which a majority of costs pertaining to the
supply of services (e.g,. payroll, maintenance, subcontractors expenses and
other expenditures) are denominated and settled, may indicate the functional
currency. In these instances, the nature of the subsidiary's operations must
also be considered. A significant change in the financial environment, or in the
foregoing factors in whole or in part, may require management to re-assess its
determination of the functional currency.
When any subsidiary's functional currency is deemed to be other than the
reporting currency, then any gain or loss associated with the translation of
that subsidiary's financial statements, for consolidation purposes, is charged
directly to a separate item in the shareholders' equity, namely "cumulative
foreign currency translation adjustments". Exchange rate differences on net
monetary items included in the subsidiary's financial statements which are
denominated in, or linked to, currencies other than the functional currency, are
recorded directly to the statements of operations. See also "Item 11.
Quantitative and Qualitative Disclosure About Market Risks - Exchange Rate
Exposure" and "Exposure to Net Investment Value of Foreign Entity"" below.
In the event the functional currency changes into a currency other than the
local one, the amount of the foreign currency translation adjustment and/or the
net income in each reported year following the date the change was implemented
could be materially affected (see below).
As described in Note 2A.(3)(iii) to our consolidated financial statements,
several countries, among them Hungary, Poland and the Czech Republic (countries
in which the majority of our operations in the field of shopping and
entertainment centers is concentrated), joined the European Union on May 1,
2004. The joining countries undertook to manage an economic policy which
conforms to certain monetary and regulatory targets, aiming at the implementing
required conditions for the adoption of the Euro as the country's legal
currency. Prior to their joining, those countries took significant actions
pertaining thereto, such as: altering their monetary and fiscal policies,
including full liberalization of their currency regimes and lifting of foreign
currency controls (such as liberty to transact, transfer and execute payment in
foreign currency, allowing free trading in the local currency abroad, lifting of
the restrictions on transferring foreign currency abroad, allowing free
unlimited trading in foreign securities, reporting, etc.). As a result, our
subsidiaries, which are incorporated and operate in Hungary, Poland and the
Czech Republic (the "Companies") deemed it necessary to reconsider their
settlement currency with lessees ("Settlement Currency"), the nature and scope
of protection of the value of their financial assets and liabilities, their
currency risk management policy, etc. In light of the foregoing and concurrently
therewith, the Companies reconsidered their operational and measurement
currency. According to the nature of the Companies' operations and the changes
in the economic environment in which they operate, and in accordance with
Israeli and U.S. Standards, we are of the opinion that as and from April 1,
2004, the Euro, rather than the local currency, more adequately reflects the
business condition and the results of operations (transactions) of the
Companies, affecting the management policy and decision-making processes as well
as the transactions (revenues and cost of acquisition/construction of assets),
the scope and prices thereof, the currency risk policy and the financing
operations thereof. Accordingly, the Euro serves as the functional currency of
the Companies starting from April 1, 2004.
For information on currencies involved in our global operations, see "Item
11. Quantitative and Qualitative Disclosure About Market Risks - Table I -
Foreign Currency Risks" below.
REVENUE RECOGNITION
Revenue recognition in the image guided treatment segment:
Revenue recognition criteria. InSightec recognizes revenue from sales of
the ExAblate 2000 in accordance with SAB 101, as amended by SAB 104 when (i)
persuasive evidence of an arrangement exists, (ii) delivery has occurred or
services has been rendered, (iii) the price is fixed or determinable and (iv)
collectibility is reasonably assured. InSightec's sales arrangements with
customers may include a number of elements or multiple deliverables that
represent individual units of accounting. These deliverables typically consist
of system sales, installation at the customer's site and training.
56
For these arrangements, we implement the guidance in EITF No. 00-21
"Revenue Arrangements with Multiple Deliverables". The principles and guidance
outlined in EITF No. 00-21 provide a framework to (a) determine whether an
arrangement involving multiple deliverables contains more than one unit of
accounting, and (b) determine how the arrangement consideration should be
measured and allocated to the separate units of accounting in the arrangement.
Each of these deliverables in the arrangement represents individual units of
accounting if the delivered system has (i) value to the customer on a
stand-alone basis; and (ii) objective and reliable evidence of fair value exists
for the installation and training. The arrangements generally do not contain a
right of return of the delivered system. Typically, the deliverables are
considered separate units of accounting when there are independent third parties
who can render the installation and training services. InSightec determines fair
value for those services based on the prices required by third parties for the
undelivered elements (i.e., installation and training) when they are sold
separately. Currently, InSightec does not have fair value for the system sold.
Therefore, InSightec uses the residual method to allocate the arrangement
consideration. Under the residual method, the amount of consideration allocated
to the delivered item equals the total arrangement consideration less the
aggregate fair value of the undelivered items. Assuming all the abovementioned
criteria for revenue recognition have been met, InSightec recognizes revenue for
system sales when delivery occurs and recognize revenue for installation and
training when the services are rendered.
In cases where the deliverables in the arrangement do not constitute
separate units of accounting, based on the criteria in EITF 00-21, InSightec
recognizes revenue when all the deliverables that are considered essential to
the functionality of the system has been delivered to the customer. This is
generally deemed to have occurred upon the completion of installation and
training.
In the past InSightec has entered into sales arrangements with customers
where payment for InSightec's product was contingent upon its receipt of FDA
approval to market the ExAblate 2000, or upon its provision of certain hardware
and software upgrades. Accordingly, InSightec did not recognize revenue from
such sales until the applicable contingency was fulfilled.
Revenue related to separately priced service contracts is recognized
ratably over the service period. All costs associated with the provision of
service and maintenance, including salaries, benefits, travel, spare parts and
equipment, are recognized in cost of revenues as incurred.
Warranty costs. Accrued warranty costs are calculated in respect of the
warranty period on InSightec's products, which is generally one-year.
InSightec's warranty reserves is based on its best estimate of the amounts
necessary to settle future claims on products sold as of the balance sheet date,
based on contractual warranty rights and its accumulated experience with regard
to service of its products. InSightec may need to revise or reconsider its
estimates in the future based on its additional accumulated experience, over
time, with respect to warranty claims. To date, InSightec's warranty reserve has
been minimal and InSightec's warranty costs have not exceeded this reserve.
Revenue recognition from sales of real estate assets and investments:
The Company recognizes gain on sales of real estate assets and investment
properties when a sale has been consummated, the buyer's initial and continuing
investment is adequate to demonstrate commitment to pay, any receivable obtained
is not subject to future subordination and the usual risks and rewards of
ownership have been transferred.
As described in Note 9B. (3) to our consolidated financial statements, we
have entered into several sale agreements with Klepierre and Dawny Day for the
sale of our shopping and entertainment centers portfolio. In the framework of
these sale agreements we took upon ourselves to have continuing involvement in
the form of a guarantee of a return on the buyer's investment for limited period
or in a limited amount, profit is recognized when there is reasonable assurance
that total estimated future rent receipts will cover operating expenses and debt
service including payments due the buyer under the terms of the transaction. In
making this determination, total estimated future rent receipts of the property
are reduced by a reasonable safety factor, unless the amount so computed is less
than the rents to be received from signed leases. For the Company, these
conditions are usually fulfilled at the time of sale.
If, according to the terms of the transaction, the Company will participate
in future profit from the property without risk of loss, and the transaction
otherwise qualifies for profit recognition under the full accrual method, the
contingent future profits are recognized when they are realized.
ACCOUNTING FOR INCOME TAXES
As part of the preparation of our Consolidated Financial Statements, we are
required to estimate our income taxes in each of the jurisdictions in which we
operate. This process involves an estimate by us of our actual current tax
exposure, together with assessing temporary differences resulting from different
treatment of items, for tax and accounting purposes. These differences result in
deferred tax assets and liabilities that are included in our balance sheet.
Considerable management judgment is required in determining our provision for
income taxes, our deferred tax assets and liabilities and any valuation
allowance recorded against our net deferred tax assets. We evaluate the weight
of all available evidence to determine whether it is probable that some portion
or all of the deferred income tax assets could be realized. As of December 31,
2005 we recorded a valuation allowance for substantially all of our deferred tax
assets (net, after provisions) primarily consisting of certain net
57
operating losses, as well as other temporary differences between book and tax
accounting, (see Note 16F. to our consolidated financial statements). The
valuation allowance was recorded due to uncertainties surrounding our ability to
utilize some or all of our deferred tax assets. In assessing the need for the
valuation allowance, we consider future taxable income, the fulfillment of
conditions stipulated in the certificates in respect of the "approved
enterprise", the time limitations on the utilization of losses (see Note 16D. to
our consolidated financial statements), and ongoing, prudent and feasible tax
planning strategies. In addition, the calculation of our tax liabilities
involves dealing with uncertainties in the application and/or interpretation of
complex tax laws, tax regulations, and tax treaties in respect of various
jurisdiction in which we operate and which frequently vary.
Tax authorities may interpret certain tax issues in a manner other than
that which we have adopted. Should such contrary interpretive principles be
adopted upon adjudication of such cases, our tax burden of the group may be
significantly increased. If the realization of deferred tax assets in the future
is considered probable, an adjustment to the deferred tax assets would increase
net income during the period in respect of which such determination is made. In
the event that actual results differ from these estimates or that we adjust
these estimates in future periods, we may incur additional taxes, which could
materially affect our financial position and results of operations. We have
recorded liabilities for anticipated tax issues based on our estimate of
whether, and the extent to which, we may become subject to additional tax
payments. If we ultimately determine that payment of these amounts is
unnecessary, we will reverse the liability and recognize a tax benefit during
the period of the determination. As to tax issues affecting our U.S. subsidiary
- - see Note 16B.(2) to our consolidated financial statements.
The computation of current and deferred tax liabilities does not include
taxes that would have arisen in the event of a sale of the investments in
investees (except those that are to be liquidated), or upon receiving the
retained earnings as dividends, since in respect of some dividends from profits
thereof and/or gains to be generated from their realization are tax exempt, and
in respect of others, it is management's policy not to dispose of such
investments and/or not to offer, in the foreseeable future, their retained
earnings as a dividend distribution or otherwise, in a manner causing a material
tax burden on us (see Note 16B.(1)c. to our consolidated financial statements).
In assessing the need to provide a tax liability in respect of the
abovementioned, we consider, among others, feasible tax planning strategies.
Different assumptions or other policies adopted by management, might
significantly affect our tax expenses.
The allocation of the proceeds in respect of properties sold at an
aggregate amount ("package"), is based on an estimate of the fair value of each
asset sold and on the basis of the provisions stipulated in the sale agreements.
A different method of allocation may cause additional liabilities and/or
expense. We believe that our estimates used as the basis for this allocation of
proceeds is reasonable under the circumstances. Certain foreign group companies
have received final tax assessments for the years through 1999, while others
have not been assessed since their incorporation. See, in addition, Note 17C.(5)
to our consolidated financial statements. Tax authorities may, at this stage,
challenge our tax strategy, and thus our income or loss for tax purposes could
be significantly affected, so that our tax expenses (current and deferred) may,
therefore, increase, Furthermore, our tax strategy might be impacted by new laws
or rulings.
CAPITALIZATION OF COSTS (TANGIBLE AND INTANGIBLE)
We capitalize direct acquisition, construction and development costs,
including initiation, pre-development and financing costs, as well as property
taxes, insurance, and indirect allocated project costs, that are associated with
the acquisition, development or construction of real estate projects, as and
from the pre-acquisition stage until the time that construction of such
real-estate project is completed and its development is ready for its intended
use, in accordance with Statement of Financial Accounting Standards ("SFAS") No.
67. Our cost capitalization method requires the use of management estimates
regarding the fair value of each project component. We base our estimates on
replacement costs, existing offers, past experience and other various
assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the fair market value
of real estate assets. Management estimation is also required in determining
whether it is probable that a real estate project in its pre acquisition stage
or in its early stage would be executed. Actual results may differ from these
estimates and anticipated returns on a project, as well as the gain or loss from
disposition of individual project components, could vary significantly from
estimated amounts. We are actively pursuing acquisition opportunities although
no assurance can be provided as to which opportunity will succeed. Costs
previously capitalized that relate to (i) an abandoned development opportunity;
(ii) a project not reasonably expected to materialize; or (iii) a project the
expected economic benefit of which is doubtful, are written off and charged to
the statement of operations.
Furthermore, should development and construction activities decrease
substantially, or be interrupted or delayed for a lengthy period, a portion of
financial costs and project expenses may no longer be eligible for
capitalization, and would be charged to the statement of operations.
Our finance costs capitalization method requires us to use critical
estimations and assumptions as well as management judgment to determine whether
a specific asset under construction or development is qualified for
capitalization. The date of commencement and/or the cessation of capitalization,
the fulfillment of conditions, the period for suspension of capitalization (if
any) and capitalization rate, are also subject to significant estimates and
assumptions. Under other conditions or assumptions, the outcome might
significantly differ.
58
In valuing certain tangible and/or intangible assets (such as capital
rental costs and costs incurred to obtain lease contracts or bank loans), we use
critical estimates and assumptions on what marketplace participants would use in
making estimates of fair value. Capitalized rental costs directly related to
revenue from specific operating leases are amortized over lease terms. Other
capitalized rental costs (not related directly to revenue) are amortized over
the period of expected benefit. The amortization period begins when the project
is substantially completed and deemed available for occupancy. Capitalized costs
for obtaining bank loans are amortized over loan periods. Estimated
unrecoverable amounts of unamortized capitalized rental costs associated with a
lease or costs of obtaining loans or a group of leases or loans, are charged to
expenses when it becomes probable that the lease or the loans will be terminated
or extinguished, as applicable. Our estimates of fair value are based upon
assumptions believed to be reasonable, but which may be reversed due to changes
in circumstances in the future (such as the assumptions regarding the period of
time the obtained lease or loan will continue to be used in our portfolio or the
level of judgment that should be used in determining whether a change or
modification of a debt instrument should be considered as a debt extinguishments
or not, etc.). Assumptions may not necessarily reflect unanticipated changes in
circumstances that may occur.
CRITICAL ACCOUNTING POLICIES WHICH EFFECT OUR U.S GAAP RECONCILIATION NOTE:
DERIVATIVE FINANCIAL INSTRUMENTS
We have adopted Statement of Financial Accounting Standards No. 133,
"Accounting for Derivative Instruments and Hedging Activities", as amended by
SFAS 149 ("SFAS 133"). Derivatives, as defined within SFAS 133 that are embedded
within non-derivative instruments, must be bifurcated from the host instrument
and accounted for when the embedded derivative is not clearly and closely
related to the host instrument. However, rental for the use of leased assets and
adjustments for inflation on similar property are considered to be clearly and
closely related. Thus, the inflation-related derivative embedded in an
inflation-indexed lease contract is not bifurcated from the host contract.
In conformity with SFAS 133, foreign currency forward contracts that are
embedded within a lease contract ("the host contract") should be bifurcated and
accounted for separately ("bifurcation"). The bifurcated forward contracts are
recorded at their fair value while changes in their fair values are charged to
the statement of operations and classified under financial income (expenses),
net. An embedded foreign currency instrument is not bifurcated from the host
contract, if (i) contracts in which specified volumes of sales of one of the
parties to the contract serve as the basis for settlement ("underlying"); and
(ii) the host contract is not a financial instrument and it requires payments
denominated in the functional currency of any substantial party to that
contract. The evaluation of whether a contract qualifies for the exception
abovementioned should be performed only at inception of each contract.
In determining the fair value of currency transactions, especially the fair
value of derivatives, we are required to make critical estimates and judgments
in respect of certain parameters, such as (i) lease contract firmness; (ii)
interest rates; (iii) exchange rates (spot rates); (iv) forward rates; and (v)
period of lease. When using our computation methodology, determination of fair
value may not practically be carried out, without significant reliance upon
critical estimations and judgment, mainly due to (a) the existence of many lease
agreements between lessees (including anchor tenants) in each of our operating
centers; (b) such leases are signed for various long term periods (between 5 to
20 years) to which volatility is highly sensitive; (c) the existence of
different type of conditions in different leases (including (i) frequency of
installments; (ii) options to extend the lease periods; and (iii) the right to
withdraw from lease agreements or to reduce, in certain events, rent fees by
significant amounts); (d) a major part of the leases were executed prior to the
issuance of SFAS 133, thus causing us extensive burden in collecting some
important unavailable market information; (e) frequent changes, in the ordinary
course of business, in the terms of leases (including (i) increase or decrease
of rental fees for the whole or a part of the lease period; (ii) alteration of
the fee base from a fixed sum to variable, and vice versa; (iii) shortage of
lease period; and the like). These changes are usually carried out in the
ordinary course of business, in accordance with changes in circumstances,
(mainly as a result of (i) poor collectibility in respect of specific tenant;
(ii) demand of a potential purchaser, in as much as same may be implemented; and
others); and (f) our lease activities that are subject to embedded derivatives
are being carried out mainly in Hungary and Poland, countries having no past
experience in quotation of complicated derivative financial instruments and in a
functional currency of which there is little experience in derivative
operations.
Lease agreements signed and executed while projects were under
construction, and which are not yet operational, are considered a firm
commitment following April 1, 2004 - the date of the change of the functional
currency of the contracted companies from the local currency into the EURO (see
Note 2A.(3)(iii) to our consolidated financial statements) - and therefore the
embedded foreign currency instrument (the Euro) is not bifurcated from the host
contract.
Determination of whether an embedded foreign currency instrument is subject
to bifurcation or is considered to be clearly and closely related to the lease
agreement (mainly due to conditions according to which volume of sales of one of
the parties to the agreement serve as the basis of settlement) requires
significant judgment and critical reasonable estimates by management.
The estimated fair values in our financial instruments have been determined
by us, using available market information and appropriate valuation
methodologies. However, considerable judgment is necessarily required in
interpreting market data to
59
develop the estimates of fair value. Accordingly, the estimates presented herein
are not necessarily indicative of the amounts that we could realize in a current
market exchange. The use of different market assumptions or estimation
methodologies may have a material effect on the estimated fair value amounts,
and accordingly on the profit and loss accounts, in accordance with U.S. GAAP.
The fair value estimates presented herein are based on pertinent
information available to management as of each date of measurement or
evaluation. Management is not aware of any factors that would significantly
affect the estimated fair value amounts as of these dates. Future estimates of
fair value and the amounts which may be paid or realized in the future may
differ significantly from amounts presented.
STOCK-BASED COMPENSATION
We calculate this amount using the Black-Scholes method of valuing the
option to estimate the fair value of the options grant. This method requires
that we make several estimates, including the volatility of our stock price, and
the expected life of the option. In making these estimates, we have used
historical data as well as management judgment to arrive at the data inputs.
We expect to comply with FASB issued Statement No. 123 (revised 2004),
"Share-Based Payment," ("Statement 123R"), beginning in the first quarter of
2006.
In August 2005, the Israel Accounting Standards Board ("IASB") published
Standard - No. 24 - "Share-Based Payment" ("Standard No. 24"). The objective of
Standard No. 24 is to specify the principles of financial reporting by an entity
where it enters into a share-based payment transaction. In particular, it
requires an entity to reflect in its profit or loss and financial position, the
effects of share-based payment transactions, including expenses associated with
transactions in which stock options are granted to employees. For equity-settled
share-based payment transactions, we should measure the goods or services
received, and the corresponding increase in equity, directly, at the fair value
of the goods or services received, unless that fair value cannot reliably be
estimated. If so, we should measure their value, and corresponding increase in
equity, indirectly, by reference to the fair value of the equity instruments
granted, by measuring their fair value at the measurement date, based on market
prices if available. If market prices are not available, fair value of the
equity instruments granted should be estimated using a valuation technique
consistent with generally accepted valuation methodologies for pricing financial
instruments, taking into account the terms and conditions upon which those
equity instruments were granted. For transactions with employees and others
providing similar services, the fair value of the transaction should be measured
directly by reference to the fair value of the equity instrument granted, at the
date of grant.
As for the impact of this standard on our 2005 consolidated financial
statements, on our reported results for the first quarter of 2006 and on the
2006 consolidated financial statements, see Note 2X. (ii) to our consolidated
financial statements included in Item 18 below.
RECENTLY ISSUED ACCOUNTING STANDARDS
For information on recently issued accounting standards under US GAAP, see
Note 25 A. to our consolidated financial statements.
For information on recently issued accounting standards under Israeli GAAP,
see Note 2 X. to our consolidated financial statements.
A. OPERATING RESULTS
PRESENTATION METHOD OF STATEMENT OF OPERATIONS AND THE CHANGE THEREOF
Significant recent global changes, particularly in the real estate business
in which we operate, enable us to utilize our relative advantage in such field
of operation. Such changes include, among others, a decrease in commercial
assets' long-term yield rates; low short term interest rates, geo-political
evolutions including rapid financial progress in developing markets and
transformation thereof to much more readily accessible geographical targets.
Concurrently with such changes and consequently thereto, a significant increase
was noted in the quest for real assets, both by private, as well as by
institutional investors, pension funds, REIT funds, and others. The above
mentioned global changes together with the completion of the July 2005
transaction between PC and Klepierre, (See "Item 10. Additional Information -
Material Contracts - Shopping and Entertainment Centers" below), led the
management to reexamine our nature of activity while attempting to strategically
alter its business. The core of such change is expressed in evolving the major
part of our business activities from the entrepreneurship, development and
operation of various commercial real estate assets in the medium to long term,
into the entrepreneurship and development of such assets supported by short term
management and operation activities with the principal objective of founding and
stabilizing the assets for their sale, as closely as possible to completion of
construction, and/or into the construction of assets under pre-sale development
agreements executed with third parties (such as investment or management
companies on the basis of turnkey construction agreements). This new business
model is intended to reap the advantages of our strengths and expertise
60
in the entrepreneurship and development of projects, rather than investing
precious financial and manpower resources for the operation of its assets for
the long term. The reexamination resulted in redefinition of the our operational
and business model so that sales of its operational assets are included therein,
whereas during previous reporting periods such sales and the results thereof
were excluded from our operational results.
Following the consummation of the various "exit" transactions which
commenced during 2004 and continued in 2005, and as a result of the change to
our business model as specified above, our management believe that the
historical presentation format of our statement of operations ("Multiple - step
form") is no longer a meaningful measure and presentation of our business
activities, nor does it optimally reflect same. Our management believes that all
costs and expenses (including selling and marketing, general and administrative
as well as finance costs) should be considered as continuously contributing to
obtaining overall income and profits, and that any attempt to classify only part
of the expenses directly to the income revenues, may be construed as artificial.
Management also believes that splitting such operational costs, to separate
items such as "cost of sale", "selling and marketing costs", and "general and
administrative expenses", is not meaningful to us, as we are a diversified
company (containing a wide range of different activities), but rather an
alternative classification should be applied which recognizes two types of
costs: (i) those directly related to the sales; and (ii) overhead expenses which
serve the business in general and are to be determined as general and
administrative expenses. Moreover, distinction between those costs which are or
are not taken into account in determining the gross profit, requires significant
discretion, often entailing inconsistent and insufficiently reliable accounting
classification.
Accordingly, we have adopted a new method for the presentation of our
consolidated statement of operations reports, whereby all expenses are presented
in one group, which is deducted as a whole from the total revenues which are
also represented in one group ("Single - Step Form"), as opposed to the previous
presentation, used through the previous reporting period ("Multiple - Step
Form"). Accordingly, expense items were classified - as part of such change - by
differentiating those costs directly relating to each income, and those which
serve the business in general.
In the view of our management, this new method of presentation more
adequately and suitably reflects the nature of our operations on a consolidated
basis, in the light of our modified strategy and goals. Comparative figures for
the previous accounting years have been reclassified accordingly.
The following table presents for the periods indicated the statements of
operation of EMI for the years period the last of which ended December 31, 2005:
2005
Reported
Convenience 2005 2004 2003
Translation Reported Reported Adjusted
----------- -------- -------- --------
$'000 (In Thousand NIS)
REVENUES
Sale of real estate assets and investments, net 61,191 281,661 131,921 --
Commercial centers operations 31,057 142,957 311,893 347,056
Hotels operations and management 58,670 270,057 218,365 189,205
Sale of medical systems 16,449 75,713 44,049 --
Realization of investments 425 1,958 16,415 45,129
Other operational income 9,648 44,409 13,238 13,495
------- ------- ------- --------
177,440 816,755 735,881 594,885
------- ------- ------- --------
COSTS AND EXPENSES
Commercial centers operations 34,248 157,640 271,392 257,913
Hotels operations and management 56,331 259,293 207,152 188,672
Cost and expenses of medical systems operation 10,771 49,577 26,039 8,720
Other operational expenses 10,166 46,793 3,655 3,510
Research and development expenses, net 12,796 58,899 38,158 43,719
General and administrative expenses 8,025 36,939 43,627 42,144
Share in losses of associated companies, net 2,613 12,028 15,968 20,951
Financial expenses, net 26,574 122,321 53,569 211,821
Other expenses, net 12,406 57,106 51,428 10,477
------- ------- ------- --------
173,930 800,596 710,988 787,927
------- ------- ------- --------
PROFIT (LOSS) BEFORE INCOME TAXES 3,511 16,159 24,893 (193,042)
Income taxes (tax benefits) 1,694 7,798 15,804 (20,217)
------- ------- ------- --------
PROFIT (LOSS) AFTER INCOME TAXES 1,816 8,361 9,089 (172,825)
Minority-interest in results of subsidiaries, Net 15,922 73,287 27,448 48,671
PROFIT (LOSS) FROM CONTINUING OPERATIONS 17,738 81,648 36,537 (124,154)
61
Profit from discontinued operations, net 1,285 5,917 6,810 12,073
Cumulative effect of accounting change at the
beginning of the year (135) (622) -- --
------- ------- ------- --------
NET INCOME (LOSS) 18,888 86,943 43,347 (112,081)
======= ======= ======= ========
FISCAL 2005 COMPARED TO FISCAL 2004
Most of our businesses, which operate in various countries, report their
operational results in their functional currency, being other than NIS (our
reporting currency). We translate our subsidiaries' result of operations into
NIS based on the average quarterly exchange rate of the functional currency
against the NIS. Therefore, a devaluation of the NIS against each functional
currency would cause an increase in our reported revenues and the costs related
to such revenues in NIS while a revaluation of the NIS against each functional
currency would cause a decrease in our revenues and costs related to such
revenues in NIS.
Revenues
Total consolidated revenues for 2005 were NIS 816.8 million ($177.4
million) compared to NIS 735.9 million for 2004, an increase of NIS 80.9
million, or 11%.
Revenues from sale of real estate assets and investments, net, for 2005
were NIS 281.7 million ($61.2 million) compared to NIS 131.9 million in 2004.
Revenues from sale of real estate assets and investments in 2005 were
derived from (i) sale of four Polish shopping and entertainment centers to
Klepierre in July 2005, which contributed net revenue of NIS 166.4 million; (ii)
purchase price adjustment to the sale transaction of 12 Hungarian shopping and
entertainment centers to Klepierre in July 2004, which contributed net revenues
of NIS 53.4 million ($11.6 million); (iii) sale of four Hungarian shopping and
entertainment centers to Dawney Day in April 2005, which contributed net
revenues of NIS 3.5 million ($0.8 million); and (iv) sale of our interest (30%)
in Shaw in December 2005, which contributed net revenues of NIS 58.4 million
($12.7 million).
Revenues from sale of real estate assets and investments in 2004 derived
from the sale of twelve Hungarian shopping and entertainment centers to
Klepierre in July 2004.
For further elaboration of these transactions see "Item 10. Additional
Information - Material Contracts - Shopping and Entertainment Centers" below.
Revenues from shopping and entertainment centers operations in 2005 were
NIS 143.0 million ($31 million) compared to NIS 311.9 million in 2004, a
decrease of NIS 168.9 million or 54%. Such decrease resulted mainly from (i) the
sale of the activities of 12 shopping centers in Hungary, which were sold to
Klepierre Group at the beginning of the third quarter of 2004 and which did not
contribute any revenues in 2005 in comparison with NIS115.5 million in the first
half of 2004; (ii) the sale of the activities of four operational centers in
Hungary which were sold to Dawny Day at the beginning of the second quarter of
2005, which contributed revenues of NIS 11.5 million ($2.5 million) in first
quarter 2005 compared to NIS 46 million in 2004; and (iii) the sale of the
activities of four operational centers in Poland which were sold to Klepierre at
the beginning of the third quarter of 2005 and which contributed revenues of NIS
40.0 million ($ 8.7 million) in the first half of 2005 compared to NIS 60.0
million in 2004.
Revenues from our hotel operations and management for 2005 were NIS 270.1
million ($58.7 million) as compared to NIS 218.4 million for 2004, an increase
of NIS 51.7 million or 23.7%. The increase in revenues in the hotel division
resulted primarily from the commencement of operations of the Riverbank Park
Plaza Hotel in April 2005, which contributed additional revenues of NIS 39.1
($8.5 million) in 2005; from an increase in revenues from the operations of
Victoria London hotel mainly attributed to higher occupancy rate and higher
average room rate; and from an increase in revenue from the Centerville
apartments hotel in Bucharest mainly attributed to renovation and commencement
of operations of an additional 60 apartments during 2005.
Revenues from InSightec's sale of medical systems in fiscal 2005 were NIS
75.7 million ($16.4 million) as compared to NIS 44.0 million in 2004. The sales
in fiscal 2005 represent sales of 15 "ExAblate 2000" Systems as compared to 10
systems in 2004.
Revenues from realization of investments in 2005 were NIS 2.0 million ($
0.4 million) which were attributed to additional proceeds received from the sale
of our interest in Algotech in November 2003 as compared to NIS 16.4 million in
2004 which were attributed to gain deriving from decrease in shareholding of our
interest in InSightec amounting to NIS 13.0 million and certain additional
proceeds received from the sale of Algotech amounting to NIS 3.4 million.
62
Revenues from other operational income in 2005 were NIS 44.4 million ($9.6
million), out of which NIS 31.8 million ($6.9 million) being revenues from the
operation of Mango which was acquired in May 2005 and NIS 12.7 million ($2.7
million) representing lease of assets, as compared to NIS 13.2 million in 2004,
all of which deriving from lease of assets.
Profits before Income Taxes
SET FORTH IS AN ANALYSIS OF OUR PROFITS BEFORE INCOME TAXES AND THE
ANALYSIS OF THE DECREASE IN OUR PROFITS BEFORE INCOME TAXES FROM NIS 24.9
MILLION IN 2004 TO NIS 16.2 MILLION ($3.5 MILLION) IN 2005:
Profit from the sale of real estate assets and investments is presented
net, after cost of assets or investments sold, therefore; the profits from such
sales are equal to the revenues derived therefrom.
Costs and expenses from shopping and entertainment centers operations less
revenues from shopping and entertainment centers in 2005 was NIS 14.7 million ($
3.2 million) compared to revenues from shopping and entertainment centers
operations less costs and expenses related to such revenues in 2004 of NIS 40.5
million. This decrease was attributable mainly to a decrease in the revenues of
the shopping and entertainment centers as a result of the project sales
described above. The decrease in revenues was not followed by a matching
decrease in other operational expenses related to the shopping and entertainment
centers operations (i.e., initiation, selling & marketing as well as general and
administrative expenses).
Revenues from hotel operations less costs and expenses related to such
revenues in 2005 was NIS 10.7million ($ 2.3 million) compared to NIS 11.2
million in 2004. This decrease is attributable mainly to the fact that the
Riverbank Hotel which commenced operation in April 2005 was not operating on a
full-scale basis while its fixed expenses (e.g. property tax, insurance,
depreciation, etc.) corresponded to full-scale operations of such hotel
resulting in losses of approximately NIS 12 million ($2.6 million) from this
hotel which are typical to hotel in its preliminary stages of operation. Such
losses were partially offset by an increase in profits of the Centerville
apartments hotel in Bucharest and the Victoria London Hotel.
Revenues from sale of medical systems less costs and expenses related to
such revenues in 2005 was NIS 26.1millions ($ 5.7 million) compared to NIS 18.0
million in 2004. This increase is attributable mainly to a growth in sales, as
described in preceding paragraphs, offset by increase in selling and marketing
expenses and general and administrative expenses attributable to sale of medical
systems from NIS 16.2 million in 2004 to NIS 30.2 million ($ 6.6 million) in
2005. This increase in selling and marketing expenses was attributable to
InSightec's extensive efforts and resources devoted to expand its scope of sales
and the increase in general and administrative expenses attributable to an
increase in InSightec's headquarters personnel in order to expand InSightec's
activities.
Profit from realization of investments is presented net, after cost of the
investments sold and therefore the profit from such item is equal to the
revenues derived therefrom.
Costs and expenses from other operational income less revenues from other
operational income in 2005 was NIS 2.4 million ($ 0.5 million) compared to
revenues from other operational income less costs and expenses related to such
revenues in 2004 of NIS 9.6 million. which include the following: (i) revenues
of Mango less costs and expenses of Mango of NIS 4.4 million ($1.0 million);
(ii) project initiation expenses of NIS 7.8 million ($1.7 million) mainly
relating EMI's tender offer to participate in Israel's Channel 2 broadcasting;
and (iii) revenues from lease of assets less costs and expenses of related to
such revenues was NIS 9.8 million ($2.1 million). Revenues from other
operational income in 2004 less costs and expenses related to such revenues
resulted from lease of assets and amount of NIS 10.0 million.
Research and development expenses, net in 2005 totaled NIS 58.9 million
($12.8 million), after deducting NIS 3.9 million ($0.8 million) granted by the
Israeli Office of the Chief Scientist ("OCS"), compared to NIS 38.2 million in
2004, after deducting NIS 7.7 million granted by the OCS. All research and
development expenses derived from InSightec's operations. InSightec expanded its
scope of research and development in 2005 to new applications of the ExAblate
2000 systems as well as costs related to the developing of new systems.
General and administrative expenses decreased in 2005 to NIS 36.9 million
($8 million) from NIS 43.6 million in the previous year. This decrease is
attributed mainly to a decrease in legal and other professional fees including,
inter alia, a one-time write off of a provision previously recorded for such
expenses as well as a decrease in headquarters salary expenses. General and
administrative expenses include corporate executive, administrative, legal and
accounting activities, rental expenses and professional fees. General and
administrative expenses related directly to EMI's operations are included in the
cost and expenses of same operations, in accordance with the Single - Step Form,
as described above.
Share in losses of associated companies, net, totaled NIS 12.0 million
($2.6 million) in 2005, compared to NIS 16.0 million in 2004. Such losses are
attributable mainly to EMI's share in losses resulted from the operations of our
venture capital investments: Gamida, Olive and Easyrun, partially offset by net
income deriving from Ercorner (the company holding the Dream Island project).
Finance expenses, net increased to NIS 122.3 million ($26.6 million) in
2005 from NIS 53.6 million in 2004. Such increase resulted from a combination of
the following factors:
63
- In 2005, EMI had an exchange rate differences loss of NIS 20.2 million
($4.4 million) as compared to an exchange rate differences gain of NIS
87.8 million in 2004 which was attributable to:
(i) In 2004, our shopping and entertainment centers segment recorded
an exchange rate differences gain of NIS 76.8 million, generated
mainly by the significant re-valuation (5%) of the Hungarian
Forint in Hungary (which until April 1, 2004 was the functional
currency of the operations in that country), in relation to the
Euro, which is the currency used in financing these activities.
This compares to PC's exchange rate differences losses in 2005
which amounted to NIS 2.1 million, since the Euro is both the
functional currency of PC's subsidiaries and the currency of its
monetary net assets. In addition, in 2005, we had an exchange
rate differences loss of NIS 12.6 million which resulted mainly
from the Arena shopping and entertainment center in Israel as a
result of an evaluation of the US dollar against the NIS which
constitute Arena's functional currency;
(ii) Our hotel segment (mainly its Romanian subsidiary) accrued
exchange rate differences loss amounting to NIS 6.0 million ($1.3
million) in 2005 compared to exchange rate differences gain of
NIS 17.4 million in 2004, attributed to the fluctuations of the
US dollar against the Romanian Lei, being the subsidiary's
functional currency;
(iii) In 2005, we recorded an exchange rate differences loss of NIS
10.3 million ($ 2.2 million), which is attributable to corporate
loans provided to us in foreign currencies (mainly the US dollar)
against the NIS. This compares to an exchange rate differences
gain of NIS 13.0 million in 2004; and
(iv) An increase in our exchange rate differences gain from cash and
bank deposits to NIS 10.8 million in 2005 ($ 2.3 million),
compared to an exchange rate differences loss of NIS 19.4 million
in 2004.
- In fiscal 2005, we incurred interest expenses and a gain/loss from
forward transactions of NIS 102.1 million ($22.2 million) as compared
to NIS 141.4 million in 2004, which was attributable to the following:
(i) In 2005, we recorded a gain from a forward transaction of NIS
14.7 million ($3.2 million) compared to a loss from such
transaction of NIS 14.9 million in 2004; Such forward
transactions were designed in order to hedge payments or proceeds
that should have been paid or received in other currencies and
which for accounting purposes do not constitute hedge
transactions and therefore, their results were recorded in the
statement of operations;
(ii) In 2005, our shopping and entertainment centers segment recorded
interest expenses of NIS 27.3 million ($5.9 million), compared to
NIS 66.4 million in 2004 mainly due to a decrease in the scope of
loans following the sale of the shopping and entertainment
centers;
(iii) Our hotels segment recorded interest expenses of NIS 52.7
million ($ 11.5 million) compared to NIS 35.7 million in 2004,
mainly due to the commencement of operations of the Riverbank
Park Plaza hotel; and
(iv) Interest expenses in respect of our corporate loans less interest
income on our deposits increased to NIS 35.5 million ($ 7.7
million) compared to NIS 24.4 million in 2004. This increase is
mainly attributable to an increase in our scope of loans and
an increase in the basic LIBOR rates for all currencies.
Other expenses, net, in 2005 totaled NIS 57.1 million ($12.4 million)
compared to NIS 51.4 million in 2004. This was the result of:
(i) In 2004 we recorded a gain of NIS 12.4 million deriving from
realization of investment-type monetary balances (i.e.
foreign currency exchange rates results with respect to
shareholder loans provided to our investee company
previously recorded directly as cumulative foreign
currency translation adjustments within shareholder
equity and which, as a result of a repayment of such
shareholder loans, were realized into the statement of
operations). In 2005 EMI did not record such a gain; and
(ii) A provision for loss resulting from expected decline in
EMI's holdings in Elscint due to the probability of
realization of Elscint' shares held by employees under the
Elscint Incentive Plan, which was recorded prior to the
consummation of the merger between EMI and Elscint,
partially offset by a decrease in loss from disposition and
impairment of assets and investments which in 2004 totaled
NIS 64.8 million compared to NIS 46.4 million recorded in
2005 ($10 million). The assets and investments impairment in
2005 included mainly impairment of our hotels and shopping
and entertainment centers and impairment of our investment
in Vcon, which is one of our venture capital investment
companies.
As a result of the foregoing factors, profit before income tax totaled in
2005 NIS 16.2 million ($3.5 million), compared to NIS 24.9 million in 2004.
Certain additional factors affecting our net profit for 2005 and 2004
included the following:
64
(a) income taxes in 2005 totaled NIS 7.8 million ($1.7 million) compared
to NIS 15.8 million in 2004;
(b) minority interest in results of subsidiaries, net, totaled NIS 73.3
million ($15.9 million) compared to NIS 27.4 million in 2004, mainly
resulting from an increase in EMI's share in Elscint's and InSightec's
losses;
The above resulted in profit from continuing operation totaling NIS 81.6
million ($17.7 million) in 2005, compared to NIS 36.5 million in 2004.
(c) profit from discontinuing operations, net, totaled NIS 5.9 million
($1.3 million) in 2005, compared to NIS 6.8 million in 2004; this
profit resulted mainly from the collection of receivables previously
written off and to exchange rate differences income attributable to
monetary assets pertaining to discontinuing operations;
(d) cumulative effect from the application of a new accounting standard,
resulted in loss of NIS 0.6 million ($0.1 million) in 2005;
The above resulted in net profit of NIS 86.9 million ($18.9 million) in
2005, compared to NIS 43.3 million for fiscal 2004.
FISCAL 2004 COMPARED TO FISCAL 2003
Revenues
Total consolidated revenues for fiscal 2004 were NIS 735.9 million compared
to NIS 594.9 million for 2003, an increase of NIS 141 million, or 23.7%.
Revenues from sale of real estate assets and investments, net, for fiscal
2004 were NIS 131.9 million. There were no such transactions in 2003.
Revenues from sale of real estate assets and investments in 2004 derived
from the sale of twelve Hungarian shopping and entertainment centers to
Klepierre in July 2004.
Revenues from shopping and entertainment centers operations for fiscal 2004
were NIS 311.9 million compared to NIS 347.1 million in 2003, a decrease of NIS
35.2 million or 10%. This decrease resulted from the exclusion of the activities
of 12 shopping centers in Hungary, which were sold to Klepierre at the beginning
of the third quarter of 2004, which contributed revenues of NIS 115.5 in the
second half of 2004 compared to NIS 219.0 million in 2003. This decrease was
offset by: (i) an increase in revenues from Arena in the amount of NIS 35
million; Arena commenced partial operations in mid June 2003 while during fiscal
2004 attaining almost full scale operations; (ii) an increase revenues in the
amount of NIS 7 million deriving from the opening of an additional shopping
center in Hungary during 2004; (iii) an increase revenues in the amount of NIS
15 million received by the center's management company (in which EMI then held
50%) during the second half of 2004, from the 12 centers sold to Klepierre; and
(iv) an increase revenues in the amount of NIS 13 million resulting from
currency fluctuations in Hungary and Poland during the fiscal year 2003.
Revenues from hotel operations and management for 2004 were NIS 218.4
million as compared to NIS 189.2 million for fiscal 2003, an increase of NIS
29.2 million or 15%. The increase in revenues resulted from: (i) commencement of
operations of the Aquotopia attraction within the Astrid Park Plaza facilities
in 2004; (ii) higher occupancy rates in Victoria London and the Sherlock Holmes
hotels; and (iii) renovations and operations of additional apartments in our
Centerville apartment hotel in Bucharest during fiscal 2004 and higher occupancy
and rental rates from this hotel.
Revenues from InSightec's sale of medical systems in 2004 were NIS 44
Million. InSightec commenced sales during the first quarter of 2004. The sales
represent sales of 10 "ExAblate 2000" Systems.
Revenues from realization of investments in 2004 were NIS 16.4 million,
compared to NIS 45.1 million in 2003. This decrease was attributable to a
decrease in our shareholding in InSightec amounting to NIS 13.0 million in 2004
and NIS 20.4 in 2003, as well as additional proceeds received from the sale of
our interest in Algotech totaling NIS 3.4 million in 2004 compared to gain
derived from the consummation of this sale of NIS 24.7 million in 2003.
Other operational income consists of revenues deriving from hotel leasing
in 2004 of NIS 13.2 million as compared to NIS 13.5 million for 2003.
65
Profits before Income Taxes
SET FORTH IS AN ANALYSIS OF THE PROFITS BEFORE INCOME TAX: Profit from the
sale of real estate assets and investments is presented in net, after cost of
assets or investments sold; therefore, the profits from such sales are equal to
the revenues derived therefrom.
Revenues from shopping and entertainment centers operations less costs and
expenses related to such revenues in 2004 was NIS 40.5 million compared to NIS
89.1 million in 2003. This decrease was mainly due to the sale of the activities
of 12 shopping centers in Hungary, which were sold to Klepierre at the beginning
of the third quarter of 2004.
Revenues from hotel operations less costs and expenses related to such
revenues in 2004 was NIS 11.2 million compared to NIS 0.5 million in 2003. This
increase resulted from increase in revenues of the hotel segment and improved
efficiency in our costs of revenues of this segment.
Revenues from sale of medical systems less costs and expenses related to
such revenues in 2004 was NIS 18.0 million compared to costs and expenses of
medical systems less revenues from sale of medical systems of NIS 8.7 million in
2003. This increase was attributed to an increase in revenues from the sales of
such systems. The costs and expenses related to medical systems operations in
fiscal 2003, consists mainly of general and administrative expenses recorded in
accordance with the Single - Step Form described above.
Profit from realization of investments is presented net, after cost of the
investments sold and therefore, the profit from such item is equal to the
revenues derived therefrom.
Revenues from sale of other operational income less costs and expenses
related to such revenues in 2004 resulted from the lease of assets.
Research and development expenses, net in 2004 totaled NIS 38.2 million
after deducting NIS 7.7 million granted by the OCS, compared to NIS 43.7 million
in fiscal 2003, after deducting NIS 7.5 million granted by OCS. All research and
development expenses derived from InSightec's operations.
General and administrative expenses, increased in 2004 to NIS 43.8 million
from NIS 42.1 million in the corresponding period of the previous year.
Share in losses of associated companies, net, totaled NIS 16.0 million in
2004, compared to NIS 21.0 million in 2003 mainly resulted from the operations
of our venture capital investments: Gamida, Olive and Easyrun, partially offset
by net income deriving from Ercorner (the company that owns the Dream Island
project). Due to the fact that from the fourth quarter of 2003, the investment
in Vcon is stated on a cost basis, the Company has not recorded any equity
income or loss regarding Vcon since that date.
Financing expenses, net in 2004, totaled NIS 53.6 million as compared to
NIS 211.8 million in 2003, a decrease of NIS 158 million. Such decrease resulted
from a combination of the following factors:
In 2004, EMI had exchange rate differences gain of NIS 87.8
million compared to exchange rate differences loss of 67.1
million in 2003, which was attributable mainly to an exchange
rate differences gain of NIS 76.7 million recorded by our an
shopping and entertainment segment in 2004, which were generated
mainly by the significant re-valuation of the Hungarian Forint
(which until April 1, 2004 was the functional currency of the
operations in that country), in relation to the Euro, which is
the currency used in financing these activities. This compared to
exchange rate differences expense losses of NIS 100.9 million in
2003 which were incurred due to substantial currency devaluation
(net of inflation) in Hungary and Poland, partially offset by:
(i) EMI's hotel segment (mainly its Romanian subsidiary) accrued an
exchange rate differences gain of NIS 17.5 million in 2004
compared to accrued exchange rate differences gain of NIS 27.1
million in 2003, attributed to the fluctuations of the US dollar
(being the Romanian's subsidiary net monetary assets currency)
against the Romanian Lei; and
(ii) Exchange rate differences loss in 2004 attributable to our
corporate loans and deposits totaled NIS 6.4 million, which
resulted mainly from fluctuations in the exchange rates of
currencies financing the operations of the Company (mainly
exchange rate of the US dollar against the NIS). This compares
with an exchange rate gain of NIS 8.6 million in 2003.
- In 2004, we incurred interest expenses of NIS 141.4 million as
compared to NIS_144.7 million in fiscal 2003, which was attributable
mainly to the decrease in interest expenses in 2004 accrued on Plaza
Center's bank loans, totaling NIS 55.0 million compared to NIS 81.5
million in 2003, which was primarily a result of a reduction in the
amount of outstanding loans due to the exclusion of the activities of
12 shopping centers in Hungary that were sold to Klepierre during the
third quarter of 2004. This was partially offset by:
66
(i) Increase in interest expenses of our hotels segment amounting to
NIS 35.7 million in 2004 compared to NIS 27.7 million in 2003,
mainly due to an increase in the scope of loans of this segment
as a result of new refinance loans; and
(ii) Increase of Arena's accrued interest expenses of NIS 11.4 million
in 2004 compared to NIS 6.4 million in 2003, mainly due to the
fact that Arena commenced operation in mid June 2003 and did not
accrue interest expenses in its statement of operations in the
first half of 2003; and
(iii) Decrease in our interest income from bank deposits to NIS 4.6
million in 2004 compared to NIS 11.2 million in 2003 mainly due
to a decrease in the amount of deposits held by EMI.
Other expenses, net, in 2004 totaled NIS 51.4 million compared to NIS 10.5
million in 2003. This was as a result of: (i) gain of NIS 12.4 million recorded
in 2004 from realization of investment type monetary balance in investees (i.e.
foreign currency exchange rates results with respect to shareholder loans
provided to our investee company previously recorded directly as cumulative
foreign currency translation adjustments within shareholder equity and which, as
a result of a repayment of such shareholder loans, were realized into the
statement of operations), compared to a gain of NIS 32.3 million in 2003
resulting from such realization; and (ii) an increase from disposition and
impairment of assets and investments in 2004 totaling NIS 64.8 million, compared
to NIS 38.0 million recorded in 2003.
As a result of the foregoing factors, profit before income tax totaled in
2004 NIS 24.9 million compared to loss before income tax NIS 193.0 million in
2003.
Additional factors affecting EMI's net profit for 2004 and 2003 are as
follows:
(a) income taxes in 2004 totaled NIS 15.8 million compared to tax
benefit of NIS 20.2 million in 2003;
(b) minority interest in results of subsidiaries, net, totaled NIS
27.4 million compared to NIS 48.7 million in 2003, mainly
resulting from increase in EMI's share in Elscint's and
InSightec's losses;
The above results in profit from continuing operations totaling NIS
36.5 million in 2004, compared to loss therefrom of NIS 124.2 million
for 2003.
(c) profit from discontinuing operation, net, totaled NIS 6.8 million
in 2004, compared to NIS 12.1 million in 2003; this profit
resulted mainly from the collection of receivables previously
written off and to exchange rate differences for income
attributed to monetary assets pertaining to discounting
operations;
The above results in net profit of NIS 43.3 million in 2004, compared to
loss NIS 112.1 million for 2003.
B. LIQUIDITY AND CAPITAL RESOURCES
GENERAL
Our capital resources include the following: (a) lines of credit obtained
from Israeli banks; (b) proceeds from sales of assets; (c) financing margins
resulting from the refinancing of loans extended to the subsidiaries building
the centers; (d) private issuance of non-convertible debentures and shares; and
(e) available cash and cash equivalents. Such resources are used for one or more
of the following purposes:
(i) equity investments in our centers and hotels constructed by our
wholly owned and jointly controlled subsidiaries (special purpose
entities that are formed for the construction of the various
centers and hotels ("Projects Companies")). We generally finance
approximately 25%-30% of such projects through equity investments
in the Project Companies, while the remaining 70%-75% is financed
through a credit facility secured by a mortgage of the project
constructed by the respective Project Company, registered in
favor of the financial institution that provide such financing.
The equity investments in the Project Companies are typically
provided by us through shareholder loans that are subordinated to
the credit facilities as therein provided;
(ii) additional investments in InSightec if necessary;
(iii) additional investment in our investees (mainly venture capital
investments); and
(iv) other investments such as project initiation.
InSightec's capital resources are obtained primarily from additional
investments in equity or in convertible notes by its shareholders and from its
revenues from sale of medical systems. Such amounts are used for research and
development activities aimed at obtaining FDA approvals for further treatments
and other general corporate expenses such as cost of revenues, marketing and
selling and general and administrative expenses.
67
LIQUIDITY
The followings items elaborate on the major transactions and events carried
out by EMI in 2005 and onwards, which resulted in material changes in EMI's
liquidity:
Sources of Cash from Major Transactions and Events - 2005 and 2006 to Date:
- On July 29, 2005, PC sold four operational shopping centers in
Poland, to Klepierre for a net cash consideration of E73.8
million ($88.7 million). The net cash consideration reflected the
sold centers' asset value as at the closing, after deduction of
bank loans and other working capital items of the sold centers
(the "first stage"). In accordance with the terms of the
agreement, an adjustment of the purchase price was set to be
conducted on the basis of the gross rentals as of December 31,
2005 (in respect of one shopping center - as of a date up to May
31, 2006), and a net asset value adjustments based on the audited
financial statements of the Sold Centers. As of the date of this
annual report such adjustments have not yet been made and we
believe that following such adjustments EMI will generate an
additional net cash consideration of E15 million.
- In April 2005, PC sold four shopping and entertainment centers in
certain peripheral cities in Hungary to Dawny Day Europe for a
net consideration of E17.2 million ($20.3 million). The net cash
consideration reflects the asset value of the sold centers after
deduction of bank loans and other working capital items of the
sold centers. We undertook within the framework of the agreement
to guarantee achieving of certain operational targets of one of
the sold centers, for a period of 3 years until December 31,
2007, which is estimated to total E1.3 million.
- On December 19, 2005, Elscint has sold its entire 30% interest in
the company owning the Shaw Hotel for net consideration of
E5.5 million ($6.5 million)
- Within the framework of an agreement signed between PC and
Klepierre in July 2004 for the sale of 12 shopping and
entertainment centers in Hungary, PC has provided Klepierre with
a bank guaranty in order to secure certain revenues achievements
of the sold centers. In the framework of the agreement signed
between PC and Klepierre in July 2005, as described above,
Klepierre released the guaranty unexercised, and PC received an
additional cash consideration from Klepierre which amounted to
E7.6 million ($9.0 million). In addition, in accordance with the
agreement signed with Klepierre in July 2004, PC deposited E6.8
million ($8.2 million) in an escrow account in order to secure
certain tax conditions set forth in the sale agreement, which
have been released to us in March 2005.
- In 2005, we continued our investments in those shopping and
entertainment centers and hotels, which are under construction,
through grants to our project companies totaling approximately
E24 million ($28 million).
- On March 2, 2006, through our jointly controlled subsidiaries,
which hold three hotels in the United Kingdom ("Holding
Companies"), we executed a refinance loan agreement together with
Park Plaza. The Holding Companies and Park Plaza are jointly and
severally borrowers under the agreement, while our share in the
loan amounted to L97.5 million ($168 million) ("Refinancing
Loan"). The Refinancing Loan bears annual interest of Libor + 3%
and is repayable over a five-year period with an option to extend
such term to seven years, subject to fulfillment of certain
condition as stipulated in the Refinancing Loan.
In the event of cash distributions deriving from the sale,
disposal or refinancing of the hotels which were financed by the
refinancing loan funds ("Transactions"), the Borrowers are
required to pay to the financing bank an amount equivalent to 15%
of the difference between the market value of the hotels as
determined in such Transactions and the value of the hotels as
set and agreed upon for the purposes of the Refinancing Loan.
The Refinancing Loan proceeds were first used for the repayment
of outstanding loans previously granted to the Holding Companies,
in which our share amounted to L60 million ($104 million).
The Holding Companies have transferred to us the surplus of the
credit-received totaling L30.6 million ($52.7 million) out of
which, L16.7 million ($28.7 million) was used to repay bank loans
that financed our equity investments in the Holding Companies.
- In February, March and June 2006, we issued unsecured
non-convertible debentures totaling NIS 527 million ($114
million) to Israeli investors. The debentures consist of two
series: Series A Debentures, in a principal amount of NIS 468.0
million ($101.7 million), bear annual interest of 6% and are
linked (principal and interest) to the increases in the Israeli
CPI. Series B Debentures, in a principal amount of NIS 59.0
million ($12.6 million), bear annual interest of LIBOR plus 2.65%
and are linked (principal and interest) to the US
68
dollar. The principal amount of Series A and Series B Debentures
are repayable in equal 10 semi-annual installments, commencing
August 2009. The Series A and Series B debentures also provide
that the debentures will be prepaid by us at the option of the
trustee or the holders of the debentures if our securities are
de-listed from trade on both the Tel Aviv Stock Exchange and on
Nasdaq Global Market. We have undertaken to use our best efforts
to register the two series of debentures for trade on the Tel
Aviv Stock Exchange not later than August 30, 2006. So long as
the debentures are not registered for trade on the Tel Aviv Stock
Exchange, we have undertaken: (i) to pay an additional interest
at a rate of 0.3% per annum; (ii) not to make any distribution as
defined in the Israeli Companies Law to our shareholders which
does not comply with the profit and solvency tests provided in
section 302(a) of the Companies Law, unless such distribution is
approved at the general meeting of holders of each series of
debentures by an unanimous vote of all holders participating in
the vote; (iii) to pre-pay the debentures at the option of the
trustee or the holders of the debentures upon the occurrence of
any of the following events: (a) the rating of the debentures in
Israel decrease in Baa2 (the equivalent rating of BBB); or (b)
the holding of Europe-Israel in us drops below 25% of our issued
share capital. Such undertaking will be terminated upon the
registration for trade of the debentures on the Tel Aviv Stock
Exchange.
- On May 17, 2006, Elscint sold through a private transaction,
524,187 dormant shares of EMI in consideration for NIS 115 per
share, generating net cash consideration of NIS 60.2 million
($13.1 million).
- On June 11, 2006, EMI issued to Israeli investors additional
series A unsecured non-convertible debentures, in an approximate
aggregate amount of NIS 68 million ($14.7 million).The newly
issued series A debentures have same terms as those governing the
previously issued series A debentures, as described above.
Use of Cash from Major Transactions and Events - 2005 and 2006 to
Date:
- On March 17, 2005, we distributed to our shareholders a dividend
in the amount of NIS 153.9 million ($34.5 million).
- On January 17, 2006, the Company distributed to its shareholders
a dividend in the amount of NIS 130.0 million ($28.2 million).
The following table sets forth the components of our cash flows statements
for the periods indicated:
YEAR ENDED DECEMBER 31,
-----------------------------------------------
2005
Convenience 2005 2004 2003
Translation NIS NIS NIS
----------- --------- --------- ---------
US $ Thousands Thousands Thousands
Net cash used in operating activities .. (21,531) (99,108) (21,562) (8,333)
Net cash provided by investing
activities .......................... 1,194 5,496 128,481 131,443
Net cash provided by (used in)
financing activities ................ 52,950 243,727 75,872 (174,995)
Net effect on cash due to changes in
currency exchange rates ............. (1,416) (6,516) (522) 3,959
Increase (decrease) in cash and cash
equivalents ......................... 31,197 143,599 182,269 (47,926)
Cash flow from operating activities
Net cash used in operating activities for fiscal 2005 was NIS 99.1 million
($21.6 million), as compared to NIS 21.5 million for fiscal 2004. This increase
in net cash used in operating activities, in the amount of NIS 77.5 was mainly
due to the following:
a decrease of NIS 116.0 million ($25.0 million) in PC's net cash provided
by its operating activities, which resulted mainly from (i) the sale of the
activities of 12 shopping centers in Hungary, which were sold to Klepierre at
the beginning of the third quarter of 2004; (ii) the sale of the activities of
four operational centers in Hungary which were sold to Dawny Day at the
beginning of the second quarter of 2005; and (iii) the sale of the activities of
four operational centers in Poland which were sold to Klepierre at the beginning
of the third quarter of 2005.
69
This was offset by:
(i) Cash flow in respect of gain from derivative financial
transactions of NIS 14.7 million ($3.1 million) in 2005
compared to loss from such transactions of NIS 13.5 million
in 2004. Consequently, the total change in cash flow from
our operating activities deriving from these transactions
amounted to NIS 28.2 million.
(ii) A decrease in the amount of NIS 15 million in InSightec's
net cash used for its operating activities as a result of an
increase in revenues generated from the sales of medical
systems.
Cash flow from investing activities
Cash flow from investment activities decreased to NIS 5.5 million ($1.1
million) in 2005 from NIS 128.5 million in 2004. This decrease was mainly
attributable to the following:
- an increase in the purchase of fixed assets to NIS 435.8 million
in 2005 from NIS 373.5 million in 2004 mainly in respect of the
construction of our shopping and entertainment centers in Poland
and the Czech Republic and the construction of the Riverbank
hotel in London.
- an increase in our investments in subsidiaries which were first
acquired and consolidated in 2005 to NIS 117.7 million ($25.6
million) from NIS 35.5 million. Such investments in 2005 are
attributed mainly to (a) the purchase of the remaining 50% not
owned by EMI in Sadyba; (b) the purchase of the entire equity and
voting right in Kerepesi; and (c) the purchase of the entire
equity and voting rights of Mango. This was partially offset by
an increase in the proceeds from sale of real estate assets and
investments to NIS 524.5 million ($113.9 million) in fiscal 2005
compared to NIS 412.0 million in 2004.
- A decrease in the proceeds from the sale of fixed assets and
investments to NIS 7.8 million ($ 1.7 million) in 2005 from NIS
59.3 million in 2004; and (iv) a decrease in realization of short
and long term deposits to NIS 37.5 ($ 8.1 million) million in
2005 from NIS 60.0 million in 2004.
Cash flow from finance activities
Cash flow from financing activities increased to NIS 243.7 million ($53.0
million) in fiscal 2005 from NIS 75.9 million in 2004. Such increase was
attributable to (i) receipt of long term bank loans - net of repayment of such
loan - of NIS 365.7 million ($79.5 million) compared to NIS 218.4 million in
2004. The proceeds from these new bank loans were used mainly for the
construction and/or purchase of our shopping and entertainment centers and
hotels; (ii) a dividend payment in fiscal 2005 of NIS 153.9 million ($33.4
million) with no such distribution in 2004 although in fiscal 2004 EMI had
acquired its shares in a total amount NIS 138.9 million with no similar purchase
in 2005; and (iii) the issuance of convertible debentures by InSightec of NIS
60.2 million in 2004 with no such issuance in 2005.
Major balance sheet changes
Major balance sheet items as a percentage of total assets as at December
31, 2005 and 2004 were as follows:
DECEMBER 31,
------------
2005 2004
---- ----
Current assets........................... 23% 16%
Current liabilities...................... 18% 18%
Long-term Investments and fixed assets... 76% 82%
Long-term liabilities.................... 50% 54%
Minority Interest........................ 0.3% 10%
Shareholders' equity..................... 28% 18%
Hotels, shopping and entertainment centers and other fixed assets decreased
by NIS 0.8 billion, to NIS 2.7 billion ($0.6 billion) at December 31, 2005 from
NIS 3.5 billion at December 31, 2004. This decrease derived primarily from: (i)
the sale of the centers to Klepierre; (ii) the sale of the centers to Dawny Day;
and (iii) the sale of the Shaw hotel. This decrease was partially offset by the
continuing investments in the shopping and entertainment centers and hotels
under construction in Europe.
Short-term credits and long term debt decreased to NIS 2,363 million
($513.3 million) at December 31, 2005 from NIS 2,956 million at December 31,
2004. The decrease in borrowings resulted primarily from repayment of long term
loans which used to finance the centers and the hotels that were sold during
2005, and the decrease wasoffset somewhat by loans obtained for the financing of
new centers and hotels.
70
Based on management's internal forecasts and assumptions relating to our
operations, that our existing cash and funds generated from operations, together
with the proceeds from the sale of assets and together with our existing
financing agreements, will be sufficient to meet our working capital and capital
expenditure requirements for the completion of those projects whose construction
has already commenced. In the event that our plans change, our assumptions
change or prove to be inaccurate, business conditions change, or if other
capital resources and projected cash flow otherwise prove to be insufficient to
fund our operations (due to unanticipated expenses or other unforeseen events),
we may be required to reduce our operating expenses or use more of our cash
reserves to fund operating expenses. In addition, we may need to seek additional
financing sooner than currently anticipated. We have no current arrangements
with respect to sources of additional financing and there can be no assurance
that we will be able to obtain additional financing on terms acceptable to us,
if at all.
Concentration of Credit Risk
Cash and amounts on deposit in Israel and abroad are deposited in banks.
For information on composition of the short and long-term investment portfolio,
see Notes 4 and 8 to our consolidated financial statements included in Item 18.
Such investments are exposed to market-price fluctuation, with the group
affected by fluctuation of the Israeli capital market, over which the group has
no control. Such changes may have an impact on the value of these investments
upon realization.
EMI and most of its investee companies (the "Group Companies") are not
materially exposed to credit risks stemming from dependence on a given customer.
The Group Companies examine, on an ongoing basis, the amount of credit extended
to their customers and, accordingly, record a provision for doubtful accounts
based on those factors affecting credit risks of certain customers in the
opinion of these companies' management.
As for sale transactions with Klepierre, see "Item 10. Additional
Information - C. Material Contracts - Shopping and Entertainment Centers" below.
In 2003, the Israeli Bank Controller instituted new regulations governing
lending by Israeli banks to groups of affiliated borrowers. Under these
regulations, the banks are limited in their maximum exposure to groups of
affiliated companies under a combined lending ceiling based on objective and
subjective guidelines. As a result, our borrowing capacity may be limited under
certain circumstances even if we have unused lines of credit, due to borrowing
by companies affiliated with shareholders that are defined by the Controller of
the Banks as controlling shareholders of EMI. In anticipation of such
developments, we are developing credit facilities that will not be affected by
the new regulations.
DERIVATIVE INSTRUMENTS
For information on financial instruments used, profile of debt, currencies
and interest rate structure, see "Item 11. Quantitative and Qualitative
Disclosure About Market Risks" below.
OTHER LOANS
A. We have entered into or assumed liability for various financing agreements,
either directly or indirectly through our subsidiaries, to provide capital for
the purchase, construction, and renovation and operation of shopping and
entertainment centers and hotels as well as for various investments in our other
segments of operations. In our opinion, our working capital is sufficient for
our current requirements; however, our subsidiaries will continue to borrow
funds from time to time to finance their various projects. Set forth below is
certain material information with respect to loans extended to EMI, its
subsidiaries and its jointly controlled companies as of December 31, 2005. The
loans granted to our jointly controlled companies are presented in the table at
their full value:
71
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING AS PRINCIPAL SECURITIES AND
BORROWER AND LENDER OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS COVENANTS
------------------- ----------------------- ---------------- ---------------------- ------------------------------
Borrower: Loan: $58 million Libor + 3.35% Loan for 10 years to Principal Securities:
EMI be repaid by 2013, in First ranking pledge on the
Amount outstanding: 18 equal semi-annual entire shares of PC and on
Lender: $50.7 million. installments, 615,500 shares of Elscint
Bank Hapoalim B.M. ($21 million + EURO 29 commencing on June 30, (approximately 3.5% of
million) 2004. Elscint's share capital).
Available amount: 0 Interest payment will PC's guarantee.
occur twice a year
commencing on December Principal Financial Covenants:
31, 2003 Adjusted Shareholder's Equity
shall represent at least 20%
of the Adjusted Balance Sheet
Value.
Net Operating Profit (before
deductions for depreciation
and amortization relating to
net operating profit) shall
be at each June 30 of every
year no less than NIS 120
million.
In the event of (i) the net
loan amount is $30 million;
(ii) the total amount
outstanding under the Europe
Israel loan agreement is less
than $30 million; and (iii)
there has been no event of
default under the loan
agreement, the above
financial covenants shall not
apply.
For a waiver provided by
lender with regard to the
financial covenants and other
issues, see "other
information".
Borrower: Loan: $25 million Libor + 3.35% Loan for 10 years to See above.
Elbit Ultrasound be repaid by 2013, in
(Netherlands) B.V. Amount outstanding: 18 equal semi-annual
(our subsidiary) EURO 15.2 million ($18 installments,
million) commencing on June 30,
2004
Lender: Available amount: 0
Bank Hapoalim B.M. Interest will be paid
twice a year
commencing on December
31, 2003
Borrower: Short term credit Libor + 3.35% Renewal every three
EMI facility $10 million months.
72
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING AS PRINCIPAL SECURITIES AND
BORROWER AND LENDER OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS COVENANTS
- ---------------------- ----------------------- ---------------- ---------------------- -----------------------------
Lender: Amount outstanding:
Bank Hapoalim B.M. $10 million
Available amount: 0
Borrower: Amount outstanding Libor + 2.5% / Renewal every 6 Principal Securities:
InSightec Ltd NIS equivalent of $5.1 or Prime + 1.1% months subject to EMI's guarantee for up to $5
million EMI's guarantee. million.
Lender:
Bank Hapoalim B.M. Liens on InSightec's MRI
system and ExAblate 2000
system installed at Sheba
Medical Center.
Borrower: Credit line of $19.1 Libor + 3.35% Renewal every 3 Principal Securities:
EMI million months. First ranking pledge of cash
deposit and securities in an
Bank Leumi Le-Israel Amount outstanding: aggregate amount of $3
Ltd. $19.1 million million.
Available amount: 0 Negative pledge over
Elscint's shares.
Borrower: Loan: $10 million will be agreed Credit will expire on Principal Securities:
InSightec Ltd by the parties June 30, 2006 First ranking pledge over the
Amount outstanding: 0 and will be entire assets of InSightec.
Lender: paid on a
Bank Leumi Le-Israel Available Amount: $10 monthly basis. First ranking pledge and
Ltd. million assignment on all rights in
the ExAblate 2000 installed
in the Shiba hospital.
Borrower: Loan: EURO 39.3 Euribor + 60% of the principal Principal Securities:
Movement Poland S.A million margin ranging to be repaid in 40 First ranking mortgage on the
from 1.5% to quarterly payments. shopping and entertainment
Lender: Amount outstanding: 0 1.9% per annum. 40% of the principal center.
Kredytbank S.A. to be repaid in one
Available amount: EURO installment at final First ranking pledge on
Project: 39.3 million repayment date (no shares of Borrower, on all of
Lublin Plaza later than March 31, its accounts and on all
2017). present and future assets
The first repayment Assignment of securities
date shall occur after (insurance, lease, hedging
a nine-month period agreement, management
commencing on the agreements, project
completion date. documents, accounts etc.) to
During the lender.
availability period
the interest will be Cost Overruns Guarantee by PC
paid on a monthly and Sol-or Holding Management
basis and thereafter Ltd. (shareholders of
in quarterly Borrower).
installments.
Corporate guarantees by PC
and Sol-or which maybe
revoked upon certain terms.
73
AMOUNT OF
LOAN AND AMOUNT
OUTSTANDING AS OF
BORROWER AND LENDER DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS PRINCIPAL SECURITIES AND COVENANTS
- ---------------------- ----------------------- ---------------- ------------------------- ----------------------------------
Principal Financial Covenants:
Debt Service Cover Ratio is not
less than 1.15.
The Loan to the Property's Value
Ratio shall not be less than 80%.
Such percentage decreases over the
years up to 50%.
Loan to Equity Contributions ratio
shall not be higher than 80:20.
Borrower: Loan: PLN equivalent of Euribor + 1.4% Either: Principal Securities:
Movement Poland S.A EURO 8.5 million per annum. on each interest payment Second ranking mortgage on the
date by any VAT refund center.
Lender: Amount outstanding: 0 amount standing on that
Kredytbank S.A day Assignment of VAT refunds.
or
Project: Available amount: PLN one day after the date
Lublin Plaza. equivalent of EURO 8.5 when relevant VAT refund Pledge on bank accounts.
million is received from the tax
office
Borrower: Loan: EURO 24.7 million EURIBOR + margin 60% of the principal to Principal Securities:
Rybnik Plaza sp.z.o.o. ranging from be repaid in 40 quarterly First ranking mortgage on the
Amount Outstanding: 0 1.45% to 1.95% payments. 40% in one property.
Lender: per annum. installment at final
Kredytbank S.A. Available amount: EURO repayment date (no later Assignment of current and future
24.7 million than Jun 30, 2017) leases of relating insurance
Project: agreements, of all rights under
Rybnik Plaza the development contracts and the
receivables under the performance
bonds.
Pledge on shares of borrower and
over the receivables under the
project's accounts.
PC's cost overruns guarantees.
PC's corporate guarantee (until
income level of 2.5 million EURO
is reached).
Principal Financial Covenants:
The Debt Service Cover Ratio shall
be no less than 1.15 during each
quarter.
74
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING AS
BORROWER AND LENDER OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS PRINCIPAL SECURITIES AND COVENANTS
- ---------------------- ----------------------- ------------------- -------------------------- ----------------------------------
Loan to Asset's Value Ratio shall
not be less than 80%. Such
percentage decreases over the
years up to 50%.
Loan to Equity Contributions
ratio shall not be higher than
80:20.
Loan shall not exceed 80% of the
project budget.
Borrower: Loan: The PLN Euribor + 1.4% per VAT amounts refunded by Principal Securities:
Rybnik Plaza sp.z.o.o. equivalent of EURO annum. the tax office on the last Second ranking mortgage on the
6.2 million day of a given interest mall.
period. Remaining Registered pledge on the
Lender: Amount Outstanding: 0 outstanding facility will borrower's assets
Kredytbank S.A. be repaid not later than Assignment of VAT refunds
Available amount: The nine months after the end
Project: PLN equivalent of of construction period,
Rybnik Plaza EURO 6.2 million however, no later than
September 30, 2007.
Borrower: Loan: EURO 27.4 million Euribor + margin 55.5% of the principal to Principal Securities:
Bestes s.r.o ranging from 1.4% be repaid in 40 quarterly First ranking mortgage on the
Amount outstanding: to 2%. installments. 45.5% in one mall.
Lender: EURO 16.8 million installment on final
MKB Bank Rt. And repayment date (latest on Assignment of leases in
Investkredit Available amount: EURO 31.12.2015) mall, of the construction
10.6 million agreements and the construction
warranties.
Project: Pledge over bank accounts, over
Novo Plaza insurance, over all present and
future assets and on the
Borrower's shares and on
Entertainment Plaza's shares.
PC cost overrun guarantee
Principal Financial Covenants:
Debt Service Cover Ratio shall not
be lower than 115%.
The Loan to Cost Ratio (i.e.
actual loan divided by budget of
construction) shall not be higher
than 75% during the term of the
construction.
The Loan to the Property's Value
Ratio shall no be higher than 75%.
75
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING
BORROWER AND LENDER AS OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS PRINCIPAL SECURITIES AND COVENANTS
- ---------------------- ----------------------- ------------------- -------------------------- ----------------------------------
Borrower: Loan: EURO 7.5 million Euribor + 1.75% per Principal will be paid in Principal Securities:
Praha Plaza s.r.o annum. 48 quarterly payments of First ranking mortgage on the
Amount outstanding: EURO 117,200, beginning on property.
Lender: EURO 6.9 million December 31st, 2004. The
Erste Bank AG remaining amount will be First ranking pre-emption right
Available amount: 0 paid in one installment on regarding the property in favor of
Project: December 31st, 2016. the lender.
Praha Plaza Commercial
Complex Interest will be paid on Pledge on shares of Borrower, on
the last day of each accounts, on receivables from the
interest period (3 months) lease agreements.
commencing utilisation
date or on the last day of Assignment of insurance.
its preceding interest
period. Principal Financial Covenants:
Maintenance of Debt Service Cover
Ratio of 1.15 or higher.
Undertaking to refill the debt
service reserve account in the
event it is reduced below a
certain minimum.
Loan to the Property's Value Ratio
shall not exceed 80%.
Borrower: Loan: EURO 3.5 million Euribor + 1.85% per Repayment in ten Principal Securities:
Tatabanya Plaza Kf.t. annum increasing installments. Pledge on quotes of Tatabanya
Amount outstanding: Last repayment done on Plaza.
Lender: EURO 1.4 million September 30, 2006.
MKB Bank Rt. Suretyship of PC.
Available amount: 0
Pledge over shares of Helios Plaza
(our subsidiary).
Borrower: Loan: EURO 10.5 million Euribor + margin Repayment in 40 increasing Principal Securities:
Tatabanya Plaza Kft ranging form 1.5% installments. Final PC guarantee (until mortgage is
Amount outstanding: to 1.8% (depending repayment date is on July registered).
Lender: EURO 5.9 million on the registration 31 2015 where a bullet
MKB Bank Rt. of the first rank payment of 43.5% of the Mortgage on the project site
Available amount: EURO mortgagae and on principal is due. following the de-merger
4.5 million debt service cover
ratio level). + Charge over borrower's shares, on
associated costs bank accounts
Assignment of insurance, of all
rental revenues of the project
Following the establishment of the
76
AMOUNT OF LOAN AND AMOUNT
OUTSTANDING AS OF PRINCIPAL
BORROWER AND LENDER DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS SECURITIES AND COVENANTS
- ---------------------- ------------------------- ------------------- ----------------------- -------------------------------
security provider, PC shall
enter into a security deposit
agreement establishing a
security deposit on the shares
of the security provider.
Principal Financial Covenants:
Debt Service Cover Ratio shall
not be less than 1.15.
Borrower: Loan: EURO equivalent of Euribor + 2% per Repayment done in 8 Principal Securities:
Szombathely 2002, Kft. HUF 1 billion (EURO 3.9 annum. equal installments First ranking mortgage on land
million) (principal + interest). in Lodz, Poland.
Lender: Final repayment date is
MKB Bank Rt. Amount outstanding: EURO 15.07.2007. Pledge on quotas of the
3.4 million Borrower and on bank accounts.
Available amount: 0 Principal Financial Covenants:
Decrease in the business volume
of more than 15% may result in
the decrease of the loan.
Borrower: Loan: EURO 2.8 million Euribor + 1.35% per Loan expires on Principal Securities:
Plaza House Kft. (our annum. 30.05.2011. Repayment First ranking mortgage on all
subsidiary) Amount outstanding: EURO done through quarterly assets of the borrower
1.7 million payments of EURO 64,920 including the building.
Lender:
HVB Bank Hungary Rt. Available amount: 0 Assignment of claims, lease
agreements, insurance; pledge
Project: on shares.
Plaza House
PC guarantee for 0.5 million
EURO.
Principal Financial Covenants:
Debt Service Cover Ratio
shall be at least 1.10.
Borrower: Loan: EURO 19 million Euribor + 1.65% per Each Borrower shall Principal Securities:
Kerepesi 2 and annum. repay the loan made to First ranking mortgage on land.
Kerepesi 3' Kft. (our Amount outstanding: EURO it in one lump sum on
subsidiaries) 19 million the 15th November 2006. Negative pledge over the
borrowers' assets.
Lender: Available amount: 0
MKB Bank Rt. And On demand guarantee of kerepesi
OTP Bank Rt 4 and kerepesi 5 (our companies
that own adjacent plots).
Project:
Arena Plaza (Kerepesi)
77
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING AS PRINCIPAL
BORROWER AND LENDER OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS SECURITIES AND COVENANTS
- ------------------- ---------------------- ------------------- -------------------------- -----------------------------
Borrower: Loan: EURO 7.5 million Euribor + 2.0% p.a. Interest will be paid on a Principal Securities:
Helios Plaza Real Estate quarterly basis. First ranking mortgage on
and Development Company Amount outstanding: Renewal every quarter. land.
S.A. (our subsidiary) EURO 7.5 million
Lender: Available amount: 0
Pireos Bank (Athens)
Borrower: Loan: $46 million LIBOR + 2.5% The financing banks have Principal Securities:
S.L.S Sails Ltd. informed us in writing as First ranking pledge on the
Amount outstanding - to their consent to extend land and the shopping center.
Lender: $46 million the term of this credit
Bank Discount Le'Israel facility until January 1, First ranking fixed lien on
Ltd. Available amount: 0 2007. shares of the subsidiary that
owns the rights to the land.
Project:
Arena (Herzliya, Israel) Floating lien on the assets
of the subsidiary that owns
the rights to the land.
Fixed and floating lien on
the assets of the owning
subsidiary, on the land, the
Arena project and on rights
with respect to current and
future tenants and debtors in
connection with the Arena
project.
Lien on the bank account of
the Arena project.
A corporate guarantee by
Elscint.
Negative pledge with regard
to the assets relating to the
project.
Borrower: Loan: EURO 5.6 million 3.35% Renewal every quarter. Principal Securities:
Plaza Centers (Europe) Cash deposit
B.V. Amount outstanding:
EURO 5.6 million
Lender:
Bank Winter & Co. AG Available amount: 0
78
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING AS PRINCIPAL SECURITIES AND
BORROWER AND LENDER OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS COVENANTS
------------------- ----------------------- ---------------- ---------------------- -----------------------------
Borrower: Loan: $3.75 million Libor + 1.9% Repayment done in 40 Principal Securities:
Plaza Centers (Europe) per annum. quarterly installments Mortgage on the aircraft.
B.V. Amount outstanding: $ of USD 53.750
3.6 million principal plus a Assignment of insurance.
Lender: bullet payment of USD
GEFA GmbH Available amount: 0 1.600.000 at the final
repayment date on June
23, 2014.
Borrower: Loan: EURO equivalent Euribor + 2% Repayment is due in 1 Principal Securities:
Ercorner Kft. of HUF 3,680,000,000 amount on March 31, First ranking Mortgage right
(EURO 14.76 million) 2007. on the real estate.
Lender:
Magyar Kulkereskedelmi Amount outstanding: Pledge on quotas of the
Bank Rt. EURO 12.7 million borrower and Dream Island.
Project: Available amount: 0 Pledge on bank accounts.
Dream Island Project
Assignment of insurance.
Option right on the real
estates granted by Dream
Island in favor of the bank.
Suretyship of Dream Island
and of EMI.
PC's guarantee.
Security assignment of all
revenues of Dream Island.
Principal Financial Covenants:
The Loan-Minus-The-Equity to
Value ratio shall not exceed
53%.
Borrower: Loan: Libor of Tranch A: 50% will be Principal Securities:
Elscint Ltd. relevant paid in 2 semi-annual First ranking pledge over the
Tranche A: EURO 20 currency + installments starting entire share capital of BEA,
Lender: million 2.85% June 30, 2006 until PEP Trust Ltd., Elscint
Bank Hapoalim B.M. December 31, 2015 and Holdings and Investments N.V.
Tranche B: EURO 9.6 For the loan one bullet repayment Astrid Park Plaza Hotel;
million + Pound Sterling taken in NIS of the additional 50% Astridplaza N.V.; Astrid
16.7 million currency - Bank to be paid in the last Hotel Holdings B.V.;
Tranche C: EURO 2.4 of Israel's payment date. Andrassy, 25 kft. (all of
million wholesale rate which are direct and indirect
+ 2.25% Tranche B: 50% to be holders of the hotels) and
Tranche D: EURO 1.4 paid on December 31, Mango.
2010 and 50% on
December 31, 2015. Second ranking pledge over
our holdings in Victory
Enterprises II
79
AMOUNT OF LOAN AND
AMOUNT
OUTSTANDING AS OF
BORROWER AND LENDER DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS PRINCIPAL SECURITIES AND COVENANTS
- ----------------------- ------------------------ ---------------- --------------------------- ----------------------------------
million (stand-by letter Tranche C: 10 semi-annual B.V., Grandis Hotel Holding B.V,
of credit) + NIS 10.2 installments starting Victoria Hotel Holding B.V.,
million December 31 2007. Last Riverbank Hotel Holding B.V.,
payment on June 30, 2012. Africana Holding B.V., Victoria
Hotel and Restaurant Investments
Tranche D: Bullet payment B.V. (all of which own directly or
on December 31, 2010. indirectly our hotels other than
our hotels in Romania and Hungary)
Interest will paid on a
semi-annual basis until An undertaken to register a
the final maturity date. pledge on the Astrid Plaza
Hotel. The pledge has not yet
been registered.
Principal Financial Covenants:
The ratio of Shareholder's Equity
to Balance Sheet Value is greater
than 1:4.
The ratio of Operating Profit of
Astrid Plaza to the Debt Service
of Tranche A for a period should
be greater than 1.2.
Revenue per Available Room of
Astrid Plaza should be no less
than:
1. EURO 52 for 2006
2. EURO 56 for 2007
3. EURO for 2008 and thereafter
Borrower: Loan: GBP 67 million + LIBOR + 2.2% Bullet payment on August Principal Securities:
Riverbank Hotel Holding credit facility 27, 2007 or the Economic First ranking pledge on all
B.V. Completion Date as assets, including leasehold rights
Amount outstanding: GBP determined in the to the land and goodwill of hotel
Lender: 70.9 million agreement. owning subsidiary
Bank Hapoalim B.M.
First ranking pledge over the
Hotel: shares of the operating company of
Riverbank Hotel the hotel.
First ranking pledge on all
borrower's shares.
Elscint's and Red Sea's guarantees
for 7.1% of the outstanding loan.
80
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING AS PRINCIPAL
BORROWER AND LENDER OF DECEMBER 31, 2005 INTEREST ON LOAN PAYMENT TERMS SECURITIES AND COVENANTS
- ------------------------ ---------------------- ------------------- -------------------------- -----------------------------
Principal Financial
Covenants:
The Average Revenue per
Available Room shall be at
least GBP 74.5.
Operating Profit to Debt
Service shall be at least
1.2:1.
Borrower: Loan: GBP 39.5 million LIBOR + 1.65% GBP 14.7 million of the Principal Securities:
Victoria Hotel Holding loan repayable in First priority mortgage on
B.V. Amount outstanding: quarterly installments the land and the building.
GBP 3 35.8 million commencing March 2003;
Lender: balance repayable in one First ranking pledge on
Bank Hapoalim B.M. payment in December 2012 borrower's shares.
Hotel: Guarantees by each of Elscint
Victoria Hotel (London) and Red Sea in the amount
equal to 2.5% of total costs
of the project.
Principal Financial
Covenants:
The Average Revenue per
Available Room shall be at
least GBP 60.86.
Operating Profit After Tax to
Debt Service shall be at
least 1.2:1.
Borrower: Loan: GBP 14.2 million LIBOR + 1.4% 50% of the loan repayable Principal Securities:
Grandis Netherlands in quarterly installments Fixed and floating charge on
Holding B.V. Amount outstanding: over 10 years commencing rights to borrower's assets,
GBP 12.1 million December 2002. Balance to including goodwill First
Lender: be repaid after 10 years ranking charge on shares of
Bank Hapoalim B.M. (December 2012) subsidiary that owns the
rights to the land
Hotel:
Sherlock Holmes Park GBP 5.4 million of the loan
Plaza Hotel is guaranteed by Elscint and
Red Sea in equal share.
Principal Financial
Covenants:
The Average Revenue per Room
shall be at least GBP 65.
Occupancy rate is not less
than 70%.
Operating Profit After Tax to
Debt Service shall be at
least 1.2:1.
81
AMOUNT OF LOSS AND
AMOUNT OUTSTANDING
AS OF DECEMBER 31, PRINCIPAL SECURITIES
BORROWER AND LENDER 2005 INTEREST ON LOAN PAYMENT TERMS AND COVENANTS
- ----------------------- -------------------- ------------------ -------------------- ---------------------
Borrowers: Loan: EURO 71.8 The Interest on EURO 112,000 to be Principal Securities:
Victoria Hotel C.V. and million (divided the loan is hedged paid at the end of Mortgage on both
Utrecht Victoria Hotel between Victoria by a swap each quarter hotels.
B.V. and Utrecht hotels: transaction, commencing December
Utrecht Victoria accordingly the 30, 2004 and ending First ranking pledge
Lender: Hotel B.V. Euro 14 fixed interest on March 30, 2007; on moveable assets,
Merill Lynch million and rate is 5.11% per bank accounts
International Victoria Hotel C.V. annum EURO 337,000 to be (operating income and
Euro 57.8 million) paid at the end of debt service
Hotels: each quarter reserve), rights of
Victoria Hotel Amount outstanding: commencing June 30, the borrowers under
(Amsterdam) and Utrecht Victoria 2007 and ending on their management
Utrecht Hotel Hotel B.V. EURO June 30, 2009; agreements and
13.9 million and insurance proceeds.
Victoria Hotel C.V. EURO 67,664,000 to
EURO 57.3 million be paid at the end First ranking pledge
of the term on shares of
Available amount: 0 (September 30, 2009) borrowers.
Borrowers shall not
create or permit to
subsist any pledge
and mortgages over
the whole or any
part of their assets.
Negative pledge on
borrowers assets.
Principal Financial
Covenants:
The amount of loans
shall not exceed 75%
of the total value
of the hotels.
On each interest
payment date net
operating income for
each of the previous
four financial
quarters shall not
be less than 135%
of the interest
service costs for
the same period.
Borrower: Loan: Prime-1% Payments commenced Principal Securities:
Park Plaza Hotel Rand 20 million on October 1, 2003 Unconditional and
(Sandton)(Proprietary) with monthly irrevocable
Ltd. Amount outstanding installments of guarantee to Lender
- Rand 18.7 million Rand 33,000. In for $500,000 in
Lender: each succeeding effect until the
Nedcor Investment Available amount: 0 year the monthly loan is fully paid.
Bank Ltd. installments will
increase by Rand Mortgage on hotel.
Hotel: 17,000 until making
Sandton Hotel full payment on Rand 5 million bond
October 1, 2013 over the hotel's
movables and debtors.
Borrower: Two loans, each for First loan-LIBOR+ Short term credit Principal Securities:
$13 facility
AMOUNT OF LOAN AND
AMOUNT OUTSTANDING
AS OF DECEMBER 31, PRINCIPAL SECURITIES
BORROWER AND LENDER 2005 INTEREST ON LOAN PAYMENT TERMS AND COVENANTS
------------------- ------------------- ------------------ -------------------- ---------------------
BEA Hotels Eastern million 1.3% Pledge on a security
Europe B.V. Second loan - deposit of $14
Amount outstanding LIBOR + 2.8% million
Lender: - $26 million
Bank Leumi Le Israel Pledge on Domino and
Ltd. Available amount: 0 Bucuresti Turism SA
shares
Lien on BEA Hotel
Eastern Europe
shares and a floating
lien on its assets
Pledge on Domino's
present and future
movable assets
Unlimited guarantee
by Elscint
Other than a refinancing loan agreement in a substantial amount, as
described below, we have entered into various loan agreements and credit
facilities agreements in the ordinary course of business.
On March 2, 2006, we through our jointly controlled subsidiaries, holding
three hotels in the United Kingdom (the "Holding Companies") (Riverbank Hotel,
Vicotria Hotel and Sherlock Holmes Park Plaza Hotel) and Park Plaza executed a
refinance loan agreement together with Goldman Sachs in an aggregate amount of
L195 million ($335 million) out of which our share in the loan amounted to
L97.5 million ($168 million). The proceeds of the refinance agreement were
used for the repayment of outstanding loans granted by Bank Hapoalim B.M. to the
Holding Companies in an aggregate amount of L120 million ($206 million)
out of which our share is L60 million ($103 million).
The loan bears interest at a rate of Libor + 3% per annum. The interest was
fixed under a swap transaction at a rate of 7.72% per annum. 0.375% of the
principal is payable in quarterly installments commencing one year as of the
draw-down for a period of 5 years and the remaining principal is due after five
years. The borrowers have an option to extend the term by two years, subject to
certain terms.
The securities provided include pledges of the entire share capital of the
Holding Companies and the entire share capital of Park Plaza, charges over each
of the hotels and an assignment of rent, insurance proceeds and the hedging
agreements, as well as a fixed charge over specified bank accounts. We undertook
towards Park Plaza to indemnify Park Plaza with respect to 50% of any damages
caused to Park Plaza under the agreement.
Under the agreement, the borrowers undertook, among other things, that the
net operating income to debt service be over 1.05. We are also not allowed to
distribute dividends.
In the event of any cash distribution deriving from the sale, disposal or
refinancing of the any hotels, which were financed by the refinancing loan funds
(transactions), the borrowers shall pay to the financing bank an amount
equivalent to 15% of the difference between the market value of the hotels as
determined in such transaction and the current agreed value of the hotels for
the purpose of the refinancing loan.
B. EMI's subsidiaries and jointly indirect controlled companies which are
engaged in construction and/or the operation of our commercial centers and
hotels entered into loan agreements with banks and financial institutions, which
include an undertaking of those companies to comply with certain financial and
operational covenants throughout the duration of the respective loans. The
covenants include: achieving certain operational milestones on certain specified
dates (e.g. scope of lease, etc.); complying with debt cover ratio; "loan
outstanding amount" to secured asset values ratio; complying with certain
restrictions on interest rates; maintaining certain cash balances for current
operations; maintaining equity to project cost ratio and net profit to current
bank's debt; occupancy percentage; average room or rental fee rates; and others.
In the event the borrowers fail to comply with these covenants, the lenders will
have the right to call the loan for immediate repayment.
MATERIAL COMMITMENTS FOR CAPITAL EXPENDITURE
See "- F. Tabular Disclosure of Contractual Obligations" below.
C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES, ETC.
The Israeli government encourages industrial companies by funding their
research and development activities through grants by the OCS.
InSightec's research and development efforts have been financed, in part,
through OCS grants. InSightec has applied and received grants totaling
$11.3_million from the OCS since its inception in 1999. It is required to repay
these grants to the OCS through royalties amounting to 3% of its revenues until
the entire amount is repaid. These costs are recorded by EMI in its cost and
expenses of medical systems operations.
82
The following table shows EMI's consolidated total research and development
expenditures and royalty-bearing participation by the Israeli government for the
years 2003 through 2005, together with the percentages of net revenues for each
year (in NIS thousands, except for percentages):
CONVENIENCE YEAR ENDED DECEMBER 31,
TRANSLATION ------------------------------------------------------------------
TO US $ 2005 2004 2003
2005 -------------------- -------------------- --------------------
THOUSANDS OF THOUSANDS % OF NET THOUSANDS % OF NET THOUSANDS % OF NET
$ OF NIS REVENUES OF NIS REVENUES OF NIS REVENUES
------------ --------- -------- --------- -------- --------- --------
Total expenditures
for research and
development 13,649 62,825 7.7 45,842 6.2 51,187 8.6
Royalty-bearing
participation from
the Government of
Israel 853 3,926 0.5 7,684 1.0 7,468 1.3
Net research and
development expenses
funded by EMI 12,796 58,849 7.2 38,158 5.2 43,719 7.3
All research and development expenses are attributed to InSightec.
D. TREND INFORMATION
SHOPPING AND ENTERTAINMENT CENTERS BUSINESS
The economies of most Central European countries are experiencing a
moderate upward trend, as evidenced by gross domestic products ranging between
3% to 7%. The shopping and entertainment centers business benefits from these
trends, which are generally manifested in increased consumer spending, but at
the same time are subject to local pressures of supply and demand. With the
growth in the number of shopping and entertainment centers, especially in the
capital and large regional cities, supply is beginning to outpace demand,
resulting in increasingly aggressive competition for patronage. However, the
negative impact of these market forces on our shopping and entertainment centers
is offset by the strong emphasis which PC places on the entertainment facilities
which it offers to its customers, which has been shown to be a dominant factor
in attracting visitors to the centers.
In the smaller regional cities, where both local and foreign investors are
reluctant to develop projects, the shopping and entertainment centers generally
operate in an environment devoid of similar concept shopping centers and thus
benefit, notwithstanding that the catchment populations are smaller and the
relative buying power of patrons is less than in the larger metropolitan
locations. However the emergence of "power centers" (i.e. "big boxes" with cheap
merchandise outside the cities) in many regional cities is impacting upon
patronage and constitute competition. The entry of Hungary, Poland, Romania, the
Czech Republic and Latvia into the European Union is anticipated to generate a
significant increase in business oriented traffic and tourism, principally into
the capital cities, which will in turn bolster the number of visitors to the
shopping centers. However this trend is offset by very aggressive competition in
the capital cities.
The shopping and entertainment centers may experience seasonal shifts in
retail activity. Generally speaking, peak holiday seasons (such as Christmas,
Easter, Passover, the Jewish New Year (with respect to the Arena shopping and
entertainment center in Herzliya, Israel) and other national holidays), will
show an increase in patron traffic, both for the purchase of holiday gifts and
for utilizing the entertainment facilities offered by the center. The periods
immediately following such periods tend to show a decrease in the number of
patrons visiting the centers and a corresponding slow down in retail activity.
However, this may be offset by the fact that the indoor facilities offer a
heated or an air-conditioned environment for shoppers and patrons which is of
particular significance in areas with severe weather conditions.
83
HOTEL BUSINESS
Our hotel business is affected by the trends in each of the geographic
areas in which it operates.
Contrary to the weak results of the hotel industry in years 2001 to 2003,
most of the western European markets experienced in 2005 an increase in revenue
per available room (RevPAR), which was derived mainly from an increase in
occupancy rates. Management believes this has resulted from the trends discussed
below.
In 2001 and 2002, the Western European hotel industry generally experienced
a decline in industry results, following the outbreak of "foot and mouth"
disease and the subsequent September 11, 2001 terrorist attacks in New York.
This trend continued in 2003 when the European hotel industry was challenged
with operating and economic conditions that were affected by the war in Iraq and
the outbreak of SARS. These events caused a continuance in the slow down of
corporate spending. In addition, weak domestic demand coupled with an
appreciating Euro has resulted in a weak growth across the Euro-zone.
In 2005, the European hotel industry continued its strong recovery, which
had begun the previous year. Events such as the war in Iraq and the London
bombing failed to have a negative impact on either the volume or value of
hotels. In addition, low cost flight is changing the travel patterns across the
region and is resulting in an increase of travel and revenues in our hotel
business.
During the last 12 months, several new travel trends have been experienced:
(i) consumers are becoming more independent and show a clear preference for
making their own travel arrangements, mainly due to the increased use and
availability of Internet booking, the increasing number of online booking
engines and the expansion of low-cost airlines; (ii) there has been an increase
in price transparency available on the Internet, which combined with economic
and social uncertainty, also means that booking lead times remain short while
price sensitivity stays high; and (iii) the preference for more frequent and
short stay trips has continued to be evident in travel patterns
Although slow in comparison to other regions of the world, hotel
performance in Europe continues to move in the right direction - ending the year
with revenue per available room up 4.1%.
The strength of the Euro against the GBP is making the United Kingdom more
price competitive for Europeans than ever before. London, in particular, has
enjoyed a remarkable comeback given the global events of the last three years.
Exchange rates have played their part, with the euro zone becoming more
attractive to visitors looking for value for money, especially those from North
America and the UK. The growth in the European market was aided by the strength
of the euro against the sterling. However, the weakness of the US dollar has
been a concern throughout 2005 as it has had an impact on the number of visitors
from the United States. Nevertheless, the United States is still the leading
overseas market, although its share declined by 6% in 2005.
Northern Europe, which comprises the United Kingdom and the Nordic
countries, achieved the highest occupancy and average room rates of all the sub
regions in Europe. This is mainly due to the strong performance of the UK
market, which achieved occupancy levels of 71.8%. In addition, the Nordic
countries have seen significant average room rate growth - up to 5.9% to 98
Euro.
After celebrating victory in the race to host the 2012 Olympic Games,
London was subjected to terrorist attacks on July 7, 2006. Following the
terrorist bombing, the United Kingdom suffered a short-term drop in visitor
numbers. However, the country bounced back, reinforcing the view that tourists
are no longer deterred by terrorist attacks in the longer term. According to the
UK national tourism agency, the United Kingdom welcomed almost 30 million
international visitors in 2005, which is an increase of 8% compared to the year
before. As a result of the above, average room rates in London grew 3.9% in
local currency in 2005.
Amsterdam, one of Europe's strongest hotel markets, has seen hotel values
gradually decline since 2001, albeit that this decline was marginal in 2004. In
2005, hotel values in Amsterdam rose by 5.7% as the city experienced a 6.5%
improvement in Revenues per Available Room ("RevPar"), compared to 2004.
However, the positive outlook and the continuation of a recovery from the
three years of decline will depend on
84
the global geopolitical situation and security stability. Appreciation of the
Euro will also encumber growth of the European economy relative to the rest of
the world.
Some of the Central European countries joining the European Union are
expected to have improved hotel operations and performance due to lower prices
and cost of living and extra travel routes with cheaper flight prices.
E. OFF-BALANCE SHEET ARRANGEMENTS
1. As of December 31, 2005, the Company guaranteed a credit facility
extended to InSightec by an Israeli bank in the amount of approximately $5
million.
2. With respect to the acquisition by a subsidiary of PC of the control of
the Hungarian company owning land on the Obuda Island, the minority shareholder
in such company was granted a put option to sell to PC's subsidiary its share in
the Hungarian company. Such put option is exercisable until April 2007, and the
purchase price payable by PC's subsidiary in the event that the put option is
exercised will reflect the cost of the shares plus annual interest at a rate of
Euribor + 2% less all dividends that shall have been paid to the minority
shareholder by the Hungarian company through the date of exercise of the put
option.
3. With respect to the purchase by PC's subsidiary of the shares in the
Hungarian company Ercorner Kft., the Company executed, in favor of a bank that
financed such share acquisition, a guarantee for the obligation assumed by PC's
subsidiary to cause the land zone of the island to be changed for office,
commerce, tourism, entertainment, recreation and hotel purposes.
4. The Company engages in the trading of derivative and other financial
trading instruments for hedging and speculative purposes. The results of such
activities, and the value of assets and liabilities arising therefrom, are
affected by the volatility in foreign exchange rates and interest rates.
5. In the course of the transaction for the sale of four operational
shopping and entertainment centers in Hungary by PC to the Dawnay Day Group, PC
agreed to guarantee certain portions of the rental revenues of one of the
acquired shopping centers for a period of three years from the time of closing,
as security for certain minimum rental revenues. EMI estimates the value of this
guarantee (as of the date of this report) to be in the aggregate amount of
approximately E1.3 million
6. Within a course of a preliminary share purchase agreement between
Klepierre and PC for the future acquisitions of four commercial centers in
Poland and in the Czech Republic, Klepierre has furnished EMI with a bank
guarantee in the amount of E115.0 million for the payment of the respective
estimated purchase price of the said commercial centers. EMI has furnished
Klepierre with its corporate guarantee for the fulfillment by PC of all its
undertaking and obligations under the definitive agreement.
F. TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS
Our contractual obligations mainly consist of long-term loans from banks
and financial institutions and long-term operational leases as well as long term
non convertible an convertible debentures These obligations are linked to
foreign currencies (mainly U.S dollar, GBP and the Euro). We summarize below our
significant contractual obligations as of December 31, 2005 in NIS, based upon
the representative exchange rate as of December 31, 2005 between the NIS and the
currency in which the obligation is originally denominated. Actual payments of
these amounts (as will be presented in the financial statements of the Company
when executed) are significantly dependent upon the exchange rate of the NIS
against the relevant foreign currencies prevailing as at the date of execution
of such obligation, and therefore may significantly differ from the amounts
presented hereinbelow:
85
Payments due by Period
(NIS in million)
-----------------------------------------------------------
Less than
Total 1 Year 2-3 Years 4-5 Years After 5 Years
------- --------- --------- --------- -------------
Contractual Obligations as
of December 31, 2005
Long-Term Debt (1) 2,586.5 140.6 807.8 610.9 1,027.2
Capital (Finance) Leases -- -- -- -- --
Operating Leases (2) 726.3 12.7 25.7 21.0 666.9
Purchase Obligations and
Commitments (3) (4) 235.2 175.8 59.4 -- --
Other Long Term Liabilities
Reflected on Balance Sheet -- -- -- -- --
------- ----- ----- ----- -------
Total 3,548.0 329.1 892.9 631.9 1,694.1
======= ===== ===== ===== =======
(1) Long term debt includes interest that we will pay from January 1, 2006
until the loan maturity dates. The majority of our loans bear variable
interest rates and the interest presented in this table is based on the Libor
rates known as of December 31, 2005. Actual payments of such interest (as will
be presented in the financial statements of the Company) are significantly
dependent upon the Libor rate prevailing as of the date of payment of such
interest. For additional information in respect of the long term loans, see Note
14 to our consolidated financial statements included in Item 18 of this report
and in Item 5 "Operating and Financial Review and Prospects - Loans" above.
(2) Our operating lease obligations are subject to periodic adjustment of
the lease payments as stipulated in the agreements. In this table we included
the lease obligation based on the most recent available information. For
additional information in respect of our operating lease obligations see Note
10B to our consolidated financial statements included in Item 18 of this report.
(3) Excludes royalty payments that InSightec may have to pay to the OCS.
InSightec partially finances its research and development expenditures under
programs sponsored by the OCS for the support of research and development
activities conducted in Israel. In exchange for OCS participation in the
programs, InSightec agreed to pay 3% of total sales of products developed within
the framework of these programs. At the time the OCS participations were
received, successful development of the related projects was not assured. The
obligation to pay these royalties is contingent on actual sales of the products
and therefore cannot be estimated.
(4) This refers to contracts with supplier and subcontractors in respect of
the construction of our projects.
86
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A. DIRECTORS AND SENIOR MANAGEMENT
The table below sets forth the directors and senior officers of EMI as of
the date of this report:
NAME AGE POSITION
- ---- --- --------
Mordechay Zisser (1) 50 Executive Chairman of the Board of Directors
Shimon Yitzhaki (1) 50 President and Director and Chief
Financial Officer
Rachel Lavine 40 Director
Yehoshua (Shuki) Forer (2) 62 Director
David Rubner (2) 66 Director
Yosef Apter (2) 51 External Director
Zvi Tropp (1)(2) 66 External Director
Abraham (Rami) Goren 46 Director
Moshe Lion 45 Director
Shmuel Peretz 66 Director
Marc Lavine 52 Corporate Secretary and General Counsel
(1) Member of the Donation Committee
(2) Member of the Audit Committee
MORDECHAY ZISSER. Mr. Zisser was appointed executive chairman of our board
of directors in May 1999. He has been President of Europe-Israel since March
1998 and its Chairman of the board of directors from March 1998, and President
and Chairman of the board of directors of Control Centers, a privately held
company, which is the parent company of Europe-Israel, since 1983. Europe-Israel
and Control Centers are engaged, through their direct and indirect wholly and
partially owned subsidiaries and affiliates, in the following core businesses:
real estate investment, hotel ownership and management, development and
operation of shopping and entertainment centers in Eastern European countries,
in the venture capital investments and in the hi-tech, medical and
bio-technology industries. Control Centers also holds direct interests in
property development projects in Israel. Since May 1999 Mr. Zisser has been the
executive chairman of Insightec Ltd, a subsidiary of the Company. Mr. Zisser is
active in charitable organizations. He is a member of the management of the
"Oranit" hostel.
SHIMON YITZHAKI. Mr. Yitzhaki was appointed as the President and a member
of our board of directors in May 1999. In March 2005 Mr. Yitzhaki was appointed
as the chief financial officer of the Company. In May 1999 he was also appointed
as a member of the board of directors of Elscint. Since March 1998, Mr. Yitzhaki
has served as the Vice President of Europe-Israel, and, since the mid-1980's, as
Vice President of Control Centers. Since May 1999 Mr. Yitzhaki has been serving
as a member of the board of directors of InSightec Ltd. Mr. Yitzhaki holds a
Bachelor of Arts degree in accounting from Bar Ilan University and is a
certified public accountant.
RACHEL LAVINE. Ms. Lavine was appointed as a member of our board of
directors in May 1999. In May 1999, Ms. Lavine was also appointed as President
and a member of the board of directors of Elscint. Since March 1998, she has
served as Vice President of Europe-Israel, and, from 1994 to 1998, Ms. Lavine
served as Chief Financial Officer of Control Centers, the parent company of EMI.
Ms. Lavine has been President and CEO of Plaza Centers since January 2005. Ms.
Lavine holds a Bachelor of Arts degree in accounting and is a certified public
accountant.
YEHOSHUA (SHUKI) FORER. Mr. Forer was appointed as a member of our board of
directors in May 1999. He is the Mayor of the City of Rehovot in Israel. Mr.
Forer is an attorney, and was the managing partner of Forer Azrieli and
Partners, a law firm with offices in Tel-Aviv and Rehovot from 1994 to 1998. Mr.
Forer was the Acting Chairman of Herzliya Marina Ltd., Ashkelon Marina Ltd. and
Control Centers from 1989 to 1994 and of Williger Ltd. from 1989 to 1991. Mr.
Forer was also Managing Director of the Israel Ministry of Industry and Commerce
from 1983 to 1986 and of the Investment Center From 1981 to 1983. Mr. Forer was
an Assistant to the Minister of Industry and
87
Commerce in charge of development areas from 1980 to 1981. Mr. Forer held
positions as a member of the boards of directors of Bank Leumi Le-Israel Ltd.,
Israel Chemicals Ltd., Negev Phosphates Company Ltd., Industrial Buildings
Corporation Ltd., Red Sea Hotels Ltd. ("Red Sea") and Ackerstein Zvi Ltd. and
was a member of the Presidium and Vice President of the Association of the
Tel-Aviv Chamber of Commerce from 1987 to 1996. Mr. Forer is currently a member
of the board of directors of Castro Model Ltd. Mr. Forer received his LL.B. with
Honors from the Hebrew University in Jerusalem.
DAVID RUBNER. Mr. Rubner was appointed as a member of our board of
directors in July 2003. Mr. Rubner serves as Chairman and Chief Executive
Officer of Rubner Technology Ventures Ltd. as well as General Partner in
Hyperion Israel Advisors Ltd., a venture capital firm. From 1991 until 2000, Mr.
Rubner served as President and Chief Executive Officer of ECI Telecom Ltd. Prior
thereto, Mr. Rubner held the positions of Chief Engineer, Vice President of
operations and Executive Vice President and General Manager of the
Telecommunications Division of ECI. Mr. Rubner serves on the boards of certain
public companies including Check Point Software Ltd., Koor Industries Ltd.,
Lipman Electronic Engineering Ltd as well as some privately held companies. Mr.
Rubner serves on the board of trustees of Bar-Ilan University, and Shaare Zedek
Hospital. Mr. Rubner holds a B.S. degree in engineering from Queen Mary College,
University of London and an M.S. degree from Carnegie Mellon University. Mr.
Rubner was recipient of the Industry Prize in 1995.
YOSEF APTER. Mr. Apter was appointed as an external director in December
2002 for a period of three years. On December 2005 Mr. Apter was re-elected as
an external director of the Company for a three-year term commencing on December
25, 2005. Since July 2005, Mr. Apter has served as a consultant at JDA
(Jerusalem Development Authority). Since 2003 Mr. Apter has been a board member
in SecureOL Ltd. Between 1980 and 2002, Mr. Apter served as a member of the
executive boards of the Center for Investigation of Driving and Casualties,
Shiloh Hesder Yeshiva, Nature Life, Zamir Systems Ltd., Binyamin Regional
Council, Binyamin Development Company and Elad Non-Profit Organization. Mr.
Apter also served as a director and vice chairman of Security Funds. Mr. Apter
is a graduate of the Jerusalem College of Technology (B.Sc.) and holds an MBA
from the Hebrew University in Jerusalem.
ZVI TROPP. Mr. Tropp was appointed as an external director in September
2004. Mr. Tropp, shall continue to serve as external director for the remainder
of his 3-year term, which terminates on September 1, 2007.Mr. Tropp has been a
senior consultant with Zenovar Consultant Ltd. since 2003. From 2000 until 2003,
Mr. Tropp served as a chief finance officer of Enavis Networks, a member of the
ECI group, a company engaged in the field of development of transport equipment
for communications networks. Mr. Tropp served as a board member of various
organizations, including Rafael (Armament Development Authority), Beit Shemesh
Engines, Rada - Electronic Industries and as the chairman of the Investment
Committee of Bank Leumi Le'israel Trust company Ltd. Since February 2006 Mr.
Tropp serves as the chairman of Rafael. Mr. Tropp holds a B.Sc. degree in
Agriculture and an M.Sc. degree in Agricultural Economics and business
administration from the Hebrew University in Jerusalem.
ABRAHAM (RAMI) GOREN. Mr. Goren became a member of our board of directors
as of April 11, 2005. Mr. Goren has also been the executive chairman of the
board of directors of Elscint from July 1999. Mr. Goren is engaged in the
explorations of new investments and heads the high-tech investment division of
the Company. In addition, until 2004, Mr. Goren served as the executive chairman
of the board of directors of Nessuah Zannex Ltd., a leading Israeli investment
house. Formerly, Mr. Goren had been a partner in the law firm of Prof. Joseph
Gross, Hodak, Greenberg & Co. (now known as Gross, Kleinhendler, Hodak, Halevy &
Co.), a leading Israeli securities and corporate law firm. From September 1989
until August 1992, Mr. Goren was an associate in the law firm of Weil, Gotshal &
Manges in New York City. Mr. Goren also serves as a director of various private
companies in Israel and abroad. Mr. Goren received his LL.B. degree from Bar
Ilan University in 1986 and an LL.M. degree from New York University in 1989.
Mr. Goren was admitted to the Israeli Bar in 1987 and to the New York State Bar
in 1990.
MOSHE LION. Mr. Lion became a member of our board of directors as of April
11, 2006. Mr. Lion is a senior partner of an accounting firm in Israel. . From
April 2003 to April 2006 Mr. Lion was the chairman of Israel Railways. From
October 2000 to December 2005, Mr. Lion served as a director of Elscint. From
December 1997 to July 1999, Mr. Lion was Director General of the Israeli Prime
Minister's Office and an economic advisor to the Israeli Prime Minister. From
January 1997 to November 1997, he served as the Head of the Bureau of the
Israeli Prime Minister's Office and as an economic advisor to the Israeli Prime
Minister. Mr. Lion serves as a director of Massad Bank and the Israel Council
for Higher Education and the Wingate Institute for Physical Education. Mr. Lion
holds a Bachelor of Arts degree in accounting and economics and a Master's
Degree in Law (LL.M.) from Bar Ilan University.
88
SHMUEL PERETS. Mr. Perets became a member of our board of directors as of
April 11, 2006. Since 1997, Mr. Perets has served as the president of the Israel
Aircraft Industries European division. From March 2003 to December 2005, Mr.
Perets served as a director of Elscint. Between 1991 and 1996, Mr. Perets served
as vice president (finance) of the Israel Aircraft Industries. Between the years
1980-2002, Mr. Perets served as a director of Elta Ltd., Magal Ltd., Medisel
Technologies Inc., SpaceCom Ltd., and Belgium Advanced Technologies (a Belgium
company). Mr. Perets holds a Bachelor of Arts degree in economics and political
science from the Hebrew University in Jerusalem, as well as an MBA from the New
York Institute of Technology.
MARC LAVINE. Mr. Lavine was appointed as our General Counsel and Corporate
Secretary in May 1999. Mr. Lavine also serves as General Counsel and Corporate
Secretary for Elscint and Europe-Israel. Prior thereto, Mr. Lavine was in
private practice as an associate and as a partner in the law firms Miron,
Bension & Priwes (Tel-Aviv) (1977 to 1997) and Raved, Magriso, Benkel & Caspi
(Tel-Aviv) (1997 to 1998). Mr. Lavine is a graduate of the University of
Zimbabwe (B.L., 1974). Mr. Lavine is married to Rachel Lavine, a director of EMI
and a President of Elscint and acting chief executive officer of PC.
B. COMPENSATION OF DIRECTORS AND OFFICERS
The aggregate compensation paid to or accrued on behalf of all of our
officers and directors for the year ended December 31, 2005, as a group, was
approximately NIS 10.1 million (approximately $2.2 million) of which
approximately NIS 447,700 (approximately $97,300) has been accrued by EMI to
provide pension and retirement benefits, and NIS 351,700 (approximately $76,400)
was paid to directors in their capacities as directors.
In addition to the above compensation, on May 31, 2006, our shareholders
approved additional compensation to certain directors and officers, as set forth
below:
(i) Payment to each of (1) Shimon Yitzhaki, our President, Chief Financial
Officer and a director, and (2) Ms. Rachel Lavine, our director who also serves
as the President of Elscint and Acting Chief Executive Officer of PC, a bonus of
$100,000 for the 2004 fiscal year and a bonus of $175,000 for the 2005 fiscal
year. For each fiscal year after 2005, the Company will pay to each of Mr.
Yitzhaki and Ms. Lavine an annual bonus within 30 days following the approval by
the board of directors of our each year's audited consolidated financial
statements which will be calculated, as follows: (i) 0.75% of the first NIS 125
million of the Company's pre-tax annual profits as disclosed on our annual
audited consolidated financial statements ("Profits"); (ii) 0.875% of Profits
between NIS 125 million and NIS 150 million; and (iii) 1% of Profits exceeding
NIS 150 million.
(ii) Payment to Mordechay Zisser, our Executive Chairman of the Board, of
an annual bonus for each fiscal year after 2005, to be paid within 30 days
following the approval by the board of directors of our each year's audited
consolidated financial statements, to be calculated as follows: (i) 0% of the
first NIS 100 million of Profits; (ii) 3% of Profits between NIS 100 million and
NIS 125 million; (iii) 3.5% of Profits between NIS 125 million and NIS 150
million; and (iv) 4% of Profits exceeding NIS 150 million.
(iii) An agreement for the receipt of executive chairman services between
EMI and a management company (the "Management Company") controlled by Mr.
Mordechay Zisser, our Executive Chairman. Under the agreement, the Management
Company will provide us with Executive Chairman services. The Management Company
may provide the Services to private subsidiaries and/or affiliates of the
Company. The Services will be provided by Mr. Zisser only, as an employee of the
Management Company. Mr. Zisser will devote at least 80% of his time, skills and
efforts to his position as Executive Chairman. The control of the Management
Company will not be changed during the term of the agreement.
We will pay the Management Company a monthly amount of $50,000 plus
applicable value added tax as well as reimbursement of expenses. In addition,
the Management Company is entitled to other benefits, such as: an appropriate
vehicle, telephone, facsimile, mobile phone, computer, printer and modem and we
shall bear all their installation costs and all reasonable expenses related
thereto.
The agreement is for a five-year term commencing retroactively on August 1,
2005. Termination of Mr. Zisser's service as Executive Chairman of the Board for
any reason whatsoever will result in an immediate termination of the agreement.
Notwithstanding the above, at our request, Mr. Zisser will serve (through the
Management Company)
89
in addition to his service as Executive Chairman or in its stead as a director
or officer of the Company, and in such event, the agreement will remain in
effect with regard to the additional or other service of Mr. Zisser in EMI.
Mr. Zisser has guaranteed all of the Management Company's obligations as
far as they relate to Mr. Zisser and has further guaranteed the Management
Company's indemnification undertakings and responsibility for damages in the
event of determination of the existence of employer-employee relations between
Mr. Zisser and EMI during the period of this agreement.
(iii) Grant of 350,000 options exercisable into 350,000 of our ordinary
shares to our Executive Chairman of the Board. The options are exercisable upon
their grant and will remain exercisable for a period of three years thereafter.
The exercise price per each option is NIS 137.44. The options were issued to our
Executive Chairman on June 8, 2006.
(iv) Grant of 353,500 options to the members of our board of directors
(except for the Executive Chairman), as follows: 90,000 options to Mr. Shimon
Yitzhaki, 75,000 options to Ms. Rachel Lavine, 50,000 options to Mr. Abraham
(Rami) Goren, 15,000 options to Mr. Yehoshua (Shuki) Forer, 16,750 options to
each of Mr. Moshe Lion and Mr. Shmuel Perets and 30,000 Options to each of
Messrs. David Rubner, Yosef Apter and Zvi Tropp. The options will be granted in
accordance with our 2006 Employees, Directors and Officers Incentive Plan. See
"- E. Share Ownership - 2006 Employees, Directors and Officers Incentive Plan"
below. As of the date of this annual report the conditions precedent to the
grant have not yet been satisfied. We expect the issuance of the options to take
place during July 2006.
For information on the ownership of shares and/or options by our directors
and executive officers, see "- E. "Share Ownership" below.
90
INSURANCE, INDEMNIFICATION AND EXEMPTION
We purchased an insurance policy covering the liability of our directors
and officers, including as directors or officers of our subsidiaries. The policy
covers a total liability of $40 million per occurrence and during the duration
of the policy, which represents the overall directors and officers liability
policy covering the directors and officers of Europe Israel, our parent, and
companies under its control (the liability of directors and officers of
Europe-Israel and companies controlled by it, other than us and companies under
our control, is limited to $10 million out of the aggregate coverage amount of
$40 million). We pay substantially all the premium for such insurance policy.
The policy is for a one-year period beginning on October 31, 2005 and ending on
October 31, 2006. The coverage of such policy also includes acts and/or
omissions performed by previous directors and officers of the Company for a
one-year period beginning on October 31, 2005 and ending on October 31, 2006
without any retroactive limitation and subject to the terms of the policy.
We provide our directors and officers (as shall be from time to time) with
a prospective undertaking to indemnify such directors and officers by virtue of
their service as our directors or officers or by virtue of their service as
directors or officers on behalf of us in companies under our control or in which
we hold interests. The aggregate indemnification amount pursuant to all our
prospective indemnification undertakings shall not exceed the lower of: (i) 25%
of our shareholders' equity, as set forth in our most recent consolidated
financial statements prior to such payment; (ii) $40 million, in excess of any
amounts paid (if paid) by insurance companies pursuant to insurance policies
maintained by us from time to time with respect to matters covered by the
prospective indemnification undertaking.
We have also granted our directors and officers (as shall be from time to
time), except to our Executive Chairman, an exemption from liability for damages
due to a breach by either of them of their duty of care towards us, in
accordance with the Israeli Companies Law.
C. BOARD PRACTICES
ELECTION OF DIRECTORS
Our directors are elected by our shareholders at the annual meeting of the
shareholders by an ordinary majority. Generally, the nominees for a director's
office are recommended by the board of directors. The directors hold office
until the next annual meeting of our shareholders. Our board of directors may
appoint additional directors to our board of directors in the event the number
of directors is less than the maximum number authorized by our articles of
association. Any director so appointed will hold office until the next annual
meeting of the shareholders. Our board of directors currently consists of 10
members. Our current directors (other than the external directors) were
appointed by our shareholders at their annual meeting on December 29, 2005 and
will hold office until the next annual meeting of our shareholders. .
Under an amendment to the Israeli Companies Law, each Israeli public
company, including us, is required to determine, no later than April 19, 2006,
the minimum number of directors with "accounting and financial expertise" that
such company believes is appropriate in light of the particulars of such company
and its activities. A director with "accounting and financial expertise" is a
person that, due to education, experience and qualifications, is highly skilled
and has an understanding of business-accounting issues and financial statements
in a manner that enables him/her to understand in depth the company's financial
statements and stimulate discussion regarding the manner of presentation of the
financial data. Our board of directors resolved on October 24, 2004 that the
minimum number of directors with accounting and financial expertise appropriate
for us in light of the size of the board of directors and nature and volume of
our operations is one director.
SUBSTITUTE DIRECTORS
Our articles of association provide that any director may appoint another
person to serve as a substitute director and may cancel such appointment. Under
the Israeli Companies Law, the following persons may not serve as substitute
directors: (i) any person who is not himself qualified to be appointed as a
director; (ii) a person who is already serving as a director; or (iii) a person
who is already serving as a substitute director for another director.
Nevertheless, a director may be appointed as a substitute director for a
committee of the board of directors if he or she
91
is not already serving as a member of the committee. Under the Israeli Companies
Law, there shall not be appointed a substitute director for an external
director.
EXTERNAL DIRECTORS; INDEPENDENT DIRECTORS
The Israeli Companies Law requires Israeli public companies to appoint at
least two external directors. The Israeli Companies Law provides for certain
qualifications that a candidate for external directorship must comply with.
Among such requirements, a person may not be appointed as an external director
if such person or person's relative, partner or employer, or any entity
controlled by such person, has, at the date of appointment, or had at any time
during the two years preceding such date, any affiliation with the company, any
entity controlling the company at the date of his appointment or any entity
controlled by the company or by the entity controlling the company. The term
"affiliation" is broadly defined in the Companies Law, including an employment
relationship, a business or professional relationship maintained on a regular
basis or control, service as a director or officer, other than service as a
director who was appointed in order to serve as an external director of a
company when such company was about to make an initial public offering.
In addition, no person may serve as an external director if such person's
position or other business creates, or may create, conflict of interest with the
person's position as an external director, or if such position or other business
may impair such person's ability to serve as a director. Until the lapse of two
years from termination of office, a company may not engage an external director
to serve as a director or officer and cannot employ or receive services from
that person, either directly or indirectly, including through a corporation
controlled by that person. The Companies Law provides for additional
qualification requirements that are imposed on such candidates.
External directors are to be elected by a majority vote at the general
meeting of shareholders, provided that(i) such majority vote at the general
meeting shall include at least one third (1/3) of the total votes of
non-controlling shareholders present and voting at such general meeting,
excluding abstaining votes, or (ii) the total number of votes of the
shareholders mentioned in clause (i) above that voted against such proposal does
not exceed one percent (1%) of the total voting rights in the company.
The initial term of an external director is three years and such term may
be extended for an additional three-year period. External directors may be
removed only in a general meeting, by the same percentage of shareholders as is
required for their election, or by a court, and in both cases only if the
external directors cease to meet the statutory qualifications for their
appointment or if they violate their fiduciary duty to us. Each committee of a
company's board of directors that is authorized to exercise powers of the board
of directors is required to include at least one external director, and all
external directors must be members of the company's audit committee.
An external director is entitled to reimbursement of expenses and to
monetary and other compensation as provided in regulations promulgated under the
Companies Law, but is otherwise prohibited from receiving any other
compensation, directly or indirectly, in connection with services provided by
such person as an external director.
Mr. Yosef Apter and Mr. Zvi Tropp were elected in December 2002 and
September 2004, respectively, as our external directors. Mr. Apter was
re-elected as an external director in December 2005 for a second three-year term
which commenced on December 25, 2005. Mr. Tropp shall continue to serve as
external director for the remainder of his 3-year term, which terminates on
September 1, 2007.
Pursuant to a recent amendment to the Israeli Companies Law at least one
external director is required to have "accounting and financial expertise" and
the other director(s) are required to have "professional expertise" or
"accounting and financial expertise". A director has "professional expertise" if
he or she satisfies one of the following:
(i) the director holds an academic degree in one of these areas:
economics, business administration, accounting, law or public
administration;
(ii) the director holds an academic degree or has other higher education,
all in the main business sector of the company or in a relevant area
for the board position; or
92
(iii) the director has at least five years' experience in one or more of
the following (or a combined five years' experience in at least two or
more of these: (a) senior management position in a corporation of
significant business scope; (b) senior public office or senior
position in the public sector; or (c) senior position in the main
business sector of the company.
A director with "accounting and financial expertise" is a person that due
to his or her education, experience and skills has high skills and understanding
of business-accounting issues and financial reports which allow him to deeply
understand the financial reports of the company and hold a discussion relating
to the presentation of financial information. The company's board of directors
will take into consideration in determining whether a director has "accounting
and financial expertise", among other things, his or her education, experience
and knowledge in any of the following:
(i) accounting issues and accounting control issues characteristic to the
segment in which the company operates and to companies of the size and
complexity of the company;
(ii) the functions of the external auditor and the obligations imposed on
such auditor;
(iii) preparation of financial reports and their approval in accordance
with the companies law and the securities law.
The above qualifications do not apply to external directors appointed prior
to January 19, 2006, such as our external directors. However, an external
director may not be appointed to an additional term unless: (i) such director
has "accounting and financial expertise"; or (ii) he or she has "professional
expertise", and on the date of appointment for another term there is another
external director who has "accounting and financial expertise" and the number of
"accounting and financial experts" on the board of directors is at least equal
to the minimum number determined appropriate by the board of directors.
Under Nasdaq Marketplace Rules, a foreign private issuer may follow its
home country practice in lieu of the requirements of Rule 4350, provided,
however, that such an issuer complies with selected rules as defined therein. We
currently comply with all mandatory requirements as are applicable to us by
virtue of our foreign status. We also comply with certain other voluntary
guidelines that correspond to certain Israeli mandatory rules, although there is
no assurance that we will continue to do so in the future should such Israeli
rules cease to apply.
Our current composition of the board of directors consists of a majority of
independent directors. Two of our independent directors serve as external
directors as defined by the Companies Law. For further elaboration as to
election, qualification and roles of external directors, see above.
Prior to such additional nomination, all our external directors served as
audit committee members and as such carried out regular executive sessions at
which only independent directors were present. Under Israeli Law, no requirement
exists to oblige independent directors to conduct executive session. Although we
will endeavor to proceed with such practice, the frequency may be reduced.
The compensation of our President is approved, under the Companies Law, by
the audit committee and board of directors. Since our President also serves as
director in us, his compensation is also approved by our shareholders.
As to procedures governing the election of our directors, see above.
Our audit committee is comprised of four members, all of whom meet the
independence and other professional requirements as stipulated by both Nasdaq
Marketplace Rules and Rule 10A-3(b)(1) under the Securities Exchange Act of
1934. The Nasdaq rules also require that at least one member of the audit
committee be a financial expert. Our board of directors has determined that Mr.
Tropp qualifies as a financial expert in terms of the Nasdaq requirements.
BOARD COMMITTEES
Our board of directors has established an audit committee and a donation
committee, as described below.
93
Audit committee. The Companies Law requires public companies to appoint an
audit committee. An audit committee must consist of at least three members, and
include all of the company's external directors. However, the chairman of the
board of directors, any director employed by the company or providing services
to the company on a regular basis, any controlling shareholder and any relative
of a controlling shareholder may not be a member of the audit committee. The
responsibilities of the audit committee include identifying and examining flaws
in the business management of a company's, in consultation with the internal
auditor and the company's independent accountants and suggesting appropriate
course of actions. In addition, an audit committee recommends approval of
transactions that are deemed interested party transactions, including directors'
compensation and transactions between a company and its controlling shareholder
or transactions between a company and another person in which its controlling
shareholder has a personal interest. An "interested party" is defined in the
Israeli Companies Law as a 5% or greater shareholder, any person or entity who
has the right to designate one director or more or the general manager of ours
or any person who serves as a director or as a general manager.
In accordance with the Sarbanes-Oxley Act of 2002 and Nasdaq requirements,
our audit committee is comprised of four members, all of whom meet the
independence and other professional requirements as stipulated by said rules.
The Nasdaq rules also require that at least one member of the audit
committee be a financial expert. Our board of directors has determined that Mr.
Tropp qualifies as a financial expert in terms of the Nasdaq requirements.
Our audit committee operates in accordance with a charter adopted prior to
the enactment of the Sarbanes-Oxley Act of 2002.
Our audit committee operates in accordance with a Charter adopted in July
2005 and written procedures governing approval of any proposed transactions with
our external auditors. Within the framework of such governing documents, the
audit committee oversees the appointment, compensation, and oversight of the
public accounting firm engaged to prepare or issue an audit report on our
financial statements. The audit committee's specific responsibilities in
carrying out its oversight role include the approval of all audit and non-audit
services to be provided by the external auditor and quarterly review the firm's
non-audit services and related fees. These services may include audit services,
audit-related services, tax services and others. The audit committee approves in
advance the particular services or categories of services to be provided to us
during the following yearly period and also sets forth a specific budget for
such audit and non-audit services. Additional services may be pre-approved by
the audit committee on an individual basis during the year. None of
Audit-related Fees, Tax Fees or Other Fees provided to us by Brightman Almagor &
Co., were approved by the audit committee pursuant to the de minimis exception
to the pre-approval requirement provided by Section 10A of the Securities
Exchange Act of 1934.
Our audit committee has the authority to retain independent legal,
accounting or other consultants as advisors, for which we will provide funding,
and handle complaints relating to accounting, internal accounting controls or
auditing matters.
Donation committee. Our articles of association authorize us to make, from
time to time, contributions of reasonable sums for worthy causes, even if such
contributions do not fall within our business considerations as referred to in
section 11 of the Companies Law, 1999. Our donation committee is authorized to
determine, in its discretion, with respect to any contribution, the amount
thereof, its purpose, the entity to receive the contribution and any other term
or condition relating thereto.
Our balance-sheet committee which was established to thoroughly peruse the
financial statements and discuss certain key issues arising there from, and to
recommend the board of directors whether or not to approve our financial
statements was canceled by our board in December 2005. The authorities of our
balance-sheet committee were transferred to our audit committee replaced the
Balance sheet committee functions. In addition, the committee of independent
directors established by our board of directors to consider and discuss a
possible business combination between us and Elscint in a share-for-share
transaction ceased to function upon completion of the merger by way of exchange
of shares with Elscint during December 2005.
94
D. EMPLOYEES
As of May 31, 2006, EMI employed 19 persons in investment, administration
and managerial services, all of whom were employed in Israel. As of May 31,
2006, PC had approximately 68 employees in Eastern Europe and 27 freelancers.
The decrease in the numbers of employees can be explained by the sale of 50%
of our Hungarian management company to Klepierre, the sale of four of our Polish
shopping and entertainment centers and our Polish management company and the
expected sale of the Novo Plaza project in the Czech Republic to Klepierre. See
"Item 10. Additional Information - Material Contracts - Shopping and
Entertainment Centers" below.
E. SHARE OWNERSHIP
2001 EMPLOYEES, DIRECTORS AND OFFICERS INCENTIVE PLAN
Our 2001 Employees, Directors and Officers Incentive Plan (the "2001 Plan")
provides for the issuance of up to 550,000 of our ordinary shares to our
employees, directors and officers and to employees, directors and officers of
companies controlled by us, of Europe-Israel and of companies controlled by
Europe-Israel. The shares are issued to a trustee for the benefit of each
recipient. Our board of directors approved on July 22, 2004 and on December 4,
2005 an increase in the number of shares available for grant under the 2001 Plan
by 34,500 and 42,400 respectively. As of May 31, 2006, we have issued all
626,900 available shares under the 2001 Plan of which 490,051 shares were sold.
All the shares issued under the 2001 Plan are purchased at a purchase price
of NIS 24.1 per share. Each recipient is granted a loan in an amount equal to
the full purchase price of the shares to be issued to such recipient. The loan
is for a five-year period bearing interest at an annual rate of 6%. The shares
issued for the benefit of each recipient serve as sole collateral for the
repayment of the loan granted to such recipient (non-recourse) except that the
loan will become a recourse loan in the event of payment of the loan prior to
the lapse of the five-year period as a result of transfer or sale of shares
issued to such recipient with respect to the interest rate for the portion of
shares so sold or transferred. On February 16, 2006, our board of directors
extended the term of the loan for an additional two years until February 24,
2008 for offerees, who do not serve as our directors or executive officers. As
of May 31, 2006, all of the shares issued under the 2001 Plan have vested and
may be exercisable.
Under the Nasdaq Marketplace rules, foreign private issuers may follow home
country practice in lieu of certain Nasdaq corporate governance requirements
provided that such foreign private issuer shall submit to the Nasdaq a written
statement from an independent counsel in such issuer's home country certifying
that the issuer's practices are not prohibited by the home country's laws.
Nasdaq has in the past required that foreign private issuers shall be granted
exemptions from its Marketplace rules before following home country practice. In
April 2004, we received an exemption from the Nasdaq Marketplace Rule requiring
shareholders approval for an increase in the number of shares available for
issuance under the Plan, and increased such number by additional 34,500 shares.
In January 2006, in accordance with applicable Israeli law, we increased the
number of shares available for issuance under the 2001 Plan by additional 42,400
shares without shareholder approval.
ELSCINT'S 2001 EMPLOYEES, DIRECTORS AND OFFICERS INCENTIVE PLAN
Elscint's 2001 Employees, Directors and Officers Incentive Plan (the
"Elscint 2001 Plan") provided for the issuance of up to 850,000 ordinary shares
of Elscint to employees, directors and officers of Elscint and its subsidiaries
and to employees of Europe-Israel or other companies controlled by
Europe-Israel. Under the Elscint 2001 Plan, 802,500 shares have been issued at a
price per share of NIS 15.65. The remaining 81,000 shares were subsequently
transferred as available shares for a subsequent option plan adopted by Elscint
in 2003, see below. The rights of the recipients to retain the shares vest over
periods of two or three years following the issuance (i.e., 50% or 33% of the
shares will become available for purchase at the end of each year). All other
terms and conditions of the Elscint 2001 Plan are substantially similar to those
of our 2001 Plan. Elscint 2001 Plan was terminated by Elscint's board of
directors on November 27, 2003.
Upon the completion of the merger by way of exchange of shares between EMI
and Elscint during November 2005, the 522,500 shares that remained outstanding
as of such date were exchanged for 276,925 shares of EMI. As of May 31, 2006,
the number of shares outstanding under the Elscint 2001 Plan was 188,485 shares
of EMI.
95
ELSCINT'S 2003 EMPLOYEES, DIRECTORS AND OFFICERS INCENTIVE PLAN
Elscint's 2003 Employees, Directors and Officers Incentive Plan (the
"Elscint 2003 Plan") provided for the grant of up to 116,000 options exercisable
into up to 116,000 ordinary shares of Elscint. Elscint granted 50,000 options
exercisable into 50,000 shares of Elscint to two of its then serving directors
at an exercise price of $4.68 per option. Elscint 2003 Plan was terminated by
Elscint board of directors on November 27, 2003. Upon the completion of the
merger by way of exchange of shares between EMI and Elscint during November
2005, the 50,000 options were exchange for 26,500 options exercisabled into
26,500 shares of EMI at an exercise price of NIS 38.67 per option. As of May 31,
2006, all of the above options were exercised into 27,964 shares of EMI (taking
into consideration adjustments for distribution of dividends) pursuant to their
terms.
2006 EMPLOYEES, DIRECTORS AND OFFICERS INCENTIVE PLAN
Our 2006 Employees, Directors and Officers Incentive Plan (the "2006 Plan")
provides for the grant of up to 1,000,000 non-marketable options to our
employees, directors and officers and to employees, directors and officers of
companies controlled directly or indirectly by us. The options will be granted
to the recipients for no consideration. The exercise price per option will be
the lower of: (i) NIS 100; or (ii) the average closing price of our ordinary
shares on the TASE during the 30-trading day period preceding the date of grant
of such options.
The options may be exercised into shares in such manner that on the
exercise date we will issue to each recipient shares equivalent to the gain from
the exercise of the options (i.e.: each option may be exercised to such number
of shares equaling to the opening price of EMI shares on the TASE on the
exercise date minus the exercise price while the difference is then divided by
the above opening price; provided however, that such opening price will not
exceed 166% of the exercise price. Accordingly, the maximum number of shares
issuable upon exercise of all of the options that may be granted under the 2006
Plan is 397,590. The rights of the recipients to exercise the options vest over
periods of three years following the grant (i.e., 33.33% of the options may be
exercised at the end of each year). The options will expire after the lapse of
five years from their date of grant. As of May 31, 2006, the conditions
precedent to the grant have not yet been satisfied. We expect the conditions to
the grant to be satisfied by July, 2006.
In accordance with Nasdaq rules applicable to foreign private issuers, we
have elected to follow home country practice, and accordingly, the 2006 Plan was
not approved by our shareholders. See "- 2001 Employees, Directors and Officers
Incentive Plan" above.
ISSUANCE OF OPTIONS TO OUR EXECUTIVE CHAIRMAN OF THE BOARD
We have granted 350,000 options to our Executive Chairman of the board of
directors. For additional information, see "- B. Compensation of Directors and
Officers" above.
INSIGHTEC EQUITY PLANS
InSightec maintains four equity incentive plans:
InSightec's 1999 Employee Stock Ownership Plan (the "1999 Plan") provides
for the grant of up to 2,650,000 options, at an exercise price of NIS 0.01. The
rights of the recipients to exercise the options vest over a four-year period
from the grant date, 50% after two years and 25% after each of the third and
fourth years. The options generally expire following seven years as of their
date of grant. On January 30, 2006, InSightec's board of directors extended the
exercise period by additional 2-year period to nine years as of their date of
grant.
InSightec's 2003 Employee Stock Ownership Plan (the "2003 Employee Plan")
provides for the grant of up to 1,094,000 options (700,000 plus 394,000 that
were transferred from the 1999 Plan), at an exercise price that varies from
$5.85 to $16. Options granted under the 2003 Employee Plan generally vest after
a two-year period from the end of calendar year in which the options were
granted. On January 30, 2005 InSightec's board resolved to amend the 2003
Employee Plan so that the options granted under the 2003 Employee Plan after
January 30, 2005, would generally vest over a four-year period from the grant
date, 50% after two years and 25% after each of the third and fourth years. The
options generally expire following seven years as of their date of grant.
96
InSightec's 2003 Service Providers Plan (the "2003 Service Providers Plan")
provides for the grant of up to 300,000 options, at an exercise price of $5.50.
The board of directors will determine vesting term. The options generally expire
following seven years as of their date of grant.
InSightec's 2006 Stock Option Plan (the "2006 Plan") provides for the grant
of up to 400,000 options, at an exercise price equal to fair value at the date
of grant. On the board of directors from January 30, 2006, a resolution was made
to transfer the balance of unallocated options from the 2003 Employee Plan and
the 2003 Service Providers Plan to the 2006 Plan, in addition to the 400,000
options. The rights of the recipients to exercise the options vest over a
four-year period from the grant date, 50% after two years and 25% after each of
the third and the fourth years. The options generally expire following seven
years as of their date of grant or following 5 years if some criterions are met
as stipulated in the 2006 Plan.
As of May 31, 2006 the total amount of options in pool sums up to
4,050,000. 472,550 are available from which 250,000 options are reserved to Mr.
Mordechay Zisser, at an exercise price of $5.50.
Among the recipients of these plans InSightec issued 100,000 options to
Shimon Yitzhaki, a director of InSightec who also serves as a director of EMI.
Such options are exercisable into ordinary shares of InSightec, at an exercise
price of $3.33 per share until May 2010. Our shareholders approved the
allotment. InSightec also granted one of our executive officers Marc Lavine
options to purchase, at par value, 7,500 ordinary shares according to 2003
Employee Plan, exercisable until May 2010.
All of these four plans automatically vest and become exercisable without
any discretion on the part of InSightec's board of directors or compensation
committee upon certain events that constitute a material change to InSightec,
such as: a change of control; a resolution of InSightec's shareholders or their
board of directors for their dissolution or a distribution in kind of most of
their assets; types of mergers etc. Each of the above four plans contains a
first refusal right among the recipients.
The following table indicates share ownership and percentage ownership as
of May 31, 2006 in EMI and its subsidiaries, of all current directors and
officers:
NUMBER OF
NAME SHARES % ENTITY
---- ---------- ----- ---------
Mordechay Zisser 12,403,634* 48.73* EMI
Shimon Yitzhaki 83,765 ** EMI
100,000 ** InSightec
Rachel Lavine 53,000 ** EMI
Yehoshua (Shuki) Forer 7,000 ** EMI
Abraham (Rami) Goren 47,700 ** EMI
Moshe Lion 13,250 ** EMI
Marc Lavine 7,500 ** InSightec
* Includes 12,053,634 shares of EMI held by Europe-Israel, which may be
deemed indirectly beneficially owned by Mr. Mordechay Zisser by virtue of
his control of Europe-Israel through his control of Control Centers, see
"Item 7. Major Shareholders and Related Party Transactions - Major
Shareholders" below. On June 8, 2006, EMI granted to Mr. Zisser 350,000
options exercisable into 350,000 ordinary shares of EMI in consideration
for NIS 137.44 per option. The options were exercisable immediately upon
their grant for a three-year term.
** Less than 1% of the outstanding ordinary shares of the respective entity.
97
EMI has one class of shares. All of EMI's ordinary shares have the same
voting and equity rights.
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A. MAJOR SHAREHOLDERS
EMI had, as of May 31, 2006, 25,454,262 shares outstanding, excluding
2,800,000 ordinary shares held by EMI which do not have any voting and equity
rights. The following table sets forth certain information as of May 31, 2006,
concerning: (i) persons or entities who, to our knowledge, beneficially own more
than 5% of the outstanding ordinary shares of EMI, (ii) the number of ordinary
shares of EMI beneficially owned by all officers and directors of EMI as a
group:
NUMBER OF SHARES
NAME AND ADDRESS BENEFICIALLY HELD (1) PERCENTAGE
---------------- --------------------- ----------
Europe-Israel (M.M.S.) Ltd. 12,053,634 47.35
13 Mozes Street
Tel-Aviv, Israel (2)
Mordechay Zisser (3) 12,403,634 48.73
All officers and directors as a group
(11 persons) (4) 12,608,349 49.53
(1) The number of shares and percentage ownership is based on 25,454,262
ordinary shares outstanding as of May 31, 2006. Such number excludes
2,800,000 ordinary shares held by EMI, which do not have any voting or
equity rights. Beneficial ownership is determined in accordance with rules
of the SEC and includes voting and investment power with respect to such
shares. All information with respect to the beneficial ownership of any
principal shareholder has been furnished by such shareholder and, unless
otherwise indicated below, we believe that persons named in the table have
sole voting and sole investment power with respect to all the shares shown
as beneficially owned, subject to community property laws, where
applicable. The shares beneficially owned by the directors include the
ordinary shares owned by their family members to which such directors
disclaim beneficial ownership.
(2) Europe-Israel is a private Israeli subsidiary wholly owned by Control
Centers. Control Centers is controlled by Mr. Mordechay Zisser, the
executive chairman of the board of directors of EMI.
(3) Mordechay Zisser serves as Executive Chairman of our board of directors. In
addition, on June 8, 2006, EMI grant to Mr. Zisser of 350,000 options
exercisable into 350,000 ordinary shares of EMI in consideration for NIS
137.44 per option. The options are exercisable immediately upon their grant
for a three-year term.
(4) Includes 12,053,634 shares of EMI held by Europe-Israel, which may be
deemed indirectly beneficially owned by Mr. Mordechay Zisser by virtue of
his control of Europe-Israel through his control of Control Centers, as
described in footnote (2) above. In addition, on June 8, 2006, EMI granted
to Mr. Zisser 350,000 options exercisable into 350,000 ordinary shares
of EMI in consideration for NIS 137.44 per option. The options are
exercisable immediately upon their grant for a three-year term. On May 31,
2006, our shareholders approved a grant of options to our directors, see
also "Item 6. Directors, Senior Management and Key Employees - E. Share
Ownership - 2006 Employees, Directors and Officers Incentive Plan" above.
As of the date of this annual report, the conditions to the grant have not
yet been satisfied, and we expect the grant to occur during July 2006.
CHANGES IN MAJOR SHAREHOLDERS' HOLDINGS DURING THE LAST THREE YEARS
The following is a list of changes in major shareholders' holdings during
the last three years:
On May 17, 2006, Elscint sold 524,187 shares of EMI in consideration for
NIS 115 for each share, through a private transaction. The aggregate
consideration with respect to such sale was approximately NIS 60.2 million
(approximately $13.1_million). Prior to the reported transaction, part of these
shares did not have voting rights inasmuch as they were held by a subsidiary of
EMI. Following the transaction the shares sold will enjoy full equity and voting
rights.
98
On March 2, 2005 Bank Leumi Le'Israel Ltd. informed us that its mutual
funds and provident funds ceased to be a major shareholder of EMI.
As a result of the completion of a merger by way of exchange of shares
between EMI and Elscint, Elscint became a wholly-owned subsidiary of EMI and
each outstanding share of Elscint (other than Elscint ordinary shares held by
EMI and by or for the benefit of Elscint) was exchanged for 0.53 ordinary shares
of EMI. On December 2, 2005, EMI issued 3,479,216 ordinary shares to Elscint
shareholders (other than Elscint ordinary shares held by EMI and by or for the
benefit of Elscint). Such number excluded approximately 26,500 ordinary shares
of EMI that were issued upon exercise of options to purchase Elscint shares,
which EMI assumed in connection with the above merger.
As of May 31, 2006, there were approximately 887 holders of record of our
ordinary shares with addresses in the United States, holding approximately
22.73% of our issued and outstanding ordinary shares (excluding 2,800,000
ordinary shares held by us which do not have any voting and equity rights).
B. RELATED PARTY TRANSACTIONS
LEASE
EMI and its direct and indirect subsidiaries lease office space from
Control Centers and Europe-Israel, the parent of EMI.. See "Item 4. Information
on the Company - D. Property, Plants and Equipment" above. The lease agreements
were approved by our audit committee and board of directors as a
non-extraordinary transaction within the meaning of the Israeli Companies Law.
AMENDMENT TO TERMS OF OPTIONS GRANTED TO OUR EXECUTIVE CHAIRMAN OF THE
BOARD
In September 2001, we granted to Mr. Mordechay Zisser, the Executive
Chairman of our board of directors, options to purchase up to 350,000 of our
ordinary shares. The exercise price of the options, originally set at NIS 35.7
per share, was later amended to reflect changes in the exchange rate between the
NIS and the U.S. dollar and in December 2002, our shareholders approved a
further amendment of the exercise price to unlinked NIS 44 per option. In
September 2004, our shareholders approved a one-year extension of the exercise
period until September 8, 2005 and amended the exercise price to NIS 45.7 per
share. These options were exercised by Mr. Zisser on February 27, 2005, in
consideration for approximately NIS 16.0 million (approximately $3.6 million).
ALLOCATION OF COSTS AGREEMENT
At the annual general meeting of shareholders held on February 21, 2001,
our shareholders approved an agreement with Europe-Israel and Elscint, beginning
retroactively from January 1, 2000 and continuing until December 31, 2002, for
the allocation of costs and expenses incurred in connection with services
rendered to those companies by their in-house legal, economic and taxation and
accounting departments. The allocation would be carried out so that
Europe-Israel bears 35%, while Elscint and EMI each bear 32.5% of such costs.
These percentage shares reflect a general estimate of the companies' management
of the actual utilization rate of these departments' services by each of the
companies based on the actual services provided thereby during the first half of
2000. Should these percentage rates deviate from the actual service rates by
more than 10%, the parties will be charged on the basis of the actual cost
allocation. In November 2002, our audit committee and board of directors
approved the extension of the agreement for a three-year term until December 31,
2005 on which date the agreement was terminated.
MANAGEMENT SERVICES
Pursuant to an agreement dated February 28, 2001 in effect as of August 1,
2000 among us, our subsidiaries, PC and Elbit Ultrasound (Netherlands) B.V. and
Triple-S Holdings N.V. ("Triple-S"), an unrelated third party, Triple-S
undertook either itself or through Mr. Shmuel S. Smucha, its controlling
shareholder who acted at that time as the President and Chief Executive Officer
of PC, to render management services to PC. As consideration for such services,
Triple-S received a monthly fee of $40,000. In addition, Mr. Smucha was eligible
to receive from PC reimbursement of reasonable living expenses, as well as other
customary benefits. Triple-S was entitled to receive from PC a monthly loan of
$5,000, bearing market interest rates and repayable no later than December 31,
2004. This agreement was
99
terminated on December 31, 2003. Mr. Smucha continued to render services to PC
for one additional month, until January 31, 2004. Upon termination of the
agreement and Mr. Smucha's services, the parties finalized and settled all open
accounts and issues.
PRIVATE ISSUANCE OF SHARES TO TRIPLE-S
In March 2004, we issued 623,362 ordinary shares to Triple-S pursuant to an
agreement, dated February 28, 2001, between us, our subsidiaries PC and Elbit
Ultrasound (Netherlands) B.V. and Triple-S,. Under the agreement, we issued
250,000 ordinary shares to Triple-S in exchange for services provided by
Triple-S to PC and Triple-S's waiver of certain rights to purchase shares of
companies held by PC. In addition, under the terms of the agreement, we
undertook, following the lapse of approximately three years from the date of
such agreement (January 15, 2004), to review the market value of the 250,000
shares issued to Triple-S. In the event that the market value of such shares
would have been lower than $6 million, we undertook to pay Triple-S the
difference between the calculated market value and $6 million, either by cash or
by way of issuance of additional shares of EMI. According to our calculation,
the market value of the 250,000 shares was lower than $6 million, and therefore,
our board of directors approved the payment to Triple-S of the aforementioned
difference by way of issuance of additional 623,362 of our shares.
AGREEMENT FOR AVIATION SERVICES
Pursuant to an agreement between us and Jet Link Ltd. ("Jet Link"), an
aviation company wholly-owned indirectly by Control Centers, which was approved
by our shareholders on September 10, 2000, we, or our subsidiaries, may purchase
aviation services from Jet Link for our operations in the shopping and
entertainment centers business for up to 150 hours per annum in consideration
for payments in accordance with Jet Link's price list to unaffiliated companies
less a 5% discount. Due to our increasing business needs, we and our
subsidiaries purchased during 2003, 2004 and 2005 additional approximately 20,
70 and 200 flight hours from Jet Link, respectively under the same terms. The
purchase of the additional flight hours was approved by our audit committee and
board of directors as a non-extraordinary transaction within the meaning of the
Israeli Companies Law.
AGREEMENT FOR THE PURCHASE OF COORDINATION, PLANNING AND SUPERVISION
SERVICES OVER CONSTRUCTION PROJECTS
Companies controlled by the executive chairman of our board of directors,
are parties to various agreements with subsidiaries of PC, pursuant to which
such entities have agreed to provide services of coordination, planning,
execution and supervision over construction projects, to PC's subsidiaries, in
consideration for 5% of the actual construction costs of each such project
(excluding land acquisition cost, financing costs and general and administrative
costs), plus VAT. In addition, PC's subsidiaries will reimburse the said
companies, for all reasonable costs incurred in connection with the services
rendered thereby, not to exceed a total of $50,000 per project. Such agreements
were entered into pursuant to a framework agreement signed by us and Control
Centers (the parent company of these two companies), which was approved by our
shareholders meeting during 2000. The framework agreement was terminated on
December 31, 2002.
Following the termination of the above framework agreement pursuant to its
terms, a similar agreement for the receipt of such services for real estate
projects, subject to certain amendments, and the receipt of aviation service was
approved by our shareholders on May 31, 2006. Under the agreement entered into
between us and Control Centers we will receive from Control Centers (either
directly or through its subsidiaries or affiliates, other than the Company)
coordination, planning, execution and supervision services over our real estate
projects and/or real estate projects of our subsidiaries and/or affiliates in
consideration for a fee equal to 5% of the actual execution costs (excluding
land acquisition costs, financing cost and the consideration for Control Centers
under the agreement) of each such project. The agreement will apply to real
estate projects initiated following the approval of the agreement by the
Company's shareholders and to the following projects: (i) a shopping and
entertainment center in Liberec, Czech Republic; (ii) a shopping and
entertainment center in Kerepesi, Hungary; and (iii) a complex of shopping and
entertainment center, hotels, congressional centers and other facilities in
Obuda, Hungary, which are currently under early stage of development.
Such fee will be paid in installments upon the meeting of milestones as
stipulated in the agreement. In addition, the Company will reimburse Control
Centers for all reasonable costs incurred in connection with the services
rendered thereby, not to exceed a total of E75,000 ($88,000) per real estate
project.
100
If the purpose of a real estate project is changed for any reason prior to
the completion of the project or if the development of the real estate project
is terminated for any reason (including the sale of the real estate project),
the payment to Control Centers will be calculated as a percentage of the budget
for the project, provided that such percentage shall not exceed the percentage
determined for the next milestone of the project had it had continued as
planned. The calculation of such payments to Control Centers will be subject to
the approval of an external accountant and the approval of the audit committee
and board of directors.
In addition, the Company and/or its subsidiaries and/or affiliates may also
purchase from Control Centers through Jet Link up to 125 flight hours per
calendar year in consideration for payments to Jet Link in accordance with its
price list to unaffiliated companies less a 5% discount. This Agreement does not
derogate from a previous agreement entered into between us and Jet Link for the
purchase of aviation services which was approved by our shareholders on
September 10, 2000, see "- agreement for aviation service" above.
The agreement with Control Centers has a five-year term commencing on May
31, 2006.
AGREEMENT FOR THE PURCHASE OF COORDINATION, PLANNING AND SUPERVISION
SERVICES OVER THE BUCURESTI HOTEL COMPLEX
In October 2001, an engagement between Bucuresti and Control Centers
(thought its wholly owned subsidiary) was approved at an Elscint shareholders'
meeting. In accordance with such engagement, Control Centers provides
coordination, planning and supervision services with respect to the renovation
works of the Bucuresti Hotel complex, for a fee equal to the lower of (i) 5% of
total actual costs of the renovation works (excluding general and administrative
as well as financing costs); and (ii) 5% of $30 million. The parties are yet to
execute a definitive agreement.
A TURN KEY CONTRACTOR AGREEMENT REGARDING THE ARENA CENTER
In May 2002, Elscint's shareholders approved a turn-key agreement by and
between S.L.S. Sails Ltd. ("SLS"), our indirect wholly owned subsidiary (which
holds the rights in the Arena Center in Herzliya, Israel), and C.D.P.M. Kft.,
("CDPM"), a subsidiary of Control Centers, for the completion of the
construction of the Arena in consideration of $57.7 million. The consideration
was determined on the basis of a calculation of the amount of work remaining to
be preformed as at February 28, 2002. The consideration was subject to
adjustments and reductions in respect of payments made by SLS to third parties
sub-contractors, suppliers and consultants from March 1, 2002, up to the
commencement of works by CDPM. In June 2003, CDPM assigned its rights and
obligations under the agreement to another company controlled by Control
Centers, Castara Construction Servicing Limited Liability Company ("CCS"). The
total consideration paid to CCS by SLS (including adjustments which were
approved by Elscint's audit committee and Elscint's board of directors
subsequent to the assignment date) amounted to NIS 161.8 million. Such
consideration includes approximately $2.3 million paid by SLS to CCS pursuant to
an arbitration held between the parties in March 2004 in connection with CCS'
allegations regarding the construction works in the Arena. Elscint received from
Control Centers a construction performance quality guarantee, in the amount, as
of December 31, 2005, of $1.6 million.
We furnished the local municipality, with a bank guarantee to secure
payment of certain land betterment tax, in an amount of approximately $1.0
million. Arbitration is currently being held as to this tax liability between
Marina Herzliya Limited Partnership Ltd. (a company controlled by Control
Centers) and the local municipality. We estimate, based on professional opinion
that no significant costs will be borne thereby, in respect of this guarantee.
TAX ARRANGEMENT
During 2004, we, Europe-Israel and Elscint have finalized an arrangement
with the Israeli Tax Authority, with effect from December 31, 2002, whereby a
new tax basis has been determined for our investments (on consolidated basis) in
foreign subsidiaries ("regulated revaluation" and "regulated assets"). The
arrangement provides for no additional tax to be imposed in Israel on gains
generated from the realization of regulated assets, and on dividends distributed
therefrom, and all up to the amount of the regulated revaluation. Provision for
those tax payments under the
101
arrangement has been recorded in our statement of operations for the years 2002
through 2004, under the tax expenses for previous years' item. Taxes which
relate to capital reserves from foreign currency translation adjustments
deriving from the regulated profits were charged to capital reserves.
LOAN AGREEMENT WITH BANK HAPOALIM B.M.
Within the framework of our loan agreements with Bank Hapoalim B.M. the
bank has agreed to waive all our financial covenants in the event certain
conditions are met, including conditions relating to Europe-Israel. See "Item 5.
Operating and Financial Review and Prospects - B. Liquidity and Capital
Resources - Other Loans" above.
COMPENSATION
For details regarding compensation granted to our directors and officers,
including securities issued to our directors and officers under different
incentive plans, see "Item 6. Directors, Senior Management and Key Employees -
B. Compensation and E. - Share Ownership" above.
INDEMNIFICATION, INSURANCE AND EXEMPTION
For details regarding the grant of insurance, exemption and indemnification
to our directors and officers, see "Item 6. Directors, Senior Management and Key
Employees - B. Compensation" above.
RELATED PARTY GUARANTEES
We provide from time to time, guarantees to financial institutions or other
unrelated parties in connection with undertakings, monetary and others, that are
assumed by our subsidiaries. Details as to material guarantees are provided in
"Item 5. Operating and Financial Review and Prospects - B. Liquidity and Capital
Resources - Loans" above.
ITEM 8. FINANCIAL INFORMATION
A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION
See our consolidated financial statements included in Item 18 below.
B. SIGNIFICANT CHANGES
LEGAL PROCEEDINGS
1. In November 1999, a number of institutional and other investors, holding
shares in Elscint, filed a lawsuit in the Haifa District Court against EMI,
Elscint, Europe Israel, Control Centers and others. The plaintiffs also
requested the certification of their claim as a class action suit on behalf of
all those who had held Elscint shares on September 6, 1999, and continued to do
so as at the filing date of the suit (excluding the Company and certain other
shareholders). The claim alleges discrimination against Elscint's minority
shareholders arising from various transactions or activities carried out by its
controlling shareholders and directors, which allegedly caused them financial
loss, manifested by the 45% ($100 million) decline in the value of Elscint's
shares in the period from February 24, 1999 to the claim's filing date.
The principal remedy requested in the claim is a court order instructing
EMI to carry out a tender offer of Elscint's shares at $14 per share as the
former allegedly undertook, in its letter to Elscint of February 1999, or
alternatively, to purchase the shares in their possession, at a price to be
determined by the Court. As another alternative, the plaintiffs requested the
court to issue an injunction prohibiting execution of the September 9, 1999
transactions (acquisition of the hotel operations and the Arena commercial
center in the Herzliya Marina, by Elscint, from Europe Israel and Control
Centers, respectively) and the refund of all and any amounts paid thereunder.
Part of the remedies were requested as a derivative claim on behalf of Elscint.
102
Although the Haifa District Court has rejected the class-action request, it
was ruled that the plaintiffs may, notwithstanding so rejecting the request for
class-action proceedings, pursue their matter. In November 2001, the plaintiff's
were granted leave to appeal to the Supreme Court regarding the Court's
decision. EMI and the plaintiffs presented their respective pleadings. As of May
31, 2006, the Court has not yet rendered its decision in the motion for leave to
appeal.
Management of EMI believes, based, inter alia, on legal opinions, that the
final outcome of this case cannot be estimated at this stage.
In January 2003, EMI received a letter from one of the insurers of Europe
Israel, EMI and Elscint, that provides insurance to the Insured companies
including insurance pertaining to the representative claim described above.
In this letter, the Insurer made certain allegations against the Insured
Companies, including, inter alia, that the Insured Companies breached their
disclosure duties under Section 6(a) to the Insurance Contract Law, 1981, by
failing to disclose to the Insurer material information prior to the issuance of
additional cover to the policy purchased by Europe Israel, effective as of July
1999, and prior to the replacement of the Policy and the Additional Cover by the
issuance of a new policy effective as of August 1999. The letter states that the
Policy, Additional Cover and Replacement Cover issued by the Insurer will be
cancelled unless the Insured Companies indicate that circumstances were
different than those described in the letter. EMI's legal counsel sent a reply
on behalf of the Insured Companies on March 20, 2003, in which the allegations
of the Insurer were rejected. As of May 31, 2006 EMI has not received an answer
from the Insurer to this letter. However, the parties are currently negotiating
to reach a settlement.
In January 2006, EMI and Elscint entered into an agreement with one of the
insurers, different from the insurer described above, which insured EMI and
Elscint, inter alia, with respect to the lawsuit described above. In accordance
with the terms of the agreement EMI, Elscint and their former and current
directors and officers released the insurer from all liabilities that will arise
from the abovementioned claim in consideration for a one-time payment in the
amount of $0.2 million (NIS 0.9 million).
2. EMI, Elscint and others were served with a claim as well as a motion to
recognize same as a class-action, in respect of damage amounting to $158
million, allegedly caused to the represented class. Underlying the claim is the
contention that EMI, through Elscint's board of directors, caused damage to and
discriminated against minority shareholders of Elscint. Both parties agreed to
postpone the hearing in this case until the Supreme Court hands down a decision
on the leave to appeal, as detailed in section (1) above. Management, based on
legal advice, is of the opinion that it is not possible at this stage to
estimate the outcome of the claim and the motion for class-action recognition.
3. As of December 31, 2005, we are a party to several additional court
claims as well as certain other written demands and/or claims, filed against us
by third parties (including governmental institutions) in connection with
terminated activity, some without any specified amount, while others, in the
aggregate amount of $41.6 million, as royalties or compensation for damages
allegedly caused as a result of the companies' actions and/or products, which
mainly relate to the medical imaging business sold by EMI and Elscint in 1998
and 1999. In respect of certain claims, totaling approximately $5.8 million, our
managements estimate, based on legal opinion and/or on past experience, that no
significant costs will accrue thereto as a result of said claims exceeding the
provisions included in respect thereof in the financial statements, and that
such provisions are adequate for covering the costs and resources required to
settle the liabilities arising therefrom. Elscint's legal advisers cannot
presently determine the outcome of other written demands, totaling $35.8
million in addition to claims without any specified amount. Elscint's management
believes that the prospects for realization of most such demands are remote,
based on the time that has elapsed since serving said demand and on the nature
thereof. We have included in our financial statements provisions that are, as
per our discretion based inter alia on specific counsels and past experience,
adequate to cover the costs and resources required to settle the liabilities
under these claims.
4. Elscint was served in 2003 with a motion filed by a third party seeking
an injunction to prohibit Elscint from using the trade name "Arena" for the
entertainment and commercial center in the Herzliya Marina in Israel, on the
grounds of unlawful usage of same, exploitation of goodwill and unfair
competition. In the event the plaintiff's contention is upheld, Elscint may
suffer certain indirect losses and costs. An application for an interim
injunction, prohibiting the use of the trade name "Arena," was dismissed by the
court. On March 20, 2006 the judge
103
dismissed the lawsuit against the Company. The Plaintiff has the right appeal
the courts decision up to April 27, 2006. Since the period to serve the appeal
has expired we expect, inter alia, on legal opinion that such appeal will not be
served.
5.
a. A criminal investigation carried out against a number of suspects
(including former officers in the State Ownership Fund of the Romanian
government who were involved in the privatization procedures and the sale of
control in Bucuresti Tourism S.A. ("Bucuresti") to a wholly owned Romanian
subsidiary of BEA known as "Domino") for certain events relating to the period
prior to the acquisition of control in Bucuresti by B.H., culminated in the
filing of an indictment against 17 defendants. Such criminal proceedings may
have an indirect effect on the validity of the privatization and thereby an
indirect effect on Domino's rights in Bucuresti, notwithstanding that Domino was
not an accused party under the indictment. The Court has decided to return the
indictment to the Prosecution Office for its resubmission. After the appeal
against this decision has been rejected by the court, this case is no longer
pending in front Romanian Courts of justice.
b. In the framework of an agreement to establish a joint company owned by
Bucuresti and a third party, which was signed prior to the acquisition of
Bucuresti by BEA, such third party undertook to invest $27.0 million (NIS 124.3
million) in the joint company and in consideration Bucuresti undertook to
transfer its rights in the Bucuresti Complex to the ownership of the joint
company. As a result of the third party's failure to meet its obligations
thereunder, Bucuresti has terminated the partnership agreement and filed an
application to the Court to liquidate the joint company. This application was
approved by the Court. The third party has submitted an appeal to the Supreme
Court. On June 3, 2005, the Supreme Court irrevocably rejected this appeal.
Accordingly, there is no risk that Bucuresti will be forced to transfer its
rights in the Bucuresti Complex to the joint company.
c. Bucuresti was served with two claims, which challenged its ownership in
the Bucuresti Hotel Complex. Both of the claims are pending on the Bucharest
Court of Appeals. Management believes based, inter alia, on legal opinion that
Bucuresti is expected to win those claims.
d. In June 2005, certain individuals submitted their final appeal to the
Supreme Court requesting the nullification of the public tender for the sale of
the Bucuresti shares, the privatization contract and the transfer of the
Bucuresti shares to Domino. This case was ruled in favour of Domino in the
previous procedural stages (first instance and appeal) on technicalities, since
the application for the cancellation of the privatization contract was served
after the 3 months term during which any interested person could file an
application for the cancellation of the privatization. EMI expects - based,
inter alia, on legal opinion- that Domino will win this case. In addition our
legal counsel stated that in the event that the Supreme Court will rule in favor
of the plaintiffs, the privatization contract will be cancelled with the effect
of returning the parties to their original position before the contract was
accepted.
e. In addition to the above, certain legal proceedings are being conducted
from time to time in Romania within the framework of which it is claimed that
resolutions passed at the general meetings of shareholders of Bucuresti
104
were not validly adopted - for procedural reasons only - and are therefore not
binding. Some were approved by the Courts, in respect of some Domino has filed
appeals, and others were rejected.
BEA's management is of the opinion that the claims will not significantly
affect BEA's rights in the shares of Bucuresti and in the Bucuresti Complex.
8. On April 5, 2006, Cukierman Real Estate Ltd. filed a summary procedure
claim before the District Court of Tel-Aviv against EMI and PC. Within the
framework of this claim, the District Court has been requested to order the
Defendants to pay the Plaintiff the amount of NIS 10,751,920 (approximately
E1,899,632) as an intermediary brokerage fee arising out of the sale by EMI
to Klepierre S.A. of its shopping centers in Poland and Czech Republic. An
application for leave to defend has not yet been filed. On May 8, 2006, EMI
filed a motion to strike out the claim in limine or alternatively to strike out
the title "summary procedure". EMI believes, based, inter alia, on legal
opinions, that the chances that a substantial part of the claim or the claim as
a whole to be dismissed are good.
9. In December 2005, Elscint was served with a statement of a claim filed
with the Regional Court by Elscint's former employee requesting that Elscint
compensate him for damages resulting from his Cancer disease, allegedly caused
to him by exposure to radiation, in the amount of NIS 315,000 and other
undefined compensation. The insurance company rejected its liability and claimed
that such radiation is excluded from the policy. Elscint has approached a
radiation expert to receive an expert opinion. A statement of defense and third
party notice against the insurance company has not yet been submitted.
Management of the Company, based, inter alia, on legal opinion received,
believes that the potential financial consequences of this claim can not be
estimated at this early stage of legal proceedings.
10. On April 11, 2006, Eliahu Razin, Bellway LLC and Monilen Enterprises
Limited filed a claim before the District Court of Tel-Aviv against Elscint, the
chairman of the board of directors of Elscint, Elscint's directors and officers
and against companies controlled by Elscint.
Pursuant to this claim, the District Court has been asked to declare that
Bellway LLC is the legal owner of 20% of the shares of Domino, to enforce an
agreement signed by the parties and to order the defendants to pay the
plaintiffs their damages in the amount of NIS 25 million (approximately $5.43
million). A Statement of Defense has not yet been filed.
EMI's management believes based, inter alia, on legal opinions that the
chances of a substantial part of the claim or the claim as a whole to be
dismissed are good.
10. In March 2005, an action was instituted at the Regional Labor Court in
Tel-Aviv-Jaffa by an employee of Europe Israel against Mr. Mordechay Zisser
(executive chairman of EMI's Board of Directors), Control Centers and Vectory
Investment Company Ltd. (controlling shareholders of EMI), in terms of which,
the Court was requested to issue a declaratory order establishing the
Plaintiff's entitlement to 14% of the shares of the companies specified in the
statement of claim - including shares of EMI, Elscint, InSightec, Gamida, Olive,
Easy Run and VCON - which are directly or indirectly, owned and/or controlled by
the defendants and/or by companies under control thereof. The Court was further
requested to order the transfer of such 14% to escrow.
The Plaintiff also filed, simultaneously, a motion to grant an interim
injunction prohibiting the defendants and/or any party on their behalf, from
making any change to and/or transfer and/or assignment and/or pledge of and/or
disposition in 14% of the shares of those companies detailed in the motion.
Underlying the claim is the contention that the Plaintiff's rights under the
statement of claim derive from agreements executed by and between the Plaintiff
and the defendant companies.
On March 27, 2005, the Labor Court dismissed substantially all of the
Plaintiff's motion, in determining that the Plaintiff failed to provide evidence
establishing: (i) his prima facie right to 14%, as he claimed; (ii) his
entitlement to rights in and to companies aside from those directly invested by
Europe Israel; (iii) his right to shares in EMI, Elscint, Insightec and Gamida.
The above action was erased at the request of the plaintiff.
The Plaintiff filed in October 2005, a lawsuit in the Regional Labor Court
in Tel-Aviv-Jaffa against Vectory. The Plaintiff requested the court to issue a
mandatory injunction against Vectory ordering it to transfer the Plaintiff
shares of the companies specified in the statement of claim - including 2,500
shares of EMI, 1,000 shares of Elscint,
105
1,250 shares of InSightec, 1,500 of Gamida, 2,000 of EasyRun, 2,000 of Olive and
shares of other companies within the Europe Israel group of companies. The
Plaintiff evaluated his claim to an aggregate amount of NIS 285,000
(approximately $61,900). In January 2006, Vectory filed a statement of defense]
Underlying the claim is the contention that the Plaintiff's rights under
the statement of claim derive from an agreement executed in 1998 by and between
the Plaintiff and Vectory. This Agreement was terminated by Vectory due to
different breaches of the Agreement by the Plaintiff. It should be noted that
the conclusions made by the court in the framework of the provisional
proceedings of the above previous claim sided with Vectory's interpretation of
the Agreement.Although we are not parties to the claim, the outcome thereof
might indirectly affect the nature and scope of their rights in their investee
companies.
Vectory is of the opinion that this claim, insofar as it relates to us as
included in the claim, is provocative, fundamentally unfounded and groundless
(both with respect to the number of the companies in which rights are sought and
with respect to the scope of rights claimed) and that it will not materially
affect its rights in us. However, the defendants' legal counsel cannot, at this
early stage, estimate the outcome of the claim.
In May 25, 2006, the Plaintiff filed an additional lawsuit in the District
Court in Tel-Aviv-Jaffa against EMI, Mr. Zisser and/or Control Centers and/or
EMI's board members and/or the management companies related to Mr. Zisser and
Control Centers, requesting the court to state the annulment of any decision
made by EMI for granting of any benefits to Mr. Zisser and/or Control Centers
using shares the subject of Plaintiff's claimed.
Alternatively, the Plaintiff requested the court to determine that the
Plaintiff's claimed rights to EMI's shares will be taken into account as an
opposing side to any decision made in any general meetings of EMI, while
reserving the Plaintiff's rights to take legal proceedings to prevent
infringement of his rights as a minority shareholder in EMI. Alternatively, the
Plaintiff requested the court to determine that in every general meeting that
convenes for determining the above stated decisions, the Plaintiff's claimed
rights to EMI's shares will not be considered as taking any side in the
decisions, while reserving his above legal rights. Management, based on legal
advice received is of the opinion that it is not possible at this early stage to
estimate the outcome of the claim.
ORDINARY COURSE OF BUSINESS
We are involved from time to time in litigation arising in the ordinary
course of our business. Although the final outcome of each of these cases cannot
be estimated at this time, our management believes, based on legal advice, that
the resolution of such litigation will not have a material adverse effect on our
financial position.
ITEM 9. THE OFFER AND LISTING
A. OFFER AND LISTING DETAILS
The ordinary shares of EMI are quoted on Nasdaq under the symbol "EMITF"
and are listed on the TASE.
The annual high and low sale prices for our ordinary shares for the five
most recent full financial years are:
NASDAQ TASE
------------------ ------------------
YEAR ENDED DECEMBER 31, HIGH ($) LOW ($) HIGH ($) LOW ($)
- ----------------------- -------- ------- -------- -------
2005 19.54 8.9 19.18 9.01
2004 10 6.92 9.97 7.21
2003 7.14 3.70 6.91 3.80
2002 7.71 4.50 7.40 4.50
2001 6.30 4.23 6.60 4.45
The quarterly high and low sale prices for our ordinary shares for the two
most recent full financial years and the first subsequent quarter are:
106
NASDAQ TASE
------------------ ------------------
HIGH ($) LOW ($) HIGH ($) LOW ($)
-------- ------- -------- -------
2006
First Quarter 20.04 15.28 20.05 15.37
2005
First Quarter 16.21 8.9 16.00 9.01
Second Quarter 19.54 14.38 19.37 14.40
Third Quarter 19.32 15.74 19.18 15.70
Fourth Quarter 16.99 14.75 16.78 14.84
2004
First Quarter 9.35 6.92 9.76 7.21
Second Quarter 8.61 7.24 8.28 7.35
Third Quarter 9.43 7.28 9.35 7.36
Fourth Quarter 10 7.71 9.97 7.82
The monthly high and low sale prices for our ordinary shares during the six
months of December 2005 through May 2006 were:
NASDAQ TASE
------------------ ------------------
MONTH HIGH ($) LOW ($) HIGH ($) LOW ($)
- ----- -------- ------- -------- -------
May 2006 26.2 23.04 26.13 23.40
April 2006 22.76 19.03 23.67 18.40
March 2006 20.04 16.16 20.05 16.43
February 2006 16.9 15.52 17.04 15.55
January 2006 17.5 15.28 17.67 15.37
December 2005 16.54 14.78 16.64 15.48
The closing price of our ordinary shares on Nasdaq on May 31, 2006 was
$24.49, and on the TASE was $24.88.
The closing prices of our ordinary shares listed on the TASE for each of
the periods referred to in the tables above have been translated into dollars
using the representative rate of exchange of the NIS to the U.S. dollar as
published by the Bank of Israel on the same dates.
B. PLAN OF DISTRIBUTION
Not applicable.
C. MARKETS
Since our initial public offering in November 1996, our ordinary shares
have been traded both on the Tel-Aviv Stock Exchange and on NASDAQ Stock Market
under ticker symbol "EMITF". Prior to such date, EMI was a privately held
corporation.
D. SELLING SHAREHOLDERS
Not applicable.
E. DILUTION
Not applicable.
F. EXPENSES OF THE ISSUE
107
Not applicable.
ITEM 10. ADDITIONAL INFORMATION
A. SHARE CAPITAL
Not applicable
B. MEMORANDUM AND ARTICLES OF ASSOCIATION AND GENERAL PROVISIONS OF ISRAELI
LAW
TRANSFER AGENT
Our transfer agent in the United States is American Stock Transfer and
Trust Company whose address is 59 Maiden Lane New York, New York 10038.
PURPOSES AND OBJECTS OF THE COMPANY
We are a public company registered under the Israeli Companies Law of 1999
as Elbit Medical Imaging Ltd., registration number 52-004303-5.
Pursuant to Section 2 of our memorandum of association, we were formed for
the purpose of operating in the development, manufacture, compilation, sale and
service of technological and electronic systems in the field of medical imaging
and ancillary products. In addition, we are also empowered to operate in any
business or matter for profit purposes as shall be determined by the board of
directors of the Company from time to time. In addition, our articles of
association authorizes us to make, from time to time, contributions of
reasonable sums for worthy causes even if such contributions do not fall within
our business considerations as referred to in Section 11 of the Companies Law.
APPROVAL OF CERTAIN TRANSACTIONS
Generally, under the Companies Law, engagement terms of directors,
including the grant of an exemption from liability, purchase of directors' and
officers' insurance, or grant of indemnification (whether prospective or
retroactive) and engagement terms of such director in other positions require
the approval of the audit committee, the board of directors and the shareholders
of the company. In addition, transactions between a public company and its
officers (other than directors) or a transaction between such company and other
person in which such officer (other than directors) has a personal interest must
be approved by such company's board of directors, and if such transaction is
considered an extraordinary transaction (as defined below) it must receive the
approval of such company's audit committee as well.
The Companies Law also requires that any extraordinary transaction between
a public company and its controlling shareholder or an extraordinary transaction
between such company and other person in which such company's controlling
shareholder has a personal interest must be approved by the audit committee, the
board of directors and the shareholders of the company by a an ordinary
majority, provided that (i) such majority vote at the shareholders meeting shall
include at least one third (1/3) of the total votes of shareholders having no
personal interest in the transaction, present and voting at the meeting
(excluding abstaining votes); or (ii) the total number of votes of shareholders
mentioned in clause (i) above who voted against such transaction does not exceed
one percent (1%) of the total voting rights in the company.
The Companies Law prohibits any director who has a personal interest in a
matter to participate in the discussion and voting pertaining to such matter in
the company's board of directors or audit committee except for in circumstances
when the majority of the board of directors have a personal interest in the
matter and then such matter must be approved by the company's shareholders.
Our articles of association further provide that, subject to the Companies
Law, all actions executed by the board of directors or by a committee thereof or
by any person acting as a director or a member of a committee of the
108
board of directors or by the general manager will be deemed to be valid even if,
after their execution, it is discovered that there was a certain flaw in the
appointment of such persons or that any one of such persons was disqualified
from serving at his or her office.
For the purpose of this section:
An "extraordinary transaction" is defined in the Companies Law as any of
the following: (i) a transaction not in the ordinary course of business; (ii) a
transaction that is not on market terms; or (iii) a transaction that is likely
to have a material impact on the company's profitability, assets or liability.
A "personal interest" is defined in the Companies Law as a personal
interest of a person in an act or transaction of a company, including: (i) a
personal interest of that person's relative (i.e. spouse, brother or sister,
parent, grandparent, child, child of such person's spouse or the spouse of any
of the above); or (ii) a personal interest of another entity in which that
person or his or her relative (as defined above) holds 5% or more of such
entity's issued shares or voting rights, has the right to appoint a director or
the chief executive officer of such entity, or serves as director or chief
executive officer of such entity. A personal interest resulting merely from
holding the company's shares will not be deemed a personal interest.
FIDUCIARY DUTY AND DUTY OF CARE OF DIRECTORS AND OFFICERS
The Companies Law codifies the duties Officers owe to a company. An
"Officer" is defined in the Companies Law as a director, general manager,
general business manager, executive vice president, vice president, any other
person assuming the responsibilities of any of the foregoing positions without
regard to such person's title and other managers directly subordinate to the
general manager. The Officer's principal duties to the company are a duty of
care and a fiduciary duty to act in good faith for the company's benefit as
detailed in the Companies Law.
DUTY OF A SHAREHOLDER
Under the Companies Law, a shareholder, in exercising his rights and
fulfilling his obligations to the company and the other shareholders, must act
in good faith and in a customary manner and refrain from improperly exploiting
his power in the company, including when voting at general or class meetings of
shareholders on: (a) any amendment to the articles of association; (b) an
increase of the company's authorized share capital; (c) a merger; or (d) the
approval of related party transactions. In addition, a shareholder shall refrain
from prejudicing the rights of other shareholders. The laws governing breach of
contracts apply, with necessary modifications, to a breach of the above
obligations. Furthermore, any controlling shareholder, any shareholder who knows
that he possesses power to determine the outcome of the shareholders' vote at a
general or a class meeting, and any shareholder that, pursuant to the provisions
of the articles of association, has the power to appoint or prevent the
appointment of an officer in the company or possesses any other power towards
the company, is subject to a duty to act in fairness towards the company. A
breach by any such shareholder of this duty is treated similarly to a breach of
a fiduciary duty of an officer, with the applicable changes. The Companies Law
does not detail the substance of this duty.
BOARD OF DIRECTORS
In accordance with our articles of association, the directors may, from
time to time, at their discretion, raise or borrow or secure the payment of any
sum or sums of money for the purposes of EMI. The directors may secure the
repayment of such sum or sums in such manner and upon such terms and conditions
in all respects as they think fit, and in particular by the issue of debentures
or debenture stock of EMI charged upon all or any part of the property of EMI
(both present and future) including its uncalled capital for the time being.
Neither our memorandum or our articles of association, nor the laws of the
State of Israel require retirement or non-retirement of directors at a certain
age, or share ownership for director's qualification, nor do they contain any
restriction on directors' borrowing powers.
109
Our articles of association provide that the board of directors may
delegate all of its powers to such committees of the board of directors as it
deems appropriate, subject to the provisions of the Companies Law. See "Item 6.
Directors, Senior Management and Employees - C. Board Practices" above.
INDEMNIFICATION, EXEMPTION AND INSURANCE OF DIRECTORS AND OFFICERS
The Israeli Companies Law permits a company to insure its directors and
officers, provide them with indemnification, either in advance or retroactively,
and exempt its directors and officers from liability resulting from their breach
of their duty of care towards the company, all in accordance with the terms and
conditions specified under Israeli law. Our articles of association include
clauses allowing us to provide our directors and officers with insurance,
indemnification and to exempt them from liability subject to the terms and
conditions set forth by the Companies Law, as described below.
Subject to statutory limitations, our articles of association provide that
we may insure the liability of our directors and officers to the fullest extent
permitted by the Companies Law. Without derogating from the aforesaid we may
enter into a contract to insure the liability of our directors and officers for
an obligation imposed on them in consequence of an act done in their capacity as
directors or officers of EMI, in any of the following cases:
- a breach of the duty of care vis-a-vis us or vis-a-vis another person;
- a breach of the fiduciary duty vis-a-vis us, provided that the
director or officer acted in good faith and had a reasonable basis to
believe that the act would not harm us;
- a monetary obligation imposed on him in favor of another person.
- any other matter in respect of which it is permitted or will be
permitted under applicable law to insure the liability of our director
or officer.
Our articles of association further provide that we may indemnify our
directors and officers, to the fullest extent permitted by the Companies Law.
Without derogating from the aforesaid, we may indemnify our directors and
officers for liability or expense imposed on him in consequence of an action
made by him in the capacity of his position as a director or officer of EMI, as
follows:
- Any financial liability he incurs or imposed on him or her in favor of
another person in accordance with a judgment, including a judgment
given in a settlement or a judgment of an arbitrator, approved by a
court.
- Reasonable litigation expenses, including legal fees, incurred by the
director or officer or which he was ordered to pay by a court, within
the framework of proceedings filed against him by or on behalf of EMI,
or by a third party, or in a criminal proceeding in which he was
acquitted, or in a criminal proceeding in which he was convicted of a
felony which does not require a finding of criminal intent.
- Reasonable litigation expenses, including legal fees he incurs due to
an investigation or proceeding conducted against him by an authority
authorized to conduct such an investigation or proceeding, and which
was ended without filing an indictment against him and without being
subject to a financial obligation as a substitute for a criminal
proceeding, or that was ended without filing an indictment against
him, but with the imposition of a financial obligation, as a
substitute for a criminal proceeding relating to an offence which does
not require criminal intent, within the meaning of the relevant terms
in the Companies Law.
- Any other obligation or expense in respect of which it is permitted or
will be permitted under law to indemnify a director or officer of ENI.
In addition, our articles of association provide that we may give an
advance undertaking to indemnify a director and/or an officer in respect of all
of the matters above, provided that with respect to the first matter above, the
undertaking is restricted to events, which in the opinion of our board of
directors, are anticipated in light of our actual
110
activity at the time of granting the obligation to indemnify and is limited to a
sum or measurement determined by our board of directors as reasonable under the
circumstances. We may further indemnify an officer therein, save for the events
subject to any applicable law. Our articles of association further provide that
we may exempt a director or officer in advance and retroactively for all or any
of his liability for damage in consequence of a breach of the duty of care
vis-a-vis EMI, to the fullest extent permitted by the Companies Law.
Notwithstanding the foregoing, the Companies Law prohibits a company to exempt
any of its directors and officers in advance from their liability towards such
company for the breach of its duty of care in distribution, as defined in the
Companies Law, for such company's shareholders (including distribution of
dividend and purchase of such company's shares by the company or an entity held
by it).
The above provisions with regard to insurance, exemption and indemnity are
not and shall not limit the Company in any way with regard to its entering into
an insurance contract and/or with regard to the grant of indemnity and/or
exemption in connection with a person who is not an officer of the Company,
including employees, contractors or consultants of the Company, all subject to
any applicable law.
All of the above shall apply mutatis mutandis in respect of the grant of
insurance, exemption and/or indemnification for persons serving on behalf of the
Company as officers in companies controlled by the Company, or in which the
Company has an interest.
The Companies Law provide that companies may not give insurance,
indemnification (including advance indemnification), or exempt their directors
and/or officers from their liability in the following events:
- a breach of the fiduciary duty, except for a breach of the fiduciary
duty vis-a-vis the company with respect to indemnification and
insurance if the director or officer acted in good faith and had a
reasonable basis to believe that the act would not harm the company;
- an intentional or reckless breach of the duty of care, except for if
such breach was made in negligence;
- an act done with the intention of unduly deriving a personal profit;
or
- a fine imposed on the directors or officer.
RIGHTS ATTACHED TO SHARES
Our registered share capital consists of a single class of 50,000,000
ordinary shares, par value NIS 1 per share, of which 28,254,262 ordinary shares
were issued and outstanding as of June 20, 2006. Such number includes 2,800,000
shares held by us or for our benefit which do not have any voting or equity
right so long as they are held by us.
The rights attached to all of the ordinary shares are as follows:
DIVIDEND RIGHTS
Subject to the rights of persons, if any, entitled to shares with special
rights as to dividend, or whose rights to dividend are limited in any way, all
dividends shall be declared and paid according to the amounts paid or credited
as paid on the shares in respect whereof the dividend is paid, but no amount
paid or credited as paid on a share in advance of calls shall be treated as paid
on the share. All dividends shall be apportioned and paid proportionately to the
amounts paid or credited as paid on the shares during any portion or portions of
the period in respect of which the dividend is paid; but if any share is issued
on terms providing that it shall rank for dividend as from a particular date,
such share shall rank for dividend accordingly.
The board of directors may propose a dividend only out of profits, in
accordance with the provisions of the Companies Law. Declaration of a dividend
requires approval by an ordinary shareholders' resolution, which may decrease,
but not increase, the amount proposed by the board of directors.
111
If a year passes after a dividend has been declared and such dividend
remains unclaimed, the board of directors is entitled to invest or utilize the
unclaimed amount of dividend in any manner to the benefit of the Company until
it is claimed. We are not obligated to pay interest on an unclaimed dividend.
VOTING RIGHTS
Holders of ordinary shares have one vote for each ordinary share held by
them on all matters submitted to a vote of the shareholders. Such voting rights
may be affected by the creation of any special rights to the holders of a class
of shares with preferential rights that may be authorized in the future in the
manner provided for under the Companies Law and our Articles of Association. The
quorum required for an ordinary meeting of shareholders consists of at least two
shareholders present in person or by proxy who hold or represent, in the
aggregate, at least 33 1/3% of the issued voting share capital. In the event
that a quorum is not present within half an hour of the scheduled time, the
meeting shall be adjourned to the same day of the following week, at the same
time and place, or to such other day, time and place as the board of directors
shall determine by notice to the shareholders. If at such adjourned meeting a
quorum is not present within half an hour of the scheduled time, the two members
present in person or by proxy will constitute a quorum.
As the Nasdaq Marketplace Rules provide for a quorum to be not less that
33.33% of the outstanding shares of the Company's common voting stock, our
independent counsel have informed Nasdaq our practice is not prohibited under
our home country's law.
RIGHTS TO THE COMPANY'S PROFITS
Our shareholders have the rights to share in our profits distributed as a
dividend and any other permitted distribution.
RIGHTS IN THE EVENT OF LIQUIDATION AND WINDING UP
If the Company shall be wound up voluntarily, the liquidators may, with the
sanction of the majority of shareholders at the general meeting, divide among
the members in specie any part of the assets of the Company, and may, with the
like sanction, vest any part of the assets of the Company in trustees upon such
trusts for the benefit of the members as the liquidators with the like sanction
shall think fit.
CHANGING RIGHTS ATTACHED TO SHARES
If at any time the share capital of the Company is divided into different
classes of shares, then, unless otherwise provided for by the terms of issuance
of that class of shares, in order to change the rights attached to any class of
shares, the consent in writing of the holders of the majority of the issued
shares of the affected class must be obtained, or at a separate meeting of the
shareholders of that class of shares convened for such purpose must adopt a
resolution to change such rights. The provisions of our articles of association
relating to general meetings shall apply, mutatis mutandis, except that the
necessary quorum required shall be two persons holding or representing by proxy
at least two-thirds of the issued shares of that class. In an adjourned meeting,
those shareholders present in person or by proxy shall be deemed to constitute a
quorum. The rights conferred upon the holders of the shares of any class issued
with preferred or other rights shall not, unless expressly provided for by the
terms of the shares of that class, be deemed to be varied by the creation or
issue of further shares ranking pari-passu with that class.
ANNUAL AND SPECIAL MEETINGS
In accordance with the Companies Law, the board of directors must convene
an annual meeting of shareholders at least once every calendar year, and no
later than within fifteen months from the last annual meeting. Notice of at
least 21 days prior to the date of the meeting is required. An extraordinary
meeting may be convened by the board of directors, either at its discretion or
upon a demand of (i) any two directors or 25% of the serving directors; or (ii)
one shareholder or more holding in the aggregate at least 5% of our issued
capital and at least 1% of the voting rights in the Company or one shareholder
or more holding at least 5% of the voting rights in the Company. An
112
extraordinary meeting must be held not more than 35 days from the publication
date of the announcement of the meeting.
LIMITATIONS ON THE RIGHTS TO OWN SECURITIES
Our memorandum and articles of association do not restrict in any way the
ownership of our shares by non-residents of Israel and neither the memorandum or
articles of association nor Israeli law restricts the voting rights of
non-residents of Israel, except that under Israeli law, any transfer or issue of
shares of the Company to a resident of an enemy state of Israel is prohibited
and shall have no effect, unless authorized by the Israeli Minister of Finance.
CHANGES TO OUR CAPITAL
Changes to our capital are subject to the approval of our shareholders at a
general meeting by an ordinary majority.
ANTI TAKEOVER PROVISIONS
The Companies Law prohibits the purchase of our shares in the event the
purchaser's holding following such purchase increase above certain percentages
without conducting a tender offer, see "Item 3. Key Information - D. Risk
Factors - Risks Relating to Israel - Anti-takeover provisions could negatively
impact our shareholders" above.
AMENDMENT OF ARTICLES OF ASSOCIATION
Any amendment to our Articles requires the approval of our shareholders by
an ordinary majority.
C. MATERIAL CONTRACTS
The following is a list of material agreements entered into by us or any of
our subsidiaries during the last two years prior to the filing of this annual
report:
SHOPPING AND ENTERTAINMENT CENTERS
SALE OF FOUR OPERATIONAL SHOPPING AND ENTERTAINMENT CENTERS IN POLAND AND
FOUR SHOPPING AND ENTERTAINMENT CENTERS UNDER DEVELOPMENT IN POLAND AND THE
CZECH REPUBLIC TO KLEPIERRE
On July 29, 2005, Plaza Centers (Europe) B.V., our indirect wholly owned
subsidiary, signed an agreements with Klepierre for the sale of four operational
shopping and entertainment centers in Poland and four shopping centers under
development in Poland and in the Czech Republic upon their construction. In
addition, PC has awarded Klepierre with an option to acquire an additional
center under development in Poland, subject to certain conditions. The
transaction is comprised of two stages.
Within the framework of the first stage of the transaction, Klepierre
(through its subsidiaries) acquired the entire equity and voting rights (100%)
of the companies owning four operational shopping centers in Poland (Sadyba Best
Center, Krakow Plaza, Ruda Slaska Plaza and Poznan Plaza) as well as the entire
outstanding share capital of PC's Polish subsidiary which operates the
operational centers. The consideration was based on asset value of the centers
sold which amounted to approximately E204 million (approximately $241 million).
The asset value was calculated on the basis of the gross rentals of such centers
as at the closing, capitalized at certain agreed yields, together with monetary
and other balances, after deduction of bank and other monetary liabilities
pertaining thereto. The net consideration received by us as of the date of
closing was approximately E73.8 million (approximately $88.7 million) which is
subject to post closing adjustments in accordance with the rental fees received
as at December 31, 2005 (with respect to three centers) and as at May 31, 2006
(with respect to the remaining center) as well as deductions in the event a
certain license is not received. As of the date of this annual report, final
settlement has not yet been finalized, but we expect to receive an additional
net consideration in the amount of approximately E15 million (approximately
$17.7 million).
113
Under the second stage of the transaction, Klepierre entered into a
preliminary share purchase agreement for the future acquisition by Kelpierre of
the entire equity and voting rights in the companies presently developing two
shopping centers in Poland (Rybnik Plaza and Sosnowiec Plaza) and two companies
developing shopping centers in the Czech Republic (Novo Plaza and Pilsen Plaza)
for an estimated asset values which amounts to approximately E158.4 million
(approximately $187.4 million). As of the date of this annual report, the
completion of the Novo Plaza shopping and entertainment center was completed in
March 2006 and delivery to Klepierre is expected to take place on June 30, 2006.
Klepierre was also awarded an option to acquire an additional shopping center
presently under development in Poland for an estimated assets value which
amounts to approximately E62 million (approximately $73.4 million), upon the
fulfillment of certain conditions. Upon the exercise of such option, the
construction and delivery of the shopping center will be subject to the same
terms and conditions applicable to the remaining centers. If Klepierre does not
exercise the option to acquire the shares of such third Polish company, PC will
be obligated to pay a penalty of up to E1.6 million (approximately $1.9
million). The option granted to Klepierre was extended to November 29, 2006.
Upon the completion and delivery of the shopping centers, Klepierre will
pay a purchase price calculated on the basis of the gross rentals on the date of
delivery, capitalized at agreed yields. A final price adjustment of the purchase
price for each of these development centers will be conducted not later than 10
months following delivery, on the basis of actual gross rentals prevailing on
their respective adjustment dates, capitalized at the agreed yields. As security
for payment of the purchase price on completion of the shopping centers,
Klepierre furnished PC at the closing held on July 29, 2005 with irrevocable
bank guarantee in the amount of approximately E115 million (approximately $136.0
million) for the payment of the respective purchase prices of those development
centers in respect of which building permits have been issued. Klepierre has
undertaken to furnish PC with a similar bank guarantee in respect of the
remaining development centers immediately upon the issuance of the building
permit. The completion of the purchase of each center under the second stage of
the transaction is subject, among other things, to completion of the
construction works, opening of the center and minimum occupancy rates.
PC has further undertaken not to own, operate or manage shopping centers
within an agreed distance of each center sold to Klepierre. EMI has undertaken
towards Klepierre to guarantee all of PC's undertakings under the agreement.
SALE OF FOUR OPERATIONAL SHOPPING AND ENTERTAINMENT CENTERS IN HUNGARY
On April 21, 2005, PC consummated the transaction for the sale of the
entire equity and voting rights in four (4) companies owning shopping centers in
Hungary to a subsidiary of the Dawnay Day Group ("Dawnay Day"). The aggregate
net cash consideration paid to PC and its subsidiaries totaled approximately
E17.2 million (approximately $20.7 million). Such consideration was determined
according to the asset value of the acquired companies on the basis of audited
financial statements as of the closing date, which was approximately E54.4
million (approximately $64.3 million) less the deduction of financial
liabilities (mainly, long term bank loans in the aggregate amount of
approximately E40 million (approximately $47.2 million).
PC also agreed to guarantee certain portions of the rental revenues of one
of the acquired shopping centers for a period of three years until December 2007
and of an additional shopping center for a 6-month period, as security for
certain minimum rental revenues. EMI estimates the value of these guarantees (as
of the date of this report) to be in the aggregate amount of approximately E1.3
million (approximately $1.5 million). In addition, EMI granted Dawnay Day a
guarantee for the fulfillment by PC of certain financial obligations and
indemnities within the framework of this transaction.
SALE BY PC TO KLEPIERRE OF TWELVE OPERATIONAL SHOPPING AND ENTERTAINMENT
CENTERS IN HUNGARY
On July 30, 2004, PC entered into an agreement with Klepierre (through its
subsidiaries), as amended, for the sale of all of PC's equity and voting rights
in 12 companies owning shopping and entertainment centers in Hungary and 50% of
PC's equity and voting rights in a Hungarian company which operates and manages
the above centers to Klepierre. The net cash consideration paid to PC and its
subsidiaries totaled approximately E94.1 million (approximately $116.5 million).
Such consideration was determined according to the asset value of the centers,
which was estimated at approximately E287 million (approximately $340 million)
in addition to monetary and other balances
114
and following deduction of banking and other monetary liabilities relating to
these centers. The sale of these centers resulted in an aggregate profit of NIS
185 million (approximately $40 million).
Such profits doe not include additional profit from a potential acquisition
of 129,000 square feet to be constructed by PC as an extension of the Duna Plaza
shopping center in Budapest, if executed. Construction of the extension and the
completion of the transaction are subject, among other things, to the execution
of a turn-key construction agreement between the parties, to obtaining
regulatory approvals and permits from various competent governmental
authorities, during a specific period stipulated in the agreement, as well as to
utilization of premises while fulfilling certain operational targets. The amount
of consideration and schedule of payments, follows an agreed upon methodology,
as well as assets value based on revenues and agreed upon capitalization rate.
A bank guarantee in the amount of E7.5 million provided by PC to Klepierre
as a security for the fulfillment of certain future revenues was returned to PC
by Klepierre unexercised and Klepierre waived any and all claims, arguments or
contentions of whatsoever nature or kind against PC relating to and/or in
connection with and/or arising out of the future sale of utilities in all or any
of the centers sold to Klepierre under this agreement in respect of which the
guarantee has been furnished. In addition, a E6.8 million deposit deposited by
PC as a security for the fulfillment of certain tax conditions was released by
Klepierre to PC against the provision by EMI of a 5-year guarantee for 125% of
the above amount in order to secure certain payments for foreign tax authorities
if imposed on the centers sold under this agreement and which relate to the
periods prior to the consummation of the sale of such centers.
Since the Duna Plaza Offices are built as part of the Duna Plaza Center,
the parties agreed to perform a de-merger between the Duna Plaza Offices and the
Duna Plaza center, and to sell the new company which will consist of the Duna
Plaza Offices to PC. The parties will conduct a settlement upon finalization of
such procedures. As part of such settlement, an amount of approximately E490,000
will be set off from PC's receivables from the Duna Plaza Offices. As of the
date hereof, the condominium was registered in June 2006 and the de-merger is
expected to be completed by the end of 2006.
PC has further undertaken not to own, operate or manage shopping centers
within an agreed distance of each center sold to Klepierre. EMI has undertaken
towards Klepierre to guarantee all of PC's undertakings under the agreement.
Under an amendment of the above agreement and concurrently with the
consummation of Stage A of the agreement with Klepierre (see above), PC sold the
remaining 50% of PC's equity and voting rights in the Hungarian company which
operates and manages the above centers to Klepierre in a net consideration for
approximately E900,000 ($1.1 million).
HOTELS BUSINESS
MANAGEMENT AGREEMENT WITH PARK PLAZA
See "Item 4. Information on the Company - B. Business Overview - Hotels -
Management of Hotels - Management Agreement with Park Plaza" above attached as
Exhibit 4.22 is a form of Management Agreement which we have entered into with
Park Plaza.
LEASED REAL ESTATE PROPERTY
LONG TERM LEASE OF ONE OF OUR HOTELS IN LONDON
See "Item 4. Information on the Company - B. Business Overview - Long Term
Lease of Real Estate Property" above.
SALE OF ONE OF OUR HOTELS IN THE UNITED KINGDOM
See "Item 4. Information on the Company - B. Business Overview - Long Term
Lease of Real Estate Property" above.
115
GENERAL
AGREEMENT AND PLAN OF MERGER AND CONSUMMATION OF THE MERGER WITH ELSCINT
On August 21, 2005, EMI and Elscint signed an Agreement and Plan of Merger
pursuant to which each ordinary share of Elscint (other than Elscint ordinary
shares held by EMI and by or for the benefit of Elscint) would be converted into
0.53 ordinary share of EMI. Immediately prior to the merger EMI held, directly
and indirectly approximately 61% of Elscint's issued and outstanding share
capital. As a result of the merger, EMI issued 3,479,216 shares of EMI to the
public shareholders of Elscint, which constituted approximately 13.71% of EMI's
issued share capital at that time. The merger was completed on November 23, 2005
and as of such date, Elscint ordinary shares have ceased to trade on the New
York Stock Exchange and Elscint became a wholly-owned subsidiary of EMI.
ISSUANCE OF NON CONVERTIBLE DEBENTURES
See "Item 5. Operating and Financial Review and Prospects - B. Liquidity
and Capital Resources - Liquidity" above.
LOAN AGREEMENTS
Two loan agreements entered into by and between EMI, Elbit Ultrasound
(Netherlands) B.V. and Bank Hapoalim B.M. and an additional loan agreement
entered into by and between Elscint and Bank Hapoalim B.M. See "Item 5.
Operating and Financial Review and Prospects - B. Liquidity and Capital
Resources - Other Loans" above.
116
D. EXCHANGE CONTROLS
In 1998, the government of Israel promulgated a general permit under the
Israeli Currency Control Law. Pursuant to such permit, substantially all
transactions in foreign currency are permitted.
Our Memorandum and Articles of Association do not restrict in any way the
ownership of our shares by non-residents and neither the Memorandum of
Association nor Israeli law restricts the voting rights of non-residents.
E. TAXATION
Following is a discussion of certain tax laws that may be material to our
shareholders, all as in effect as of the date of this report and all of which
are subject to changes, possibly on a retroactive basis, to the extent that such
laws are still subject to judicial or administrative interpretation in the
future. This discussion is not intended, and should not be construed, as legal
or professional tax advice and does not cover all possible tax considerations.
For further information as to taxes that apply to us and our subsidiaries, see
Note 16 to our consolidated financial statements included in Item 18 below.
WE ENCOURAGE EACH INVESTOR TO CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO
THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE PURCHASE, OWNERSHIP AND
DISPOSITION OF OUR ORDINARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE ISRAELI,
U.S. FEDERAL, STATE, AND LOCAL, AND FOREIGN TAX LAWS AND POSSIBLE CHANGES IN
SUCH TAX LAWS.
TAXATION IN ISRAEL
In general, the corporate tax rate applicable to companies in Israel in
2005 is 34% which will gradually decrease in the coming years from 31% in 2006
through 25% tax rate in 2010.
TAXATION UNDER INFLATIONARY CONDITIONS
The Income Tax Law (Inflationary Adjustments) (1985), or the Inflationary
Adjustments Law, affects the taxation of earnings of Israeli companies. This
statute attempts to overcome some of the problems presented to a traditional tax
system by an economy undergoing rapid inflation, which was the case in Israel at
the time the law was enacted. Israel's inflation rate has been materially
reduced in recent years.
The Inflationary Adjustments Law is characterized by a high degree of
complexity. Its main features can be described generally as follows:
(a) A special tax adjustment for the preservation of equity whereby certain
corporate assets are classified broadly into Fixed (inflation resistant) Assets
and Non-Fixed (soft) Assets. Where a company's equity, as defined in the law,
exceeds the depreciated cost of Fixed Assets, a deduction from taxable income
that takes into account the effect of the applicable annual rate of inflation on
the excess is allowed, up to a ceiling of 70% of taxable income in any single
tax year, with the unused portion permitted to be carried forward on a linked
basis. If the depreciated cost of Fixed Assets exceeds a company's equity, then
the excess multiplied by the applicable annual rate of inflation is added to
taxable income.
(b) Subject to certain limitations, depreciation deductions on Fixed Assets
and losses carried forward are adjusted for inflation based on the increase in
the consumer price index.
(c) Gains on the sale of certain traded securities are taxable in certain
circumstances, subject to detailed rules which were modified as of January 1,
1999.
Today, all Israeli companies, except certain companies which are wholly
owned by individuals, are subject to reporting and taxation requirements under
this law. Dealers in securities are subject to the regular tax rules applicable
to business income in Israel.
117
TAX REFORM IN ISRAEL
As of January 1, 2003, statutory provisions came into force, concerning,
among other things, tax reform in Israel, in connection with:
(1) (i) Taxation of profits of foreign resident companies regarded as
Controlled Foreign Companies ("CFC"), if: (i) its shares or its
rights on it are not listed in a stock exchange, however if they
are partly listed, then less than 30% of the shares or of the
rights of the company were offered to the public(ii) most of
their revenues are passive, as defined by law, or most of their
profits derive from passive revenues, (iii) the tax rate applying
to their passive profits in their country of residence does not
exceed 20%, and (iv) over 50% of the means of control in them are
held, directly or indirectly, by Israeli residents or more than
40% of one of its means of control are held by Israeli residents,
who together with a relative of one of them hold more than 50% of
one or more of its means of control, or an Israeli resident has
the right to prevent adoption of substantive management decisions
in it. In accordance with the statutory provisions, a controlling
shareholder, which is an Israeli resident holds more than 10% in
the company's means of control, in such companies that have
unpaid profits, as defined by law, will be deemed to have
received his relative proportion in these profits as a dividend
(hereinafter: "deemed dividend").
(ii) Taxation of a dividend received in Israel, originating in profits
generated or accrued outside Israel, as well as a dividend
originating outside Israel.
A deemed dividend and/or the distribution of dividends, as
stated, will be subject to a tax rate of 25%, or, upon election
by the company and provided certain conditions are met, the
income from which the dividend was distributed may be subject to
tax at the corporate tax rate (for instance, 34% in 2005) less
taxes paid abroad in respect of these profits (including under
certain circumstances taxes paid by a company held by the
distributing company), as the case may be.
(2) Taxation of an Israeli resident's profits accrued or generated outside
Israel (until the end of 2002, Israeli residents were taxed on such profits only
if received in Israel).
(3) Taxation of capital gains from the realization of assets at a reduced
rate of 25%. The reduced rate will apply to realization of assets commencing
January 1, 2003 and onwards, and will be calculated for the part of the profits
relating to the period subsequent to this date up to the realization date.
(4) Guidance on the ability to offset losses - regarding business losses,
capital losses, passive losses and CFC losses.
(5) Imposition of capital gains tax on capital gains realized by
individuals as of January 1, 2003, from the sale of shares of publicly traded
companies (such gain was previously exempt from capital gains tax in Israel).
For information with respect to the applicability of Israeli capital gains taxes
on the sale of ordinary shares, see " - Capital Gains Tax on Sales of Our
Ordinary Shares" below;
(6) Introduction of a new regime for the taxation of shares and options
issued to employees and officers (including directors);
CAPITAL GAINS TAX ON SALES OF OUR ORDINARY SHARES
Israeli law generally imposes a capital gains tax on the sale of capital
assets located in Israel, including shares in Israeli companies, by both
residents and non-residents of Israel, unless a specific exemption is available
or unless a double tax convention concluded between Israel and the shareholder's
country of residence provides otherwise. The law distinguishes between real gain
and inflationary surplus. The inflationary surplus is equal to the increase in
the
118
purchase price of the relevant asset attributable solely to the increase in the
Israeli consumer price index between the date of purchase and the date of sale.
The real gain is the excess of the total capital gain over the inflationary
surplus.
Prior to the tax reform, sales of our ordinary shares by individuals were
generally exempt from Israeli capital gains tax so long as (i) our ordinary
shares were quoted on Nasdaq or listed on a stock exchange in a country
appearing on a list approved by the Controller of Foreign Currency and (ii) we
qualified as an Industrial Company.
Pursuant to the tax reform, generally, capital gains tax is imposed at a
rate of 15% on real gains derived on or after January 1, 2003, from the sale of
shares in companies (i) publicly traded on the Tel Aviv Stock Exchange ("TASE")
or; (ii) (subject to a necessary determination by the Israeli Minister of
Finance) Israeli companies publicly traded on a recognized stock exchange or
regulated market outside of Israel. This tax rate is contingent upon the
shareholder not claiming a deduction for financing expenses and does not apply
to: (i) dealers in securities; (ii) shareholders that report in accordance with
the Inflationary Adjustment Law; or (iii) shareholders who acquired their shares
prior to an initial public offering (that are subject to a different tax
arrangement). The tax basis of shares acquired prior to January 1, 2003 will be
determined in accordance with the average closing share price in the three
trading days preceding January 1, 2003. However, a request may be made to the
tax authorities to consider the actual adjusted cost of the shares as the tax
basis if it is higher than such average price(however, if a calculation based on
the latter request, in converse to the first calculation, constitutes a loss,
this loss cannot be offset against future profit).
Non-Israeli residents are exempt from Israeli capital gains tax on any
gains derived from the sale of shares publicly traded on the TASE, and are
exempt from Israeli capital gains tax on any gains derived from the sale of
shares of Israeli companies publicly traded on a recognized stock exchange
outside of Israel, provided such shareholders did not acquire their shares prior
to an initial public offering. However, non-Israeli corporations will not be
entitled to such exemption if an Israeli resident (i) has a controlling interest
of 25% or more in such non-Israeli corporation, or (ii) is the beneficiary or is
entitled to 25% or more of the revenues or profits of such non-Israeli
corporation, whether directly or indirectly.
In any event, the provisions of the tax reform shall not affect the
exemption from capital gains tax for gains accrued before January 1, 2003, as
described above.
In some instances where our shareholders may be liable to Israeli tax on
the sale of their ordinary shares, the payment of the consideration may be
subject to the withholding of Israeli tax at the source.
U.S.-ISRAEL TAX TREATY
Pursuant to the Convention between the Government of the United States of
America and the Government of Israel with Respect to Taxes on Income, as amended
(the "the U.S.- Israel Tax Treaty"), the sale, exchange or disposition of
ordinary shares by a person who (i) holds the ordinary shares as a capital
asset, (ii) qualifies as a resident of the United States within the meaning of
the U.S.-Israel Tax Treaty and (iii) is entitled to claim the benefits afforded
to such resident by the U.S.-Israel Tax Treaty generally will not be subject to
Israeli capital gains tax unless either such resident holds, directly or
indirectly, shares representing 10% or more of the voting power of a company
during any part of the 12-month period preceding such sale, exchange or
disposition, subject to certain conditions, or the capital gains from such sale,
exchange or disposition can be allocated to a permanent establishment in Israel.
In the event that the exemption shall not be available, the sale, exchange or
disposition of ordinary shares would be subject to such Israeli capital gains
tax to the extent applicable; however, under the U.S.-Israel Tax Treaty, such
residents would be permitted to claim a credit for such taxes against U.S.
federal income tax imposed with respect to such sale, exchange or disposition,
subject to the limitations in U.S. laws applicable to foreign tax credits. The
U.S.-Israel Tax Treaty does not relate to state or local taxes.
TAXATION OF NON-RESIDENTS
Non-residents of Israel are subject to income tax on income accrued or
derived from sources in Israel. Such sources of income include passive income
such as dividends, royalties and interest, as well as non-passive income from
services rendered in Israel. On distributions of dividends other than bonus
shares or stock dividends, income tax at the rate of 25% is withheld at source,
unless a reduced rate is provided in double tax convention concluded between
Israel
119
and the shareholder's country of residence. Under the U.S.-Israel Tax Treaty,
the maximum tax on dividends paid to a holder of ordinary shares who is a U.S.
resident will be 25%; provided, however, that under the Investment Law,
dividends generated by an Approved Enterprise are taxed at the rate of 15%.
Furthermore, dividends not generated by an Approved Enterprise paid to a U.S.
company holding 10% or more of our ordinary shares in the 12 month period
preceding the distribution of such dividends, are taxed at a rate of 12.5%.
Under an amendment to the Inflationary Adjustments Law, non-Israeli
corporations may be subject to Israeli taxes on the sale of securities of an
Israeli company, subject to the provisions of any applicable taxation treaty or
unless a specific exemption is available.
FOREIGN EXCHANGE REGULATIONS
Dividends (if any) paid to the holders of our ordinary shares, any amounts
payable upon our dissolution, liquidation or winding up, and as the proceeds of
any sale of our ordinary shares in Israel may be paid in non-Israeli currency
or, if paid in Israeli currency, may be converted into freely repatriable
dollars at the rate of exchange prevailing at the time of conversion.
TAXATION OF DIVIDENDS DISTRIBUTIONS
On distributions of dividends to Israeli individuals, income tax at the
rate of 25% is withheld while a distributions to an Israeli companies is
tax-exempt. Dividend distributions from Approved Enterprises earnings is subject
to 15% tax withheld at source to both Israeli individuals and Israeli companies,
if the dividend is distributed during the tax exemption period or within a
specified period. In addition a company that distributed dividends out of income
that was tax exempt according to the Investment Law would be subject to company
tax in the year the dividend is distributed in respect of the amount distributed
at the rate that would have been applicable had the company not elected the
tax-exempt course (generally 25%).
LAW FOR THE ENCOURAGEMENT OF CAPITAL INVESTMENTS, 1959
Two investment programs of InSightec were granted the status of an
"Approved Enterprise" ("AE"). Pursuant to the Law for the Encouragement of
Capital Investments, 1959 (under this heading: the "Law"), under which income
stemming from an AE will be exempt from tax during the initial two years,
starting from the first year in which the AE has taxable income, and
subsequently subject to a reduced tax rate of 25% during the remaining five-year
period. In January 2004, InSightec's expansion program of the existing factory
has been approved.
Should the holding rate of foreign residents in InSightec exceeds 25%, the
period of benefits would then increase from seven to ten years. If this rate
exceeds 49%, the tax rate would decrease from 25% to 10%-20%, based on the level
of ownership by non-Israeli investor in each relevant taxable year. The benefits
period to these AEs, is limited to the earlier of either 12 years from
commencement of production or 14 years following receipt of the approval
documents. The benefits are determined by the ratio of the additional revenues
during the benefits period over the revenues in the entire last year of
production prior to the activation of each program (adjusted for the change in
the wholesale price index of the industrial output) to total annual revenues
during the benefit period.
Those benefits are subject to the conditions stipulated in the Law, the
regulation thereunder and the approval documents based on which the investments
were made. Failure to meet those conditions may lead to the cancellation of the
benefits and to demand for reimbursement of the amounts received on account of
these benefits (in whole or in part), including interest and linkage. Change in
ownership structure of a company owned by an AE, including a public offering of
over 49%, or any private placement during the period of the approved investment
program through the end of the benefits period, is subject to the advanced
approval by the Investment Center.
In the event of a distribution of tax-exempt earnings such as dividend, as
aforementioned, the distributing company would be subject to tax of up to 25%.
In the event of a distribution of earning of an AE as dividends, recipient will
be subject to tax of up to 15% (for a period of 12 years from the end of the
benefit period).
U.S. FEDERAL INCOME TAX CONSIDERATIONS
120
Subject to the limitations described herein, this discussion summarizes the
material U.S. federal income tax consequences of the purchase, ownership and
disposition of our ordinary shares to a U.S. holder. A U.S. holder is a holder
of our ordinary shares who is:
- an individual citizen or resident of the U.S. for U.S. federal income
tax purposes;
- a corporation or partnership (or another entity taxable as a
corporation or partnership for U.S. federal income tax purposes)
created or organized under the laws of the United States or any
political subdivision thereof;
- an estate, the income of which may be included in the gross income for
U.S. federal income tax purposes regardless of its source; or
- a trust (i) if, in general, a U.S. court is able to exercise primary
supervision over its administration and one or more U.S. persons have
the authority to control all of its substantial decisions or (ii) that
has in effect a valid election under applicable U.S. Treasury
regulations to be treated as a U.S. person.
Unless otherwise specifically indicated, this discussion does not consider
the U.S. tax consequences to a person that is not a U.S. holder and considers
only U.S. holders that will own the ordinary shares as capital assets.
This discussion is based on current provisions of the Internal Revenue Code
of 1986, as amended (the "Code"), current and proposed Treasury regulations
promulgated under the Code and administrative and judicial interpretations of
the Code, all as currently in effect and all of which are subject to change,
possibly with a retroactive effect. This discussion does not address all aspects
of U.S. federal income taxation that may be relevant to any particular U.S.
holder based on the U.S. holder's particular circumstances. In particular, this
discussion does not address the U.S. federal income tax consequences to U.S.
holders who are broker-dealers or who own, directly, indirectly or
constructively, 10% or more of our outstanding voting shares, U.S. holders
holding the ordinary shares as part of a hedging, straddle or conversion
transaction, U.S. holders whose functional currency is not the U.S. dollar, real
estate investments trusts, regulated investment companies, insurance companies,
tax-exempt organizations, financial service entities, financial institutions,
certain former citizens or long term residents of the United States and persons
subject to the alternative minimum tax, who may be subject to special rules not
discussed below. Additionally, the tax treatment of persons who are, or hold the
ordinary shares through, a partnership or other pass-through entity is not
considered, nor is the possible application of U.S. federal estate or gift taxes
or any aspect of state, local or non-U.S. tax laws.
EACH HOLDER OF OUR ORDINARY SHARES IS ADVISED TO CONSULT HIS OR HER TAX
ADVISOR WITH RESPECT TO THE SPECIFIC U.S. FEDERAL, STATE, LOCAL AND FOREIGN
INCOME TAX CONSEQUENCES TO HIM OR HER OF PURCHASING, HOLDING OR DISPOSING OF OUR
ORDINARY SHARES.
DISTRIBUTIONS
Subject to the discussion below under "Tax Consequences if We are a Passive
Foreign Investment Company," a distribution paid by us with respect to the
ordinary shares to a U.S. holder will be treated as dividend income to the
extent that the distribution does not exceed our current and accumulated
earnings and profits, as determined for U.S. federal income tax purposes. The
amount of a distribution with respect to the ordinary shares will equal the
amount of cash and the fair market value of any property distributed and will
also include the amount of any Israeli taxes withheld as described above under
"Taxation of Non-Residents." Dividends that are received by U.S. holders that
are individuals, estates or trusts will be taxed at the rate applicable to
long-term capital gains (a maximum rate of 15%), provided that such dividends
meet the requirements of "qualified dividend income." Dividends that fail to
meet such requirements, and dividends received by corporate U.S. holders are
taxed at ordinary income rates. No dividend received by a U.S. holder will be a
qualified dividend (1) if the U.S. holder held the ordinary share with respect
to which the dividend was paid for less than 61 days during the 121-day period
beginning on the date that is 60 days before the ex-dividend date with respect
to such dividend, excluding for this purpose, under the rules of Code section
246(c), any period during which the U.S. holder has an option to sell, is under
a contractual obligation to sell, has made and not closed a short sale of, is
the grantor of a deep-in-the-money or otherwise nonqualified option to buy, or
has otherwise diminished its risk of loss by holding other positions with
respect to, such ordinary share (or substantially identical securities); or (2)
to the extent that the U.S. holder is under an obligation (pursuant to a short
sale or otherwise) to make related payments with respect to positions in
property substantially similar or related to the ordinary share with respect to
which the dividend is paid. If we were to be a "passive foreign investment
company" (as such
121
term is defined in the Code) for any year, dividends paid on our ordinary shares
in such year or in the following year would not be qualified dividends. In
addition, a non-corporate U.S. holder will be able to take a qualified dividend
into account in determining its deductible investment interest (which is
generally limited to its net investment income) only if it elects to do so; in
such case the dividend will be taxed at ordinary income rates.
The amount of any distribution which exceeds the amount treated as a
dividend will be treated first as a non-taxable return of capital, reducing the
U.S. holder's tax basis in its ordinary shares to the extent thereof, and then
as capital gain from the deemed disposition of the ordinary shares. Corporate
holders will not be allowed a deduction for dividends received in respect of the
ordinary shares.
Dividends paid by us in NIS will be included in the income of U.S. holders
at the dollar amount of the dividend (including any Israeli taxes withheld
therefrom), based upon the spot rate of exchange in effect on the date the
distribution is included in income. U.S. holders will have a tax basis in the
NIS for U.S. federal income tax purposes equal to that dollar value. Any
subsequent gain or loss in respect of the NIS arising from exchange rate
fluctuations will generally be taxable as U.S. source ordinary income or loss.
Subject to certain conditions and limitations set forth in the Code and the
Treasury regulations thereunder, including certain holding period requirements
U.S. holders may elect to claim as a foreign tax credit against their U.S.
federal income tax liability the Israeli income tax withheld from dividends
received in respect of the ordinary shares. The limitations on claiming a
foreign tax credit include, among others, computation rules under which foreign
tax credits allowable with respect to specific classes of income cannot exceed
the U.S. federal income taxes otherwise payable with respect to each such class
of income. In this regard, dividends paid by us will be foreign source "passive
income" for U.S. foreign tax credit purposes or, in the case of a financial
services entity, "financial services income" (and, for the years beginning after
2006, as "general category income"). U.S. holders that do not elect to claim a
foreign tax credit may instead claim a deduction for the Israeli income tax
withheld if they itemize deductions. The rules relating to foreign tax credits
are complex, and U.S. holders should consult their tax advisors to determine
whether and to what extent they would be entitled to this credit.
DISPOSITION OF ORDINARY SHARES
Subject to the discussion below under "Tax Consequences if We are a Passive
Foreign Investment Company," upon the sale, exchange or other disposition of our
ordinary shares, a U.S. holder will recognize capital gain or loss in an amount
equal to the difference between the amount realized on the disposition and the
U.S. holder's tax basis in the ordinary shares. The gain or loss recognized on
the disposition of the ordinary shares will be long-term capital gain or loss if
the U.S. holder held the ordinary shares for more than one year at the time of
the disposition and is eligible for a maximum 15% rate of taxation for
individuals. Capital gain from the sale, exchange or other disposition of
ordinary shares held for one year or less is short-term capital gain and taxed
at a maximum rate of 35%. Gain or loss recognized by a U.S. holder on a sale,
exchange or other disposition of ordinary shares will be treated as U.S. source
income or loss for U.S. foreign tax credit purposes. A U.S. holder that receives
foreign currency upon disposition of ordinary shares and converts the foreign
currency into dollars after the settlement date (in the case of a cash method
tax paper) or trade date (in the case of an accrual method tax paper ) will have
foreign exchange gain or loss based on any appreciation or depreciation in the
value of the foreign currency against the dollar, which will generally be U.S.
source ordinary income or loss.
TAX CONSEQUENCES IF WE ARE A PASSIVE FOREIGN INVESTMENT COMPANY
We will be a passive foreign investment company, or PFIC, if either (1) 75%
or more of our gross income in a taxable year is passive income; or (2) 50% or
more of the value, determined on the basis of a quarterly average, of our assets
in a taxable year are held for the production of passive income. If we own
(directly or indirectly) at least 25% by value of the stock of another
corporation, we will be treated for purposes of the foregoing tests as owning
our proportionate share of the other corporation's assets and as directly
earning our proportionate share of the other corporation's income. If we are a
PFIC, a U.S. holder must determine under which of three alternative taxing
regimes it wishes to be taxed.
The "QEF" regime applies if the U.S. holder elects to treat us as a
"qualified electing fund" ("QEF") for the first taxable year in which the U.S.
holder owns our ordinary shares or in which we are a PFIC, whichever is later,
and if we comply with certain reporting requirements. If the QEF regime applies,
then each year that we are a PFIC such U.S. holder will include in its gross
income a proportionate share of the our ordinary earnings (which is taxed as
ordinary
122
income) and net capital gain (which is taxed as long-term capital gain), subject
to a separate election to defer payment of taxes, which deferral is subject to
an interest charge. These amounts would be included in income by an electing
U.S. holder for its taxable year in which our taxable year ends, whether or not
such amounts are actually distributed to the U.S. holder. A U.S. holder's basis
in our ordinary shares for which a QEF election has been made would be increased
to reflect the amount of any taxed but undistributed income. Generally, a QEF
election allows an electing U.S. holder to treat any gain realized on the
disposition of its ordinary shares as capital gain.
Once made, the QEF election applies to all subsequent taxable years of the
U.S. holder in which it holds our ordinary shares and for which we are a PFIC
and can be revoked only with the consent of the Internal Revenue Service. A
shareholder makes a QEF election by attaching a completed Internal Revenue
Service Form 8621, including the PFIC annual information statement, to a timely
filed United States federal income tax return. Even if a QEF election is not
made, a U.S. person who is a shareholder in a PFIC must file a completed
Internal Revenue Service Form 8621 every year.
If a QEF election is made after the first taxable year in which a U.S.
holder holds our ordinary shares and we are a PFIC, then special rules would
apply.
A second regime, the "mark-to-market" regime, may be elected so long as our
ordinary shares are "marketable" (i.e., regularly, traded on certain securities
exchanges). Pursuant to this regime, an electing U.S. holder's ordinary shares
are marked-to-market each year and the U.S. holder recognizes as ordinary income
or loss an amount equal to the difference as of the close of the taxable year
between the fair market value of our ordinary shares and the U.S. holder's
adjusted tax basis in our ordinary shares. Losses are allowed only to the extent
of net mark-to-market gain previously included by the U.S. holder under the
election for prior taxable years. An electing U.S. holder's adjusted basis in
our ordinary shares is increased by income recognized under the mark-to-market
election and decreased by the deductions allowed under the election.
Under the mark-to-market election, gain on the sale of our ordinary shares
is treated as ordinary income, and loss on the sale of our ordinary shares, to
the extent the amount of loss does not exceed the net mark-to-market gain
previously included, is treated as ordinary loss. The mark-to-market election
applies to the tax year for which the election is made and all later tax years,
unless the ordinary shares cease to be marketable or the Internal Revenue
Service consents to the revocation of the election.
If the mark-to-market election is made after the first taxable year in
which a U.S. holder holds our ordinary shares and we are a PFIC, then special
rules would apply.
A U.S. holder making neither the QEF election nor the mark-to-market
election is subject to the "excess distribution" regime. Under this regime,
"excess distributions" are subject to special tax rules. An excess distribution
is either (1) a distribution with respect to shares that is greater than 125% of
the average distributions received by the U.S. holder from us over the shorter
of either the preceding three taxable years or such U.S. holder's holding period
for our shares, or (2) 100% of the gain from the disposition of our shares
(including gain deemed recognized if the ordinary shares are used as security
for a loan).
Excess distributions must be allocated ratably to each day that a U.S.
holder has held our ordinary shares. A U.S. holder must include amounts
allocated to the current taxable year, as well as amounts allocated to taxable
years prior to the first year in which we were a PFIC, in its gross income as
ordinary income for that year. All amounts allocated to prior years of the U.S.
holder during which we were a PFIC would be taxed at the highest tax rate for
each such prior year applicable to ordinary income. The U.S. holder also would
be liable for interest on the deferred tax liability for each such prior year
calculated as if such liability had been due with respect to each such prior
year. The portions of gains and distributions that are not characterized as
"excess distributions" are subject to tax in the current year under the normal
tax rules of the Code.
A U.S. person who inherits shares in a foreign corporation that was a PFIC
in the hands of the decedent (who did not make a QEF election either of the
elections described above), is denied the otherwise available step-up in the tax
basis of such shares to fair market value at the date of death.
We believe that we were not a PFIC in 2005 or in prior years. However,
since the determination of whether we are a PFIC is based upon such factual
matters as the valuation of our assets and, in certain cases, the assets of
companies held by us, there can be no assurance with respect to the position of
the Internal Revenue Service on our status as a PFIC. In addition, there can be
no assurance that we will not become a PFIC for the current fiscal year
123
ending December 31, 2006 or in a future year. We will notify U.S. holders in the
event we conclude that we will be treated as a PFIC for any taxable year to
enable U.S. holders to consider whether or not to elect to treat us as a QEF for
U.S. federal income tax purposes, or to "mark - to - market" the ordinary shares
or to become subject to the "excess distribution" regime.
U.S. holders are urged to consult their tax advisors regarding the
application of the PFIC rules, including eligibility for and the manner and
advisability of making, the QEF election or the mark-to-market election.
U.S. holders (other than exempt recipients such as corporations) generally
are subject to information reporting requirements with respect to dividends paid
on Ordinary Shares in the United States or by a U.S. payor or U.S. middleman or
the gross proceeds from disposing of Ordinary Shares. U.S. holders generally are
also subject to backup withholding (currently 28% for taxable years through
2010) on dividends paid in the United States or by a U.S. payor or U.S.
middleman on Ordinary Shares and on the gross proceeds from disposing of
Ordinary Shares, unless the U.S. holder provides an IRS Form W-9 or is otherwise
exempt from backup withholding.
Non-U.S. holders generally are not subject to information reporting or
backup withholding with respect to dividends paid on Ordinary Shares in the
United States or by a U.S. payor or U.S. middleman or the gross proceeds from
the disposition of Ordinary Shares, provided that such Non-U.S. holder certifies
to its foreign status, or is otherwise exempt from backup withholding or
information reporting.
The amount of any backup withholding may be allowed as a credit against a
holder's U.S. federal income tax liability and may entitle such holder to a
refund provided that certain required information is timely furnished to the
IRS.
F. DIVIDENDS AND PAYING AGENTS
Not applicable.
G. STATEMENT BY EXPERTS
Not applicable.
H. DOCUMENTS ON DISPLAY
EMI is subject to the informational requirements of the Securities Exchange
Act of 1934, as amended. In accordance with these requirements, EMI files annual
reports with and furnishes other information to the SEC. These materials,
including this annual report and the exhibits hereto, may be inspected and
copied at the SEC's Public Reference Room at 100 F Street, N.W., Washington,
D.C. 20549. Copies of the materials may be obtained from the Public Reference
Room of the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed
rates. The public may obtain information on the operation of the SEC's Public
Reference Room by calling the SEC in the United States at 1-800-SEC-0330.
Additionally, copies of the materials may be obtained from the SEC's website at
http://www.sec.gov.
I. SUBSIDIARY INFORMATION
Not applicable.
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKS
EXCHANGE RATE EXPOSURE
OPERATIONS
The main transactions and balances (including long-term bank loans) of
companies in our hotels segment, in our shopping and entertainment centers
segment and in our image guided treatment segment, which are measured as
autonomous entities, are denominated or linked to the functional currency of
each company. As of December 31,
124
2005 and for the year then ended, our hotels and/or centers segments did not
have any significant exchange rate exposure, except for the hotel division's
operations in Romania.
Significant changes in the exchange rate between certain currencies in a
given territory (mainly, Euro, GBP, Lei and dollar) is likely to affect the
respective prices of hotel services in our hotel division, for overseas
customers. Such changes may result in a gap between price levels of services
paid in different countries. As a result, the revenue might decrease and the
revenues mix between geographic segments may also vary as a result of these
currency fluctuations.
MONETARY ASSETS (LIABILITIES), NET
The functional currency of our holding companies in Israel is the NIS,
while the same of our holding subsidiaries which operate in the Netherlands, is
the Euro. We have monetary assets and monetary liabilities in substantial
amounts, denominated in or linked to the U.S. dollar, and are therefore exposed
to a substantial fluctuations thereof. We do not actively hedge against
fluctuations of the NIS and/or the Euro in relation to the U.S. dollar.
NET INVESTMENT VALUE OF FOREIGN INVESTEES
As for the translation method of our foreign autonomous entities to their
holding company's functional currency and the changes therein during 2005, see
Note 2A.(3)(i) to our consolidated financial statements.
Our exposure to fluctuations in exchange rates of foreign currencies, in
respect of inter-company balances (see table I below) is reflected only by the
value of the net investment in the autonomous entities (capital and
shareholders' loans with a nature of investments). A decrease/increase in the
value of foreign currencies of the autonomous investees in relation to their
holding companies' functional currency may, therefore, have a negative/positive
impact on our shareholders' equity. In order to mitigate our exposure to the
effect of frequent fluctuations in the exchange rate of these currencies, as
mentioned above, some of our bank loans that have been obtained, mainly to
finance investments in foreign subsidiaries in our hotels division, in the same
currency of the investee's functional currency.
At the end of May 2005, Arena converted the linkage currency of certain
bank loans (NIS 213.0 million obtained, from U.S. dollar into NIS, which is the
functional currency of the Arena). See also "- Table I - Foreign Currency Risks"
below.
In addition, our exposure to the foregoing fluctuations has an impact on
the extent of the assets, liabilities and operations of the autonomous
companies, as reflected in our financial statements, and on the date-to-date and
period-to-period comparison of our financial statements.
Further details about our foreign currency exposure, as of December 31,
2005 are set forth in Table I below.
RATE OF INFLATION
As for the accounting principle regarding the adjustment of financial
statements to the inflation and for the changes therein commencing January 1,
2004, see Note 2A.1 to our consolidated financial statements.
Fluctuations in the rate of inflation may impact labor costs in
circumstances where labor contracts are linked to domestic CPI, whether by
mandatory rules or by union agreements. An increase in inflation could also
result in an increase in the cost of our variable rate borrowings. Failure to
adjust revenues of companies (especially in the hotel segment) with the rate of
inflation may result in a decrease in operating profits. This potential loss
will be more clearly reflected as we had changed, commencing January 2004, our
reporting method to the nominal basis (instead of adjusted basis). However, most
of our leases, in the commercial centers' businesses, contain provisions
designed to partially mitigate the adverse impact of inflation. Most of our
leases contain effective annual rent escalations (that are, indexed based on the
Consumer Price Index or other related indices). A portion of the lease
125
agreements include conditions enabling us to receive percentage rents based on a
tenant's gross sales above predetermined levels, which sales generally increase
as prices rise. Accordingly, we do not believe that our earnings or cash flows
from real estate operations (in the commercial centers' businesses) are subject
to a significant economic risk of inflation.
INTEREST RATE RISKS
Part of the credit and the deposits are obtained at or invested at fixed
interest rates while most of the credit and deposits are obtained at or invested
at variable rates (see Table III below). Changes in short-term interest rates in
the countries in which we operate will affect our results of operations and our
future cash flows. In general, we do not actively hedge against the impact of
the interest rate risks on our net monetary assets/liabilities. We limit, in
certain cases, a part of these risks by using derivative financial instruments
to manage or hedge interest rate risk, especially, on long term bank loans (see
Note 23D. to our consolidated financial statements).
We are also subject to the risk of increases in long-term variable interest
rates that may occur over a period of several years. This may affect our
discount rate applicable to our assets and consequently may decrease the overall
value of our real estate.
Short-term interest rates influence directly and indirectly on the economic
and business atmosphere, which, in turn, has an effect on the commercial and
leisure industry. An increase in the short-term interest rates generally results
in the decrease in the spending of monies for leisure purposes and may result in
a decrease in our operational results.
CREDIT RISKS
Cash, cash equivalents and bank deposits are maintained with reputable
banks. In the commercial centers business and in the hotels segment, services
and sales are rendered to a large numbers of customers and we are not
significantly exposed to credit risks arising from dependence on any single
customer. In relation to anchor tenants, see "Item 3 - Key Information - Risk
Factors - Risk Relating to the Shopping and entertainment centers Business".
The balance of long term receivables as of December 31, 2005 included:
1. Two loans in the aggregate amount of NIS 23.0 million ($5.0 million)
which were granted by us to the Management Company in the framework of
an option agreement to acquire 33% of the Park Plaza chain in Europe
(See Notes 8A.(2)(i) and 17A.(2) to our financial statements).
2. PC has invested an amount of NIS 19.1 million in Joint Venture Project
Company which is in excess of the amount invested by the JV partner.
Part of this loan amount to NIS 10.9 million arising from the
shareholders agreement with the JV partner and the remaining amount is
due to excess investments of Shareholders loan by PC over the JV
partner as a result of a dispute with the JV partner regarding the
increase in the budget of the Project. See Note 8A. (ii) and 10 B.6 to
our consolidated financial statements.
Realization of these debts substantially depends on the financial stability
of the debtors in the long run.
See also "Item 3 - Key Information - Risk Factors" above.
MARKETABLE AND EQUITY SECURITIES
For information on the or composition of the short and long-term investment
portfolio- see Note 4 and Note 9 to our consolidated financial statements
included in Item 18 below. Such investments are exposed to market-price
fluctuation.
126
VENTURE CAPITAL INVESTMENTS
For information on exposures relating to venture capital investments, see "Item
3. Key Information - D. Risk Factors - Risks relating to our Other Activities"
above.
RENT INCOME FROM SHOPPING AND ENTERTAINMENT CENTERS
For information on risks relating to the market price of lease of spaces in
commercial centers, see "Item 3. Key Information - Risk Factors - Risk Relating
to the Shopping and entertainment centers Business" above.
Our financial results are affected by general economic conditions in the
markets in which our properties are located. An economic recession, or other
adverse changes in general or local economic conditions could result in the
inability of some of our existing tenants to meet their lease obligations and
could otherwise adversely affect our ability to attract or retain tenants.
LAND AND REAL ESTATE RATES
Some of our real estate properties are subject to leases of land or buildings.
Annual payments for those leasehold properties are linked to various real estate
indexes. Strength in the real estate market may influence the level of those
indexes and result in increasing annual payments. However, we are generally able
to offset higher rental fees paid by us with greater revenues from our tenants.
FINANCIAL INSTRUMENTS
From time to time, throughout the reported year, we engage in the trading
of derivative and other financial instruments for hedging and speculative
purposes. The results of such activities and the value of the trading
instruments are affected by the changes and volatility in foreign exchange rates
and interest rates and equity indices. Changes in Israeli and global foreign
exchange rates, interest rates and equity indices may significantly affect our
financial results and our assets, liabilities, equity capital and cash flow, as
a result of the aforementioned trading activity.
The highest balance of open positions of derivatives for currency sale and
purchase during 2005 was NIS 717 million ($155.7 million). Subsequent to
December 31,2005 the maximum balance of open positions totaled NIS 60 million
($13.0 million). It should be noted that due to the high volatility of global
financial markets, foreign exchange, interest rate and equity trading involve
significant risks, mainly in the short term.
For currency transactions outstanding as at December 31, 2005, see Table II
- - Derivative contracts on foreign exchange rates below.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company's and its subsidiaries' financial instruments include monetary
assets (cash and cash equivalents, short and long-term deposits, trade accounts
receivable, marketable securities as well as other receivables and current
account) and monetary liabilities (short-term credits, long-term liabilities,
trade accounts payable as well as payables and other credit balances). Due to
the nature of the financial instruments included in working capital, their fair
values approximate those presented in the balance sheet.
The fair value of long term trade accounts receivable, deposits and other
long-term liabilities is ordinarily based on the present value of future
receipts and payments, discounted by the interest rate applicable to our lending
or borrowing activities under similar terms as of the balance sheet date, and it
is not materially different from what is presented in the financial statements.
For information on the presentation of long-term balances not under market
conditions - see Note 2K to our consolidated financial statements included in
Item 18 below.
127
Derivative financial instruments that have an active market were valued
based on market value.
The assets included among long term investments or that are stated as
treasury stock, for which market value differ from their carrying amount, are as
follows:
December 31, 2005
------------------------------
Carrying amount Market value
--------------- ------------
NIS (in millions)
Elbit - treasury stock (see Note 18A. to
our consolidated financial statements) 162.3 243(1)
Bucuresti (See Note 9.B(4), to our
consolidated financial statements.) 235.7 44.0(2)
(1) Includes 2,842,400 shares held by EMI and 524,187 shares held by Elscint.
Shares are traded on the Tel Aviv Stock Exchange and in the NASDAQ.
(2) Shares are traded on the Bucharest stock exchange, in Romania ("RASDAQ").
TABLE I - FOREIGN CURRENCY RISKS
The table below provides information as at December 31, 2005 regarding our
financial assets and liabilities (including - inter company balances)
denominated or linked to foreign currencies:
NIS (IN MILLIONS)
BRITISH
POUND
ISRAELI SHEKELS STERLING ROMANIAN
(NIS) (L) EURO (E) LEI (ROL) RECONCILIATION
FUNCTIONAL CURRENCY ----------------- -------- --------- ---------- OTHERS FOR
Linkage Currency (2) $ E L E $ L E $ (1) CONSOLIDATION TOTAL
- -------------------- --- --- --- -------- ---- --- ---- ---- ------ -------------- ------
CURRENT ASSETS:
Cash and cash equivalents 17 -- 26 -- 1 1 -- -- 444 -- 489
Short term deposits and
investments 145 -- -- -- 1 -- 1 2 91 -- 240
Trade accounts receivable and
other debit balances 3 -- -- -- -- -- -- -- 106 3 112
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
165 -- 26 -- 2 1 1 2 641 3 841
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
LONG TERM INVESTMENTS AND
RECEIVABLES:
Deposits, debentures, loans
and receivables -- (4) -- -- 23 -- -- -- 43 -- 62
Investments in investees and
other companies:
Shares 21 400 -- -- (25) (85) -- -- (699) 445 57
Loans 552 276 137 -- 118 133 -- -- 433 (1,649) --
Assets related to
discontinuing operations 3 -- -- -- -- -- -- 10 13
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
573 675 137 -- 116 48 -- -- (213) (1,204) 132
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
TOTAL ASSETS 738 675 163 -- 118 49 1 2 428 (1,201) 973
=== === === ==== ==== === ==== ==== ====== ====== ======
CURRENT LIABILITIES:
Short term credits 140(4) -- -- -- 1 -- 39 127 94 59 460
Trade accounts payable and
other credit balances 6 6 1 -- 8 -- -- 2 223 (14) 232
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
146 6 1 -- 9 -- 39 129 317 45 692
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
LONG TERM LIABILITIES:
Long term liabilities:
Group companies 69 -- -- 200 552 136 98 -- 565 (1,620) --
Others 307(4) 334(3) 133(3) -- 20 -- 1 -- 1,206 (36) 1,965
128
BRITISH
POUND
ISRAELI SHEKELS STERLING ROMANIAN
(NIS) (L) EURO (E) LEI (ROL) RECONCILIATION
FUNCTIONAL CURRENCY ----------------- -------- --------- ---------- OTHERS FOR
Linkage Currency (2) $ E L E $ L E $ (1) CONSOLIDATION TOTAL
- -------------------- --- --- --- -------- ---- --- ---- ---- ------ -------------- ------
Liabilities related to
discontinuing operations 57 5 -- -- -- -- -- -- -- -- 62
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
433 339 133 200 572 136 99 -- 1,771 (1,656) 2,027
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
TOTAL LIABILITIES 579 345 134 200 581 136 138 129 2,088 (1,611) 2,719
--- --- --- ---- ---- --- ---- ---- ------ ------ ------
TOTAL ASSETS LESS TOTAL
LIABILITIES (5) 159 330 29 (200) (463) (87) (137) (127) (1,660) 410 (1,746)
=== === === ==== ==== === ==== ==== ====== ====== ======
FOOTNOTES:
(1) Includes mainly, unlinked balances of financial assets (liabilities) and
linkage currencies which total financial assets or financial liabilities
that are denominated therein or linked thereto, do not exceed 5% of total
financial assets or financial liabilities, respectively (on a consolidated
basis).
(2) As for investments in investees' shares - "linkage currency" means the
functional currency of each investee. As for loans to investees with nature
of investment - "linkage currency" means the currency that the loan is
denominated in or linked to.
(3) Primarily loans for financing an investment in an autonomous investee taken
in the functional currency of the investee (for hedging, qualified hedges
for accounting purposes). The effect of the exchange rates on these loans
are charged directly to shareholders equity and not to the statements of
operations.
(4) NIS 46 million short term bank loan and NIS 92 long term bank loans used
for financing an investment in an autonomous investee taken in the
functional currency of the investee (for hedging, qualified hedges for
accounting purposes). The effect of the exchange rates on these loans are
charged directly to shareholders equity and not to the statements of
operations.
(5) Comprised as follows:
BRITISH
POUND
STERLING ROMANIAN
ISRAELI SHEKELS (NIS) (L) EURO (E) LEI (ROL) RECONCILIATION
FUNCTIONAL CURRENCY --------------------- -------- ---------- ----------- OTHERS FOR
Linkage Currency (2) $ E L E $ L E $ (1) CONSOLIDATION TOTAL
- -------------------- ---- ---- ---- -------- ---- --- ---- ---- ------ -------------- ------
Net monetary items (6) (345) (346) (108) -- (4) 1 (39) (127) (829) (6) (1,803)
Intercompany balances
(loans with nature of
investment) (7) 483 276 137 (200) (434) (3) (98) -- (132) (29) --
Investment in investees'
shares (7) 21 400 -- -- (25) (85) -- -- (699) 445 57
---- ---- ---- ---- ---- --- ---- ---- ------ --- ------
159 330 29 (200) (463) (87) (137) (127) (1,660) 410 (1,746)
==== ==== ==== ==== ==== === ==== ==== ====== === ======
(6) The impact of exchange rates exposure, on net monetary items, is charged
directly to the statements of operations.
(7) The impact of exchange rates exposure on these items is charged directly to
the shareholders equity and not to the statements of operations.
(8) Exchange rates:
BRITISH
POUND 1,000
STERLING EURO ROMANIAN
ISRAELI SHEKELS (NIS) (L) (E) LEI (ROL)
FUNCTIONAL CURRENCY --------------------- -------- ----- -------------
Linkage Currency $ E L E $ $ E
- ------------------- ----- ----- ----- -------- ----- ----- -----
May 31, 2006 4.518 5.810 8.478 0.685 0.778 27.56 35.43
===== ===== ===== ====== ===== ===== =====
December 31, 2005 4.603 5.447 7.941 0.6857 0.845 31.08 31.77
===== ===== ===== ====== ===== ===== =====
December 31, 2004 4.308 5.877 8.308 0.704 0.732 29.07 39.66
===== ===== ===== ====== ===== ===== =====
(9) Changes in the exchange rates (%)
129
BRITISH
POUND
STERLING EURO 1,000 ROMANIAN
ISRAELI SHEKELS (NIS) (L) (E) LEI (ROL)
FUNCTIONAL CURRENCY --------------------- -------- ----- --------------
Linkage Currency $ E L E $ $ E
- ------------------- ----- ----- ----- -------- ----- ------ -----
May 31, 2006 (1.85) 6.67 6.77 (0.10) (7.97) (11.32) (3.35)
===== ===== -==== ===== ===== ====== =====
December 31, 2005 6.85 (7.32) (4.42) (2.64) 15.44 6.92 (7.29)
===== ===== ===== ===== ===== ====== =====
December 31, 2004 (1.62) 6.21 5.85 (0.07) (7.87) (10.82) (3.54)
===== ===== ===== ===== ===== ====== =====
TABLE II - DERIVATIVE CONTRACTS ON FOREIGN EXCHANGE RATES
The following presents a summary of the currency transactions outstanding
at December 31, 2005:
(1) As for loans denominated in foreign currency obtained for the purpose
of accounting hedging - see comment (3) to Table 1 above.
(2) Swap transaction - in order to hedge the risk on variable interest rate
on long-term loans - see Note 23A. to our consolidated financial statements.
TABLE III - INTEREST RISKS
The following table presents a summary of balances classified according to
interest rate, at December 31, 2005:
1. LONG TERM LOANS AND DEPOSITS - (IN MILLIONS NIS)
REPAYMENT YEARS
-------------------------------------------------------
FUNCTIONAL LINKAGE 5 AND NOT YET
CURRENCY CURRENCY INTEREST RATE % 1 2 3 4 THEREAFTER DETERMINED TOTAL
- ---------- --------- --------------- --- --- --- --- ---------- ---------- -----
EURO US Dollar (1) 8 16 24
EURO EURO 1.95-4.9 9 27 36
NIS US Dollar Libor + 1.5-2.0 1 1 2
NIS NIS -- 20 20
--- --- --- --- --- --- ---
21 8 -- -- 9 44 82
=== === === === === === ===
(1) See Note 8A.(2)(i) to our consolidated financial statements.
2. LONG TERM LOANS - (IN MILLIONS NIS)
REPAYMENT YEARS
AVERAGE ---------------------------------------------------
FUNCTIONAL LINKAGE INTEREST 6 AND
CURRENCY CURRENCY INTEREST RATE % RATE % 1 2 3 4 5 THEREAFTER TOTAL
- ---------- -------- --------------- -------- --- --- --- --- --- ---------- -----
EURO EURO 5.1(i) 5.1 2 3 4 186 -- -- 195
EURO USD Libor +1.9% 5.9 1 1 1 1 1 12 17
EURO EURO Euribor +
1.5-3.35 3.8-5.7 44 85 17 17 17 204 384
UK Pound UK Pound
Sterling Sterling Libor +
1.4-1.65 6.4 8 12 23 24 24 382 473
130
REPAYMENT YEARS
AVERAGE ---------------------------------------------------
FUNCTIONAL LINKAGE INTEREST 6 AND
CURRENCY CURRENCY INTEREST RATE % RATE % 1 2 3 4 5 THEREAFTER TOTAL
- ---------- -------- --------------- -------- --- --- --- --- --- ---------- -----
US Libor +
NIS Dollar 2.5-3.35 6.5-7.3 -- 305(ii) -- -- -- -- 305
NIS EURO Euribur +
2.85-3.35 5.5 4 165(ii) 8 8 34 115 334
UK
Pound
NIS Sterling Libor + 2.85 7.6 -- -- -- -- 66 66 132
SA Rand SA Rand Prime-1 9.5 -- -- -- -- -- 4 4
NIS NIS Prime+2.25 7.6 -- 2 -- -- 11 -- 13
--- --- --- --- --- --- -----
59 573 53 236 153 783 1,857
=== === === === === === =====
(i) The interest rates on this loan have been fixed by swap transactions.
(ii) See Note 14D&F to our consolidated financial statements.
3. SHORT TERM CASH AND DEPOSITS - see notes 3 and 4 to our financial
statements.
4. SHORT TERM LOANS - see note 12 to our consolidated financial statements.
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
Not applicable.
PART II
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
None.
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF
PROCEEDS
Not applicable.
ITEM 15. CONTROLS AND PROCEDURES
(A) DISCLOSURE CONTROLS AND PROCEDURES.
Our chief executive officer and chief financial officer, after evaluating
the effectiveness of our disclosure controls and procedures (as defined in Rule
13a-15(e) of the Securities Exchange Act of 1934, as amended) as of December 31,
2005, have concluded that, as of such date, our disclosure controls and
procedures were effective to ensure that information required to be disclosed by
us in reports that we file or submit under the Exchange Act is accumulated and
communicated to our management, including our chief executive officer and chief
financial officer, to allow timely decisions regarding required disclosure and
is recorded, processed, summarized and reported within the time periods
specified by the SEC's rules and forms.
(B) INTERNAL CONTROL OVER FINANCIAL REPORTING.
Not Applicable.
(C) ATTESTATION REPORT OF THE REGISTERED PUBLIC ACCOUNTING FIRM.
131
Not Applicable.
(D) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING.
There has been no change in our internal control over financial reporting
(as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) identified
with the evaluation thereof that occurred during 2005, that has materially
affected, or is reasonably likely to materially affect our internal controls
over financial reporting.
ITEM 16. [RESERVED]
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
Our board of directors has determined that Mr. Zvi Tropp is an "audit
committee financial expert" as defined in Item 16A of the instructions to Form
20-F and is independent in accordance with the Nasdaq listing standards for
audit committees applicable to us.
ITEM 16B. CODE OF ETHICS
Our principal executive officer, principal financial officer, principal
accounting officer or controller or persons performing similar functions, as
well as all other directors, officers and employees are bound by a Code of
Ethics and Business Conduct. Our Code of Ethics was filed as an exhibit to our
annual report on Form 20-F for the year ended December 31, 2003. On December 11,
2005, following the merger by way of exchange of shares between us and Elscint,
we amended our Code of Ethics and Business Conduct so that it would apply to
Elscint, as a wholly owned subsidiary of us. We will provide any person, without
charge, upon request, a copy of such code. Any person so requesting a copy is
required to submit such request to the Corporate Secretary at 13 Mozes St.,
Tel-Aviv, Israel, 67442 and provide a mailing address for such person.
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Brightman Almagor & Co., a firm of certified public accountants in Israel
and a member firm of Deloitte Touche Tohmatsu have served as our independent
registered public accounting firm for the fiscal year ended December 31, 2005,
for which audited financial statements appear in this annual report on Form
20-F.
(A) AUDIT FEES
The aggregate fees billed for professional services constituting Audit
Fees, rendered to us by Brightman Almagor & Co., in 2004 and 2005 were $482,000
and $447,000, respectively.
(B) AUDIT RELATED FEES
The aggregate fees billed for professional services constituting Audit
Related Fees, rendered to us by Brightman Almagor & Co., in 2005 were $108,000.
Such fees were incurred in connection with our merger by way of exchange of
shares with Elscint and a preparation of a prospectus for the initial public
offering of one of our subsidiaries. During 2004 we were not provided with any
Audit Related Fees.
(C) TAX FEES
The aggregate fees billed for professional services constituting Tax Fees,
rendered to us by Brightman Almagor & Co., in 2004 and 2005 were $66,000 and
$99,000, respectively. Such services related to tax consulting services provided
to us.
(D) ALL OTHER FEES
The aggregate fees billed for professional services constituting All Other
Fees rendered to us by Brightman Almagor & Co., in 2005 were $28,000. During
2004, we did not receive any other service from our auditors which do not fall
within the Audit Services, Audit Related Fees and Tax Fees.
132
(E) PRE-APPROVAL POLICIES AND PROCEDURES
Our Audit Committee oversees the appointment, compensation, and oversight
of the public accounting firm engaged to prepare or issue an audit report on the
financial statements of the Company. The audit committee's specific
responsibilities in carrying out its oversight role include the approval of all
audit and non-audit services to be provided by the external auditor and
quarterly review the firm's non-audit services and related fees. These services
may include audit services, audit-related services, tax services and other
services, as described above. The audit committee approves in advance the
particular services or categories of services to be provided to the Company
during the following yearly period and also sets forth a specific budget for
such audit and non-audit services. Additional services may be pre-approved by
the audit committee on an individual basis during the year.
None of Audit-related Fees, Tax Fees or Other Fees provided to us by
Brightman Almagor & Co., were approved by the Audit Committee pursuant to the de
minimis exception to the pre-approval requirement provided by Section 10A of the
Securities Act of 1934.
(F) PERCENTAGE
Not applicable.
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
Not Applicable.
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE COMPANY AND AFFILIATED
PURCHASERS
(D) MAXIMUM NUMBER
(C) TOTAL NUMBER (OR APPROXIMATELY
OF SHARES PURCHASED DOLLAR VALUE) OF
(A) TOTAL NUMBER AS PART OF PUBLICLY SHARES THAT MAY YET
OF SHARES (B) AVERAGE PRICE ANNOUNCED PLANS OR BE PURCHASED UNDER
PERIOD PURCHASED PAID PER SHARE PROGRAMS THE PLANS OR PROGRAMS
------ ---------------- ----------------- ------------------- ---------------------
February 2005 350,000(1) NIS 45.7 ($10.47) -- --
February 2006 287,259(2) $16.35 -- --
March 2006 22,757(2) $19.05 -- --
May 2006 14,517(2) $24.96 -- --
(1) On February 27, 2005, Mr. Mordechay Zisser, our Executive Chairman of the
Board of Directors, who owns a controlling interest in us, exercised the
350,000 options held by him into 350,000 ordinary shares of par value NIS 1
each of the Company at a total price of approximately $ 3.7 million.
(2) Between February 2006 and May 2006 Europe-Israel purchased a total of
324,533 shares of EMI in consideration for $5,492,382.
ITEM 17. FINANCIAL STATEMENTS.
In lieu of responding to this item, we have responded to Item 18 of this
annual report.
ITEM 18. FINANCIAL STATEMENTS.
The information required by this item is set beginning on page F-1 of this
annual report.
133
PART III
ITEM 19. EXHIBITS
Exhibits.
---------
1.1(1) Memorandum of Association of the Company.
1.2(1) Articles of Association of the Company.
1.3(2)@ Notice dated March 4, 2001, sent by the Registrant to the Israeli
Companies Registrar with respect to an amendment to the Articles of
Association.
4.2(3) Loan facility agreement dated January 22, 2002 between OVAG, MKB and
OPT banks, Amanati Ltd., Duna Plaza Kft. Sopron Plaza Kft. and Plaza
Centers Europe BV with respect to a credit facility in the amount of
Euro 82.9 million.
4.3(2)@ Loan facility agreement dated September 27, 2000, between the
Registrant and Bank Hapoalim BM with respect to a $150 million line
of credit.
4.4(2) Loan Agreement dated March 1, 2001, between Krakow Plaza Sp.z.o.o.
and OVAG with respect to a credit facility in the amount of $35
million.
4.5(4) Loan agreement among, inter alia, Depfa Bank AG, Victoria Hotel C.V.
and Utrecht Victoria Hotel B.V. dated March 24, 1999.
4.6(4) Hotel management agreement between Euston Road Hotel Operators Ltd.
and Park Plaza Europe Ltd. dated December 1997.
4.7(4) Management agreement between Victoria Hotel C.V. and Park Plaza Hotel
Europe, Ltd. (previously Prestige Hotels International Ltd.) dated
October 4, 1993.
4.8(4) Management support and sub-license agreement between Astrid Park
Plaza N.V. and Park Plaza Hotels Europe Ltd. dated April 15, 1997.
4.9(5) Loan agreement dated December 21, 2000 with Bank Hapoalim B.M. with
respect to the financing of the Victoria Park Plaza Hotel.
4.10(5)@ Loan facility agreement dated October 23, 2000 between Elscint and
Bank Hapoalim BM with respect to a $110 million line of credit.
4.11(5)@ Development agreement dated December 17, 2000 between Elscint and the
Israeli Land Administration with respect to the Monfort Project.
4.12(6)@ Agreement dated April 14, 2002 between SLS Sails Ltd. and C.D.P.M.
Kft. for the completion of the construction works of Elscint's
commercial and entertainment center in Herzliya.
4.13(8) Framework Transaction Agreement, dated as of July 30, 2004, by and
among Klepierre S.A., Klepierre Hongrie S.A.S., LP7 S.A.S. and
Segece, as Buyers, and Plaza Centers (Europe) B.V., Elbit Ultrasound
Netherlands B.V., Szeged 2002 Kft., and Plaza Centers Management
B.V., as Vendors.
4.14(8) Transaction Agreement, dated January 31, 2005, Plantridge Limited, as
Purchaser, Plaza Centers (Europe) B.V., Elbit Ultrasound Netherlands
B.V., and Amanati Limited, as Vendors.
4.15* Framework Transaction Agreement, dated of July 29, 2005, by and among
Klepierre S.A., Klepierre Sadyba Sp.z.o.o. Klepierre Krakow
Sp.z.o.o., Klepierre Poznan Sp.z.o.o, LP7 S.A.S. and Segece S.C.S, as
Buyers, and Plaza Centers (Europe) B.V. as Vendor.
4.16* Share Sale And Purchase Agreement relating to the shares in Shaw
Hotel Holding B.V. dated 19 December 2005 by and between Euro Sea
Hotel N.V., B.E.A. Hotels N.V.and Shawpark Investments B.V. as
Sellers and WG Mitchell (Scotland) Ltd as Purchaser
4.17* Unofficial Translation of Deed of Trust dated February 21, 2006,
entered into between the Company and Orora Fidelity Trust Company
Ltd. for the issuance of series A debentures.
4.18* Unofficial Translation of Deed of Trust, dated February 21, 2006,
entered into between the Company and Orora Fidelity Trust Company
Ltd. for the issuance of series A debentures.
4.19(9) Agreement and Plan of Merger dated August 21, 2005 between the
Company and Elscint.
4.20* Amended and Restated Loan Agreement, Multicurrency Term Credit
Facility, dated December 5, 2005, between Elscint and Bank Hapoalim
B.M.
134
4.21* Lease Agreement dated January 6, 2003 between Euston Road Hotel
Limited and Accor SA for a long term lease of the hotel property
located on Euston Road in London, England (previously Bernard Shaw
Park Plaza) for a period of 25 years.
4.22* A form of Hotel Management Agreement entered into with Park Plaza.
4.23* Amended and Restated Loan Agreement dated July 9, 2003 between
Elscint and Bank of Hapoalim B. M.
4.24* Amended and Restated Loan Agreement dated July 9, 2003 between
Elbit Ultrasound (Netherlands) B. V. and Bank of Hapoalim B. M.
8.1* List of subsidiaries (Incorporated by reference to "Item 4 -
Information on Company - Organizational Structure).
10.1* Consent of Brightman Almagor & Co.
10.2* Consent of KPMG Hungaria kft.
10.3* Consent of Mazars Paar de Koper Hoffman N. V.
10.4* Consent of Kost, Forer Gabbay & Kasierer.
11.1* Code of Ethics and Business Conduct for Directors, Officers and Other
Employees
12.1* Certification of the Principal Executive Officer and Principal
Accounting Officer pursuant to Section 302 of the Sarbanes Oxley Act
of 2002
13.1* Certification of the Principal Executive Officer and Principal
Accounting Officer pursuant to Section 906 of the Sarbanes Oxley Act
of 2002
- ----------
(1) Previously filed as an Exhibit to EMI's Annual Report on Form 20-F, File
No. 0-28996, filed with the Securities and Exchange Commission on November
22, 1996 and incorporated by reference herein.
(2) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2000, File No. 0-28996, filed with the Securities
and Exchange Commission on July 16, 2001 and incorporated by reference
herein.
(3) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2001, File No. 0-28996, filed with the Securities
and Exchange Commission on July 1, 2002 and incorporated by reference
herein.
(4) Previously filed as an Exhibit to Elscint's Annual Report on Form 20-F for
the year ended December 31, 1999, File No. 2-44872, filed with the
Securities and Exchange Commission on June 2, 2000, and incorporated by
reference herein.
(5) Previously filed as an Exhibit to Elscint's Annual Report on Form 20-F for
the year ended December 31, 2000, File No. 2-44872, filed with the
Securities and Exchange Commission on July 10, 2001 and incorporated by
reference herein.
(6) Previously filed as an exhibit to Elscint's Annual Report on Form 20-F for
the year ended December 31, 2001, File No. 2-44872, filed with the
Securities and Exchange Commission on June 28, 2002 and incorporated by
reference herein.
(7) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2003, File No. 0-28996, filed with the Securities
and Exchange Commission on June 30, 2004 and incorporated by reference
herein.
(8) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2004, File No. 0-28996, filed with the Securities
and Exchange Commission on June 30, 2005 and incorporated by reference
herein.
(9) Previously filed as an exhibit to Joint Proxy Statement Prospectus filed
with the Securities and Exchange Commission on September 21, 2005 and
incorporated by reference herein.
* Filed herewith.
@ Translation from Hebrew.
135
SIGNATURES
The Registrant hereby certifies that it meets all of the requirements for
filing on Form 20-F and that it has duly caused and authorized the undersigned
to hereby sign this annual report on its behalf.
Elbit Medical Imaging Ltd.
By: /s/ Shimon Yitzhaki
------------------------------------
Name: Shimon Yitzhaki
Title: President & Chief Financial
Officer
Date: June 30, 2006
136
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2005
CONTENTS
PAGE
--------
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 2 - 3
CONSOLIDATED FINANCIAL STATEMENTS:
Balance sheets 4 - 5
Statements of operations 6
Statements of changes in shareholders' equity 7 - 8
Statements of cash flows 9 - 11
Notes to the consolidated financial statements 12 - 131
Appendix 132
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
TO THE SHAREHOLDERS AND THE BOARD OF DIRECTORS OF
ELBIT MEDICAL IMAGING LTD.
We have audited the accompanying consolidated balance sheets of Elbit
Medical Imaging Ltd. and its subsidiaries ("the Company"), as of December
31, 2005 and 2004, and the related consolidated statements of operations,
statements of changes in shareholders' equity, and the consolidated
statements of cash flows, for each of the three years in the period ended
December 31, 2005. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits. We did not audit the financial
statements of certain subsidiaries, whose assets included in consolidation
constitute 31% and 37% of the total consolidated assets, as of December 31,
2005 and 2004, respectively, and whose revenues included in consolidation
constitute 45%, 44% and 50% of total consolidated revenues for the years
ended December 31, 2005, 2004 and 2003, respectively. We also did not audit
the financial statements of affiliates accounted for by use of the equity
method. The Company's equity of NIS 35 million and NIS 33 million in those
affiliates' net assets as of December 31, 2005 and 2004, respectively, and
of NIS 7 million, NIS 4 million and NIS 7 million in those affiliates' net
loss for each of the three years ended December 31, 2005, respectively, are
included in the accompanying financial statements. The financial statements
of those companies prepared in accordance with International Financial
Reporting Standards or in accordance with accounting principles generally
accepted in the United States of America or in accordance with accounting
principles generally accepted in Israel, as applicable, were audited by
other auditors whose reports thereon were furnished to us, and our opinion,
insofar as it relates to amounts included for those companies, on such
basis of accounting, is based solely on the reports of the other auditors.
We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. The
Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. Our audit included
consideration of internal control over financial reporting as a basis for
designing audit procedures that are appropriate in the circumstances, but
not for the purpose of expressing an opinion on the effectiveness of the
Company's internal control over financial reporting. Accordingly, we
express no such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements
(including the Company's conversion of amounts in the financial statements
of subsidiaries and affiliates, prepared in accordance with International
Financial Reporting Standards or accounting principles generally accepted
in the United States of America or accounting principles generally accepted
in Israel to amounts in accordance with generally accepted accounting
principles in Israel and in the United States of America). An audit also
includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits and the reports of other auditors
provide a reasonable basis for our opinion.
In our opinion, based on our audits and on the reports of the other
auditors, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Elbit Medical
Imaging Ltd. and its subsidiaries as of December 31, 2005 and 2004, and the
consolidated results of operations and cash flows, for each of the three
years in the period ended December 31, 2005, in conformity with accounting
principles generally accepted in Israel.
-2-
Accounting principles generally accepted in Israel vary in certain respects
from accounting principles generally accepted in the United States of
America. Information relating to the nature and effect of such differences
is presented in Note 25 to the consolidated financial statements.
As described in Note 2A(2), the financial statements for dates and reported
periods subsequent to December 31, 2003 are presented in reported amounts,
in accordance with the accounting standards of the Israeli Accounting
Standards Board. The financial statements for the year ended in December
31, 2003 are presented in values adjusted until then, based on the changes
in the general purchasing power of the Israeli currency and in accordance
with the pronouncements of the Institute of Certified Public Accountants in
Israel.
As discussed in Note 17B, claims have been filed against Group companies.
For some of those claims petitions have been filed for certification as
class actions.
As discussed in Note 2L, the Company has adopted effective January 1, 2005,
Standard No. 19 of the Israel Accounting Standards Board, "income taxes".
Our audits also comprehended the translation of New Israeli Shekel amounts
into U.S. dollar amounts and, in our opinion, such translation has been
made in conformity with the basis stated in Note 2A(1). Such U.S. dollar
amounts are presented solely for the convenience of readers in the United
States of America.
BRIGHTMAN ALMAGOR & CO.
CERTIFIED PUBLIC ACCOUNTANTS
A MEMBER FIRM OF DELOITTE TOUCHE TOHMATSU
Tel-Aviv (Israel), April 9, 2006
The accompanying notes to the financial statements constitute an integral
part thereof.
-3-
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31
-----------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
NOTE REPORTED REPORTED TRANSLATION
---- --------- --------- -----------
(IN THOUSAND NIS) US$'000
CURRENT ASSETS
Cash and cash equivalents (3) 489,344 345,745 106,310
Short-term deposits and investments (4) 240,072 278,021 52,155
Trade accounts receivable (5) 35,404 39,102 7,691
Receivables and other debit balances (6) 76,680 66,140 16,659
Inventories (7) 24,132 7,331 5,243
--------- --------- -------
865,632 736,339 188,058
--------- --------- -------
LONG-TERM INVESTMENTS AND RECEIVABLES
Long-term deposits, debentures, loans
and other long-term balances (8) 62,139 113,785 13,500
Investments in investees and other companies (9) 56,798 71,608 12,339
--------- --------- -------
118,937 185,393 25,839
--------- --------- -------
REAL ESTATE AND OTHER FIXED ASSETS (10) 2,758,465 3,527,988 599,275
--------- --------- -------
OTHER ASSETS AND DEFERRED EXPENSES (11) 30,476 55,859 6,621
--------- --------- -------
ASSETS RELATED TO DISCONTINUING OPERATION (22) 12,607 14,700 2,739
--------- --------- -------
3,786,117 4,520,279 822,532
========= ========= =======
The accompanying notes to the financial statements constitute an integral
part thereof.
-4-
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31
-----------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
NOTE REPORTED REPORTED TRANSLATION
---- --------- --------- -----------
(IN THOUSAND NIS) US$'000
CURRENT LIABILITIES
Short-term credits (12) 460,270 536,937 99,994
Suppliers and service providers 82,013 74,358 17,817
Payables and other credit balances (13) 149,995 183,446 32,586
--------- --------- -------
692,278 794,741 150,397
--------- --------- -------
LONG-TERM LIABILITIES (14) 1,902,391 2,418,897 413,294
--------- --------- -------
LIABILITIES RELATED TO DISCONTINUING OPERATION (22) 62,430 71,986 13,563
--------- --------- -------
CONVERTIBLE DEBENTURES 62,159 -- 13,504
--------- --------- -------
MINORITY INTEREST 11,449 430,687 2,487
--------- --------- -------
COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (17)
SHAREHOLDERS' EQUITY (18) 1,055,410 803,968 229,287
--------- --------- -------
3,786,117 4,520,279 822,532
========= ========= =======
- ------------------------------------- ----------------------------------------
MORDECHAI ZISSER SHIMON YITZHAKI
CHAIRMAN OF THE BOARD OF DIRECTORS CEO, A MEMBER OF THE BOARD OF DIRECTORS
AND THE SENIOR FINANCIAL OFFICER OF
THE COMPANY
APPROVED BY THE BOARD OF DIRECTORS ON APRIL 9, 2006.
The accompanying notes to the financial statements constitute an integral
part thereof.
-5-
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED STATEMENT OF OPERATIONS
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 (*) 2003 (*) CONVENIENCE
NOTE REPORTED REPORTED ADJUSTED TRANSLATION
---- -------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
(EXCEPT FOR PER-SHARE DATA)
REVENUES
Sale of real estate assets and investments, net (19A) 281,661 131,921 -- 61,191
Commercial centers operations 142,957 311,893 347,056 31,057
Hotels operations and management (19B) 270,057 218,365 189,205 58,670
Sale of medical systems 75,713 44,049 -- 16,449
Realization of investments (19C) 1,958 16,415 45,129 425
Other operational income (19D) 44,409 13,238 13,495 9,648
------- ------- ------- -------
816,755 735,881 594,885 177,440
------- ------- ------- -------
COSTS AND EXPENSES
Commercial centers operations (19E) 157,640 271,392 257,913 34,248
Hotels operations and management (19F) 259,293 207,152 188,672 56,331
Cost and expenses of medical systems operation (19G) 49,577 26,039 8,720 10,771
Other operational expenses (19H) 46,793 3,655 3,510 10,166
Research and development expenses, net (19I) 58,899 38,158 43,719 12,796
General and administrative expenses (19J) 36,939 43,627 42,144 8,025
Share in losses of associated companies, net 12,028 15,968 20,951 2,613
Financial expenses, net (19K) 122,321 53,569 211,821 26,574
Other expenses, net (19L) 57,106 51,428 10,477 12,406
------- ------- ------- -------
800,596 710,988 787,927 173,930
------- ------- ------- -------
PROFIT (LOSS) BEFORE INCOME TAXES 16,159 24,893 (193,042) 3,510
Income taxes (tax benefits) (16) 7,798 15,804 (20,217) 1,694
------- ------- ------- -------
PROFIT (LOSS) AFTER INCOME TAXES 8,361 9,089 (172,825) 1,816
Minority interest in results of subsidiaries, net 73,287 27,448 48,671 15,922
------- ------- ------- -------
PROFIT (LOSS) FROM CONTINUING OPERATION 81,648 36,537 (124,154) 17,738
Profit from discontinuing operation, net (22) 5,917 6,810 12,073 1,285
cumulative effect of accounting change at the
beginning of the year (2L) (622) -- -- (135)
------- ------- ------- -------
NET INCOME (LOSS) 86,943 43,347 (112,081) 18,888
======= ======= ======= =======
EARNINGS (LOSS) PER SHARE - (IN NIS) (19M)
Basic earnings (loss) per share:
From continuing operation 3.66 1.59 (5.56) 0.80
From discontinuing operation 0.27 0.30 0.54 0.06
Cumulative effect for the beginning of the year due to
a change in accounting method (0.03) -- -- (0.01)
------- ------- ------- -------
Basic earnings (loss) per share 3.90 1.89 (5.02) 0.85
======= ======= ======= =======
(*) Reclassified - see Note 2C. below.
The accompanying notes to the financial statements constitute an integral part
thereof.
-6-
ELBIT MEDICAL IMAGING LTD.
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
DIVIDEND
CUMULATIVE LOANS TO DECLARED
FOREIGN EMPLOYEES TO AFTER
SHARE CURRENCY ACQUIRE BALANCE
CAPITAL CAPITAL TRANSLATION RETAINED GROSS TREASURY COMPANY SHEET
(1) RESERVES ADJUSTMENTS EARNINGS AMOUNT STOCK SHARES DATE TOTAL
------- -------- ----------- -------- --------- -------- ------------ -------- ---------
(IN THOUSAND NIS)
BALANCE - JANUARY 1, 2003
(ADJUSTED AMOUNTS) 33,028 465,766 135,748 481,728 1,116,270 (40,291) (14,443) -- 1,061,536
Loss for the year -- -- -- (112,081) (112,081) -- -- -- (112,081)
Differences from
translation of autonomous
foreign entities' financial
statements (2) -- -- 4,191 -- 4,191 -- -- -- 4,191
Employee shares premium -- 1,073 -- -- 1,073 -- (1,073) -- --
------ ------- ------ ------- --------- -------- ------- ------- ---------
BALANCE - DECEMBER 31, 2003
(ADJUSTED AMOUNTS) 33,028 466,839 139,939 369,647 1,009,453 (40,291) (15,516) -- 953,646
Net income for the year -- -- -- 43,347 43,347 -- -- -- 43,347
Issuance of shares (Note 18B(ii)) 623 18,283 -- -- 18,906 -- -- -- 18,906
Differences from
translation of autonomous
foreign entities' financial
statements (2) -- -- (89,321) -- (89,321) -- -- -- (89,321)
Self-purchase of Company's shares
(Note 18B(iv)) -- -- -- -- -- (138,519) -- -- (138,519)
Sale of treasury stock
(Note 18B(iii)) -- (2,725) -- -- (2,725) 16,427 -- -- 13,702
Employee shares premium -- 1,821 -- -- 1,821 -- 386 -- 2,207
Declared dividend in respect of
shareholders outside the
group, other than employees
(Note 18D(i)) -- -- -- (153,938) (153,938) -- -- 153,938 --
------ ------- ------ ------- --------- -------- ------- ------- ---------
BALANCE - DECEMBER 31, 2004
(REPORTED AMOUNTS) 33,651 484,218 50,618 259,056 827,543 (162,383) (15,130) 153,938 803,968
Net income for the year -- -- -- 86,943 86,943 -- -- -- 86,943
Issue of shares to the minority
shareholders of Elscint (Note
9B(1)) 3,479 288,728 -- -- 292,207 -- -- -- 292,207
Exercise of warrants
(Note 20A(4)) 350 15,645 -- -- 15,995 -- -- -- 15,995
Differences from translation of
autonomous foreign entities'
financial statements (2) -- -- 23,806 -- 23,806 -- -- -- 23,806
Dividend paid (Note 18D(i)) -- -- -- -- -- -- -- (153,938) (153,938)
Repayment of loans as a result of
the realization by employees
of rights to shares -- -- -- -- -- -- 6,781 -- 6,781
Loans to employees of Elscint in
relation to shares issued as
part of the merger -- -- -- -- -- -- (10,112) -- (10,112)
Employee shares premium -- 573 -- -- 573 -- (573) -- --
Declared dividend in respect of
shareholders outside the
group, other than employees
(Note 18D(ii)) -- -- -- (126,839) (126,839) -- -- 126,839 --
------ ------- ------ ------- --------- -------- ------- ------- ---------
37,480 789,164 74,424 219,160 1,120,228 (162,383) (19,034) 126,839 1,065,650
Cumulative effect of accounting
change at the beginning of the
year -- -- (6,552) (3,688) (10,240) -- -- -- (10,240)
------ ------- ------ ------- --------- -------- ------- ------- ---------
BALANCE - DECEMBER 31, 2005
(REPORTED AMOUNTS) 37,480 789,164 67,872 215,472 1,109,988 (162,383) (19,034) 126,839 1,055,410
====== ======= ====== ======= ========= ======== ======= ======= =========
(1) As of December 31, 2005 - net of 2,842,400 "dormant" shares and 524,187
shares held by Elscint Ltd.
The accompanying notes to the financial statements constitute an integral part
thereof.
-7-
(2) Net, after realization of capital reserves (see Note 19A.(i) below).
The accompanying notes to the financial statements constitute an integral part
thereof.
-8-
ELBIT MEDICAL IMAGING LTD.
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
DIVIDEND
CUMULATIVE LOANS TO DECLARED
FOREIGN EMPLOYEES TO AFTER
SHARE CURRENCY ACQUIRE BALANCE
CAPITAL CAPITAL TRANSLATION RETAINED GROSS TREASURY COMPANY SHEET
(1) RESERVES ADJUSTMENTS EARNINGS AMOUNT STOCK SHARES DATE TOTAL
------- -------- ----------- -------- ------- -------- ------------ -------- -------
CONVENIENCE TRANSLATION INTO US$'000
BALANCE -
JANUARY 1, 2005 7,311 105,196 10,997 56,280 179,784 (35,278) (3,287) 33,443 174,662
Net income for the year -- -- -- 18,888 18,888 -- -- -- 18,888
Issue of shares to the minority
shareholders of Elscint (Note
9B(1)) 756 62,726 -- -- 63,482 -- -- -- 63,482
Exercise of warrants
(Note 20A(4)) 76 3,399 -- -- 3,475 -- -- -- 3,475
Differences from translation of
autonomous foreign entities'
financial statements (2) -- -- 5,172 -- 5,172 -- -- -- 5,172
Dividend paid
(Note 18D(i)) -- -- -- -- -- -- -- (33,443) (33,443)
Repayment of loans as a result of
the realization by employees of
rights to shares -- -- -- -- -- -- 1,473 -- 1,473
Loans to employees of Elscint in
relation to shares issued as
part of the merger -- -- -- -- -- -- (2,197) -- (2,197)
Employee shares premium -- 124 -- -- 124 -- (124) -- --
Declared dividend in respect of
shareholders outside the group,
other than employees
(Note 18D(ii)) -- -- -- (27,556) (27,556) -- -- 27,556 --
----- ------- ------ ------- ------- ------- ------ ------- -------
8,143 171,445 16,169 47,612 243,369 (35,278) (4,135) 27,556 231,512
Cumulative effect of accounting
change at the beginning of the
year -- -- (1,424) (801) (2,225) -- -- -- (2,225)
----- ------- ------ ------- ------- ------- ------ ------- -------
BALANCE - DECEMBER 31, 2005 8,143 171,445 14,745 46,811 241,144 (35,278) (4,135) 27,556 229,287
===== ======= ====== ======= ======= ======= ====== ======= =======
(1) As of December 31, 2005 - net of 2,842,400 "dormant" shares and 524,187
shares held by Elscint Ltd.
(2) Net, after realization of capital reserves (see Note 19A.(i) below).
The accompanying notes to the financial statements constitute an integral part
thereof.
-9-
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED STATEMENT OF CASH FLOWS
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
CASH FLOWS FROM OPERATING ACTIVITIES
Net profit (loss) for the year 86,943 43,347 (112,081) 18,888
Adjustments required to present cash and
cash equivalents from continuing
operating activities (Appendix A) (189,640) (64,553) 109,794 (41,199)
-------- -------- -------- -------
Net cash used in continuing operating activities (102,697) (21,206) (2,287) (22,311)
Net cash provided by (used in) discontinuing
operating activities 3,589 (356) (6,046) 780
-------- -------- -------- -------
NET CASH USED IN OPERATING ACTIVITIES (99,108) (21,562) (8,333) (21,531)
-------- -------- -------- -------
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in initially-consolidated subsidiaries
(Appendix C) (117,666) (35,546) (18,070) (25,563)
Purchase of fixed assets and other assets (435,810) (373,454) (540,299) (94,680)
Proceeds from realization of fixed assets,
investments and loans 7,811 59,310 14,444 1,697
Proceeds from realization of investments in
subsidiaries (Appendix D) 524,482 412,005 -- 113,945
Investments (including by loans) in investee and
other companies (10,815) (3,090) (30,027) (2,350)
Proceeds from realization of long term deposits 18,579 8,965 252,124 4,036
Short-term deposits and marketable securities,
net 18,915 58,147 358,551 4,109
-------- -------- -------- -------
Net cash provided by continuing investing
activities 5,496 126,337 36,723 1,194
Net cash provided by (used in) discontinuing
investing activities -- 2,144 94,720 --
-------- -------- -------- -------
NET CASH PROVIDED BY INVESTING ACTIVITIES 5,496 128,481 131,443 1,194
-------- -------- -------- -------
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, by a subsidiary, to its
minority shareholders -- 13,492 12,469 --
Excercise of options into shares 15,995 -- -- 3,475
Dividend Paid (153,938) -- -- (33,443)
Self-purchase of Company's shares -- (138,519) -- --
Issuance of convertible debentures by a
subsidiary to its minority shareholders -- 60,234 -- --
Receipt of long-term loans 437,407 722,089 521,506 95,027
Repayment of long-term loans (71,669) (503,706) (523,715) (15,570)
Short-term credit, net 15,932 (77,718) (185,255) 3,461
-------- -------- -------- -------
NET CASH PROVIDED BY (USED IN) FINANCING
ACTIVITIES 243,727 75,872 (174,995) 52,950
-------- -------- -------- -------
NET EFFECT ON CASH DUE TO CURRENCY EXCHANGE RATES
CHANGES (6,516) (522) 3,959 (1,416)
-------- -------- -------- -------
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 143,599 182,269 (47,926) 31,197
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE
YEAR 345,745 163,476 211,402 75,113
-------- -------- -------- -------
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR 489,344 345,745 163,476 106,310
======== ======== ======== =======
The accompanying notes to the financial statements constitute an integral part
thereof.
-10-
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED STATEMENT OF CASH FLOWS (CONT.)
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
APPENDIX A -
ADJUSTMENTS REQUIRED TO PRESENT CASH AND
CASH EQUIVALENTS FROM CONTINUING OPERATING
ACTIVITIES
INCOME AND EXPENSES NOT INVOLVING CASH FLOWS:
Discontinuing operation (5,917) (6,810) (12,073) (1,285)
Depreciation and amortization (including
impairment of investments and assets) 129,356 191,752 175,346 28,103
Share in losses of associated companies 12,028 15,968 20,951 2,613
Minority interest in results of subsidiaries (73,287) (27,448) (48,671) (15,922)
Loss from realization of assets and liabilities 21,836 12,201 7,808 4,744
Exchange-rate differences on loans and
deposits, net 25,677 (104,679) 62,646 5,578
Profit from realization of investments (283,619) (148,334) (45,129) (61,617)
Profit from realization of monetary balances of a
capital-nature in investee companies -- (12,378) (32,253) --
Deferred taxes 2,682 12,516 (29,580) 583
Others 3,761 (274) (1,886) 817
CHANGES IN ASSETS AND LIABILITIES:
Trade accounts receivables (24,140) (6,023) 12,774 (5,244)
Receivables and other debit balances (10,142) 15,102 (9,694) (2,203)
Long-term receivables (2,946) (5,354) (5,113) (640)
Inventories (12,952) (2,646) (1,069) (2,814)
Suppliers and service providers 13,502 (1,997) 5,416 2,933
Payables and other credit balances 14,521 3,851 10,321 3,155
-------- -------- ------- -------
(189,640) (64,553) 109,794 (41,199)
======== ======== ======= =======
APPENDIX B -
NON-CASH TRANSACTIONS
Acquisition of fixed assets and other assets by credit 62,533 18,570 34,064 13,585
======== ======== ======= =======
The accompanying notes to the financial statements constitute an integral part
thereof.
-11-
ELBIT MEDICAL IMAGING LTD.
CONSOLIDATED STATEMENT OF CASH FLOWS (CONT.)
YEAR ENDED DECEMBER 31
------------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
---------- ---------- -------- -----------
(IN THOUSAND NIS) US$'000
APPENDIX C -
INITIALLY CONSOLIDATED SUBSIDIARIES
Deficit in working capital (excluding cash), net 1,769 28 3,535 384
Long-term receivables, investments and deposits (387) -- -- (84)
Fixed assets and other assets (226,469) (35,706) (32,955) (49,200)
Long-term liabilities 107,421 132 11,350 23,337
---------- ---------- ------- --------
(117,666) (35,546) (18,070) (25,563)
========== ========== ======= ========
APPENDIX D -
PROCEEDS FROM REALIZATION OF INVESTMENTS IN
SUBSIDIARIES
Working capital (excluding cash), net 17,775 1,347 -- 3,862
Fixed assets and other assets 1,167,940 1,585,181 -- 253,734
Long term loans (1,022,113) (1,091,661) -- (222,054)
Other long term receivables 39,563 (61,452) -- 8,595
Profit from realization of subsidiaries 281,661 131,921 -- 61,191
Realization of capital reserves from foreign
currency translation adjustments 39,656 (153,331) -- 8,617
---------- ---------- ------- --------
524,482 412,005 -- 113,945
========== ========== ======= ========
The accompanying notes to the financial statements constitute an integral part
thereof.
-12-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - GENERAL
A. The Company engages, directly and through its investee companies, in Israel
and abroad, mainly in the following areas:
- Initiation, construction, operation, management and sale of commercial
and entertainment centers in Israel and in Central and Eastern Europe
(see also Note 2C. below).
- Hotels ownership, primarily in major European cities, as well as
operation, management and sale of same.
- Long term leases of real estate property.
- Investments in the research and development, production and marketing
of magnetic resonance imaging guided focused ultrasound treatment
equipment, through Insightec Ltd. (formerly - Insightec - Image Guided
Treatment Ltd.) ("Insightec").
- Distributing and marketing of woman's fashion and accessories through
its wholly owned Israeli subsidiary - Mango Israel Clothing and
Footwear Ltd. ("Mango").
- Venture-capital investments.
B. The Company's shares are registered for trade on the Tel Aviv Stock
Exchange and in the United States on NASDAQ.
C. DEFINITIONS:
The Company - Elbit Medical Imaging Ltd. ("EMI").
Subsidiaries
(consolidated companies) - companies which over 50% of voting rights
thereof or of rights to appoint directors
therein are vested with the Company.
Proportionately consolidated
companies - companies and joint ventures (including
partnerships) which the Company holds,
together with other entities, among which
there exists a contractual agreement for
joint control, and the decision making in
areas vital to the joint venture is to be
made jointly and with the consent of all
interest-holders, and which financial
statements are consolidated with those of
the Company by the proportionate
consolidation method.
Associated companies - companies in which the Company's (direct or
indirect) rights entitle it to exercise
significant influence on their financial and
operational policies, which have been
included on the basis of the equity method
in accordance with the principles
established by Opinion No. 68 of Institute
of the Certified Public Accountants in
Israel ("ICPAI") and which are not fully or
proportionately consolidated.
Investee companies - consolidated companies, proportionately
consolidated companies and associated
companies. For a list of principal investee
companies - see Appendix to these financial
statements.
Acquisition and/or holding
and/or ownership
and/or control - whether directly or indirectly, through
Israeli or foreign subsidiaries.
-13-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Group - the Company and its investee companies.
-14-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - GENERAL (CONT.)
C. DEFINITIONS (CONT.):
Parent company - Europe Israel (M.M.S.) Ltd. ("EIL").
Europe Israel Group - Europe Israel (M.M.S.) Ltd. and its investee
companies.
Control Centers - Control Centers Ltd. - the controlling
shareholder of Europe Israel (M.M.S.) Ltd.
Control Centers Group - Control Centers and its investee companies.
Related parties - as defined in terms of Opinion No. 29 of the
ICPAI.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
A. FINANCIAL STATEMENTS IN REPORTED AMOUNTS
(1) GENERAL
Through December 31, 2003, the Company's financial statements were
prepared in adjusted values (in NIS of constant purchase power), on
the basis of changes in the consumer price index ("Inflation" and
"CPI"), in accordance with Opinions No. 36 and 50 of the ICPAI
("Opinion 36" and "Opinion 50"). On January 1, 2004, Accounting
Standard No. 12 of the Israel Accounting Standards Board ("IASB") came
into force and effect ("Standard 12"). In accordance with the
provisions of Standard 12, adjustment of financial statements to the
inflation shall cease commencing January 1, 2004, with adjusted
amounts of non-monetary items which were included in the balance sheet
as of December 31, 2003, used as basis for the nominal financial
reporting as and from January 1, 2004. Amounts presented in the
financial statements for periods commencing January 1, 2004 were,
therefore, included in values to be hereinafter referred to as -
"Reported amounts".
The Company maintains its accounting records on a current basis in
nominal NIS. Nominal amounts were adjusted to their respective
reported amounts herein, based on the principles detailed in section 2
below, in accordance with the provisions of Standard 12. Therefore,
commencing January 1, 2004, the financial statements are presented on
the basis of the historical (original) values convention, in reported
amounts.
The term "cost" in the financial statements indicates cost in reported
amounts (or adjusted, as the case may be), unless otherwise stated.
CONVENIENCE TRANSLATION
The financial statements as of December 31, 2005 and for the year then
ended have been translated into U.S. dollar using the representative
exchange rate as of that date (U.S.$1.0 = NIS 4.603). Such translation
was made solely for the convenience of the U.S. readers. The dollar
amounts so presented in these financial statements should not be
construed as representing amounts receivable or payable in dollars or
convertible into dollars but rather a translation of reported amounts
into U.S. dollars, unless otherwise indicated.
-15-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
A. FINANCIAL STATEMENTS IN REPORTED AMOUNTS (CONT.)
(2) PRINCIPLES OF ADJUSTMENT OF NOMINAL VALUE AMOUNTS TO THEIR RESPECTIVE
REPORTED AMOUNT
BALANCE SHEET
The balance-sheet items have been included in the following manner:
Non-monetary items (mainly fixed assets and other assets, depreciation
thereof, and share capital) have been adjusted according to the
changes in the CPI from their respective acquisition or formation
date, as the case may be, through December 2003 and from such date (or
the acquisition or formation date, whichever be the later) through the
balance-sheet date - with no further adjustment (in nominal values).
Monetary items (representing amounts receivable or payable at par
value or which are presented in realizable values) are included in
their nominal values.
The value of investments in investee companies and minority interest
in subsidiaries have been determined on the basis of the financial
statements of those companies, in reported values (through 2003 - in
adjusted values). As to foreign autonomous investee companies - see
section (3) below.
Reported values (or adjusted, as the case may be), of non-monetary
assets do not necessarily represent realizable or actual economic
value, but rather the original values calculated in accordance with
the above stated principles.
STATEMENT OF OPERATIONS
Statement of operations' items have been included in the following
manner:
Revenues and expenses, including financial expenses and excluding
those generated from non-monetary items, have been recorded in their
nominal values (such revenues and expenses with the exclusion of
financial expenses were adjusted - during the year ended December 31,
2003 - to the changes in the CPI from the date of each transaction
through December 31, 2003; the financing item reflected financial
expenses net of financial income in real terms (e.g. interest on
deposits and credits), results of marketable securities, activities
and inflationary erosion of monetary items deriving from transactions
included in the statements of operations).
Income and expenses stemming from non-monetary items (mainly
depreciation, amortization and changes in inventories) have been
recorded on the basis of principles used for the inclusion in the
balance sheet, of the items to which they relate.
The Company's share as well as minority interest in the results of
investee companies were determined on the basis of the financial
statements thereof in reported amounts (in adjusted values - though
December 2003). As to foreign autonomous investee companies - see
section (3)(i), below.
-16-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
A. FINANCIAL STATEMENTS IN REPORTED AMOUNTS (CONT.)
(3) FOREIGN INVESTEE COMPANIES
(i) Investee companies that operate outside the borders of the state
of residence of their holding entity, and which constitute
autonomous entities, prepared their financial statements through
December 31, 2003 in accordance with the principles established
in Opinion 36 (including Interpretations No. 8 and 9 thereon) in
the currency of their country of residence adjusted to changes in
the CPI of such country. Such financial statements were
translated into the holdings entity's reporting currency using
the exchange rate prevailing as at the balance sheet date
("translation" and "closing rate"). Differences between (i)
adjusted amount of the holding entity's investment in the
investee companies (including monetary balances of a
capital-nature), based on changes in the CPI of the country of
residence of such holding entity; and (ii) the holding entity's
share in the adjusted shareholders' equity of these investee
companies as aforestated, as translated into the reporting
currency of the holding entity as per closing rates, are charged
to the "Capital reserve from foreign currency translation
adjustments of autonomous foreign entities' financial statements"
within shareholders' equity. Exchange differences relating to
foreign currency loans used to finance investments in autonomous
foreign entities in same currency, were also charged to said
capital reserve. Income taxes relating to such differences have
also been included in that item of shareholders' equity.
Upon the realization of an autonomous foreign entity, in whole or
in part (including realization as a result of a decline in
holding percentage arising from the issuance of shares to a third
party or through the repayment of monetary balances of a
capital-nature), such foreign currency translation adjustments
relating to the realized investment are charged to the statement
of operations as other income (expense).
As from January 1 2004, financial statements of autonomous
foreign entities were prepared based on principles detailed in
section (2) above. On January 1, 2004, accounting standard No. 13
of the IASB came into force and effect, regarding the effect of
the changes in foreign currency exchange rates, which provides
for translation of foreign currency transactions and foreign
operations' financial statements for the inclusion thereof in the
financial statements of the reporting entity ("Standard 13"). The
principal provisions of Standard 13 that differ from accounting
principles used through December 31, 2003 and are relevant to the
group companies' autonomous foreign entities, are:
- Translation of revenues and expenses as well as cash flows,
of foreign operations constituting "autonomous foreign
entities" based on exchange rate as at the date of
transaction or cash flow, as the case may be, or for sake of
practicality - using average exchange rate for the period,
as opposed to principles used prior to December 31, 2003
which provided for translation of all items of the
"autonomous foreign entities" financial statements based on
closing rates. Exchange rate differences that result from
the difference between translation method of revenues and
expenses (average) to that of the shareholders' equity
(closing rate) are charged to the "Capital reserve from
foreign currency translation adjustments of autonomous
foreign entities' financial statements" within shareholders'
equity.
- Goodwill generated upon acquisition of an "autonomous
foreign entity" shall be regarded as an asset of such
autonomous foreign entity and be translated based on closing
rates, as opposed to principles used prior to December 31,
2003 whereby said goodwill was considered an independent
non-monetary item, of the holding entity.
-17-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
A. FINANCIAL STATEMENTS IN REPORTED AMOUNTS (CONT.)
(3) FOREIGN INVESTEE COMPANIES (CONT.)
(i) (Cont.)
- Classification of foreign operations as "autonomous foreign
entity" or as an "integral foreign operation of the Company"
based on indicators stipulated in the standard, while
exercising management discretion, as opposed to principles
used prior to December 31, 2003 which provided for the
fulfillment of certain cumulative tests in order to define
foreign operations as "autonomous foreign entity" with no
management discretion.
- Adjustment of financial statements of "autonomous foreign
entities" prior to translation thereof to the reporting
currency of the reporting entity, which, as per the
principles in effect prior to December 31, 2003 was possible
in any case, shall only be carried out when the "autonomous
foreign entity" operates in a hyper-inflationary
environment. In such instances, translation of the entire
financial statements shall be carried out based on closing
rates.
(ii) The entering into effect of Standards 12 and 13 have superseded,
the provisions of Opinion 36 (which determined the CPI of the
country of residence to be the measurement basis of the adjusted
financial statements) and Interpretations 8 and 9 thereon
(pertaining to the principles governing the determination of the
measurement basis and translation rules of autonomous foreign
entities). Upon the termination of Opinion 36 (including
Interpretations 8 and 9) on January 1, 2004, and given the
absance of any specific standard in Israel as to the "functional
currency" of autonomous foreign entities, group companies
constituting autonomous foreign entities, adopted the principles
set forth by international standards (International Accounting
Standard No. 21 (as revised) (IAS- 21) and SIC19). Accordingly,
the functional currency is that of the primary economic
environment in which the investee company operates (normally
being the currency in which it primarily generates and expends
cash) and that, in the judgment of management, exercised based on
qualitative criteria stipulated in the standard, reflects the
economic substance of the underlying events and circumstances
relevant to such investee company, a currency which has been used
to a significant extent in its operations or alternatively which
has a significant impact thereon (mainly, the economic currency
which serve as basis for determination of: (i) selling and
settlement prices with customers; (ii) transactions prices for
land acquisition and construction services or settlement with
suppliers and subcontractors; (iii) currency policy of the
investee company; (iv) its financing activities, etc.).
-18-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
A. FINANCIAL STATEMENTS IN REPORTED AMOUNTS (CONT.)
(3) FOREIGN INVESTEE COMPANIES (CONT.)
(iii) On May 1, 2004, several countries, among them Hungary, Poland
and the Czech Republic (countries in which the majority of the
operation of Plaza Centers (Europe) B.V. ("PC") in the field of
commercial and entertainment centers, is concentrated), joined
the European Union. The joining countries undertook to manage an
economic policy, that conforms to certain monetary and regulatory
targets, aiming at implementing required conditions for the
adoption of the Euro as the country's legal currency. Prior to
their joining, those countries took significant action pertaining
thereto, such as: alterating their monetary and fiscal policies,
including full liberalization of their currency regimes and
lifting of foreign currency controls (such as liberty to
transact, transfer and execute payment in foreign currency,
allowing free trading in the local currency abroad, lifting of
the restrictions on transferring foreign currency abroad,
allowing free unlimited trading in foreign securities, reporting,
etc.). As a result, the PC Group companies that are incorporated
and operate in Hungary, Poland and the Czech Republic (the
"Companies") deemed it necessary to reconsider their settlement
currency with lessees ("Settlement Currency"), the nature and
scope of protection of the value of their financial assets and
liabilities, their currency risk management policy, etc. In light
of the foregoing and concurrently therewith, the Companies
reconsidered their operational and measurement currency.
Following examination of the international standards criteria (as
hereinabove mentioned), and according to the nature of the
companies' operations and the changes in the economic environment
in which they operate, PC's management is of the opinion that as
of April 1, 2004 and thereafter, the Euro, rather than the local
currency, reflects, more adequately, the business condition and
the results of operations (transactions) of the companies,
affecting the management policy and decision-making processes as
well as the transactions (revenues and cost of
acquisition/construction of assets), the scope and prices
thereof, the currency risk policy and the financing operations
thereof. Accordingly, the Euro serves as the functional currency
of these companies starting from April 1, 2004. Book value of
non-monetary items included in the balance for March 31, 2004
have been translated into Euro based on its prevailing exchange
rate with local currencies at that date, and such amounts served
as basis for the value of such items (in Euro), as recorded in
the financial statements for reporting periods commencing April
1, 2004.
B. CONSOLIDATED FINANCIAL STATEMENTS
The consolidated financial statements include the financial statements of
the Company and its subsidiaries. Results of operations of subsidiaries are
included, as from the date of incorporation or proximate to the date of
acquisition thereof by the Company, as the case may be, through each
balance-sheet date, or a date proximate to sale thereof (or voluntary
liquidation), whichever be the earlier.
Assets, liabilities and operations of jointly controlled companies and
ventures have been included in the consolidated financial statements, on
the basis of the proportionate-consolidation method, in accordance with
principles established by Opinion no. 57 of the ICPAI.
Data extracted from amounts included in financial statements of
subsidiaries, have been included within the consolidated financial
statements following adjustments required for compliance with unified
accounting principles used by the Group.
Material inter-company balances and transactions (including convertible
debentures issued by a subsidiary and partially acquired by the Company)
have been eliminated in the consolidated financial statements.
-19-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
B. CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
Profits generated from intercompany transactions, the results of which are
attributable to assets, which at the respective balance-sheet date had not
been realized to third parties, were eliminated in the consolidated
financial statements.
C. PRESENTATION METHOD OF STATEMENT OF OPERATIONS AND THE CHANGE THEREOF
Significant recent global changes, particularly in the real estate business
in which the Company operates, enable it to utilize its relative advantage
in same. Such changes include, among others, decrease in commercial assets'
long-term yield rates; low short term interest rates, rapid financial
progress in developing markets and transformation thereof to more readily
accessible geographical targets. Concurrently with such changes and
consequently thereto, a significant increase was noted in the demand for
real assets, both by private, as well as by institutional investors,
pension funds, REIT funds, and others. The above mentioned global changes
together with the completion of the July 2005 transaction between PC and
Klepierre, (as elaborated in Note 9B(3)d., below), led the management to
reexamine the Company's nature of activity while attempting to
strategically alter its business. The core of such change is expressed in
evolving, the major part of the Company's business activities from the
entrepreneurship, development and operation of various commercial real
estate assets in the medium to long term, into the entrepreneurship and
development of such assets supported by short term management and operation
activities with the principal objective of founding and stabilizing the
assets for the sale thereof, as closely as possible to completion of
construction, and/or into the construction of assets under pre-sale
development agreements executed with third parties. The reexamination
resulted in redefinition of the Company's operations and business, such
that sales of its operational assets, are included therein, whereas during
previous reporting periods such sales and the results thereof were excluded
from the Company's operational results.
Following the consummation of the various "exit" transactions which
commenced during 2004 and continued in 2005, and in consequence of the
change to the Company's business model as specified above, the Company's
management believes that the historical presentation format of its
statement of operations ("Multiple - step form") is no longer a meaningful
measure and presentation of the Company's business activities. The
Company's management believes that all costs and expenses (including
selling and marketing, general and administrative and financial expenses)
should be considered as continuously contributing to the obtaining of the
overall income and profits, and that any attempt to classify only part of
the expenses directly to revenues, would be less representational.
Management also believes that splitting such operational costs, directly
relating to identified operations, to separate items such as "cost of
sales", "selling and marketing expenses", and "general and administrative
expenses", is not meaningful to the Company, (which has a wide range of
different activities), and alternative classification should be applied
which recognizes two types of costs: (i) those directly related to
revenues; and (ii) overhead expenses which serve the business in general
and are to be determined as general and administrative expenses. Moreover,
distinction between those costs, which are or are not taken or not taken
into account in determining the gross profit, requires significant
discretion, often entailing inconsistent and insufficiently reliable
accounting classification.
Accordingly, from the third quarter of 2005, the Company has adopted a new
method for the presentation of its consolidated statement of operations
reports, whereby all expenses are presented in one group, which is deducted
as a whole from the total revenues which are also represented in one group
("Single - Step Form"), as opposed to the previously practiced presentation
used ("Multiple - Step Form"). Accordingly, profit and loss items have been
classified, as part of such change, by differentiating those costs directly
relating to each revenue type, and those which serve the business in
general.
-20-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
C. PRESENTATION METHOD OF STATEMENT OF OPERATIONS AND THE CHANGE THEREOF
(CONT.)
In view of the Company's management, this new method of presentation
reflects more appropriately and suitably the nature of the Company's
operations on a consolidated basis, in the light of the Company's modified
strategy and goals. Comparative figures for the previous accounting years
have been reclassified accordingly.
D. CASH AND CASH EQUIVALENTS
Cash equivalents include unrestricted liquid deposits, maturity period of
which, as at the date of investments therein, does not exceed three months.
E. ALLOWANCE FOR DOUBTFUL DEBTS
The allowance has been specifically determined in relation to debts, the
collection of which, in the opinion of management of the companies, is
doubtful.
F. MARKETABLE SECURITIES
Investments in marketable securities, designated by management for sale in
the short term, are included in current assets at their market value as at
the balance-sheet date. Changes in the value of such securities are
recorded in the statement of operations as incurred. Investments in
marketable securities not designated by management for sale in the short
term and which are not part of the Group's liquid resources are presented
at cost excluding events when, in the opinion of management, there exists a
decline in value of other - than -temporary nature.
G. INVENTORIES
Inventory is stated at the lower of cost or market value, with cost
determined as follows:
Hotel inventory and merchandise - by the "first-in, first-out" method;
Raw materials - by the weighted average method;
Work-in-process and finished goods - by cost of material, labor and
indirect manufacturing costs.
H. INVESTMENTS IN INVESTEE AND OTHER COMPANIES
Investments in associated companies are presented by the equity method.
In circumstances where the Company's ownership in an investee company
(mainly, venture capital investments) is in the form of preferred
securities or other senior securities, the Company records equity losses
based on the ownership level of the particular investee securities or loans
extended by the Company to which the equity method losses are being
applied.
In calculating Company's share equity of investee companies, losses (if
any) deriving from expected realization of convertible securities or
exercise of vested rights to shares issued by such investee companies
(including shares financed by loans, when such securities constitute the
sole security for repayment of loans), are taken into consideration, if
such conversion or exercise is probable. As for accounting standard No. 22,
which is effective from January 1, 2006 - see Note 2X.(i).
The excess of the investment's cost over the Company's share in the fair
value of the investee companies' net identified assets at acquisition (or
upon the change from the cost method to the equity method, as applicable),
is recorded as goodwill and amortized over its estimated economic benefit
period, (generally 10 years). As for accounting standard No. 20, which is
effective from January 1, 2006 - see Note 2X.(v).
-21-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
H. INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
Financing costs in respect of credit used for investment (shares and loans)
in companies engaged solely in the construction of projects, have been
capitalized to cost of investment.
Gain from issuance of shares to a third party by a research and development
stage investee company, has been recorded as deferred income and charged
to the statements of operations as other income, over three years or up to
the holding entity's share in the losses of the investee company, whichever
is higher on a cumulative basis for each given year.
I. FIXED ASSETS
(1) Fixed assets are stated at cost. Investment grants have been deducted
from cost of assets for which they have been granted.
The cost of the land and building construction includes, among other
things, costs in respect of contractual obligations for the
acquisition of land when the group companies' obligations thereunder
are substantially finalized at the financial statement date (i.e., all
major conditions required for the conclusion of the transaction and
its implementation had been fulfilled) and the amounts thereof are
determined. Amounts not yet paid as at each respective balance-sheet
date are presented, accordingly, as a liability.
Improvements and renovations are charged to cost of assets.
Maintenance and repair costs are charged to the statement of
operations as incurred.
Consideration paid for multiple assets acquired at an aggregate amount
("package") is allocated to the cost of the assets on the basis of
value estimation and relatively to their fair value in that package.
Financing costs in real terms in respect of credit used for
acquisition or construction of buildings (including acquisition of
related land) as well as direct supervision and construction costs
incurred in the pre-operating period, have been capitalized to the
cost of the buildings. As to the borrowing costs capitalization
principles - see item U below.
Fixed assets acquired from controlling shareholders of the Company are
included according to their reported book value in the controlling
shareholders' financial statements immediately prior to acquisition
thereof.
(2) Depreciation is calculated by the straight-line method at annual rates
deemed sufficient to depreciate the assets over their estimated useful
lives. Leasehold improvements are amortized over the estimated useful
period of use not exceeding the lease period (including the period of
renewal options that the company intends to exercise).
Annual depreciation rates are as follows:
%
-----------------
Freehold land 0
Leasehold land Over lease period
Hotels 1.1 - 1.5
Commercial centers 2.0
Other buildings 2.0 - 2.5
Building operating systems 7.0 (average)
Other fixed assets (*) 6.0 - 33.0
-22-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(*) Consists of motor vehicles, aircraft, office furniture and equipment,
machinery and equipment, electronic equipment, computers and peripheral
equipment, software, leasehold improvements, etc.
-23-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
J. OTHER ASSETS AND DEFERRED EXPENSES
(1) ACQUIRED PATENT RIGHTS, TECHNICAL KNOW-HOW, INTELLECTUAL PROPERTY AND
DISTRIBUTION RIGHTS - are stated at cost and amortized by the
straight-line method over its estimated benefit period (10 years).
(2) PRE-OPERATING HOTEL AND/OR COMMERCIAL CENTER PRE-OPENING COSTS -
mainly - employee training, testing of systems and preparation of the
hotel/center for opening, operation and occupancy, are stated at cost
and amortized over a three-year period from commencement of full-scale
operations.
(3) OPERATING COSTS RELATING TO INITIATION ACTIVITIES - (prior to
finalization of the investment transaction or land acquisition, etc.)
are capitalized as incurred, when an investment or a property
acquisition transaction is reasonably foreseeable, and are charged to
the cost of the investment or the real estate project cost upon the
execution of the investment or the acquisition. In circumstances where
execution of investment or transaction is not probable or the expected
economic benefit is doubtful, these costs are charged to the statement
of operations.
(4) ENTERTAINMENT AND LEISURE FACILITIES OPERATING RIGHTS - are included
at cost and amortized by the straight line method over their estimated
benefit period.
(5) COSTS OF OBTAINING LOANS - Includes costs related to refinancing
loans, which in effect constitutes an extension of previous loans
(including costs deriving from prepayment of loans), are capitalized
as incurred and are charged to the statement of operations over the
loans' period of benefit and in relation to their balance.
(6) COST OF OBTAINING LONG-TERM LEASES - are capitalized as incurred and
charged to the statements of operations over the respective lease
period or on an average basis, as applicable. When a termination of a
contract, or a group of contracts is reasonably expected, or when the
expected economic benefit of these costs is doubtful, these costs are
charged to the statement of operations.
(7) ACQUISITION COSTS OF A LONG-TERM SERVICE CONTRACT - are stated at cost
and amortized over the service period (5 years).
K. LONG-TERM RECEIVABLES AND LIABILITIES
(1) Long-term fixed period liabilities, which do not bear specified
interest or that bear interest at below market rates, and the
difference between the nominal book value of which and the present
value of which at the time of loan receipt, is material, are stated at
present value (discounted at market interest rates customary for
similar loans). The effective interest is charged to the statement of
operations over the term of the liability.
(2) Suppliers credits and other short term liabilities, as well as
short-term bank borrowings used for construction of commercial centers
and/or hotels and whose repayment sources are funded by long-term
financing agreements with financial institutions, have been included
as long-term liabilities. Repayment schedules of such loans are
included in accordance with the terms of the respective long-term
credits, according to agreements with the lenders.
-24-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
L. INCOME TAXES
Deferred taxes are calculated in respect of all temporary differences,
including (i) differences between the timing of record of income and
expenses in the financial statements and the recognition thereof for income
tax purposes; (ii) differences between the reported value of non-monetary
depreciable assets (through December 31, 2004 - excluding the adjustment
component for buildings - see below) and the amount deductible for income
tax purposes (except for temporary differences generated upon initial
recognition of goodwill and/or asset or liability, not in connection with a
business combination and that which at the initial recognition thereof had
no effect on the accounting or tax net income); (iii) tax losses and
deductions that may be carried forward for future years or used against
previous years; and (iv) differences between fair value of identified
assets and liabilities of subsidiaries upon acquisition of the investment
therein (through 2004 excluding assets, depreciation of which is not tax
deductible), and tax base of same (value for tax purposes) at that date
provided that such differences relate to transactions occurred after
January 1, 2005. Deferred taxes have also been calculated in respect of
temporary differences generated from the measurement currency in the
financial statements being other than that according to which profit (loss)
is determined for tax purposes (and accordingly, tax base of assets and
liabilities).
The calculation of tax liabilities (current and deferred) does not include
taxes that would have arisen in the event of a realization of investments
in investee companies (except those that are to be liquidated), or upon
receiving their retained earnings as dividends, since, in respect of some,
dividends from profits thereof and/or gains to be generated from their
realization, are tax exempt, and in respect of others, it is management's
policy not to realize and/or to declare dividend out of their retained
earnings, or other form of profit distributions, in the foreseeable future,
in a manner which entails additional substantial tax burden on the group,
except for the effect of the Israeli tax laws that would apply to
undistributed profits of foreign investee companies as from January 1, 2003
- See Note 16B(1)(b).
A tax benefit is recorded as an asset, only when its realization against
future taxable income is probable, or when sufficient taxable temporary
differences, the timing of reverse of which does not precede the
realization timing of the tax benefit, as aforestated, exist. Tax assets
and liabilities (current and deferred), are calculated according to the tax
rates and relevant laws expected to apply upon utilization thereof, as are
in effect (or enactment thereof is practically completed) as at the balance
sheet date. Current and deferred taxes relating to capital reserve from
foreign currency translation adjustments or to other capital items are
charged directly to shareholders' equity. Deferred taxes deriving from
changes in the tax rate (including those in respect of balances previously
created on temporary differences within a business combination) are charged
to the income tax item in the statement of operations, or in the capital
reserve from foreign currency translation adjustments, as applicable.
On July 2004, Accounting Standard No. 19 - Income Taxes ("Standard 19") was
published by the IASB. Standard 19 sets forth principles for recognition,
measurement, presentation and disclosure of income taxes in financial
statements. Standard 19 applies to financial statements for periods
commencing on or after January 1, 2005. Initial implementation of Standard
19, mainly for the initial inclusion of deferred taxes in respect of
adjustment component for land and buildings, is included as "cumulative
effect for the beginning of the year due to a change in accounting method"
in the statement of operations and in the statement of changes of
shareholders' equity for the current period.
Deferred taxes in respect of exempt profits of an approved enterprise - see
Note 16B.1.d below.
-25-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
M. EXCHANGE RATES AND LINKAGE BASES
Foreign currency balances or those linked thereto are included in the
financial statements on the basis of the exchange rate in effect as at the
balance-sheet date.
Balances linked to various indices or security rates, are included on the
basis of the relevant index or rate, as applicable to each linked asset or
liability.
RATE OF EXCHANGE OF NIS, IN EFFECT, IN RELATION TO FOREIGN CURRENCY (IN
NIS)
DECEMBER 31
-------------
2005 2004
----- -----
US Dollar ($) 4.603 4.308
EURO (E) 5.446 5.877
British Pound (L) 7.940 8.308
1,000 Romanian New Lei (RON) 1.480 1.480
SCOPE OF CHANGE IN THE EXCHANGE RATE, IN EFFECT, OF THE NIS IN RELATION TO
THE FOREIGN CURRENCY (%)
YEAR ENDED DECEMBER 31
----------------------
2005 2004 2003
----- ----- -----
US Dollar ($) 6.84 (1.62) (7.56)
EURO (E) (7.32) 6.21 11.33
British Pound (L) (4.42) 5.85 2.83
Romanian New Lei (RON) (0.03) 9.63 (4.93)
N. FINANCIAL INSTRUMENTS
(1) Financial instruments - see Note 23 below.
(2) Results of derivatives and financial instruments designated for
hedging purposes of existing assets and liabilities, or against
fluctuations in the exchange rates in which firm commitments are
denominated, as well as those designated as a hedge against
fluctuations of interest rates of variable-interest loans, are charged
to the statement of operations concurrently with the charging of the
results from the hedged assets and liabilities and/or the realization
of the relevant transaction and/or the charging of the interest
according to the interest rate specified in the loan agreement, as
applicable.
Derivative financial instruments not designated for hedge purposes are
presented at their estimated fair value. Changes in their fair value
during the reported period are charged to the statement of operations.
O. IMPAIRMENT OF LONG-LIVED ASSETS
The Company applies Standard No.15 of the IASB - "Impairment of Assets".
The standard sets forth the accounting treatment and method of presentation
required in the event of asset impairment (including investments in
associated companies), and provides for the assets of a corporation not to
be presented in amounts exceeding the higher of their net selling price or
their value in use based on future discounted cash flow expected to be
generated from such an asset ("recoverable amount"). Standard No. 15
stipulates that the recoverable amount must be assessed whenever indicators
point to
-26-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
a possible impairment of an asset. Any impairment of assets is to be
recorded as a loss in the statement of operations.
-27-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
P. CONVERTIBLE DEBENTURES
Are included based on conversion probability tests and presentation
regulations, as set out in Opinion No. 53 of the ICPAI. Debentures, whose
conversion is not probable, are presented at their liability value.
Debentures, whose conversion are probable are included as a quasi - equity
item between liabilities and shareholders equity, at the higher of their
monetary or non-monetary value. As for Accounting Standard No. 22 which is
effective from January 1, 2006 - see Note 2X(i).
Q. SHARE CAPITAL
Company shares held (directly or through a subsidiary) by the Company
("dormant shares"), are presented at cost and deducted from share capital
of the Company according to the "treasury stock" method.
The sale of "treasury stock" or the issuance of company`s shares to third
parties is recorded based on the fair value of the assets or cash received
in consideration thereof or the fair market value of shares issued (see
also Note 9B.(1) below), as applicable.
Loans granted to employees for purchasing Company shares which constitute
the sole security for the loans' repayment, and which shall be repaid out
of proceeds of the sale thereof, are included in the balance sheet as a
deduction from shareholders' equity.
R. REVENUE RECOGNITION
(i) Revenues from the leasing of property and management fees, as well as
other revenue relating to the operations of commercial and
entertainment centers, are recorded pro rata over the term of the
lease and/or the service.
(ii) Revenues from hotel operations are recorded upon performance of
service.
(iii) Revenues from operating lease (based on a long term firm commitment
with a fixed period), which increase gradually over the period of the
lease, are charged to the statement of operations by the straight-line
method throughout the period of the lease.
(iv) The Company recognizes gain on sales of real estate assets and
investment properties when a sale has been consummated, the buyer's
initial and continuing investment is adequate to demonstrate
commitment to pay, any receivable obtained is not subject to future
subordination and the usual risks and rewards of ownership have been
transferred.
For sales transactions with continuing involvement by the Company in
the form of a guarantee of a return on the buyer's investment for
limited period or in a limited amount, profit is recognized when there
is reasonable assurance that total estimated future rent receipts will
cover operating expenses and debt service including payments due the
buyer under the terms of the transaction. In making this
determination, total estimated future rent receipts of the property
are reduced by a reasonable safety factor, unless the amount so
computed is less than the rents to be received from signed leases. For
the Company, these conditions are usually fulfilled at the time of
sale.
If, according to the terms of the transaction, the Company will
participate in future profit from the property without risk of loss,
and the transaction otherwise qualifies for profit recognition under
the full accrual method, the contingent future profits are recognized
when they are realized.
-28-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
R. REVENUE RECOGNITION (CONT.)
(v) Revenues from the sale of medical products are recognized in
accordance with SAB 101, as amended by SAB 104, provided that
persuasive evidence of an arrangement exists, delivery has occurred or
services have been rendered, the price is fixed or determinable and
collectibility is reasonably assured. For sale arrangements which
include multiple deliverables such as system sales, installation at
the customer's site and training, the revenue is recognized by
implementing the guidance of EITF No. 00-21 "Revenue Arrangements with
Multiple Deliverables" ("EITF 00-21"). In accordance with the guidance
in EITF No. 00-21, multiple deliverable arrangements are assessed to
determine whether they can be separated into more than one unit of
accounting. A multiple deliverable arrangement is separated into more
than one unit of accounting if all of the following criteria are met:
(i) The delivered item has value to the customer on a stand-alone
basis; (ii) There is objective and reliable evidence of the fair value
of the undelivered item; and (iii) If the arrangement includes a
general right of return relative to the delivered item, delivery or
performance of the undelivered items is considered probable and
substantially in control of the Company. If these criteria are not
met, then revenue recognition is deferred until such criteria are met
or until the last undelivered element is delivered, unless the
undelivered element is considered inconsequential or perfunctory.
If there is objective and reliable evidence of fair value for all
units of accounting in an arrangement, the Company allocates the
arrangement consideration to the separate units of accounting based on
their relative fair value. In instances, which there is objective and
reliable evidence of the fair value of the undeliverable item in an
arrangement but no such evidence for the delivered item, the Company
allocates the arrangement consideration to the deliverables using the
residual method. Under the residual method, the amount of
consideration allocated to the delivered item equals the total
arrangement consideration less the aggregate fair value of the
undelivered items.
(vi) Service revenues from product support agreements are recognized
ratably over the service period.
(vii) Revenues from the sale of goods in the fashion industry are
recognized upon delivery.
S. ACCRUED WARRANTY COSTS
A subsidiary provides a warranty as to the quality of its products sold
thereby, for a limited period of time following provision thereof
(generally one year). In order to allow for the fulfillment of this
liability, a provision is included based on past experience and management
estimation.
T. RESEARCH AND DEVELOPMENT COSTS
Research and development costs, net of grants and third party participation
(mainly the Government of Israel - the OCS), are charged to the statement
of operations, as incurred. The accrual for grant receivable is determined
based on the terms of the project, provided that the criteria for
entitlement have been met.
-29-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
U. CAPITALIZATION OF BORROWING COSTS
Borrowing costs are capitalized in accordance with Standard No. 3 of the
IASB. Accordingly, both specific and non-specific borrowing costs are
capitalized to qualified assets (assets in preparation or under
construction not yet in their designated use and whose preparation for this
purpose requires a prolonged period of time). Non-specific borrowing costs
are capitalized to qualified assets (or portion thereof) not financed by
specific borrowing, by using a rate constituting a weighted average of the
costs in respect of the Group's borrowings not specifically capitalized.
Capitalization of borrowing to assets, continues, generally until the
completion of all the activities necessary to prepare the asset for its
designated use, except in events where capitalization is suspended as a
result of a prolonged interruption of the asset construction, as
aforestated.
V. EARNINGS (LOSS) PER SHARE
Earnings (loss) per share is calculated in accordance with Opinion No. 55
of the ICPAI based on the weighted-average of outstanding paid-up share
capital during the year (net of treasury stock shares).
The number of shares used for the computation of basic earnings (loss) per
share, takes into account convertible securities or other rights to vested
shares (including shares issued against loans which constitute the sole
security for the loans repayment), if conversion or realization may
reasonably be assumed. Diluted earnings (loss) per share take into account
all those securities excluded from the basic earnings (loss) per share
computation if their effect is dilutive. Net income which has been taken
into account in calculating diluted earnings per share has been deducted by
the periodic change in the necessary provision, if any, assuming the full
exercise of the Company's and/or investee company's securities not taken
into account in the computation of basic earnings (loss) per share. As for
Accounting Standard No. 21 - see Note 2X.(iv).
W. USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires of Group companies' managements to
make estimates and rely upon assumptions and assessments affecting the
reported balance-sheet amounts of assets and liabilities, the disclosure of
contingent assets and liabilities as at the financial statements date, and
the amounts of revenues and expenses during the reporting periods. Actual
data and operating results may differ from these estimates.
X. RECENTLY ISSUED ACCOUNTING STANDARDS
(I) In July 2005 the IASB published a new standard No. 22 - Financial
instruments: Disclosure and presentation ("Standard 22"). Standard 22
contains requirements for the presentation of financial instruments
and identifies the information that should be disclosed about them.
The presentation requirements apply to (i) the classification of
financial instruments into financial assets, financial liabilities and
equity instruments; (ii) the classification of related interest,
dividends, losses and gains; and (iii) the circumstances in which
financial assets and financial liabilities should be offset. Standard
22 requires disclosure of information about factors that affect the
amount, timing and certainty of an entity's future cash flows relating
to financial instruments and the accounting policies applied to those
instruments. Standard 22 also requires disclosure of information about
the nature and extent of an entity's use of financial instruments, the
business purposes they serve, the risks associated with them, and
management's policies for controlling those risks.
Standard 22 provides for an issuer of non-derivative financial
instruments (including those issued before January 1, 2006 and had not
been converted or exercised until that date) to evaluate, as from
January 1, 2006, the terms of each financial instrument in order to
determine whether it contains both a liability and an equity
component. Such components shall be classified separately as financial
liabilities, financial assets or equity instruments, in accordance
with the substance of the contractual arrangement and the definitions
of a financial liability, a financial asset and an equity instrument.
-30-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
X. RECENTLY ISSUED ACCOUNTING STANDARDS (CONT.)
(I) (CONT.)
Standard 22 shall be applied, prospectively, in financial statements
for periods commencing on or after January 1, 2006. Standard 22, upon
going effect will supersedes the provisions of Opinions No. 48 and No.
53 of the ICPAI, regarding the accounting treatment of convertible
securities (options, warrants and convertible debentures). The
provision included in the financial statements as of January 1, 2006,
for a loss resulting from a shareholding decrease in an investee
company, assuming realization of all rights to convert and/or to
exercise the outstanding convertible securities, will be included in
the statement of operations as "cumulative effect for the beginning of
the year due to a change in accounting method", in the first quarter
of 2006.
The impact of the implementation of standard 22 on 2006 consolidated
financial statements are: classification of convertible debentures
amounted to NIS 62.2 from quasi-equity item to long-term liabilities
and classification of cost of obtaining loans, net amount to NIS 10.4
million from other assets and deferred charges to long-term
liabilities.
(II) In August 2005, the IASB published Standard No. 24 - "Share-Based
Payment" ("Standard 24"), the objective of which is to specify the
principles of financial reporting by an entity where it enters into a
share-based payment transaction. In particular, it requires an entity
to reflect in its statement of operations and financial position, the
effects of share-based payment transactions, including expenses
associated with transactions in which stock options are granted to
employees. For equity-settled share-based payment transactions, the
goods or services received, and the corresponding increase in equity,
should be measured directly, at the fair value of the goods or
services received, unless that fair value cannot reliably be
estimated. If so, their value, and corresponding increase in equity,
should be measured indirectly, by reference to the fair value of the
equity instruments granted, by measuring their fair value at the
measurement date, based on market prices if available. If market
prices are not available, fair value of the equity instruments granted
should be estimated using a valuation technique consistent with
generally accepted valuation methodologies for pricing financial
instruments, taking into account the terms and conditions upon which
those equity instruments were granted. For transactions with employees
and others providing similar services, the fair value of the
transaction should be measured directly by reference to the fair value
of the equity instrument granted, at the date of grant. Standard 24 is
to be effective for periods beginning on or after January 1, 2006
("effective date"). Pursuant to the transition provisions set forth in
the standard, the company shall apply this standard to grants of
shares, stock options or other equity instruments that were granted
after March 15, 2005 and had not yet vested at the effective date.
In accordance with the provision of standard 24 the Company will
retrospectively apply its financial statements for the year ended
December 31, 2005 in the first quarter of 2006 and will record an
additional expenses in the amount of NIS 1.2 million.
The impact of implemantion of standard 24 on the Company financial
statement for the year ended December 31, 2006 based on the existing
options plans as of December 31, 2005 is estimated to NIS 2.2 million.
-31-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
X. RECENTLY ISSUED ACCOUNTING STANDARDS (CONT.)
(III) On February 2006 the IASB issued Standard No. 25 - Revenues
("Standard 25"). The standard determines the principles of
recognition, measurement, presentation and disclosure of revenues
arising from different types of transactions, such as sales of goods,
rendering of services as well as use, by others, of entity's assets
yielding interest, royalties and dividends. The standard determines
that revenues shall be measured at the fair value of the consideration
received or receivable.
Standard 25 shall be applied, prospectively, in financial statements
for periods commencing on or after January 1, 2006. Assets and
liabilities which are included in the financial statements as of
December 31, 2005 at amounts which differ from those that would have
been included should the provisions of Standard 25 so implemented,
will be adjusted on January 1, 2006, in order to reflect the latter
amounts as of that date. The adjustment will be recorded in the
statement of operations, in the first quarter of 2006, as "cumulative
effect for the beginning of the year due to a change in accounting
method".
The Company is currently evaluating the impact of the implementation
of Standard 25 on its consolidated financial statements.
(IV) In February 2006 the IASB issued Accounting Standard No. 21, "Earnings
per Share" ("the Standard").
The Standard establishes that an entity is to compute its basic
earnings per share in regard to income or loss attributable to
ordinary shareholders of the reporting entity, and that the entity
shall compute its basic earning per share with respect to income or
loss from continuing operations attributable to the ordinary
shareholders of the reported entity, should such be presented.
Basic earnings per share is to be computed by dividing income or loss
attributed to holders of ordinary shares of the reporting entity
(numerator), by the weighted average of the outstanding ordinary
shares (denominator) during the period.
In the computation of diluted earnings per share, the entity must
adjust its income or loss attributable to the ordinary shareholders of
the reporting entity and the weighted average of the outstanding
shares for the effects of all the dilutive potential ordinary shares.
The entering into effect of Standard 21 will terminate the provisions
of Opinion No. 55 of the ICPAI regarding Earnings Per Share.
In accordance with the Standard's guidance, the Standard will apply to
financial statements for periods starting January 1, 2006 and
thereafter. The Standard further establishes that its guidance is to
be applied retroactively in respect of comparative earnings per share
data relating to prior periods.
The Company is currently evaluating the impact of the implementation
of Standard 21 on its consolidated financial statements.
-32-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.)
X. RECENTLY ISSUED ACCOUNTING STANDARDS (CONT.)
(V) In March 2006 the IASB published the revised Standard No. 20
("Accounting Treatment of Goodwill and Other Intangibles upon the
Acquisition of an Investee"), which applies to financial statements
covering periods beginning on January 1, 2006 ("Effective Date").
According to the standard, the excess of acquisition cost of an
investee over the share of the company holding in the fair value of
identifiable assets, including intangibles, net of the fair value of
identifiable liabilities (after tax allocation) at acquisition,
constitutes goodwill. The allocation of excess acquisition cost to an
acquired intangible asset will take place only if it is identifiable
by the criteria established by this standard. Goodwill in respect of
subsidiaries, will not be amortized but will be examined once a year
or more frequently should there be an indication of goodwill
impairment. Goodwill in respect of associated companies, will be
examined for impairment should there be an indication ofgoodwill
impairment in respect of the investment in the associated company as
whole. Moreover, should negative goodwill be created upon acquisition
it would be recognized as a gain and immediately be included in
operations and not amortized.
The standard distinguishes between intangible assets which have
defined useful lives and those that do not, stating that the former be
amortized while latter not so amortized but rather examined once a
year or should any signs indicate impairment.
Comparative figures for prior years, covering periods before the
standard's effective date should not be restated and, starting on the
effective date, the positive goodwill presented in the balance sheet
on December 31, 2005 will no longer be amortized, including goodwill
in the investment account of an affiliate. The balance of the negative
goodwill presented in the balance sheet on December 31, 2005 will be
fully written off on the effective date and directly included in
retained earnings. Moreover, starting on the effective date the
Company is to discontinue the amortization of its intangible assets
having indefinite useful lives arising from the acquisition of an
investee included in the 2005 annual financial statements, to be
followed by future periodic examinations of their value.
The standard's implementation will discontinue the amortization of
goodwill arising from the acquisition of investees, whose balance in
the consolidated balance sheet on December 31, 2005 amounts to NIS
29.1 million (US$6.3 million).
The annual amortization of goodwill in the 2005 and 2004 annual
financial statements amounted to NIS 4.6 million (US$1.0 million) and
NIS 4.4 million, respectively.
-33-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3 - CASH AND CASH EQUIVALENTS
DECEMBER 31
--------------------------------------------
2005 2005
------------------- REPORTED
INTEREST 2004 CONVENIENCE
RATE REPORTED REPORTED TRANSLATION
-------- -------- -------- -----------
% (IN THOUSAND NIS) US$'000
In foreign currency:
US dollar 3.9-4.1 64,792 255,184 14,076
Euro 1.5-2.2 363,736 64,989 79,022
British Pound 4.0 34,230 3,997 7,436
Other (mainly, Forint & Zloty) 1.0-3.0 19,009 16,606 4,130
In NIS 2.8-4.4 7,577 4,969 1,646
------- ------- -------
489,344 345,745 106,310
======= ======= =======
NOTE 4 - SHORT-TERM DEPOSITS AND INVESTMENTS
A. COMPOSITION:
DECEMBER 31
--------------------------------------------
2005 2005
------------------- REPORTED
INTEREST 2004 CONVENIENCE
RATE REPORTED REPORTED TRANSLATION
-------- -------- -------- -----------
% (IN THOUSAND NIS) US$'000
DEPOSITS WITH BANKS AND
FINANCIAL INSTITUTIONS(1)
DENOMINATED IN OR LINKED TO
THE:
US dollar 3.5-3.9 148,211 141,043 32,198
Euro 1.0-3.4 45,070 88,794 9,791
Other 1.0-5.0 25,322 24,064 5,501
In NIS 3.3-4.3 13,739 13,007 2,985
------- ------- ------
232,342 266,908 50,475
MARKETABLE SECURITIES 7,450 6,958 1,619
------- ------- ------
239,792 273,866 52,094
CURRENT MATURITIES OF
LONG-TERM LOANS AND
RECEIVABLES 280 4,155 61
------- ------- ------
240,072 278,021 52,155
======= ======= ======
(1) NIS 121 million serve as security for short term credit.
B. LIENS - see Note 17D.
-34-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 - TRADE ACCOUNTS RECEIVABLE
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Outstanding accounts 44,643 66,454 9,698
Less - allowance for doubtful debts 9,239 27,352 2,007
------ ------ -----
35,404 39,102 7,691
====== ====== =====
NOTE 6 - RECEIVABLES AND OTHER DEBIT BALANCES
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Government institutions 23,414 31,772 5,087
Prepaid expenses 15,755 7,381 3,423
Employees(*) 13,450 3,284 2,922
Receivables in respect of
realization of medical equipment -- 12,202 --
Receivables in respect of
realization of investments (**) 11,072 -- 2,405
Control Center Group companies 3,186 521 692
Other 9,803 10,980 2,130
------ ------ ------
76,680 66,140 16,659
====== ====== ======
(*) Mainly loans in respect of realization of shares - see Note 18B(i) below.
(**) See Note 9B.(3)d.
NOTE 7 - INVENTORIES
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Hotels inventories 2,729 2,433 593
Image Guided Treatment:
Raw materials 9,747 2,459 2,118
Products under process and
finished goods 3,622 2,439 787
Fashion - merchandise 8,034 -- 1,745
------ ----- -----
24,132 7,331 5,243
====== ===== =====
-35-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 - DEPOSITS, DEBENTURES, LOANS AND OTHER LONG-TERM BALANCES
A. COMPOSITION:
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Deposits at banks and financial institutions (1) 8,222 68,238 1,786
Loans to interest holders in investee companies (2) 44,296 29,965 9,623
Loan to former associated company (3) 19,997 17,806 4,344
Loans to anchor tenants (4) 1,233 4,383 268
Loans to venture capital companies (5) 1,232 1,232 268
Receivables in respect of long-term lease transaction (6) -- 11,107 --
Deferred taxes 6,356 6,104 1,381
Others 6,467 654 1,405
------- ------- ------
87,803 139,489 19,075
Less - allowance for doubtful debts (25,384) (21,549) (5,515)
------- ------- ------
62,419 117,940 13,560
Less - current maturities (280) (4,155) (60)
------- ------- ------
62,139 113,785 13,500
======= ======= ======
(1) Deposits pledged as security for the repayment of loans obtained by Group
companies and/or to secure guarantees provided thereby in favor of third
parties, have been included as due and payable concurrently with the loan
repayment dates or upon release of guarantees for which they have been
pledged.
(2) (i) Loans to the management company or to its controlled companies. A loan
of NIS 7.7 million ($1.7 million) is linked to the US dollar, bears
annual interest at a rate of Libor+1%, due and payable on December 31,
2006. A loan of NIS 15.3 million ($3.3 million) may be converted into
shares - see Note 17A.(2) below. Should BEA Hotels N.V. (B.H.) decide
not to exercise its option to convert the loan into shares, the loan
would then be subject to the linkage and interest terms outlined
above. According to the agreement, the amounts to be received by the
management company from the Group companies in respect of the former's
interest in hotels owned by the latter (other than hotel management
fees - see Note 17A.(1)a. and b. below) will be used as security for
the repayment of the loans. A loan NIS 2.1 million ($0.5 million ) is
linked to the EURO and bears annual interest at a rate of 4.9%. B.H.
received no security for these loans.
(ii) NIS 19.1 million ($4.1 million) - loans to shareholders of a jointly
held company (50%) within the PC group - see Note 10B.(6), below.
(3) An allowance for all outstanding balance of the debt is recorded, since
maturity date of the loan has been elapsed, and no securities for its
repayment have been received.
(4) Linked mainly to the US Dollar, bears annual interest of Libor + 1.5% to
2.5%.
(5) Loans to companies engaged in the biotechnology field, linked to the US
Dollar, bears annual interest at customary commercial rates and are
convertible into shares of the lender, under certain condition as
stipulated in the agreements. An allowance for all outstanding balances of
the loans is recorded.
-36-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(6) See Notes 2R.(iii) above and 19A(ii) below.
-37-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 - DEPOSITS, DEBENTURES, LOANS AND OTHER LONG-TERM BALANCES (CONT.)
B. REPAYMENT DATES:
DECEMBER 31 2005
REPORTED
-------------------------------
CONVENIENCE
TRANSLATION
-----------
(IN THOUSAND NIS) US$'000
2006 - Current maturities 280 61
2007 10,318 2,242
2008 935 203
2009 2,297 499
Undetermined 48,589 10,555
------ ------
62,419 13,560
====== ======
C. LIENS - see Note 17D.
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES
A. COMPOSITION AND ACTIVITY
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
ASSOCIATED COMPANIES:
Shares (1):
Cost (*) 98,140 87,260 21,321
Accumulated losses, net (39,133) (27,105) (8,509)
Adjustment arising from translation of
autonomous investees' financial statements 4,337 4,281 949
------- ------- ------
Total shares 63,344 64,436 13,761
Loans (see (2) and B.(3)f. below) 16,392 16,664 3,561
------- ------- ------
79,736 81,100 17,322
Provision for impairment of investment (22,938) (24,170) (4,983)
------- ------- ------
56,798 56,930 12,339
------- ------- ------
OTHER COMPANIES - AT COST
Vcon Telecommunications Ltd. ("Vcon") - shares (3) -- 14,678 --
------- ------- ------
56,798 71,608 12,339
======= ======= ======
(*) Including - goodwill:
COST(ii) NET BOOK VALUE
-------- --------------
DECEMBER 31
AMORTIZATION -------------------------
RATE(i) 2005 2005 2004
------------ ---- ---- ----
% (IN MILLION)
NIS 10 47.9 29.1 38.8
=== ==== ==== ====
Convenience translation into US Dollar 10.4 6.3
==== ====
(i) See also Note 2H. above.
(ii) Net, after provision for impairment.
-38-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
A. COMPOSITION AND ACTIVITY (CONT.)
(1) VENTURE CAPITAL INVESTMENTS - ASSOCIATED COMPANIES - SHARES:
A. GENERAL
The company invests in hi-tech associated companies ("Invested
Companies"). The Invested Companies engage in research and
development operations and have not yet attained financial
stability. The value of these investments is thus contingent upon
the continued operation of the Invested Companies, which entails
certain risks stemming from the nature of their operations
including the uncertainty as to the success of development and
marketing potential of the product. It is therefore, difficult to
objectively assess the fair value of most of these investments
due to the lack of a verifiable market value. Nevertheless, the
company's management is of the opinion that the fair value of the
investments is not lower than their cost (net of provisions for
decline in value, to the extent applicable).
As to a law-suit filed by an employee of the EIL group - see Note
17B.(7) below.
B. BIOTECHNOLOGY COMPANIES:
GAMIDA CELL LTD. ("GAMIDA") (THROUGH ELSCINT BIO MEDICAL LTD.)
Gamida is engaged in the expansion of hematopoietic (blood) stem
cells therapeutics in clinical development for cancer and
autoimmune diseases, as well as future regenerative cell-based
medicines including cardiac and pancreatic repair.
The Company is a party to an agreement, in terms of which, mainly
the existing shareholders of Gamida have invested therein, on
July 28, 2005, a total amount of $4.0 million, for the
consideration of the allotment to such investors of securities
having same rights as those issued by Gamida during its recent
equity financing round. The Company's share in the investment
totaled approximately $1.4 million. Subsequent to the investment
and as of December 31, 2005, the Company holds 33.46% of the
equity and voting rights in Gamida and the right to appoint 25%
of its directors. The shares held by the Company are in part
ordinary shares and in part preferred having anti-dilution rights
and liquidation preference (US Dollar linked return of its
investment in Gamida bearing 8% annual interest, prior to any
distribution to ordinary share holders or holders of preferred
shares with subordinated rights). Should all the convertible
securities of Gamida be so converted or exercised, then and in
such an event, the Company shall be diluted to 30.3%.
On February 16, 2005, Teva Pharmaceutical Industries Ltd.
("Teva") - one of Gamida's shareholders - decided to exercise its
option to enter into a joint venture ("JV") with Gamida to
develop and commercialize certain products being the subject
matter of Gamida's developing technology ("the products").
On February 12, 2006 Gamida, Teva and the JV signed a founders
agreement which set forth the establishment, funding and
management of the JV. The sole purpose of the JV shall be
commercialization of the products and obtaining all required
registrations and marketing approvals. Teva shall make an equity
investment in the JV of up to $25.0 million in consideration for
up to 50% of the JV shares. The funding shall be payable as
follow: as of the closing date, Teva will sign an irrevocable
commitment for payment of total amount of $10.0 million payable
in installments. The additional funding totaling $15 million
shall be paid quarterly based on the budget of the JV. Teva shall
be entitled to accelerate the funding payments schedule.
-39-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
A. COMPOSITION AND ACTIVITY (CONT.)
(1) VENTURE CAPITAL INVESTMENTS - ASSOCIATED COMPANIES - SHARES: (CONT.)
B. BIOTECHNOLOGY COMPANIES (CONT.):
GAMIDA CELL LTD. ("GAMIDA") (THROUGH ELSCINT BIO MEDICAL LTD.)
(CONT.)
In the framework of the agreement Gamida and the JV shall sign on
a license agreement according to which Gamida shall grant the JV
a royalty free, worldwide license to exploit the products and
Gamida's IP necessary for developing, manufacturing sale and
distribution of the product and a royalty free, illimitable,
worldwide exclusive license to manufacture, develop, market,
offer for sale, distribute and sell the products and the right to
sublicense.
Certain cancellation arrangements were determined between the
Company and Teva.
As to a dispute between Elscint Bio Medical and its former CEO -
see Note 17B.(8) below.
C. TELECOMMUNICATION COMPANIES:
OLIVE SOFTWARE INC. ("OLIVE")
Olive is engaged in the development and marketing of products
enabling a transparent link between traditional newspaper
printing systems and the world of e-publishing, as well as
digital archiving services for newspapers and libraries.
In March 2004, Olive and its shareholders entered into an
agreement with the Sequoia Fund according to which, the latter
invested in Olive $6.0 million in consideration of 26% (on a
fully diluted basis) of the equity and control in Olive. In
August 2005, Olive and its shareholders entered into an agreement
with the Sequoia Fund and with the Pitango Fund, under which the
latters invested in Olive an aggregate amount of $9.0 million
(NIS 41.4 million), in consideration of 5% and 15.0% (on a fully
diluted basis), respectively, of the equity and control in Olive.
The issued shares have anti-dilution rights as well as
liquidation preference to receive the amount of their investment
with the addition of 8% annual interest thereon, prior to any
distribution to other shareholders of Olive (including EUN).
EUN's holdings have consequently been diluted to 22.6. EUN's
shares entitle it to anti-dilution rights as well as liquidation
preference (return of its investment in Olive plus interest at
LIBOR + 2% per annum, prior to any distribution to holders of
ordinary shares or subordinated preferred shares). Assuming all
of Olive's convertible securities be so converted into shares,
EUN's interest in Olive would then be diluted to 18.3%.
EASY RUN LTD. ("E.R.")
E.R. is engaged in the development and marketing of "call center"
solutions, which support under a single platform, diversified
infrastructure ranging from historical telephonia through to
futuristic telecom equipment (IP switchboards) and modern
e-commerce applications.
The Company holds 42% of the equity and voting rights in E.R. as
well as the right to appoint 40% of its directors. The shares
held by the Company entitle it to anti-dilution rights as well as
liquidation preference (as defined in the investment agreements).
-40-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
A. COMPOSITION AND ACTIVITY (CONT.)
(1) VENTURE CAPITAL INVESTMENTS - ASSOCIATED COMPANIES - SHARES: (CONT.)
C. TELECOMMUNICATION COMPANIES (CONT.):
EASY RUN LTD. ("E.R.") (CONT.)
Within the framework of the rights offering executed by E.R. in
August 2004, the Company invested $0.4 million (out of a $0.65
million total funding) calculated at $0.13 per share. In
consideration for its investment, the Company was also granted
warrants exercisable into shares, at $0.13 per share, up to a
total amount of $0.8 million. In addition thereto, the Company
converted a $0.3 million loan into shares of E.R. Assuming all
loans (including those granted subsequently to the balance sheet
date) be converted and warrants be exercised, as afore and below
stated, the Company's interest in E.R. would then increase to
53.94% (fully diluted).
(2) VENTURE CAPITAL INVESTMENTS - ASSOCIATED COMPANIES - LOANS:
A dollar linked $0.7 million (NIS 3.2 million) loan, bearing Libor +
2% interest, convertible, at any time until repayable into E.R.
preferred shares having anti-dilution rights and liquidation
preferences, using a conversion rate of mainly, $0.35 per each share.
Additionally, the Company has a right to be granted upon conversion
and without further consideration, warrants convertible into E.R.
shares (vested with same rights) at a principal conversion price of,
$0.81 per warrant, up to a total amount of NIS 3.0 million.
An additional loan was granted to E.R. during 2005, at an aggregate
amount of $0.6 million, bearing 6% interest and convertible into E.R.
shares at $0.13 per share, or, subject to certain conditions, at 80%
discount of the next financing round price.
(3) INVESTMENTS IN ANOTHER COMPANY:
On August 17, 2005, Vcon reported that following the failure in its
previously announced fund raising negotiationsit has determined that
it can no longer independently pursue its current mode of operations,
and has entered into an agreement for the sale of its business,
activities and the majority of its assets to the Emblaze group.
Following this transaction, Vcon is engaged only, under the given
circumstances, in maximizing the payments and satisfaction of its
debts to its creditors and in its dissolving. Vcon estimates that none
of the consideration will be allocated to its shareholders. As a
result, the Company included in the 2005 financial statements, a loss
at the amount of NIS 13.9 million ($3.0 million), which constitute all
balance of its investment in Vcon.
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF
(1) ELSCINT LTD.
On November 22, 2005 the Company consummated a merger with Elscint,
pursuant to which the Company purchased all Elscint ordinary shares,
other than those held by the Company and by Elscint. Following such
purchase the Company owns all issued and outstanding share capital of
Elscint and Elsicnt ordinary shares are no longer traded on the NYSE.
Under the terms of the merger, each ordinary share of Elscint (other
than ordinary shares of Elscint held by the Company and Elscint) was
exchanged for 0.53 ordinary share of the Company.
-41-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(1) ELSCINT LTD. (CONT.)
The merger is treated in these financial statements as a "purchase"
for accounting purposes, which means that the purchase price -
calculated based on the Company's number of shares issued in
consideration for Elscint's minority shares (3,479,216 ordinary shares
and 26,500 warrants of the Company) and based on the Company's average
share market price close to the date of the announcement of the
exchange ratio of the Merger ($18.6) - is allocated to Elscint's
assets and liabilities based on the fair value of the assets acquired
and the liabilities assumed. As a result, the Company's shareholders'
equity increased by NIS 292.2 million ($63.4 million). The excess of
the fair value of Elscint's net identified assets acquired over the
purchase price at acquisition ("Negative Initial Difference"), at the
amount of NIS 66.3 million ($14.4 million), was set-off, at the date
of the consummation of the transaction, in the consolidated financial
statements of the Company, first against any intangible asset of
Elscint, with the balance set-off against non-monetary tangible assets
pro rata to their fair value.
As a result of the merger, certain limitations shall apply (as per law
and the tax authorities' approval) for a period of two years from the
merger (through December 31, 2007), mainly pertaining to the
realization, subject to certain conditions, of Elscint's shares held
by the Company and/or by its wholly owned subsidiary. The Company, its
controlling shareholders and Elscint will be subject to certain
restrictions, mainly pertaining to the realization of the majority of
the assets (as defined by law) that were transferred within the
framework of the merger and/or the majority of their existing assets.
Should the companies fail to fulfill the terms of the approval and/or
the provisions of the law, validity of the approval should be
terminated retroactively.
(2) INSIGHTEC LTD. (FORMERLY - INSIGHTEC - IMAGE GUIDED TREATMENT LTD.)
("INSIGHTEC")
A. Insightec is engaged in the development, manufacture and sale of
noninvasive means for the treatment of blood vessel tumors
(benign and malignant) and the localized injection of medication,
as well as the development of decision support systems for
operating rooms and trauma units. In October 2004, Insightec
received Food and Drug Administration (FDA) approval for
commercial use of the ExAblate system for removal of benign
uterine fibroids, as developed thereby.
B. In 2003, GE exercised an option granted thereto for the
acquisition of additional 5% of Insightec's capital, in
consideration for $3.0 million. Following the exercise of the
option, GE holds approximately 19% of Insightec's shares. The
agreement with GE for the acquisition of the shares (in December
2001) stipulates several limitations on the execution of certain
material transactions or activities not in the ordinary course of
business, without obtaining GE's prior approval.
C. In March 2004, Insightec and its shareholders executed an
agreement with Meditech Advisors LP ("MTA") a group of private
investors, under which MTA invested in Insightec $3.0 million
($7.3 per share) in consideration of approximately 2.7% of equity
and voting rights in Insightec (fully diluted).
Within the framework of the agreement, the Company was granted
warrants, convertible through a 3 year period, into 977,552
ordinary shares of Insightec (constituting approximately 6.5% of
equity and voting rights of Insightec), at an aggregate
conversion amount of $7.1 million, concurrently with extension of
the loans and guarantees provided by the Company to Insightec
until March 2007. The Company and Insightec have agreed that
prior to Insightec's IPO the Company shall exercise its warrants
into Insightec's shares in consideration of (i) a cash payment of
$5.0 million; and (ii) a conversion of the loan granted by it to
Insightec at the amount of $2.1 million.
-42-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(2) INSIGHTEC - IMAGE GUIDED TREATMENT LTD. ("INSIGHTEC") (CONT.)
D. CONVERTIBLE SECURITIES - OPTION PLANS
NUMBER OF SHARES (THOUSANDS)
--------------------------------------------------
SERVICE
EMPLOYEE OPTIONS DIRECTORS OPTIONS PROVIDERS
----------------- ----------------- OPTIONS
1999 2003 1999 2003 2003
PLAN(1) PLAN(2) PLAN PLAN PLAN
------- ------- ----- ----- ---------
Shares issued to trustee through December 31, 2002
as per the "1999 plan" 2,500 150
Shares issued to trustee in 2003 - as per the "2003 plan" 500 200 300
Designated shares transferred to the "2003 plan" (673) 673 (50) 50
Undesignated shares transferred to the "2003 plan" (311) 311
Shares transferred to offerees (56)
------- ----- ----- ----- -----
Shares held by trustee on December 31, 2005 1,460 1,484 100 250 300
======= ===== ===== ===== =====
Shares designated and issued:
Through December 31, 2002 1,460 100
During 2003 928 250 20
During 2004 201
During 2005 191 15
------- ----- ----- ----- -----
Through December 31, 2005 1,460 1,320 100 250 35
Undesignated shares as at December 31, 2005 164 265(4)
------- ----- ----- ----- -----
1,460 1,484 100 250 300
======= ===== ===== ===== =====
Vesting of designated and issued shares:
Through December 31, 2005 (5) 1,460 862 100 250 35
As and from 2006 and thereafter 458
------- ----- ----- ----- -----
1,460 1,320 100 250 35
======= ===== ===== ===== =====
TERMS OF PLAN:
Exercise price of each option into NIS 0.01 par
value ordinary share NIS0.01 (3) $3.33 $3.33 $5.35
------- ----- ----- ----- -----
Exercise period following date of grant (years) (6) 9 7 9 7 7
======= ===== ===== ===== =====
(1) Granted in 1999 through 2001 (mainly 1999).
(2) Includes 100,000 issued to Company's CEO and 50,000 issued to one who
served, at the grant date, as a director of the Company.
(3) 928,000 options - at NIS 0.01; 260,000 options - at $5.85; 133,000 options
- at $16.00; 163,000 options - not yet determined.
(4) The Company's board of directors and audit committee have approved in 2003
issuance of 250,000 options in Insightec, for no consideration, to the
Company's chairman of the board (its controlling shareholder), at an
exercise price of $5.5 each. Issuance is subject to approval of the
Company's shareholders meeting; designation of 15,000 options has not yet
been determined.
(5) In January 2005, Insightec decided to change the vesting period of options
granted under the 2003 plan to be 50% after 2 years from the date of grant,
25% after 3 years from the date of grant, and another 25% after 4 years
from the date of grant.
(6) In January 3, 2006 Insightec's decided to extend the exercise period under
the 1999 Plan, extending the exercise period, for 2 additional years,
meaning 9 years from the effective date as defined in the 1999 Plan.
(7) On January 31, 2006 Insightec's Board of Directors approved and adopted a
new options plan ("2006 Plan"). The total number of options under the 2006
Plan shall be 400,000 options. The balance of unallocated options from the
previous option plan ("2003 Plan"), after allocating the currently approved
options would be transferred to 2006 Plan, in addition to the 400,000
options. As of March 31, 2006 Insightec granted 260,000 options from the
2006 Plan.
-43-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(2) INSIGHTEC - IMAGE GUIDED TREATMENT LTD. ("INSIGHTEC") (CONT.)
E. As to Company's investment in debentures, convertible into
Insightec shares - see Note 14G. below.
F. Assuming conversion of all of Insightec's outstanding convertible
securities, on December 31, 2005 the Company's interest would
have been diluted to 52.15%.
G. At year-end of 2002, the operations of Insightec and its wholly
owned subsidiary (TxSonics) were merged. In 2005, Insightec and
its shareholders on one hand, and the Israeli Tax Authorities on
the other, have concluded the principles, subject to which the
merger of Insightec and TxSonics was approved under Section 103
of the Income Tax Ordinance, retroactively from December 31,
2002. As per law and approval, taxable consolidated loss of
Insightec and TxSonics may be offset against future taxable
income, over a 7 year period (16% each year), however not
exceeding 50% of annual taxable net income per each year.
Said approval provides, inter alia, that profit generated by EUN
from the sale of its holdings in Insightec shall be considered as
C.F.C. profits and shall be taxable at a rate of 25%, or any
lower rate as determined by tax authorities. EUN undertook, among
other things, to deposit its Insightec shares with a trustee, as
security of the tax payment to the Israeli Tax Authorities, upon
realization of the shares by EUN.
Should the companies fail to fulfill the terms of the approval
and provisions of the law, validity of the approval shall be
terminated retroactively.
(3) COMPANIES WITHIN THE PLAZA CENTERS (EUROPE) B.V. ("P.C.") GROUP
A. On July 30, 2004, a transaction was consummated, within the
framework of which, Klepierre - a French group of companies, and
the owner and operator of shopping centers in Europe
("Klepierre") - acquired from PC (EMI's wholly owned subsidiary)
all equity and voting rights in and to the companies owning 12
Hungarian shopping centers ("the sold centers"), as well as 50%
of the equity and voting rights in and to a wholly owned
subsidiary of PC which operates as the management company of the
Hungarian commercial and entertainment centers ("Hungarian
Management Company"). The remaining 50% of the equity and voting
rights in the Hungarian Management Company (which were retained
by PC under the 2004 transaction) were subsequently acquired by
Klepierre within the framework of the 2005 transaction, as
detailed in paragraph d. below, for E0.9 million.
The value of the sold centers and Hungarian Management Company
(E287.0 million; NIS 1,565.0 million; $340.0 million) was
determined according to a methodology stipulated in the
agreement, which is based, mainly, on the revenues thereof (net
of certain operating costs and management fees at an agreed rate)
and on agreed upon capitalization rates. The cash consideration
paid to PC, amounting to E94.1 million (NIS 513.0 million;
$111.0 million), was determined according to the value of the
sold centers with an addition of monetary and other balances, net
of banking and other monetary liabilities relating to the said
assets. As security for achieving certain future revenues, PC had
provided a bank guarantee totaling E7.5 (NIS 40.8 million;
$8.9 million) million which will decrease annually during the
period commencing on the fourth anniversary of the closing of the
transaction through to the tenth anniversary of that date. Within
the framework of the transaction detailed in paragraph d. below,
Klepierre has returned the guarantee unexercised. Klepierre,
furthermore waives all and any future claims, arguments or
contentions of whatsoever nature or kind against PC relating to
and/or in connection with and/or arising out of the future sale
of utilities in all or any of the sold centers and/or the
revenues derived therefrom, in respect of which the guarantee had
been furnished. As a result, the Company recorded in the
financial statements of the current year an additional pre-tax
gain of NIS 27.5 million ($6.0 million), the discounted amount
which had been initially deferred for recognition gradually over
the years 2008-2014.
-44-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(3) COMPANIES WITHIN THE PLAZA CENTERS (EUROPE) B.V. ("P.C.") GROUP
(CONT.)
A. (CONT.)
As security of fulfillment of certain tax conditions set forth in
the sale agreement (to the extent relevant, if at all), PC
deposited E6.8 million (NIS 37.0 million; $8.2 million) in an
escrow account, which was released to the Company, in accordance
with the terms of the agreement, on March 2005. As a condition to
such release of the escrow funds and concurrently therewith, the
Company provided, in favor of Klepierre, a 5 year guarantee, at a
basic amount of E6.8 million (NIS 37.0 million; $8.2 million)
together with an additional amount equal to 25% of the basic
amount of the guarantee, in order to secure certain payments to
foreign tax authorities, if and to the extent imposed on the sold
companies and which relate to the periods prior to the
consummation of the sale. As a result of the deposit release, the
Company released in its financial statements for the current
year, the relevant part of the consideration at the amount of
E5.8 million (NIS 31.0 million; $6.8 million) which was
previously presented as deferred income, was released to the
statement of operations.
The revenues of those entities holding the sold centers and their
operating profits, as recorded in the consolidated financial
statements in 2003, totals E40.0 million (NIS 217.8 million) and
E15.8 million (NIS 86.0 million), respectively.
The transaction also included provisions relating to the possible
future acquisition by Klepierre of additional property measuring
approximately 12,000 sq.m. to be constructed (if and to the
extent) by PC on their behalf, as an extension to the Duna Plaza.
Construction of the extension and the completion of the
transaction are subject, among other things, to the execution of
a turn-key construction agreement between the parties, to
obtaining regulatory approvals and permits from various competent
governmental authorities, during a specific period stipulated in
the agreement, as well as to utilization of premises while
fulfilling certain operational targets. The amount of
consideration and schedule of payments, follows an agreed upon
methodology, as well as asset value based on revenues and agreed
upon capitalization rate.
The Company guaranteed fulfillment of PC's undertakings under the
detailed agreements.
-45-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(3) COMPANIES WITHIN THE PLAZA CENTERS (EUROPE) B.V. ("P.C.") GROUP
(CONT.)
B. In April 2005, a transaction was consummated by and between PC
and the Dawnay Day Europe group - an international funds
management company of the United Kingdom ("Purchaser") - in
accordance with which PC sold to the Purchaser all the equity and
voting rights (100%) in 4 companies owning 4 commercial and
entertainment centers in certain peripheral cities in Hungary
("Sold Centers"). The asset value of the sold centers at the
aggregate amount of E54.4 million (NIS 296.2 million; $64.3
million), was calculated according to an agreed upon methodology
and is based, mainly, on revenues thereof (net after deduction of
certain operational costs and management fees). The net cash
consideration which was paid to PC amounted to E17.2 million (NIS
93.7 million; $20.7 million) and was determined according to the
asset value of the Sold Centers together with monetary and other
balances, after deduction of bank and other monetary liabilities
pertaining thereto, and with the addition of a variable amount,
determined based on the period that lapsed from the reference
date of the transaction (January 1, 2005) through consummation
thereof. As a result, the Company recorded in these financial
statements a pre-tax gain of approximately NIS 3.5 million ($0.8
million). The Company undertook within the framework of the
agreement to guarantee achieving certain operational targets of
one of the Sold Centers, for a period of 3 years through December
31, 2007. The Company's management estimates that the maximum
exposure of the guarantee expected to be materialized totals E1.1
million (NIS 5.8 million; $1.3 million) and accordingly, a part
of the gain deriving from this transaction has been deferred, in
these financial statements, for recognition gradually through
December 31, 2007. The Company undertook to guarantee fulfillment
of all of PC's undertakings under the detailed agreements.
The book value of the assets of the companies holding the Sold
Centers, their revenues and operating profits thereof, as
recorded in the consolidated financial statements as of December
31, 2004 and for the year then ended, totals E55.4 million (NIS
301.7 million), E8.4 million (NIS 45.7 million) and E2.5
million (NIS 13.6 million), respectively.
C. On May 17, 2005 PC completed the acquisition of the 50% not owned
by it, in the Sadyba commercial and entertainment center in
Warsaw, Poland, for a purchase price of $20.0 million (NIS 92.0
million).
D. On July 29, 2005, a transaction was consummated by and between PC
and Klepierre for the sale by PC of all equity and voting rights
(100%) of the companies owning 4 operational shopping centers in
Poland ("Sold Centers"), for a consideration of E73.8 million
(NIS 401.9 million; $87.3 million) based on the Sold Centers'
asset value amount to E204.0 million (NIS 1,111 million; $241.0
million). The asset value, calculated on the basis of the gross
rentals of the Sold Centers as at the closing, was discounted at
certain agreed yields, together with monetary and other balances,
after deduction of bank and other monetary liabilities pertaining
thereto ("the first stage"). An adjustment of the purchase price
will be conducted on the basis of the gross rentals as of
December 31, 2005 (in respect of one shopping center - as of a
date up to May 31, 2006), discounted at the agreed yields. In
addition, a net asset value adjustment will be conducted in 2006,
on the basis of audited financial statements as at the closing
date. As part of the transaction, Klepierre has acquired all
outstanding share capital of the Polish subsidiary of PC which
operates and manages the acquired operational shopping centers.
As a result, the Company recorded in these financial statements a
pre-tax gain of approximately NIS 166.4 million ($36.1 million).
An additional pre-tax gain of approximately E8.0 million (NIS
43.6 million; $9.5 million) deriving from the completion of this
first stage - part of which is subject to the fulfillment of
certain conditions specified in the agreement - expected to be
included in the company's results of operations during 2006.
-46-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(3) COMPANIES WITHIN THE PLAZA CENTERS (EUROPE) B.V. ("P.C.") GROUP
(CONT.)
D. (CONT.)
The book value of the assets of the companies holding the Sold
Centers, their revenues and operating profits thereof, as
recorded in the consolidated financial statements as of December
31, 2004 and for the year then ended, totals E100.8 million
(NIS 549.0 million; $119.3 million), E10.9 million (NIS 59.3
million; $12.9 million) and E4.0 million (NIS 21.8 million;
$4.7 million), respectively.
In addition, on July 29, 2005 PC and Klepierre signed a
preliminary share purchase agreement for the future acquisition
by Klepierre of all equity and voting rights (100%) in the
companies presently developing 2 shopping centers in Poland, as
well as a further 2 companies developing shopping centers in the
Czech Republic, for an estimated assets value amount to
E158.4 million (NIS 862.7 million; $187.4 million) ("the
second stage"). Klepierre also has an option to acquire all
equity and voting rights of a third company developing a shopping
center in Poland, for an estimated asset value amount to
E62.0 million (NIS 337.6 million; $73.4 million) upon the
fulfillment of certain conditions. Upon the exercise of the
option, the construction and delivery of the shopping center will
be subject to the same terms and conditions applicable to the
remaining centers. If Klepierre does not exercise the option to
acquire the shares of such third Polish company, the Company will
be obligated to pay a penalty in the amount of E1.6 million
(NIS 8.7 million; $1.9 million). The consideration was determined
based on forecasted gross rentals at the date of the execution of
the agreement. Upon the completion and delivery of each of these
centers, in accordance with certain pre-agreed terms as
determined in the preliminary agreement, and upon the fulfillment
of certain pre-conditions, Klepierre will pay to PC the purchase
price of each specific center owning company which will be
calculated based on gross rentals prevailing at a date close to
delivery, capitalized at agreed yields. A final price adjustment
of the purchase price for each of these development centers will
be conducted not later than 10 months following delivery, on the
basis of actual gross rentals prevailing on their respective
adjustment dates, discounted at the agreed yields. In addition, a
net asset value adjustment will be carried out on the basis of
audited financial statements as at the delivery date. Klepierre
has furnished the Company with a bank guarantee in the amount of
E115.0 million (NIS 626.3 million; $136.0 million) for the
payment of the respective purchase prices of those development
centers in respect of which building permits have been issued.
Klepierre has undertaken to furnish the Company with a similar
bank guarantee in respect of the remaining development centers
immediately upon the issuance of the building permit. These bank
guarantees may be exercised in accordance with an agreed
mechanism provided for therein. The Company has furnished
Klepierre with its corporate guarantee for the fulfillment by PC
of all its undertakings and obligations under the definitive
agreements.
E. On November 15, 2005, PC signed an agreement and consummated a
transaction for the acquisition of an area of land (measuring
122,857 square meters) situated on Kerepesi Street in central
Budapest, the former site of the Hypodrome ("Site"). Building
permits for the construction of a large shopping and
entertainment center have been issued in respect of the Site, the
rights to which were also acquired. The acquisition was carried
out by the purchase of all equity rights (100%) of 4 companies
holding all freehold ownership and usage rights to the Site. The
purchase price of all equity rights represent a Site value of
E21.0 million (NIS 114.0 million; $24.8 million). The
financing of the Site was provided by a consortium of
International Banks, and constitute approximately 90% of the
above value.
-47-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(3) COMPANIES WITHIN THE PLAZA CENTERS (EUROPE) B.V. ("P.C.") GROUP
(CONT.)
F. PC's jointly controlled subsidiary ("AC"), owns approximately
60.0% of the ownership and voting rights of a Target Company,
which owns 320,000 sq.m. of land on the island of Obuda in the
Danube River, located in the heart of Budapest. Such investment
was financed by a loan of E12.7 million (NIS 69.4 million; $
15.0 million) granted to AC by Hungarian commercial bank (the
"Bank"), which owns the remaining 50% of the equity and voting
rights in AC. The loan is linked to the Euro, bears interest at
Euribor + 2% per annum, and is repayable on March 31, 2007. As
security for the loan, AC, among other things, pledged its shares
in the Target Company. In addition, the Company undertook to
guarantee repayment of the loan in the event that the
construction plans are not approved, as detailed hereinafter.
Shareholders rights in the Target Company are subordinated to the
Bank loan. One of the minority shareholders (30%) was granted a
put option that is to be expire on April 2007, to sell his shares
in the Target Company to AC in consideration for a price which is
to reflect the cost of the Target Company's shares acquired by AC
with the addition of interest at a rate of Euribor +2% per annum
and less profits distributed thereby prior to sale.
Resolutions of the Target Company are to be approved by majority
of votes while exercising certain minority rights in specific
extraordinary matters, in which a 75% majority of votes of
shareholders or directors, as the case may be, is required. The
parties undertook to complete their respective investments in the
Target Company's shareholders equity, up to a rate of
shareholders' equity and bank loans not less then 20% and 80%,
respectively.
10% of equity and voting rights of the Target Company are held by
ESI - a company owned by PC's former manager - which were granted
to it in consideration for acquisition cost thereof, by AC from
the Hungarian Privatization Board. The purchase by ESI of its
interests is financed through loans which were granted thereto by
the shareholders of the Target Company, pro rata to their
shareholdings, in the aggregate total amount of E0.6 million
(NIS 3.3 million; $0.7 million), repayable until March 2008.
The Target Company intends to obtain construction rights for
300,000 sq.m. designated for offices, commerce, tourism,
entertainment, recreation and hotels. Structures with an area of
55,000 sq.m. are presently built up on the land and leased to
offices, restaurants and entertainment businesses. The parties
intend to act to change the zoning according to the urban
building plan, with a view to enhancing the value of the land and
the construction thereon. As for approval of local town planning
scheme, of the Budapest General Assembly in May 2006 - see Note
24H.
Financial statements of AC and the Target Company are included in
the consolidated financial statements of the Company by the
equity method.
(4) COMPANIES IN BEA HOTELS N.V. ("B.H.") GROUP
B.H. holds, through a wholly owned and controlled subsidiary
incorporated in Romania ("Domino") - approximately 70% of SC Bucuresti
Turism S.A. ("Bucuresti") which in turn owns a complex consisting of a
hotel, an apartment hotel, commercial areas and a restaurant, situated
in the heart of Bucharest, Romania ("the Bucuresti Complex").
Bucuresti was purchased through a privatization tender published by
the State Ownership Fund of the Romanian government ("SOF"). The
tender procedure was approved by a decision of the Supreme Court of
Romania.
-48-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
B. ADDITIONAL INFORMATION AS TO INVESTMENTS IN SUBSIDIARIES AND CHANGES
THEREOF (CONT.)
(4) COMPANIES IN BEA HOTELS N.V. ("B.H.") GROUP (CONT.)
The acquisition of most of the rights in Bucuresti was carried out
within the framework of a memorandum of understanding ("MOU") for the
establishment of a joint venture, 80% of the rights of which were to
be held by B.H. and 20% of the rights by an unrelated third party
("Third Party Shareholder"). Pursuant to the provisions of the MOU,
B.H. is entitled to receive 100% of Domino's profits to be distributed
as dividends up to an aggregate amount of $2.0 million. Income in
excess of such amount is to be distributed according to holdings ratio
(80%:20%). In addition, B.H. has a Put Option to oblige the Third
Party Shareholder to increase its interest from 20% up to 50% (based
on full investment cost) for period and in terms to be agreed upon by
the parties. The parties undertook to finance the renovation of the
hotel, should same be required. Should one of the parties fail to
provide the financing pro rata to its share, the shareholdings of the
delinquent party will be diluted based on a methodology to be agreed
upon.
As a result of a breach of agreements and undertakings by the Third
Party Shareholder, B.H. announced the termination of all agreements
and simultaneously filed, together with its subsidiary a law-suit
against the Third Party Shareholder for all damages incurred by it due
to the latter's breach of contracts and undertakings. B.H. withheld,
prior to filing the claim, the Third Party Shareholder's shares (20%)
as security for fulfillment of its undertakings. As a result of the
agreements' termination and the filing of the lawsuit, the Company
believes, based on legal advice, that it is no longer required to
transfer said shares to the Third Party Shareholder, which follows
that B.H. is in effect the holder of the entire share capital and all
voting rights (indirectly) in Domino.
B.H. filed a monetary claim against the Third Party Shareholder for
noncompliance with the indemnity conditions, in the framework of which
liens were imposed on the Third Party Shareholder's assets. The Third
Party Shareholder filed a statement of defense against the suit.
Mediation proceeding between the parties failed, and a notice to that
effect was filed by B.H. in January 2005 to the competent court,
accompanied by a request to schedule a preliminary hearing. Such
hearings are scheduled to commence in July 2006.
For information in respect of additional lawsuit filed by the Third
Party Shareholder - see Note 24A.
For information concerning legal actions filed in connection with the
purchase and ownership of Bucuresti shares, and the real estate owned
thereby- See Note 17B.(4), below.
Bucuresti shares are traded on the Romanian stock exchange. The value
of B.H.'s holdings in Bucuresti shares, based on the price of a
Bucuresti share as of December 31, 2005, amounts to NIS 44.0 million
($9.5 million), and their book value as of that date amount to NIS
235.7 million ($51.2 million).
(5) MANGO ISRAEL CLOTHING AND FOOTWEAR LTD.
On May 2005, Elscint completed the acquisition of all (100%) of the
equity and voting rights of Mango Israel clothing and footwear Ltd.
("Mango"), the Israeli distributor and retailer of the internationally
renowned retail brand name MANGO-MNG(TM). The book value of the assets
of Mango, its revenues and its operating loss, for the period from its
acquisition, initially consolidated in the financial statements as of
December 31, 2005 and for the year then ended, totals NIS 26.8 million
($5.8 million), NIS 31.8 million ($6.9 million) and NIS 3.8 million
($0.8 million), respectively.
The excess of cost over fair value of identified tangible assets of
Mango at the date of acquisition, in the amount of NIS 2.3 million
($0.5 million), was attributed to the distribution rights acquired.
-49-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
C. THE FOLLOWING IS SUMMARIZED DATA OUTLINING THE GROUP'S SHARE IN ITEMS OF
THE PROPORTIONATELY CONSOLIDATED COMPANIES FINANCIAL STATEMENTS
AT DECEMBER 31, 2005 AND FOR THE YEAR THEN ENDED:
(IN THOUSAND NIS)
--------------------------------------
PROPORTIONATELY CONSOLIDATED COMPANIES
REPORTED
--------------------------------------
50% 33.3% 30% TOTAL
-------- ------- ------ --------
SHAREHOLDING
Current assets 44,449 420 34 44,903
Fixed assets and other assets 965,691 4,239 -- 969,930
Long-term deposits, loans and receivables 20,220 791 -- 21,011
Current liabilities (60,676) (841) (8) (61,525)
Long-term liabilities (662,410) (4,302) -- (666,712)
-------- ------- ------ --------
307,274 307 26 307,607
======== ======= ====== ========
Liabilities to (of) group companies 311,610 10,871 (1,242) 321,239
Shareholders' equity (deficiency) (4,336) (10,564) 1,268 (13,632)
-------- ------- ------ --------
307,274 307 26 307,607
======== ======= ====== ========
Revenues 194,884 2,077 12,619 209,580
======== ======= ====== ========
Profit (loss) before income taxes (48,727) (351) 1,639 (47,439)
======== ======= ====== ========
Net profit (loss) (49,886) (351) 1,639 (48,598)
======== ======= ====== ========
CONVENIENCE TRANSLATION (US$'000)
------------------------------------
PROPORTIONATELY CONSOLIDATED
COMPANIES
REPORTED
------------------------------------
50% 33.3% 30% TOTAL
-------- ------ ----- --------
SHAREHOLDING
Current assets 9,657 91 7 9,755
Fixed assets and other assets 209,796 921 -- 210,717
Long-term deposits, loans and receivables 4,393 172 -- 4,565
Current liabilities (13,182) (183) (2) (13,367)
Long-term liabilities (143,908) (935) -- (144,843)
-------- ------ ----- --------
66,756 66 5 66,827
======== ====== ===== ========
Liabilities to (of) group companies 67,697 2,362 (270) 69,789
Shareholders' equity (deficiency) (942) (2,295) 275 (2,962)
-------- ------ ----- --------
66,755 67 5 66,828
======== ====== ===== ========
Revenues 42,338 451 2,741 45,531
======== ====== ===== ========
Profit (loss) before income taxes (10,586) (76) 356 (10,306)
======== ====== ===== ========
Net profit (loss) (10,838) (76) 356 (10,558)
======== ====== ===== ========
-50-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - INVESTMENTS IN INVESTEE AND OTHER COMPANIES (CONT.)
C. THE FOLLOWING IS SUMMARIZED DATA OUTLINING THE GROUP'S SHARE IN ITEMS OF
THE PROPORTIONATELY CONSOLIDATED COMPANIES FINANCIAL STATEMENTS (CONT.)
AT DECEMBER 31, 2004 AND FOR THE YEAR THEN ENDED:
(IN THOUSAND NIS)
PROPORTIONATELY CONSOLIDATED COMPANIES
REPORTED
------------------------------------------
50% 33.3% 30% TOTAL
--------- ------- -------- ---------
SHAREHOLDING
Current assets 61,774 782 4,479 67,035
Fixed assets and other assets 1,046,759 4,520 117,828 1,169,107
Long-term deposits, loans and receivables 11,253 735 11,104 23,092
Current liabilities (258,833) (776) (4,102) (263,711)
Long-term liabilities (476,855) (4,781) (151,164) (632,800)
--------- ------- -------- ---------
384,098 480 (21,855) 362,723
========= ======= ======== =========
Liabilities to (of) group companies 325,818 11,413 (14,674) 322,557
Shareholders' equity (deficiency) 58,280 (10,933) (7,181) 40,166
--------- ------- -------- ---------
384,098 480 (21,855) 362,723
========= ======= ======== =========
Revenues 171,303 2,080 13,241 186,624
========= ======= ======== =========
Profit before income taxes 1,207 496 1,507 3,210
========= ======= ======== =========
Net profit (loss) (888) 496 1,505 1,113
========= ======= ======== =========
-51-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS
A. COMPOSITION:
DECEMBER 31
--------------------------------------------------------------------------------------------------
2005 2004
REPORTED REPORTED
-------------------------------------------------------------------------------------- ----------
REAL ESTATE
----------------------------------------------------
HOTELS COMMERCIAL CENTERS
------------------- -----------------------------
UNDER UNDER OTHER
CONST- CONST- FIXED CONVENIENCE
ACTIVE RUCTION ACTIVE RUCTION OTHER ASSETS TOTAL TRANSLATION TOTAL
--------- -------- ---------- -------- ------- ------- ---------- ----------- ----------
(IN THOUSAND NIS) US$'000 NIS'000
COST:
Balance as of January 1 1,195,999 642,106 1,534,329 420,046 223,137 33,452 4,049,069 879,659 5,219,989
Initially consolidated
companies -- -- 113,983 123,777 -- 36,985 274,745 59,688 36,906
Deconsolidated companies (132,519) -- (1,160,047) -- -- -- (1,292,566) (280,809) (1,757,941)
Adjustments resulting from
translation of foreign
subsidiaries financial
statements (66,457) (22,867) (53,861) (32,075) (15,311) 1,013 (189,558) (41,181) 289,374
Additions during the year (2) 26,400 98,381 (26,469) 291,232 2,556 32,878 424,978 92,326 336,758
Commercial centers and hotels
whose construction ended
during the year 468,863 (468,863) 246,893 (246,893) -- -- -- -- --
Land whose ultimate designation
is yet to be determined -- -- (18,371) 18,371 -- -- --
Disposals in reported year (8,677) -- (47) -- (12,646) (3,167) (24,537) (5,331) (80,430)
--------- -------- ---------- -------- ------- ------- ---------- -------- ----------
Balance as of December 31 1,483,609 248,757 654,781 537,716 216,107 101,161 3,242,131 704,352 4,044,656
--------- -------- ---------- -------- ------- ------- ---------- -------- ----------
ACCUMULATED DEPRECIATION:
Balance as of January 1 205,728 43,370(1) 98,911 -- 15,491 10,937 374,437 81,346 487,828
Initially consolidated companies -- -- 25,427 -- -- 22,906 48,333 10,500 --
Deconsolidated companies (18,485) -- (77,479) -- -- -- (95,964) (20,848) (247,083)
Adjustments resulting from
translation of foreign
subsidiaries company's
financial statements (13,000) (14) (3,341) -- (1,804) 638 (17,521) (3,806) 29,539
Additions during the year 42,852 -- 48,444 -- 9,481 10,836 111,613 24,248 132,318
Disposals in reported year (4,783) -- (6) -- (3,156) (2,582) (10,527) (2,287) (28,164)
--------- -------- ---------- -------- ------- ------- ---------- -------- ----------
Balance as of December 31 212,312 43,356 91,956 -- 20,012 42,735 410,371 89,153 374,438
--------- -------- ---------- -------- ------- ------- ---------- -------- ----------
Payments on account of fixed
assets -- -- -- -- -- -- -- -- 4,419
--------- -------- ---------- -------- ------- ------- ---------- -------- ----------
Provision for impairment of
investments and assets (See
C. below) 53,151 -- 5,893 -- 14,251 -- 73,295 15,924 146,649
--------- -------- ---------- -------- ------- ------- ---------- -------- ----------
DEPRECIATED BALANCE NET BOOK
VALUE:
As at December 31 2005 1,218,146 205,401 556,932 537,716 181,844 58,426 2,758,465 599,275
========= ======== ========== ======== ======= ======= ========== ========
As at December 31 2004 938,179 598,735 1,355,273 420,045 193,252 22,504 3,527,988
========= ======== ========== ======== ======= ======= ==========
- ----------
(1) In respect of a hotel, closed during 2003, for renovations.
(2) Include Negative Initial Differences - See Note 9 B. (1).
-52-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS (CONT.)
A. COMPOSITION (CONT.):
COST OF FIXED ASSETS INCLUDES:
NET BOOK VALUE
DECEMBER 31
---------------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------------- -----------
(IN THOUSAND NIS) US$'000
Financial expenses capitalized to cost of
the buildings under construction 31,033 130,052 6,742
====== ======= =====
B. COMPOSITION OF LAND AND BUILDINGS, DISTINGUISHED BETWEEN FREEHOLD AND
LEASEHOLD RIGHTS:
NET BOOK VALUE AS AT DECEMBER 31, 2005
REPORTED AMOUNTS
----------------------------------------------------------------------------------
HOTELS COMMERCIAL CENTERS
------------------------ -------------------
UNDER UNDER
CONST- CONST- CONVENIENCE
ACTIVE RUCTION ACTIVE RUCTION OTHERS TOTAL TRANSLATION
--------- ------- ------- ------- ------- --------- -----------
(IN THOUSAND NIS) US$'000
Freehold (1) 720,779 205,401 16,942 354,642 151,167 1,448,931 314,780
Leasehold:
Capitalized 34,264(2) -- 539,990(6) 183,074 30,677 788,005 171,194
Uncapitalized 463,103(4)(3) -- -- -- -- 463,103 100,609
--------- ------- ------- ------- ------- --------- -------
1,218,146 205,401 556,932 537,716 181,844 2,700,039 586,583
========= ======= ======= ======= ======= ========= =======
(1) Majority of the rights are registered in the name of those subsidiaries,
which own the rights thereto.
(2) Leasehold rights (capitalized for a 50-year period until 2036), of the land
area on which the Utrecht Park Plaza Hotel is situated, were acquired from
the municipality of Utrecht. The execution of any change in the use of the
land or the demolition of a building constructed thereon requires the
consent of the municipality. The lessee has no rights of leasehold
termination. The municipality has the rights to terminate the leasehold
rights should it determine that the land is required for public use or in
the event a court determines that the lessee failed to fulfill its
undertakings under the terms of the lease.
(3) The sub-lease rights, of the Sherlock Holmes Park Plaza Hotel, are for a
period of 99 years (through 2095), in exchange for an annual fixed amount.
The average annual rent payments for the years 2005 and 2006 are L0.6
million (NIS 4.8 million; US$1.0 million). The rent payments are adjusted
every five years on the basis of "open market value". First such adjustment
is to be carried out in October 2006. The company holding the property has
an option to terminate the lease in 2059 with an advance notice of 2.5
years.
A Red Sea Group company ("guarantor") guaranteed fulfillment of all
undertakings of the lessee as if it was a principal party to the agreement.
The guarantee contains a provision, by which, in the event the guarantee is
exercised, the land-owners may require the guarantor to assume the lessee's
position as a lessee. Two documents were executed between the guarantor and
B.H., which establish the indemnification procedures amongst them, in
relation to said guarantee.
-53-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS (CONT.)
B. COMPOSITION OF LAND & BUILDINGS, DISTINGUISHED BETWEEN FREEHOLD AND
LEASEHOLD RIGHTS (CONT.):
(4) The leasehold rights to a land area on which the Riverbank Park Plaza
Hotel is located, are for a period of 125 years, in consideration for
annual payment of L0.6 million (NIS 4.8 million; $1.0 million),
adjusted every five years based on the CPI in England, with the next
adjustment to be carried out in May 2010. The leasehold is subject to
various previous rights exists on this property, as well as easements
granted to certain authorities, contingent upon which the leasing of
the property had been carried out; The lessee may not assign its
rights to a third party without the lessor's consent; Should the
lessee breach any of its undertakings under the agreement, then the
lessor would have a right of forfeiture of the property, all as
stipulated in the lease agreement.
(5) Capitalized lease rights in respect of the Arena entertainment and
commercial center are for a period of 49 years with an option for an
additional 49 year lease period. The option period will expire in
2086, subject to the lessee's compliance with the terms of the lease.
(6) PC entered, in May 2002, into a JV agreement (as amended on November
2003) for the purchase of 50% of the ownership of a company registered
in Lublin, Poland ("MPSA"). MPSA holds a perpetual usufruct in and to
the land - being the subject matter of the project - have been leased
from the local municipality for a period of 99 years, with a view of
constructing thereon a complex, consisting of: commercial area, a
hotel, offices, convention center and the like. MPSA has a right to
acquire the land, upon completion of construction, at an agreed upon
price (PLN 8.5 million; NIS 12.0 million; $2.6 million) net (after
deducation) of accumulated lease fees paid until the exercise of such
right. The local municipality is entitled to terminate the perpetual
usufruct if and to the extent the use of the land does not correspond
to the approved usage and/or in the event unauthorized delays or
schedule deviations occur. Should perpetual usufruct be so terminated,
MPSA shall be entitled to demand reimbursement of its investment in
the construction of the complex through termination.
In November 2004 MPSA and the local municipality amended the agreement
so as to divide the project into two stages, subject to the first
(construction of the convention center and commercial area) being
completed by August 31, 2006. The second stage (construction of the
hotel and office area) shall commence by no later than September 30,
2009 and conclude by the end of 2011. The parties are allowed, with
written consent, to increase or decrease the areas provided for
offices and a hotel or to change those functions. Should MPSA fails to
comply with the timetable of the second stage a penalty shall be
imposed thereon in the amount of PLN 2.5 million (NIS 3.5 million;
$0.8 million).
According to the JV Agreement, financing of the project to be
constructed by MPSA is to be borne by both parties in equal shares,
except for initial payment of $4.0 million which is to be provided by
PC, with half of such amount to be considered as a loan to the other
shareholder (the "JV Partner"). Through December 31, 2005, PC has
invested (mainly in loans, Libor + 2.5% annually interest bearing),
indirectly, in MPSA's project, E8.4 million (NIS 45.9 million;
$10.0 million).
PC and the JV partner are currently in dispute regarding the
shareholders' loan ("equity loans") required to be invested by the JV
partner. The JV Partner alleges that the increase in the project
budget, in comparison with the original one, was caused by the acts or
omissions of PC, and accordingly that PC alone should bear all
additional equity loans. PC refutes such allegation and has demanded
the fulfillment of the JV Agreement on its terms as indicated above,
namely all additional amounts, over the initial $4.0 million, required
for the financing of the project, should be financed by the parties in
equal parts. This dispute has not yet been resolved.
Within the framework of the 2005 sale agreement with Klepierre, as
stated in Note 9B.(3)d. above, PC awarded an option to Klepierre to
acquire 100% of the equity rights of MPSA, subject to the acquisition
by PC of the entire interest of the JV Partner in MPSA, by not later
than the end of November 2006 (the "first option"). In the event that
PC shall fail to acquire JV partner's rights by that date, then and in
such event Klepierre shall automatically have an additional option to
acquire the 50% of such equity rights in MPSA which are held
(indirectly) by PC (the "second option").
-54-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS (CONT.)
B. COMPOSITION OF LAND & BUILDINGS, DISTINGUISHED BETWEEN FREEHOLD AND
LEASEHOLD RIGHTS (CONT.):
(6) (CONT.)
The exercise by Klepierre of the second option shall be subject, at
all times, to (i) the JV Partner's rights of "first offer" which
entitles the JV Partner to acquire PC shares in the event that PC
wishes to of sell its shares to third party; and to (ii) the
"tag-along" rights which entitles the JV Partner to demand that
Klepierre shall also acquire its shares together with PC Shares on the
identical terms and conditions, pro rata. In the event that the JV
Partner shall exercise its rights of first offer to acquire PC shares,
as aforesaid, then the second option shall automatically lapse and be
of no further force and effect.
Until the date on which the second option would have lapsed, PC
covenants not to amend, modify, and/or terminate the JV Agreement,
without the prior approval of Klepierre, and to abstain from taking
any actions which may prejudice the rights and/or interests (present
or future) of Klepierre under or in connection with this option.
In the event the transaction for the sale and transfer of all equity
rights in MPSA to Klepierre shall not have been consummated for any
reason or in the event that the JV Partner shall exercise its "first
offer" rights, then and in such evens PC undertakes to pay to
Klepierre a Commitment Penalty in the amount of E1.6 million (NIS
8.7 million; $1.9 million), without prejudice to the rights of
Klepierre to be further indemnified in the event that such
non-consummation would result from a breach by PC of its contractual
obligations. In the event that Klepierre shall have elected to
exercise the second option and the acquisition by Klepierre of the PC
shares cannot be fully consummated for any reason, then and in such
event PC undertakes to pay to Klepierre a Commitment Penalty in a
reduced amount of E0.8 million (NIS 4.4 million; $0.9 million).
In the event that the JV Partner shall exercise its "tag-along" rights
and in the event that Klepierre shall actually acquire both the PC
shares and the JV Partner shares, then and in such event PC shall be
severally and jointly liable with JV Partner with respect to the sale
of the JV Partner shares and PC shall grant to Klepierre the same
indemnifications provisions guarantee with respect to the JV Partner's
shares to the extent that the JV Partner fails or refuses to do so.
Upon the exercise of either of the options abovementioned, PC shall
assume full liability for the performance of the obligation made by
MPSA in favor of the local municipality in terms of the ground lease
to construct a hotel above or adjacent to the commercial center
project and shall furnish Klerierre with a full indemnity against such
liability and/or against any harm which may be suffered by Klepierre
and/or by MPSA in consequence of the failure to construct the hotel as
aforesaid.
Upon delivery and receipt of one of the options, the project shall be
included as a project under development for all purposes in terms of
the 2005 sale agreement (see Note 9B.(3)d.) and that the provisions
this agreement shall apply, mutatis mutandis, to the project, such as
conditions for delivery, conditions for closing, methodologies for the
determination of the final purchase price of the sold center as well
as of the MPSA shares.
(7) In 2004, PC entered into an agreement for the acquisition of 50% of
the ownership in and to a Latvian corporation which owns land
property, with the view of constructing thereon a commercial and
entertainment center. Throughout 2004 and 2005 the Latvian corporation
acquired additional land properties. The construction permit issued in
respect of the land, which was valid at the time of PC's acquisition
thereof, has expired in September 2004. Following the additional land
acquisitions, and in light of the possibility which has arisen to
substantially upgrade the scope of the project (including the
construction of an underground parking, reducing construction costs,
alterating the form of the project while improving same in comparison
with the previous plans, etc.) PC has extensively changed the
structure of the project, which required revision to be made to the
building permit, in order to allow for the approval of the project in
its expanded scope.
-55-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS (CONT.)
B. COMPOSITION OF LAND & BUILDINGS, DISTINGUISHED BETWEEN FREEHOLD AND
LEASEHOLD RIGHTS (CONT.):
(7) (CONT.)
In February 2005, approval in principle was granted for the structural
changes and expansion of the project. Such approval while not
constituting, per se, a construction permit, represents however a
material milestone in the preliminary proceedings of filing various
documents and requirements to the municipality, required for the
issuance of the revised construction permit. PC is of the opinion that
there is no reason, which may prevent the issuance of the building
permit, and that same is expected, as per PC's estimate, to be granted
by the summer of 2006.
PC's investment in loans (mainly Libor +2.5% interest) as of December
31, 2005 amounts to E5.1 million (NIS 27.8 million; $6.0 million).
(8) On May 2000 a Greek subsidiary ("Helios") obtained a building permit
for the construction of a commercial and entertainment center on the
area of land owned thereby. The book value of the investment in and to
the land (including development and other costs) totaled, on December
31, 2005, E22.5 million (NIS 122.5 million; $26.6 million).
Excavation works commenced in 2001, but shortly thereafter the works
were suspended due to archeological findings at the site. Final
clearance issued by the competent archeological authorities was
obtained on February 2002. However, in terms of the archeological
clearance, and in order to comply with the provisions of an
environmental and traffic impact plan, Helios was required to carry
out certain modifications to the architectural plans of the commercial
and entertainment center. Upon completion of the new requirements,
Helios submitted an application for a revised building permit. In
December 2003, the local governmental authorities placed a one year
suspension (moratorium) on the issuance of all building permits and
constructions along the Piraeus side of the National Highway (which
includes the land owned by Helios).
In November 2004 a ministerial decision was issued, which changed the
land uses along the National Highway (Piraeus Avenue), restricting the
use of the Helios site only to office buildings and/or residential
buildings and/or small size retail activities. Under the new land uses
Helios may no longer build a shopping center. During the term of such
suspension Helios's building permit expired (building permits in
Greece have an intial four-year term). On April, 2005 Helios submitted
an application to the competent authorities requesting the renewal of
its building license, which was refused. In consequence, Helios filed
a petition with the constitutional court for an order determining that
the refusal to re-issue the building license was unconstitutional and
directing the competent authorities to re-issue the building license.
The first hearing date for this petition has not yet been and is
expected within the next 24 months.
In the meantime, a series of unrelated judgments by the constitutional
court have been handed down which reverse the regulatory civil
planning framework in Greece, namely that the civil planning powers
granted to the government by a law of 2002, were declaired void by
reason of the fact that the law which conferred such powers on the
government was declared to be unconstitutional. Given that Helios's
project was affected by a Ministerial Decision issued by virtue of a
law which has now been held to be void, it appears that such
Ministerial Decision is unconstitutional and accordingly invalid.
However, Helios has no direct means to create a practical result out
of this event, since the period during which Helios is permitted to
challenge the Ministerial Decision has expired, and there appears to
be no direct way to compel the Civil Planning Agency to issue a new
building permit on the basis of the previous permit (already expired)
or of the amendment that would allow Helios to construct a shopping
center. The Company is presently seeking legal advise how to proceed
and to protect its interests in the circumstances which have arisen.
The Company intends to again apply for the re-issuance of the building
permit and/or to petition the constitutional court on additional
grounds.
Considering the unclear nature of the status of the initial building
permit, the application for the amended building permit and the recent
legislative changes which affect the project, the management of PC is
currently considering the alternative possible solutions which are
available to it, in order to finalize the project as originally
planned. In addition, PC's management is examining, simultaneously,
the possibility that substantial changes may be required to be made to
the extent and nature of the project, the viability of such
alternative projects, and the commercial and financial implications of
such changes.
Notwithstanding the aforestated, PC's management estimates that the
project cost, as recorded in Helios' books of record, does not exceed
its recoverable amount.
-56-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS (CONT.)
B. COMPOSITION OF LAND & BUILDINGS, DISTINGUISHED BETWEEN FREEHOLD AND
LEASEHOLD RIGHTS (CONT.):
(9) In August 2001, a subsidiary, located in Lodz, Poland, received a
construction permit for the construction of a commercial and
entertainment center, which expired prior to the balance sheet date.
Construction works in respect of this project have not commenced as at
the approval date of these financial statements. The cost of
investment in the land (including demolition and other development
costs) amounts to E5.6 million (NIS 31.0 million; $6.7 million).
No zoning plans exist as at the balance sheet date, in respect of the
area surrounding the respective land. Once construction plans are
determined, new requests will be filed for a revised building permit.
PC's management estimates that no additional substantial costs will be
incurred thereby, in relation to obtaining the revised building permit
and that the book value of the asset, as recorded in the financial
statements, does not exceed its recoverable amount.
(10) Within the framework of the 2004 sale agreement, detailed in Note
9B(3)a. above, Klepierre has acquired from PC all equity rights in
Duna Plaza. Duna Plaza is the registered and legal owner of the entire
right, title and interest in and to the Duna Plaza Complex, which is
comprised of Duna Plaza shopping center (the "Sold Center" or "Duna
Plaza") and the Duna Plaza Offices ("DPO"). Since DPO was specifically
excluded from the framework of the 2004 transaction, Klepierre and PC
have agred to implement certain procedures to cause: (i) the
registration of the DPO as a separate title unit in a condominium the
rights of which shall initialed be held by Duna Plaza; (ii) thereafter
to implement a de-merger of Duna Plaza in such manner that DPO will be
recorded in the name of a new company to be incorporated under the
de-merger ("DPO Owner"); and (iii) to cause the sale and transfer to
PC of all equity and voting rights of DPO Owner holding ownership of
DPO (the "de-merger procedures"). The assets of Duna Plaza shall be
divided in such manner that Duna Plaza shall retain the right, title
and interest to the Sold Center, while DPO owner shall be recorded as
the owner and holder of the right, title and interest in and to the
DPO. The liabilities of Duna Plaza shall be divided in such a manner
that Duna Plaza shall retain the liabilities associated with the Sold
Center, while DPO Owner shall assume the liabilities associated with
the DPO. PC shall indemnify Duna Plaza for the liabilities assumed by
DPO Owner.
All costs, liabilities and expenses incurred or to be incurred in
respect of and/or in connection with and/or pertaining to the
de-merger procedures or the implementation of the provisions of the
agreement thereof, shall be for the sole cost of PC.
During the period until the consummation of the de-merger procedures
("interim period") PC shall be entitled to all rental and other
revenues (excluding from the sale of utilities) which shall be
received by Duna Plaza from the DPO tenants, net after deducting the
aggregate amount of: (i) all those direct costs and expenses and taxes
which shall be incurred and/or disbursed by Duna Plaza which directly
relate to and/or connected with the ownership, operation and
management of the DPO; and (ii) that proportion of the general costs
and expenses taxes of the Duna Plaza Complex, which may reasonably be
attributed and apportioned to the DPO. During the Interim Period, PC
shall be responsible for and shall manage and operate the DPO. Duna
Plaza shall have a lien over DPO's funds, as security for payment of
the DPO costs. PC shall warrant and indemnify Klepierre for and
against any cost, debt, actions, suits and liability, that may arise
as a result of or in connection with the ownership, possession,
operation and transfer of the DPO.
Following the completion of the de-merger procedures PC shall be the
owner (100%) of the DPO equity rights.
Through the approval date of these financial statements the de-merger
process has not yet been completed.
(11) As for information regarding the acquisition of ownership rights in a
plot of land situated in Kerepesi Street in Budapest - see Note
9B.(3)e. above.
-57-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10 - REAL ESTATE AND OTHER FIXED ASSETS (CONT.)
C. IMPAIRMENT OF LONG-LIVED ASSETS:
(1) Repeated delays in the execution of infrastructure works by the
Belgian authorities in the vicinity of the hotel owned by a Belgian
subsidiary, which are beyond its control, are having an adverse effect
on the activity and the operation of the Aquatopia, which is located
in the hotel site. In light of these delays the Company deemed it
necessary to re-examine the book value of its investment in the
Aquatopia. As a result of this examination, the Company included in
its financial statements for 2005, a provision for the adjustment of
the value of the investment to its fair value, which amounts to NIS
9.5 million ($2.1 million).
(2) As part of the group's policy, project companies examine from time to
time, the maximization of the economic potential of rental areas in
the commercial and entertainment centers (under construction and
operating), and accordingly make (during construction or operation)
changes in the nature and/or classification and/or design of rental
and/or self-operated areas. These changes sometimes substitute
investments that were made during the course of construction of the
center and/or shortly after the commencement of its operation. In view
of the changes that are being implemented in or planned, certain
project companies deemed it necessary to reexamine the economic value
of some investments previously executed. As a result thereof and based
on management's experience in realization of Hungarian centers as
stated in Note 9B(3)a-b above and the ancillary proceedings, the
project companies included in their 2005 financial statements a
provision for loss, the Company's share in which amounts to NIS 5.5
million ($1.2 million).
D. ANNUAL DEPRECIATION RATES - see Note 2I above.
E. LIENS - see Note 17D below.
NOTE 11 - OTHER ASSETS AND DEFERRED EXPENSES
A. COMPOSITION:
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
COST
Acquired patent rights, distribution rights, technical
know-how and other intellectual property 31,022 26,863 6,740
Hotels' and/or commercial centers'
pre-opening expenses 9,316 20,048 2,024
Leisure and entertainment facilities operating rights 20,571 22,197 4,469
Cost of obtaining loans 12,124 31,324 2,634
Project initiation costs 3,066 3,242 666
Cost of obtaining long-term leases 8,734 19,177 1,897
Cost of long-term service contract 4,063 3,208 883
------ ------- ------
88,896 126,059 19,313
------ ------- ------
ACCUMULATED AMORTIZATION
Acquired patent rights, distribution rights, technical
know-how and other intellectual property 20,266 16,114 4,404
Hotels' and/or commercial centers'
pre-opening expenses 7,376 16,404 1,602
Leisure and entertainment facilities operating rights 20,571 22,197 4,469
Cost of obtaining loans 1,677 3,807 364
Cost of obtaining long-term leases 6,384 10,474 1,387
Cost of long-term service contract 2,146 1,204 466
------ ------- ------
58,420 70,200 12,692
------ ------- ------
AMORTIZED COST (NET BOOK VALUE) 30,476 55,859 6,621
====== ======= ======
-58-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
B. AMORTIZATION RATES - see Note 2J. above.
-59-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 12 - SHORT-TERM CREDITS
A. COMPOSITION:
DECEMBER 31
-----------------------------------------------------
2005 2005
---------------------------- REPORTED
INTEREST 2004 CONVENIENCE
RATE REPORTED REPORTED TRANSLATION
----------------- -------- -------- -----------
% (IN THOUSAND NIS) US$'000
Short-term bank Loans:
US dollars Libor+ 1.00-3.35 267,350 276,512 58,083
Euro Euribor+ 2.60-4.0 79,854 84,320 17,348
Euro 3.40 30,239 -- 6,569
Pounds sterling Libor+ 2.90 -- 1,394 --
NIS Prime+ 1.10 23,475 23,067 5,100
------- ------- ------
400,918 385,293 87,100
Current maturities (1) 59,352 151,644 12,894
------- ------- ------
460,270 536,937 99,994
======= ======= ======
(1) As to loans with long-term nature - see Note 14F., below.
B. LIENS - See Note 17D.
NOTE 13 - PAYABLES AND OTHER CREDIT BALANCES
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Government institutions 24,724 28,182 5,371
Wages and fringe benefits 29,730 23,289 6,459
Accrued interest payable 5,428 5,640 1,179
Prepaid income 16,946 16,768 3,682
CC Group companies 3,153 830 685
Deferred taxes -- 3,970 --
Deferred gain from realization of
commercial centers (Note 9B.(3)a, above) -- 40,021 --
Expenses accrued in connection with the
realization of commercial centers 4,336 -- 942
Advances in respect of land sale 515 6,310 112
Accrued expenses, commissions and others 65,163 58,436 14,156
------- ------- ------
149,995 183,446 32,586
======= ======= ======
-60-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 14 - LONG-TERM LIABILITIES
A. COMPOSITION:
DECEMBER 31
-----------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
--------- --------- -----------
(IN THOUSAND NIS) US$'000
LOANS -
From Banks and financial institutions 1,856,828 2,415,616 403,395
Less - current maturities (59,352) (151,644) (12,894)
--------- --------- -------
1,797,476 2,263,972 390,501
--------- --------- -------
CONVERTIBLE DEBENTURES (see G. below) -- 58,101 --
--------- --------- -------
OTHER LIABILITIES:
Deferred income taxes 39,928 31,522 8,674
Taxes on income - provision -- 7,022 --
Suppliers 26,355 14,579 5,725
Pre-paid rent income 31,335 11,470 6,809
Deferred gain from realization of
commercial centers (Note 9B.(3)a and
(b), above) 5,822 31,758 1,265
Accrued severance pay (*) 1,475 473 320
--------- --------- -------
104,915 96,824 22,793
--------- --------- -------
1,902,391 2,418,897 413,294
========= ========= =======
(*) See Note 15, below.
B. LINKAGE BASIS AND INTEREST RATES ON LOANS:
DECEMBER 31 2005
----------------------------------------------------
REPORTED
-------------------------------
CONVENIENCE
INTEREST RATES TRANSLATION
------------------ -----------
% (IN THOUSAND NIS) US$'000
Loans classified per currency:
Euro Euribor+ 1.50-3.35 717,598 155,899
Euro (*) 5.10 195,045 42,373
Pound sterling Libor+ 1.40-2.85 604,854 131,404
US dollar Libor+ 1.90-3.35 321,667 69,882
NIS Prime+ 2.20 13,161 2,859
South African rand Prime- 1.00 4,503 978
--------- -------
1,856,828 403,395
========= =======
(*) The interest on this loan is hedged by a Swap transaction - see Note 23A.
-61-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 14 - LONG-TERM LIABILITIES (CONT.)
C. REPAYMENT SCHEDULE:
DECEMBER 31, 2005
REPORTED
-------------------------------
CONVENIENCE
TRANSLATION
-----------
(IN THOUSAND NIS) US$'000
First year - current maturities 59,352 12,894
Second year 572,624 124,403
Third year 52,409 11,386
Fourth year 235,883 51,245
Fifth year 153,308 33,306
Sixth year and thereafter 783,252 170,161
--------- -------
1,856,828 403,395
========= =======
D. Loans obtained by the Company and EUN from an Israeli bank, totaling
NIS319.0 million ($69.3 million), will be repaid (principal and interest)
in equal semi-annual installments, through December 31, 2012. As part of
the agreement, an arrangement to accelerate repayment was established as
follows: (i) net amounts received by the Company and/or EUN, from public or
private offerings of securities of the Company (and/or of its subsidiaries
which were financed by the loan funds), as part of a business merger, as
the result of the realization of assets and/or investments, or as the
result of refinancing or any other receipt of capital by the Company
(and/or its subsidiaries, as above), will be used first to repay the loans;
(ii) net amounts so received from realization of the shares of PC or shares
of a Project Company (by means of sale or issuance to a third party) or the
sale of a project owned thereby (in full or part), will serve to repay part
of the loans (relative to the portion sold) that were received to finance
the investment in shares or projects realized, as the case may be; (iii)
part of the net amounts to be received from refinancing will be used
initially to repay the loans, as long as the total balance of the loans
exceeds $40.0 million.
Upon consummation of the transaction for the sale of the commercial and
entertainment centers, in July 2004, in April 2005 and in July 2005 and the
issuance of non convertible debentures (see Note 24A) by the Company in
February 2006, the Company and EUN are conducting negotiations with the
bank with the view of mutually rescheduling the rate and scope of
repayments and the other terms of credit. In the framework of re-examining
various terms contained in the loan agreements, the bank has informed the
Company that (i) repayment of the loans which the Company and EUN were
obliged to repay as a result of such sales of the commercial centers and
the debenture issuance, as stipulated in the loan agreements, is not yet
required; (ii) repayment of the short-term credit (principal and interest;
including current maturities of long-term banking credit), which the bank
had provided the Company with, and which repayment dates had fallen prior
to December 31, 2005, will not be required until January 1, 2007, with the
exception of credit in the amount of NIS 82.7 million (US$18.0 million),
which had accrued for payment, as abovestated and which would become due
and payable, upon the bank's demand, by January 1, 2007; (iii) the bank has
consented, subject to certain conditions, to the conversion of the linkage
currency of the entire (100%) balance of the loans provided to the Company,
from US Dollar to EURO, at the request of the Company and/or EUN.
Accordingly, the balance of the bank credits (with the exception of the
aforementioned NIS 82.7 million ($18.0 million)), was classified as
long-term loans.
In May 2005, the Company and EUN exercised their option to convert the
linkage currency from the dollar ($) into Euro (E), thus, an amount of
$56.0 million was converted into E45.2 million (NIS 246.2 million; $53.5
million) for a one-year period.
-62-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 14 - LONG-TERM LIABILITIES (CONT.)
E. In December 2005, Elscint reached a long term loan agreement with an
Israeli bank, which constitutes its principal lender, according to which
the bank has rescheduled the repayment of Elscint's outstanding loans at
that date (NIS 308.0 million; $66.9 million), for a period of up to 10
years. As part of the agreement, an arrangement to accelerate repayment was
established as follows: (i) net amounts received by Elscint, and/or by its
subsidiaries which were financed by the loan funds ("funded subsidiaries"),
from any public offering or private placement of its securities, as part of
a business merger, as the result of the realization (in whole or in part)
of assets and/or investments, or as the result of refinancing or any other
receipt of any distribution by Elscint (and/or by its funded subsidiaries),
will be used first to repay the loans; (ii) net amounts so received from
realization of the shares of B.H. or shares of a Target Company (by means
of sale or issuance to a third party) or the sale of a project owned
thereby (in full or part), will serve to repay the part of the loans
attributed to the project sold as the case may be. As for securities for
the loan - see Note 17D.(2) below. On March 3, 2006 Elscint paid to the
bank an amount of GBP 16.7 million (NIS 132.5 million; US$28.8 million) as
a result of refinancing loan provided to three hotels which were financed
by the loan funds- See Note 24B.
F. Within the framework of agreements for the receipt from Israeli banks of
long-term foreign currency credit facilities in an aggregate amount, in
which the Company's share totals NIS 212.8 million ($46.2 million), (for
the financing hotels and/or entertainment and commercial centers
construction), the companies owning the properties undertook in favor of
the banks to comply, throughout the duration of the credit, with certain
financial and operating covenants. Should such companies fail to comply
with all or any of such covenants, or upon the occurrence of certain events
as detailed in the agreements, the banks will then be entitled to demand
the immediate repayment of the loans. As of December 31, 2005, the
borrowers are yet to comply with certain covenants, which in the opinion of
the managements thereof do not affect their repayment ability (principal
and/or interest) to the banks on a regular basis and the actual repayments,
as aforesaid. The parties to the agreements follow the terms and conditions
provided therein in respect of the long term repayment schedule or in
accordance with the agreement with the bank, as the case may be. The
borrowers' managements are of the opinion, based on previous experience,
that the banks will not call for immediately repayment of the credit, as a
result of such temporary breaches. The Company's management believes
therefore that these loans are vested with a long-term nature. In addition,
the banks have informed the Company in writing as to their consent to
extend the term of the above-mentioned credit facilities until January 1,
2007.
G. Debentures (issued to the existing shareholders of Insightec) bear annual
interest at the rate of LIBOR + 3% (payable or accruable thereon containing
with the same terms as the principal amount, as per Insightec's sole
discretion; to be increased by an additional 2% upon an event of continuing
default for a period of 30 days as defined in the agreement and an
additional 3% upon an event of a second continuing default for a period of
30 days as defined in the agreement) and are repayable on September 2009.
The debentures (principal and interest, if relevant), are convertible at
any time (in whole or in part), into ordinary shares of Insightec (subject
to adjustments in certain instances), based on the lower of (i) a premoney
valuation of Insightec - $110.0 million ($7.3 per share); or (ii) at an 85%
of the next equity financing round price per share (as defined in the
investment agreement). In the event of a qualified IPO of Insightec shares
(as defined in the investment agreement) occurring after September 2007,
the debentures will automatically be converted into Insightec shares. The
debentures were recorded as per their net aggregate value after deducting
of the Company's share in the total investment - namely $7.5 million (NIS
34.5 million) (with GE's share being $7.5 million (NIS 34.5 million) and
that of MTA $6.0 million (NIS 27.6 million).
In accordance with opinion No. 53 of the ICPAI, as is in effect through the
end of 2005, convertible debentures issued by Insightec, are included in
these financial statements, as a quasi - equity item, since their
conversion became probable, based on conversion probability tests set forth
in this opinion (see Note 2x.(i) above, regarding the accounting method
that will be in effect as from January 1, 2006).
-63-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 14 - LONG-TERM LIABILITIES (CONT.)
H. In February 2, 2006 the Company's Board of Directors authorized a private
issuance of unsecured non-convertible debentures to investors in Israel in
a maximum aggregate principal amount of approximately NIS 630.0 million ($
136.8 million).
In February and in March 2006, the Company agreed with Israeli investors to
issue NIS 459.0 million ($99.7 million) aggregate principal amount of
unsecured non-convertible debentures, consisting of two series, to
investors in Israel. Series A Debentures, at the principal amount of NIS
400.0 million ($86.8 million), will bear interest at a rate of 6% per annum
and will be linked (principal and interest) to the increases in the Israeli
CPI. Series B Debentures, at the principal amount of NIS 59.0 million
($12.6 million) will bear interest at a rate of LIBOR plus 2.65% per annum,
and will be linked (principal and interest) to the U.S. dollar. The
principal amount of the Series A and Series B Debentures will be repayable
in 10 semi-annual equal installments commencing August 2009. The Series A
and Series B Debentures also provide that the debentures will be prepaid by
the Company at the option of the trustee or the holders of the debentures,
if the Company's securities are de-listed from trade on the Tel Aviv Stock
Exchange and on the Nasdaq National Market jointly.
The Company has undertaken to use its best efforts to register the two
series of debentures for trade on the Tel Aviv Stock Exchange ("TASE") no
later than August 30, 2006. So long as the debentures are not registered
for trade on the TASE the Company has undertaken: (i) to pay an additional
interest at an annual rate of 0.3%; (ii) not to make any distribution (as
defined in the Israeli Companies Law of 1999 - "the law") to its
shareholders which does not comply with the profit and solvency tests
provided in section 302(a) law, unless such distribution is approved at the
general meeting of holders of each series of debentures by a unanimous vote
of all holders participating in the vote; (iii) to prepay the debentures at
the option of the trustee or the holders of the debentures, upon the
occurrence of any of the following events: (a) the rating of the debentures
in Israel decreases below Baa2 (the equivalent rating of Tripple B) (b) the
holdings of EIL in the Company drop below 25% of the Company's issued share
capital. Such undertakings will be terminated upon the registration for
trade of the debentures on the TASE.
The total cost of obtaining these debentures expected to be approximately
NIS 3.1 million.
I. On March 2, 2006, Elscint through its jointly controlled subsidiaries which
hold three hotels in the UK ("Holding Companies"), entered into a refinance
loan agreement together with Park Plaza Hotels Europe Holdings BV ("Park
Plaza"), as joint and several borrowers ("Borrowers"), in which Elscint's
share in the loan amount to L97.5 million (NIS 774 million; $168
million)("Refinancing Loan").
The Refinancing Loan is repayable over five years with an option to
extended the term to seven years subject to fulfillment of certain
condition stipulated in the loan agreement, and bears interest at the rate
of Libor + 3%, which is hedged by a SWAP transaction to a fixed rate of
7.7% per annum.
In the event of cash distributions deriving from the sale, disposal or
refinancing of the hotels which were financed by the refinancing loan funds
or for any other reasons ("Transactions"), the Borrowers shall pay to the
financing bank an amount equivalent to 15% of the difference between the
market value of the hotels as determined in such Transactions and the
current agreed value of the hotels for the purposes of the Refinancing
Loan.
In addition, B.H. and Elscint have took upon themselves to irrevocably
indemnify Park Plaza for 50% of the cost and damages which will be incurred
by it in connection with the loan agreement. The Refinancing Loan funds
used first for the repayment of outstanding bank loans previously granted
to the Holding Companies in which Elscint's share amount to L60 million
(NIS 476 million; $104 million) The Holding Companies have transferred to
Elscint the surplus of the credit received amount to L30.6 million (NIS 243
million; $52.7million). As a result, Elscint will record in the first
quarter of 2006 a pre-tax gain from realization(repayment) of investment-
type monetary balances in investees in the amount of NIS 29.4($6.4
million).
The bank has been provided with a charge over the borrowers tangible fixed
assets and pledge over the borrowers' shares. In addition, the borrowers
have taken upon themselves to comply with financial and operational
covenants as specified in the loan agreement.
J. LIENS - see Note 17D.
-64-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 15 - ACCRUED SEVERANCE PAY
A. COMPOSITION:
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Provision for severance pay 3,816 2,841 829
----- ----- ---
Less - amounts deposited in the severance-pay fund 1,259 1,286 274
- Europe Israel (M.M.S.) Ltd. 1,082 1,082 235
----- ----- ---
2,341 2,368 509
----- ----- ---
1,475 473 320
===== ===== ===
B. IN ISRAEL:
The Group companies' liability to employees upon their retirement includes,
primarily, voluntary and/or involuntary termination severance payments as
well as adaptation grants. The liabilities are partially covered by
ordinary deposits to employees' accounts at accredited pension and
severance-pay funds and/or by acquiring insurance policies. Such deposits
are not under the custody or management of the Group companies and,
therefore, are not reflected in the balance sheet. Insightec reached an
agreement with its employees, according to which they would accept the
provisions of Section No.14 of the Severance Compensation Act, 1963
("Section 14"). Section 14 allows Insightec to make deposits in the
severance pay funds according to the employees' current salary. Such
deposits release Insightec from any further obligation with this regard.
The deposits made are available to the employee at the time when the
employer-employee relationship comes to end, regardless of cause of
termination. The balance of such payment obligations not covered by the
above-mentioned deposits and/or insurance policies is stated at the balance
sheet as a liability for employment termination. An amount equal to such
obligation is deposited on behalf of the respective companies in an
accredited severance-pay fund. The chairman's term of employment by EIL
shall be taken into consideration in calculating the period of his
employment by the Company, for all purposes. EIL undertook in terms of the
agreement to transfer to the Company's ownership all amounts deposited in
severance-pay funds, in order to cover all rights accumulated throughout
the period of the Chairman's employment with EIL. As of the financial
statements approval date, balances of NIS 0.9 million ($0.2 million) have
not yet been transferred to the Company.
C. ABROAD:
The obligations of foreign subsidiaries in respect of severance-pay to
their respective employees, in terms of the laws of their respective
countries of residence, and various valid labor agreements, are generally
covered by ordinary payments executed to that end to governmental
institutions, as well as by current payments to insurance companies for
pension benefits and by the balance-sheet accrual.
-65-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES
A. COMPOSITION:
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Current 1,847 3,495 942 401
Deferred 607 12,516 (29,580) 132
In respect of prior years 5,344 (207) 8,421 1,161
----- ------ ------- -----
7,798 15,804 (20,217) 1,694
===== ====== ======= =====
B. PRINCIPLE TAX LAWS APPLICABLE TO THE MAJOR GROUP COMPANIES IN THEIR COUNTRY
OF RESIDENCE:
(1) ISRAEL
A. The Company and its Israeli subsidiaries are subject to income
tax under the provisions of the Income Tax Law (Inflationary
Adjustments), 1985, which introduced the concept of measuring
results for tax purposes on a real basis. Corporate tax rate
applicable to companies in Israel in 2005 is 34% which will
gradually decrease from 31% in 2006 through 25% in 2010.
B. As from January 1, 2003, certain statutory provisions came into
force and effect, concerning, among other things, the tax reform
in Israel in respect of the following:
1. (a) Taxation of profits of foreign companies considered as
Controlled Foreign Companies ("CFC"), if: (i) majority
of revenues thereof are passive, as same is defined by
law, or majority of profits thereof derive from passive
revenues; (ii) the tax rate applying to the passive
profits thereof in their country of residence does not
exceed 20%; and (iii) over 50% of the means of control
therein are held, directly or indirectly, by Israeli
residents. In accordance with the statutory provisions,
a controlling shareholder in those companies having
unpaid profits, as same is defined by law, is deemed to
have been distributed with a dividend representing its
respective share in such profits (hereinafter:
"notional dividend"). A notional dividend, will be
subject to a 25% tax rate, less withholding taxes which
would have been paid abroad in respect of such
dividend, had it in fact been distributed.
(b) Taxation at a rate of 25% of a dividend received in
Israel, out of profits generated or accrued abroad, as
well as a dividend originating abroad.
Each Israeli assessee has the right to elect, at his sole
discretion, to be assessed according to the Israeli
corporate tax rate less taxes actually paid abroad in
respect of such profits.
2. Capital gain tax from the realization of assets at a reduced
rate of 25%. The reduced rate is to apply to realization of
assets, which were acquired after January 1, 2003 and
thereafter, and will be calculated for the portion of the
gain relating to the period subsequent to this date through
realization.
-66-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
3. Method of loss offsetting - regarding business losses,
capital losses, passive losses and CFC losses.
-67-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES (CONT.)
B. PRINCIPLE TAX LAWS APPLICABLE TO THE MAJOR GROUP COMPANIES IN THEIR COUNTRY
OF RESIDENCE (CONT.):
(1) ISRAEL (CONT.)
C. During 2004, the Company, EIL and Elscint have finalized an
arrangement with the Israeli Tax Authorities, with effect from
December 31, 2002, whereby a new tax basis has been determined
for the Company's investments (on a consolidated basis) in
foreign subsidiaries ("regulated revaluation" and "regulated
assets"). The arrangement provides for no additional tax to be
imposed in Israel on gains generated from the realization of
regulated assets, and on dividends distributed therefrom, and all
up to the amount of the regulated revaluation. Provision for
those tax payments under the arrangement has been recorded in the
company's statement of operations for the years 2002 through
2004, under the tax expenses for previous years' item. Taxes
which relate to capital reserves from foreign currency
translation adjustments deriving from the regulated profits were
charged to said capital reserves.
D. Insightec's enterprise was granted the status of "approved
enterprise" ("AE") pursuant to the Law for the Encouragement of
Capital Investments - 1959 ("the Law"), in respect of an
investment (which has been completed, through December 31, 2005),
of $0.4 million (NIS 1.8 million). This law provides for
tax-exemption on undistributed income generated from the AE for a
period of two years commencing the first year in which the AE has
taxable income, and provides also for a reduced tax rate (25%)
for the remaining five-year period. As at December 31, 2005, the
benefit period had not yet commenced. Insightec has received, in
Jaunary 2004, an approval for its $0.2 million (NIS 0.9 million)
expansion plan, to its existing enterprise.
Insightec's benefit period is eligible for an increase from 7 to
a 10-year period, in the event the investment therein, of foreign
residents (as defined by Law) exceeds 25%. In the event such
foreign residents' investment exceeds 49%, then the tax rate may
decrease from a 25% rate to 10%-20%, depending on the level of
ownership by non-Israeli investors, in each relevant taxable
year.
The period of benefits to these AE are limited to the earlier of
12 years from the commencement of production or 14 years
following receipt of the approval document. Scope of benefit is
determined by the ratio of the additional sales revenues during
each benefited period over the sales revenue in the entire last
year of production prior to the activation of each program
(adjusted for the change in the wholesale-price index of the
industrial output), divided by the total sales revenues in each
of the tax-benefit years.
The benefits as abovementioned are subject to fulfillment of the
conditions stipulated in the Law, the regulations promulgated
thereunder and the criteria set forth in the certificates of
approval. Failure to meet those conditions may lead to the
termination of the benefits and trigger a demand for
reimbursement of the amounts received (in whole or in part), with
the addition of interest and linkage difference. Change in the
ownership structure of a company owning an AE, including a public
offering of over 49% or any private placement during the period
of execution of the approved investment program through the end
of execution of the period of benefits, is subject to the advance
approval by the Investment Center.
In the event of a distribution of tax-exempt earnings, as noted,
in the form of a dividend, the distributing company would be
subject to tax of up to 25%, while the distribution of earnings
of an AE as dividends would be taxable to the recipient at an
additional rate of 15% (for a period of 12 years from the end of
the benefit period).
-68-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES (CONT.)
B. PRINCIPLE TAX LAWS APPLICABLE TO THE MAJOR GROUP COMPANIES IN THEIR COUNTRY
OF RESIDENCE (CONT.):
(2) USA
A. US tax laws set limitations on the utilization of carry-forward
tax losses in companies that have undergone a material change in
ownership. Accordingly, should the transfer of the Company's
shares to EIL (in 1999) be defined as a material change in
ownership of Elscint, then the ability to utilize the accumulated
tax-losses of a US subsidiary against future income will be
considerably limited. Management is of the opinion that there
will be no limitation to the utilization of the carry - forward
losses. As of December 31, 2005 the accumulated carry-forward
losses utilized against current profits amount to approximately
$6.9 million (NIS 31.7 million). No deferred income tax assets
have been recorded in respect of the unutilized balance of the
carry-forward losses.
B. A non-US company may (under certain conditions) be deemed for US
income tax purposes as a Passive Foreign Investment Company
("PFIC") on the basis of an "income test" and an "assets test",
as determined by the IRS. Once so defined, the US shareholders
may be subject to additional taxes upon the distribution of
earnings or assets and/or upon their realization of their
holdings in such a defined company. Following the sale of the
Company's and Elscint's activities and due to their entry into
other areas of activity, the management of the Company believes -
based on advice received for this matter - that in light of
existing indicators they may not - under the circumstances - be
considered as a PFIC. Nevertheless, there is no certainty that
the companies' position would prevail with the IRS.
(3) THE NETHERLANDS
A. Corporate tax applicable to companies incorporated in the
Netherlands is 31.5% and shall gradually decrease to 30.0% in
2007.
B. Under the "Participation Exemption", a dividend received by a
Dutch company in respect of an investment in shares of other
companies, is exempt from corporate tax in Holland. Any profit
(positive and negative) with regard to qualified participation
exemption, is exempt from corporate income tax, subject to the
fulfillment of certain conditions stipulated in the law
(including the holding percentage, the nature of activities of
the holding and the investee company, etc.). Dividends
distributed from the Netherlands to Israel are subject to 5%
withholding tax when, among others, the shareholder owns at least
25% of the shares of the subsidiary. In other situations, 15%
withholding tax will be due.
(4) ENGLAND
A. Operating income and capital gains generated by the British
resident group companies are subject to a 30% tax rate. Dividends
received from a U.K. resident company are taxed in accordance
with the jurisdiction of the Company receiving the dividend (in
the Netherlands - tax exempt); No tax credits are allowed for
distributed dividends.
B. Net rental income from real estate held as an investment and let
in the U.K. by companies not resident in the U.K., are charged to
U.K. income tax at 22%. Any gains on disposal are not taxable in
the U.K.
-69-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES (CONT.)
B. PRINCIPLE TAX LAWS APPLICABLE TO THE MAJOR GROUP COMPANIES IN THEIR COUNTRY
OF RESIDENCE (CONT.):
(5) ROMANIA
Through December 31, 2004, the corporate income tax rate for resident
companies and non-resident entities with a permanent establishment in
Romania is 25% (including capital gains). Commencing 2005, the tax
rate has been reduced to 16%. Dividends paid to resident and
non-resident corporations are subject to a final withholding tax of
15% (commencing 2006 - 16%), unless lower double taxation treaty rates
apply. Losses may be offset against taxable income for a period of
five years from the incurrence year-end.
(6) HUNGARY
The corporate tax applicable to the income of Hungarian subsidiaries
(including capital gains) is 16%. Dividends paid out of these profits
are taxed at an additional 20%, subject to any respective double
taxation treaty. Through December 31, 2003 a 5% withholding tax
applied to the distribution of dividends from Hungary to the
Netherlands. As and from May 2004 such distributions are exempt from
withholding tax. Losses incurred as and from the fourth year of the
entity's operations may be offset against taxable income for a period
of 5 years, subject to compliance with a turnover expenses ratio, in
accordance with the income tax regulations. Losses incurred during the
first three years of operation may be offset indefinitely. Losses
incurred from 2004 may be offset indefinitely.
(7) POLAND
The corporate tax applicable to income of Polish subsidiaries
(including capital gains) is 19%. Dividends paid out of these profits
are subject to an additional (final) tax rate of 20%, subject to the
relevant double taxation treaty. Through December 31, 2003 a 5%
withholding tax applied to the distribution of dividends from Poland
to the Netherlands. As from May 2004 through December 2004 such a
distribution will be exempt from withholding tax. Losses may be offset
against taxable income over a 5 year period, subject to a maximum
annual utilization of up to 50% of the accumulated loss.
-70-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES (CONT.)
C. EFFECTIVE TAX RATE:
The following is a reconciliation between the income tax expense computed
on the pretax income at the ordinary tax rates ("the theoretical tax") and
the tax amount included in the consolidated statement of operations:
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Company's statutory tax rate (%) 34 35 36 34
======= ======= ======= =======
Income (loss) before income taxes -
per statement of operations 16,159 24,893 (193,042) 3,510
======= ======= ======= =======
The theoretical tax 5,494 8,712 (69,495) 1,194
Differences in tax burden in respect of:
Utilization of prior-year losses for which deferred taxes
had not previously been recorded (49,556) (25,213) (19,753) (10,766)
Losses and other timing differences for which deferred
taxes had not been created 102,066 77,764 70,124 22,174
Variances from different measurement principles applied
for the financial statements and those applied for
income tax purposes (including exchange differences) (24,943) (15,763) (17,204) (5,419)
Differences in tax rates on income of foreign subsidiaries 4,442 (11,143) 7,370 965
Adjustment due to changes in tax rate 728 (1,992) (8,709) 158
The Company's share in results of associated companies 4,089 5,589 7,542 888
Taxes for prior years 5,344 (207) 8,421 1,161
Other differences, net (1) (39,866) (21,943) 1,487 (8,661)
------- ------- ------- -------
7,798 15,804 (20,217) 1,694
======= ======= ======= =======
(1) Mainly tax-exempt income and non-deductible expenses.
-71-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES (CONT.)
D. CARRYFORWARD LOSSES AND DEDUCTIONS:
As of December 31, 2005 the Group companies had accumulated tax losses and
deductions amounting to NIS 384.3 million ($83.5 million), which may be
utilized in the coming years against taxable income at rates ranging from
16% to 34% depending on the country of residence. The realization of the
carryforward losses is subject to taxable income available in those periods
when these losses are deductible.
Hungarian, Polish and Romanian tax laws have set a time limitation on the
utilization of losses (see B.(5) to (7) above). Accordingly, the right to
utilize carryforward losses in the amount of NIS 70.4 million ($15.3
million), against taxable income, will gradually expire over the following
years:
DECEMBER 31, 2005
REPORTED
-------------------------------
CONVENIENCE
TRANSLATION
-----------
(IN THOUSAND NIS) US$'000
2006 28,747 6,245
2007 7,636 1,659
2008 11,498 2,498
2009 12,282 2,668
2010 10,256 2,228
------ ------
70,419 15,298
====== ======
Computation of said carryforward taxable losses includes Insightec's losses
in an aggregate amount of NIS 220.8 million ($48.0 million). Insightec's
management estimates that its income, throughout the utilization period of
said losses, will be tax-exempt, hence no tax benefits are expected in
respect of these losses, in the foreseeable future. As to the limitation on
utilizing Insightec's losses as a result of a merger pursuant to section
103 of the Income Tax Ordinance, at the amount of NIS 105.8 million ($23.0
million) - see Note 9B.(2)g., above.
E. DEFERRED TAXES IN RESPECT OF NON-MONETARY ASSETS:
Deferred taxes, not recorded in respect of net book value of assets which
were aquired through December 31, 2004 and for which depreciation is not
deductible for tax purposes (for which it was determined not to record
deferred income taxes), amounted as at December 31, 2005, to approximately
NIS 19.1 million ($4.2 million).
-72-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 16 - INCOME TAXES (CONT.)
F. DEFERRED INCOME TAXES:
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
Accelerated depreciation differences in respect of fixed assets 21,602 1,779 4,693
Difference between fair value of real estate at acquisition and
related cost for income tax purposes 14,094 8,786 3,062
Timing differences - income and expenses (6,860) (12,665) (1,490)
Carryforward tax losses and deductions (212,056) (353,040) (46,069)
-------- -------- -------
(183,220) (355,140) (39,804)
Valuation allowance 216,792 384,528 47,097
-------- -------- -------
Total (*) 33,572 29,388 7,293
======== ======== =======
(*) Presented among:
Long-term liabilities 39,928 31,522 8,674
Short-term liabilities -- 3,970 --
Long-term receivables (6,356) (6,104) (1,381)
-------- -------- -------
33,572 29,388 7,293
======== ======== =======
G. FINAL TAX ASSESSMENTS:
The Company, Elscint and certain Israeli subsidiaries have received final
tax assessments, part of them through 1998 - 1999 and others - through
2003. Certain foreign group companies have received final tax assessments
for the years through 1999 while others have not been assessed since
incorporation. See in addition - Note 17C.(5), below.
In 2005 the Company and Elscint (each of them separately) agreed with the
Israeli Tax Authorities on final tax assessments for the years 1999 through
2002 (the Company - through 2003), the outcome of which has resulted in (i)
an aggregate decrease in the carry forward losses, in the amount of NIS
267.0 million ($58.0 million), in respect of which a full valuation
allowance was previously recorded; (ii) an amount of NIS 35.0 million
business lossess which were changed into capital losses; and (iii) an
additional payment by Elscint of NIS 5.0 million ($1.1 million) for which a
provision has been previously recorded.
-73-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS
A. COMMITMENTS
(1) A. The Company's hotels (located in the Netherlands, Belgium and
England) are managed by Park Plaza Hotel Europe B.V. (the
"Management Company"), in consideration for an annual fee of 2%
of the room revenue (the "Base fee") as well as 7% of the gross
operating profit (the "Incentive fee") as defined in the
agreements. The companies also participate in certain portions of
the expenses incurred by the Management Company in the course of
performance of its due obligations, up to 3% of the gross
operating profit. Upon a sale of any hotel or the transfer of
control therein to a third party, the companies owning the
respective hotel are obliged to pay to the Management Company an
amount equal to the Base fee, the Incentive fee and the Franchise
fee (see sub-section b. below) paid to the Management Company in
the 12 months period preceding such sale or transfer. In the
specific event of a sale of the Victoria Hotel in Amsterdam, then
the Management Company shall also be entitled to receive 2.5% of
any profit generated from such a sale.
The Management Company is vested with ownership rights at a rate
of 5% or 10% (excluding voting rights), as the case may be, in
several corporations which are held by B.H. jointly with Red Sea
Hotels Group ("RSG").
B. Within the terms of the management agreements, B.H. Group
companies ("the Companies") were granted a sub-franchise by the
Management Company allowing them the utilization, throughout the
term of the management agreements, of the "Park Plaza" name, in
relation to the hotels owned and operated thereby, in
consideration for royalties not exceeding 1.5% of the room
revenues (the "Franchise fee").
C. Two Group companies have agreed with the Rezidor group, on the
future management of two hotels, currently under construction
and/or renovation (the National Ballet Building in Hungary, that
is intended to operate under the "Regent" brand name and the
Bucuresti hotel in Bucharest that is planned to operate under the
brand name "Radisson SAS"). The 20 year management period shall
commence once construction and/or renovation is completed. The
managing company undertook within the framework of the management
agreements, to guarantee that the adjusted operating income will
not decrease below a fixed annual amount, as stipulated in the
agreements. The total aggregate amount of the guarantee will not,
however, exceed, cumulatively during the term of the agreements,
those amounts as stipulated in the agreements. Under the
management agreement relating to the Bucharest hotel, the hotel
owning company has undertaken to ensure that the aggregate of the
fees payable to the operator (base fees and incentive fees) shall
not be less than certain agreed amounts as specified in the
management agreement, provided that the owning company's
obligation in this regard is capped at a total agreed amount.
(2) B.H. was granted an option exercisable until December 31, 2006, to
purchase from the Management Company, 33% of the latter's' ownership
and control rights in a company owned thereby, incorporated with the
view to acquire the businesses (including tangible assets, hotel
management agreements, management rights, rights to use trade names,
etc.) of the Park Plaza chain in Europe (the "Acquired Company"). B.H.
has granted the Management Company a loan, under the terms of the
agreement, of $5.0 million (NIS 23.0 million) (see Note 8A.(2),
above). The scope of B.H.'s investment may increase by $2.25 million
(NIS 10.4 million), if, and to the extent such amount is required to
finance acquisition of additional assets by the Acquired Company. The
Management Company has an option, exercisable, in the event
disagreements arise between the parties as to the Management Company's
rights, to acquire, at any time, the B.H. shares, in consideration for
an amount equal to the cost of B.H.'s original investment.
-74-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
A. COMMITMENTS (CONT.)
(3) The Company and/or its subsidiaries are bound by the following
agreements, with Control Centers Ltd. ("CC") and/or companies
controlled thereby:
A. A framework agreement to provide coordination, planning and
supervision services over projects for the construction of
commercial centers, the initiation of which began during the term
of the agreement (through December 31, 2002), in consideration
for 5% of the actual costs of execution of each project
(excluding land acquisition costs, general and administrative
expenses and financing costs), payable according to milestones
stipulated in the specific agreement for each project.
Additionally, CC will be entitled to reimbursement of reasonable
expenses directly incurred thereby for fees of external
consultants required for the provision of the services and the
like, at an amount not to exceed $50,000 per project.
B. An agreement with Jet Link Ltd., (a company controlled by CC) for
the provision of aviation services, (up to 150 flight hours per
annum) for the operations, in connection with projects abroad, in
consideration for payment calculated on the basis of the price
list of Jet Link Ltd., net of a 5% discount.
(4) In 2005 Insightec entered into a worldwide distribution and sale
representation agreement with GE Healthcare (a part of GE group),
granting GE Healthcare the exclusive worldwide distribution rights to
market and promote Insightec's product subject to the achievement of
minimum sales targets, except in territories where Insightec already
has existing distributors and representatives. Subject to the terms of
the agreement, in consideration of the services rendered, Insightec
shall pay to GE Healthcare a commission as a share from the net sales
invoiced and actual payments received by Insightec for each order for
the sale of products from an end-user in the Territory, resulting from
GE Healthcare's activities. Insightec retains the right to promote,
market and sell its products to end-users directly, through its
employees. The agreement is for five years, effective immediately,
unless earlier terminated in accordance with the terms of the
agreement. Thereafter the agreement shall automatically renew for an
additional one year, unless either party provides a written notice of
its intent to terminate the agreement.
Insightec was commited to pay MTA (a shareholder thereof) a success
fee commission of 2% of the value of any signed purchase order, for
which MTA was involved. In March 2006 Insightec notified MTA that it
is terminating the agreement.
(5) Insightec is obliged to pay royalties to the Israeli Office of the
Chief Scientist ("OCS") - in respect of products, in the development
of which the OCS has participated, by way of grants - at a rate of 3%
of revenues, for the first three years from the date of the first
repayment and 3.5% of revenues beginning the fourth year therefrom and
up to the amount of the grants received. Total grants received through
December 31, 2005, net of royalties paid or occurred, amount to $11.0
million (NIS 50.6 million), see also D(7), below.
(6) In accordance with an agreement between Bucuresti and Control Centers'
wholly owned subsidiary ("CCS"), which was approved at the
shareholders' meeting of Elscint., CCS is to provide coordination,
planning and supervision services with respect to the renovation works
of the Bucuresti Hotel complex, for a fee equal to the lower of (i) 5%
of total actual costs of the renovation works (excluding general and
administrative as well as financing costs); and (ii) 5% of $30
million. The parties are yet to execute a definitive agreement.
-75-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
A. COMMITMENTS (CONT.)
(7) A subsidiary incorporated in Praha, Czech Rep. ("Bestes") is a party
to an agreement with a third party ("the lessee"), for the lease of
commercial areas in a center constructed on property owned thereby,
for a period of 30 years, with an option to extend the lease period by
additional 30 years, in consideration for E6.9 million (NIS 37.6
million; $8.2 million). Through December 31, 2005 Bestes received on
account an amount of E4.5 million (NIS 24.4 million; $5.3
million). According to the lease agreement, the lessee has the right
to terminate the lease subject to fulfillment of certain conditions as
stipulated in the agreement.
(8) In 2001, the "Elezra Group" won the right to purchase, through
privatization, the shares of the state owned Afridar - Ashkelon
Housing and Development Ltd. ("Afridar"). The Elezra Group consists of
Elezra Developments and Investments Ltd. ("Elezra") and Elbit Medical
Holdings Ltd. - a subsidiary of the Company ("Elbit Holdings"), as
well as the Company and Mr. Eli Elezra as an interested party
(altogether: the "Group"). Immediately following the win of the right,
the members of the Group signed a principle-agreement so as to
regulate and govern the relations thereby, according to which Elezra
would bear the entire acquisition costs of the Afridar shares (NIS 80
million), while the Company and/or Elbit Holdings would hold the
Afridar shares, which would be registered in their name, in trust for
Elezra.
Transfer of the shares among the members of the Group is subject to
the approval of the Israeli Governmental Companies Authority ("IGCA").
In the absence of such approval, the Company and/or Elbit Holdings
will remain the owners of the Afridar shares until such time that the
restriction on transfer thereof is lifted. Elbit Holdings and Elezra
would remain, under such circumstance, jointly and severally, liable
to IGCA as well as to the State of Israel for all undertakings
applicable to purchasers of Afridar shares. The sale of control in and
to Afridar (directly or indirectly) is contingent on the assignment to
the purchaser of all seller's obligations in favor of IGCA, all as
stipulated in the agreement. Elezra undertook to indemnify the Company
and/or Elbit Holdings for any expense and/or damage and/or claim
and/or loss and/or payment demand and/or any other expense incurred by
the Company and/or Elbit Holdings in connection with the acquisition
of the Afridar shares, the holding of same in trust, transfer thereof
by and between the parties and the abovementioned principle-agreement.
As of the date of approval of these financial statements, the rights
in and to Afridar, had not been assigned. Company's management
estimates that it is not exposed to any costs and/or damage in respect
of these holdings.
(9) Currency transactions - see Note 23A, below.
(10) Minimum future rental payments due under the Company's current
operating leases (see Note 10B. above) as of December 31, 2005 are as
follows:
REPORTED
-------------------------------
CONVENIENCE
YEAR ENDED DECEMBER 31, TRANSLATION
- ----------------------- -----------
(IN THOUSAND NIS) US$'000
2006 12,714 2,762
2007 14,125 3,069
2008 11,586 2,517
2009 10,521 2,286
2010 10,521 2,286
Thereafter 666,899 144,884
------- -------
726,366 157,804
======= =======
-76-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
A. COMMITMENTS (CONT.)
(11) Aggregate amount of commitments in respect of construction services
totaled, as of December 31, 2005, approximately NIS 235 million ($51.1
million).
(12) PC is a party to an agreement with third parties, for the provision of
manpower, management, supervisory and logistical services, in exchange
for a payment of a certain commission.
(13) Mango is a party to distribution, support and service agreements with
third party for a 10-year period, subject to fulfillment of certain
conditions, which entitled it to market the brand name MANGO-MNG(TM)
in the territory of Israel. In the framework of the agreements Mango
has furnished the third party with a bank guarantee in the amount of
E1.4 million (NIS 7.6 million; $1.7 million) in order to secure
payments to the third party under the agreements.
B. CLAIMS
(1) In November 1999, a number of institutional and other investors,
holding shares in Elscint, filed a lawsuit in the Haifa District Court
against the Company, Elscint, EIL, Control Centers and others. The
plaintiffs also requested the certification of their claim as a class
action suit on behalf of all those who had held Elscint shares on
September 6, 1999, and continued to do so as at the filing date of the
suit (excluding the Company and certain other shareholders). The claim
alleges discrimination against Elscint's minority shareholders arising
from various transactions or activities carried out by its controlling
shareholders and directors, which allegedly caused them financial
loss, manifested by the 45% ($100.0 million) decline in the value of
Elscint's shares in the period from February 24, 1999 to the claim's
filing date.
The principal remedy requested in the claim is a court order
instructing the Company to carry out a tender offer of Elscint's
shares at $14.0 per share as the former allegedly undertook, in its
letter to Elscint of February 1999, or alternatively, to purchase the
shares in their possession, at a price to be determined by the Court.
As another alternative, the plaintiffs requested the court to issue an
injunction prohibiting execution of the September 9, 1999 transactions
(acquisition of the hotel operations and the Arena commercial center
in the Herzliya Marina, by Elscint, from EIL and Control Centers,
respectively) and the refund of all and any amounts paid thereunder.
Part of the remedies were requested as a derivative claim on behalf of
Elscint.
Although the Haifa District Court has rejected the class-action
request, it was ruled that the plaintiffs may, notwithstanding so
rejecting the request for class action proceedings, pursue their
matter. In November 2001, the plaintiffs were granted leave to appeal
to the Supreme Court regarding the Court decision. The Company and the
plaintiffs presented their respective pleadings. As of the date of
approval of these financial statements, the Court has not yet rendered
its decision in the motion for leave to appeal.
Managements of the Company believes - based, inter alia, on legal
opinions - that the final outcome of this case cannot at this stage,
be estimated.
-77-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
B. CLAIMS (CONT.)
(2) The Company, Elscint and others were served with a claim as well as a
motion to recognize same as a class-action, in respect of $158.0
million (NIS 727.3 million) damage allegedly caused to the represented
class. Underlying the claim is the contention that the Company,
through Elscint's board of directors, caused damage to and
discriminated against minority shareholders of Elscint. Both parties
agreed to postpone the hearing in this case until the Supreme Court
hands down a decision on the leave to appeal, as detailed in section
(1) above. Management, based on legal advice, is of the opinion that
it is not possible at this stage to estimate the outcome of the claim
and the motion for class-action recognition.
(3) Elscint and its subsidiaries are parties to several court claims as
well as certain other written demands, filed against them by third
parties (including governmental institutions), some without any
specified amount, and others in the aggregate amount of $41.6 million
(NIS 191.5 million), as royalties or compensation for damages
allegedly caused as a result of the companies' actions and/or
products, which mainly relate to the medical imaging business sold and
Elscint in 1998 and 1999. In respect of certain claims, totaling
approximately $5.8 million (NIS 26.7 million), managements of the
companies estimate, based on legal opinion and/or on past experience,
that no significant costs will accrue thereto as a result of said
claims exceeding the provisions included in respect thereof in the
financial statements, and that such provisions are adequate for
covering the costs and resources required to settle the liabilities
arising therefrom. Elscint's legal advisers cannot presently determine
the outcome of other written demands, totaling $35.8 million (NIS
164.8 million). Elscint's management believes that the prospects for
realization of most such written demands are remote, based on the time
that has elapsed since serving said demand and on the nature thereof.
The companies have included in their financial statements provisions
that are, as per their discretion based inter alia on specific
counsels and past experience, adequate to cover the costs and
resources required to settle the liabilities under these written
claims.
(4) A. A criminal investigation carried out against a number of suspects
(including former officers in SOF who were involved in the
privatization procedures and the sale of control in the Bucuresti
Hotel to Domino) for certain events relating to the period prior
to the acquisition of control in Bucuresti by B.H. culminated in
the filing of an indictment against 17 accused. Such criminal
proceedings may have an indirect effect on the validity of the
privatization and thereby an indirect effect on Domino's rights
in Bucuresti, notwithstanding Domino not being an accused party
under the indictment. On December 22, 2005, the Court has decided
to return the indictment to the Prosecution Office for its
resubmission. This ruling is definitive and the file is not
longer pending in front of Romania Courts of Justice. Domino
estimates, based on the advice of legal counsel, that the
prospects of these proceedings having a material affect on its
rights in the Bucuresti shares are remote.
B. A former shareholder in Domino had terminated a partnership
agreement with a third party ("the Plaintiff") regarding the
joint investment thereof, in Domino, prior to its acquisition by
B.H.. Termination was on the grounds of non-compliance by the
Plaintiff with material obligations under the partnership
agreement. The Plaintiff has filed, as a result, a monetary claim
to the Romanian courts against Domino and other defendants,
claiming; (i) an amount of $2.5 million, for commissions
allegedly due to the Plaintiff in terms of the partnership
agreement, (to which Domino was a party), pertaining to the
tender which allowed the acquisition of control in Bucuresti; and
(ii) the termination of an agreement with an Israeli bank within
the framework of which the shares of Domino in Bucuresti were
pledged in favor of such bank, as security for the repayment of a
loan granted to Domino for the acquisition of such shares. Such
former Shareholder provided
-78-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
B.H. with an indemnity against these claims.
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
B. CLAIMS (CONT.)
(4) (CONT.)
b. (cont.)
At the hearing on March 23, 2005 the Court suspended the file due
to the fact that the Plantiff failed to fulfill his procedural
obligations established by the court at the previous hearing. On
December 8, 2005 the Court decided to erase this case from the
Court's registry on the ground that the plaintiff took no action
during the six months term foreseen by the Romanian law.
C. In the framework of an agreement to establish a joint company
owned by Bucuresti and a third party, which was signed prior to
the acquisition of Bucuresti by B.H., such third party undertook
to invest $27.0 million (NIS 124.3 million) in the joint company
and in consideration Bucuresti undertook to transfer its rights
in the Bucuresti Complex to the ownership of the joint company.
As a result of the third party's failure to meet its obligations
thereunder, Bucuresti has terminated the partnership agreement
and filed an application to the Court to liquidate the joint
company. This application was approved by the Court. The third
party has submitted an appeal to the Supreme Court. On September
3, 2005, the Supreme Court irrevocably rejected this appeal.
Accordingly, there is no risk that Bucuresti will be forced to
transfer its rights in the Bucuresti Complex to the joint
company.
D. Two claims are pending against Bucuresti, which challenge its
ownership in and to its properties. Both claims are pending on
the Bucharest Court of Appeals. Management believes, based
inter-alia, on Legal opinion that Bucuresti is expected to win
those claims.
E. In mid 2005 certain individuals submitted their final appeal to
the Supreme Court requesting the nullification of the public
tender for the sale of the Bucuresti shares, the privatization
contract and the transfer of the Bucuresti shares to Domino. This
case was ruled in favor of Domino in the previous procedural
stages (first instance and appeal) on technicalities, since the
application for the cancellation of the privatization contract
was served after the three months term during which any
interested person could file an application for the cancellation
of the privatization. The Company expects - based, inter alia, on
legal opinion - that Domino will win this case. Notwithstanding
in the event that the Supreme Court will rule in favor of the
plaintiffs, the privatization contract will be cancelled with the
effect of restitution in integrum.
F. In addition to the above, certain legal proceedings are being
conducted from time to time in Romania within the framework of
which it is claimed that resolutions passed at the general
meetings of shareholders of Bucuresti, were not validly adopted -
for procedural reasons only - hence not binding. Some were
approved by the Courts, in respect of which Domino has filed
appeals, and others were rejected.
B.H.'s management is of the opinion that the claims are
provocative and tendentious and will not significantly affect
B.H.'s rights in the shares of Bucuresti and in the Bucuresti
Complex, owned thereby.
-79-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
B. CLAIMS (CONT.)
(5) Elscint was served, in 2003, with a motion filed by a third party
seeking an injunction to prohibit Elscint from using the trade name
"Arena" for the entertainment and commercial center in the Herzliya
Marina in Israel, on the grounds of unlawful usage of same,
exploitation of goodwill and unfair competition. In the event the
plaintiff's contention is upheld, Elscint may suffer certain indirect
losses and costs. An application for an interim injunction,
prohibiting the use of the trade name "Arena," was dismissed by the
court. On March 20, 2006 the judge dismissed the lawsuit against the
Company. The Plaintiff has the right appeal the courts decision up to
April 27, 2006.
(6) Elscint is a formal party to a claim filed by a number of employees,
holding shares of Algotech (sold to a third party in November 2003),
against the majority shareholder in Algotech, in the framework of
which the Court issued an injunction precluding the transfer of funds
from Algotech to that shareholder. No remedies were requested against
Elscint and the injunction does not affect the transfer of title to
funds which are received as proceeds of the sale. The Company's
management estimates that the said claim will not affect its assets.
(7) In March 2005, an action (hereinafter: "the "Action") was instituted
at the Regional Labor Court in Tel-Aviv-Jaffa by an employee of the
EIL group (hereinafter: the "Plaintiff") against Mr. Mordechai Zisser
(Chairman of the Company's board of directors), Control Centers and
Vectory Investments Company Ltd. (controlling shareholders of the
Company), in terms of which, the Court was requested to issue a
declaratory order establishing the Plaintiff's entitlement to 14% of
the shares of the companies specified in the statement of claim -
including: shares of the Company, Elscint, Insightec, Gamida, Olive,
E.R. and Vcon (see Note 9 above) - which are directly or indirectly,
owned and/or controlled by the defendants and/or by companies under
control thereof. The Court was further requested to order the transfer
of such 14% to escrow.
The Plaintiff also filed, simultaneously, a motion to grant an interim
injunction prohibiting the defendants and/or any party on their
behalf, from making any change to and/or transfer and/or assignment
and/or pledge of and/or disposition in 14% of the shares of those
companies detailed in the motion. Underlying the claim is the
contention that the Plaintiff's rights under the statement of claim
derive from agreements executed by and between the Plaintiff and the
defendant companies.
On March 27, 2005, the Labor Court dismissed substantially all of the
Plaintiff's motion, in determining that the Plaintiff failed to
evidence: (i) his prima facie right to 14%, as he claimed; (ii) his
entitlement to rights in and to companies aside from those directly
invested by EIL; (iii) his right to shares in the Company, Elscint,
Insightec and in Gamida.
After the above Action was erased at the request of the Plaintiff, the
Plaintiff filed in October 2005, a lawsuit in the Regional Labor Court
in Tel-Aviv-Jaffa against Vectory. The Plaintiff requested the court
to issue a mandatory injunction against Vectory ordering it to
transfer the Plaintiff shares of the companies specified in the
statement of claim - including 2,500 shares of EMI, 1,000 shares of
Elscint, 1,250 shares of Insightec, 1,500 of Gamida, 2,000 of E.R,
2,000 of Olive and shares of other companies within the EIL Group. The
Plaintiff evaluated his claim to an aggregate amount of NIS 285,000.
In January 2006 Vectory filed a statement of defense.
Underlying the claim is the contention that the Plaintiff's rights
under the statement of claim derive from an agreement executed in 1998
by and between the Plaintiff and Vectory. This Agreement was
terminated by Vectory due to different breaches of the Agreement made
by the Plaintiff. It should be noted that the conclusions made by the
court in the framework of the provisional proceedings of the above
previous claim, sided with Vectory's interpretation of the Agreement.
-80-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
B. CLAIMS (CONT.)
(7) (CONT.)
Control Centers is of the opinion that this claim, insofar as it
relates to the Company and/or to its subsidiaries as included in the
claim, is provocative, fundamentally, unfounded and groundless (both
with respect to the number of the companies in which rights are sought
and with respect to the scope of rights claimed) and that it will not
materially affect its rights in the Company and its subsidiaries.
However, the defendants' and the Company's legal counsels cannot, at
this early stage, estimate the outcome of the claim.
The Company and its subsidiaries are not parties to the claim, however
the outcome thereof might indirectly affect the nature and scope of
their rights in their investee companies. No adjustments were made in
these financial statements in respect of these claims which may be
required, should it be sustained, in full or in part.
As for additional lawsuit filed on May 25, 2006 by the Plaintiff - See
Note 24B.
(8) Elscint Bio Medical Ltd. ("Bio") was bound by agreements with a
company controlled by its former CEO (the "CEO"), entitling the CEO to
shares representing 2% of Bio's issued and paid-up capital, in
consideration for their nominal value. It was also provided that
venture capital investments of Bio would be carried out such that Bio
would invest 92% and the CEO - 8%, and that for the purpose of
financing the CEO's investment, Bio would grant him a dollar-linked
non-recourse loan bearing LIBOR+1% interest. It was further provided
that should this agreement (or another agreement between them for the
provision of consulting services) be canceled, Bio would be entitled,
according to the conditions specified in the agreement, to acquire all
or any of the CEO's holdings in the venture capital investments and in
Bio at cost and/or at market value, as relevant (depending on the
purchase date). In 2002, Bio and the CEO terminated the employment
agreement then existing between them. Further to the termination of
the agreement, Elscint transferred to itself the CEO's rights in Bio
and in the venture capital investments (mainly in Gamida), as payment
for the loans, which it had provided to the CEO for acquisition
thereof. A dispute arose between the parties, with the CEO contending
that Bio had lost its right to acquire his holdings, as aforesaid,
since the deadline, according to the agreement, for giving notice of
its intention in this regard had expired. Bio's management disputes
this contention and is acting to realize its rights under the
agreement. The parties have not yet signed a full and final agreement
for the waiver and/or settlement of their mutual claims. The Company's
management estimates that, it will not incur significant costs from
the termination of the agreements, beyond those reflected in the
financial statements.
(9) In December 2005, Elscint was served with a statement of a claim filed
with the Regional Court by Elscint's former employee requesting that
Elscint compensate him for damages resulting from his Cancer disease,
allegedly caused to him by exposure to radiation, in the amount of NIS
315,000 and other undefined compensation. The insurance company
rejected its liability and claimed that such radiation is excluded
from the policy. Elscint has approached a radiation expert to receive
an expert opinion. A statement of defense and third party notice
against the insurance company has not yet been submitted. Management
of the Company, based inter alia, on legal opinion received, believes
that the potential financial consequences of this claim can not be
estimated at this early stage of legal proceedings.
(10) The Company and its subsidiaries are currently involved in various
legal proceeding to their ordinary course of activities. Although the
final outcome of these claims cannot be estimated at this time, the
managements of these companies believe based on legal advice, that the
claims will not materially impact the Group companies.
C. OTHER CONTINGENT LIABILITIES
(1) The General Meeting of the Company's shareholders approved the grant
of prospective indemnification undertaking to directors and officers
(including in their capacity as officers of subsidiaries). Total
indemnification shall not exceed the lower of 25% of the shareholders'
equity as recorded in the Company's financial statements as at the
indemnification or $40.0 million, and all in addition to amounts, if
any, which are to be paid by insurance companies under certain risk
policies. The General Meeting also approved an exemption of directors
and officers (other than controlling parties) from liability for any
damage caused by breach of a duty of towards the Company.
-81-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
C. OTHER CONTINGENT LIABILITIES (CONT.)
(2) Elscint's shareholders approved in their General Meeting, the grant of
prospective indemnification undertaking to directors and officers
(including in their capacity as officers of subsidiaries). Total
indemnification shall not exceed the lower of 25% of the shareholders'
equity as recorded in Elscint's financial statements as at the
indemnification or $50.0 million, and all in addition to amounts, if
any, which are to be paid by insurance companies under certain risk
policies. The General Meeting also approved an exemption of directors
and officers from liability in respect of any damage caused to Elscint
by breach of duty of care.
(3) (i) The Company received, in 2003, a letter from a certain insurer
("the Insurer") of EIL, Elscint and the Company (the "Insured
Companies"), which insured against, inter alia, the lawsuit as
described in item B(1) above, alleging against the Insured
Companies, inter alia, that the Insured Companies have breached
their disclosure duties under Section 6(a) to the Insurance
Contract Law 1981, by failing to disclose to the Insurer material
information prior to the issuance of additional cover to the
policy purchased by EIL (the "Policy"), effective as of July 1999
(the "Additional Cover"), and prior to the replacement of the
Policy and the Additional Cover by the issuance of a new policy
effective as of August 1999 (the "Replacement Cover"). The letter
states that the Policy, Additional Cover and Replacement Cover
(the "Insurance Cover") issued by the Insurer will be cancelled
unless the Insured Companies indicate that circumstances as at
the issuance of the Insurance Cover differ from those stated in
the letter. The Company's legal counsel replied on behalf of the
Insured Companies on March 20, 2003, rejecting all allegetations.
As of the approval of these financial statements the Company has
not received any reply thereto from the Insurer. The parties are
nonetheless negotiating a settlement.
(ii) In January 2006, the Company and Elscint entered into an
agreement with one of the insurers of both the Company and
Elscint which insured the Company and Elscint, inter alia, with
respect to the lawsuit described in item B(1) above. In
accordance with the terms of the agreement the Company, Elscint
and their former and current directors and officers released the
insurer from all liabilities that will arise from the
abovementioned claim in consideration for a one-time payment in
the amount of $0.2 million (NIS 0.9 million).
(4) Within the framework of the agreement for the sale of Elscint's plant,
in the end of 2002, Elscint undertook to indemnify the purchasers for
any losses incurred in connection with, and as a result of, the
liabilities not acquired thereby, and in respect of any income-tax
liability incurred by the plant up to December 31, 2002 (including
those arising from environmental matters, relating to employee
benefits (including subcontractor and workers of manpower agencies),
relating to breach of the Israel Lands Administration's leasehold,
relating to taxes applicable to Elscint in respect of transfer of
title to purchasers, etc.). The liabilities are generally for
unlimited periods of time. Some are limited in amount while others are
not. Total indemnification shall not, under any circumstance
(excluding environmental matters), exceed $4.0 million (NIS 18.4
million).
(5) A number of Israeli and foreign subsidiaries of the Company are
currently undergoing tax assessments for the years up to and including
2002. The managements of the companies estimate that they will not
incur additional costs following final tax assessments, which are to
be issued as a result of these proceedings, over and above those for
which a provision was recorded in the financial statements.
As to certain subsidiaries, in respect of which the assessment
proceedings are at a preliminary stage, their outcome may not, at this
stage, be estimated. Nonetheless, their respective managements
estimate, based on professional advice, that they will not incur any
additional substantial costs following final tax assessments.
Accordingly, no provision has been made in these financial statements
in respect thereof.
-82-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
C. OTHER CONTINGENT LIABILITIES (CONT.)
(6) Final approval for completion of construction of the Arena commercial
center is contingent on the furnishing, to the local municipality, of
a bank guarantee to secure payment of the land betterment tax, for an
amount of approximately NIS 4.6 million ($1.0 million). Arbitration is
currently being held as to such liability between Marina Herzliya
Limited Partnership Ltd. (of the Control Centers Group) and the local
municipality. The Company's management estimates, based on
professional opinion that no significant costs will be borne thereby,
in respect of this guarantee.
(7) As for guarantee to Klepierre - see Note 9B.(3)d.
D. LIENS AND COLLATERAL
(1) A. As security for a loan of NIS 339.0 million ($73.6 million)
granted to the Company and its subsidiary by an Israeli bank, the
Company undertook to comply with financial covenants, including,
among other things, an undertaking to maintain throughout the
term of credit a minimum ratio of "adjusted shareholders equity"
of the Company to its "adjusted balance sheet," all as defined in
the agreement. The Company also committed to a minimum "net
operating profit", before financial expenses and before
depreciation and amortization deductions. The Company further
committed to a minimum "net asset value" of PC (after deduction
of loans, including shareholder loans) which is to be determined
by an external appraiser. The covenants will remain in full force
and effect for as long as the credit provided by the Bank to the
Company or to EIL exceeds $30.0 million (NIS138.0 million).
The Company's subsidiary (EUN) has pledged and assigned to and in
favor of the Bank all shares held thereby in PC, as a security,
unlimited in amount, for the loan received. The Company also
undertook not to pledge, in favor of third parties, any existing
and prospective assets, without the bank's prior consent
(excluding pledges of new assets and/or projects granted in favor
of those who financed or refinanced -the acquisition and/or
execution of same). The Company further undertook to provide
under certain circumstances, some additional securities as
detailed in the agreement, including a secondary lien on assets
and interests acquired through funds provided by the credit line.
Should the Company fail to comply with all or any of said
financial covenants, or upon the occurrence of an event of
default (including failure to provide the additional securities),
the bank shall then be entitled to demand the immediate repayment
of the loan.
Notwithstanding the aforestated, following re-evaluation of the
loan agreements by and between the Company, EUN and the bank, and
in light of the realization of assets during 2004 and 2005, as
detailed in Note 9B.(3)a.- d. above, the bank has informed the
Company and EUN that it does not require, at this stage,
compliance with the financial covenants included in the
agreement, with the exception of that referring to the "adjusted
shareholders' equity" to the "adjusted balance sheet" ratio, and
all by and through January 1, 2007 (see also Note 14D. above).
B. As security for loans totaling $19.2 million (NIS 88.5 million)
granted to the Company by another Israeli bank, the Company
undertook, in favor thereof, not to pledge the majority of its
shares in Elscint, without the bank's prior consent.
-83-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
D. LIENS AND COLLATERAL (CONT.)
(2) As security of a long term credit facility of approximately NIS 308.0
million ($66.9 million) received from an Israeli bank, Elscint
undertook to comply with certain financial covenants, namely
maintaining, throughout the duration of the credit, of a minimum ratio
of shareholders' equity to total balance sheet assets. Elscint has
registered, as a security for the credit, a first-ranking pledge in
favor of the bank on the B.H. shares and granted certain additional
first and second ranking pledges on shares of subsidiaries owned
thereby. Elscint also undertook not to grant any floating or fixed
charges of any rank, on any existing and prospective assets, in favor
of third parties, without the bank's prior consent (excluding pledges
of assets and/or projects granted in favor of those who financed or
refinanced -the acquisition and/or execution of same). Elscint further
undertook to provide additional collateral, as detailed in the
agreement, including first or second ranking pledges on assets and
interests acquired by means of the credit line, and all as may be
required by the bank. Should Elscint fails to comply with the
financial covenant, or upon the occurrence of certain events of
default, then and in such events, the bank shall be entitled to demand
immediate payment of the loans.
(3) A. PROJECTS UNDER CREDIT FACILITIES
Certain Project Companies which engaged in the purchase,
construction or operation of hotels and/or commercial centers
("Project Companies") have secured their respective credit
facilities awarded by financing banks, in a total amount of NIS
1,228 million ($266.8 million), engaged in the first or second
ranking (fixed or floating) charges on property owned thereby,
including right in and to real estate property as well as the
financed projects, on goodwill and other intangible assets, on
rights pertaining to certain contracts (including lease,
operation and management agreements), on rights arising from
insurance policies, and the like. Shares of Project Companies
were also pledged in favor of the financing banks.
Shareholders loans as well as any other rights and/or interests
of shareholders in and to the Project Companies were subordinated
to the respective credit facilities. Payment is permitted to the
shareholders (including the distribution of dividends but
excluding management fees) subject to fulfilling of certain
preconditions.
Certain loan agreements include an undertaking to fulfill certain
financial and operational covenants ("covenants") throughout the
duration of the credit, namely: achieving certain operational
milestones on certain specified dates (e.g. scope of lease,
etc.); complying with "a minimum debt services cover ratio",
"loan outstanding amount" to secured assets value ratio;
complying with certain restrictions on interest rates;
maintaining certain cash balances for current operations;
maintaining equity to project cost ratio and net profit to
current bank's debt; occupancy percentage; average room or rental
fee rates, a minimum "ratio of total room revenue per available
rooms" and others.
Several Project Companies undertook not to make any disposition
in and to the secured assets, not to sell, transfer or lease any
substantial part of their assets without the prior consent of the
financing bank. In certain events the Project Companies undertook
not to allow, without the prior consent of the financing bank:
(i) any changes in and to the holding structure of the Project
Companies nor to allow for any change in their incorporation
documents; (ii) execution of any significant activities,
including issuance of shares, related party transactions and
significant transactions not in the ordinary course of business;
(iii) certain changes to the scope of the project; (iv) the
assumption of certain liabilities by the Project Company in favor
of third parties; (v) receipt of loans by the Project Company
and/or the provision thereby of a guarantee to third parties; and
the like.
B. As of the balance sheet date, Elscint guarantees fulfillment of
certain obligations relating to financing agreements of various
B.H. Project Companies up to an amount equal to a certain
percentage of the loan amount or the cost of construction, as
applicable, up to GBP 8.3 million (NIS 65.8 million; $14.3
million). On March 2, 2006 B.H. Project Companies repaid the
underlying loans as part of refinance loan - see Note 14I.
-84-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 17 - COMMITMENTS, CONTINGENCIES, LIENS AND COLLATERALS (CONT.)
D. LIENS AND COLLATERAL (CONT.)
(3) (CONT.)
B. As of the balance sheet date, Elscint guarantees fulfillment of
certain obligations relating to financing agreements of various
B.H. Project Companies up to an amount equal to a certain
percentage of the loan amount or the cost of construction, as
applicable, up to GBP 8.3 million (NIS 65.8 million; $14.3
million). On March 2, 2006 B.H. Project Companies repaid the
underlying loans as part of refinance loan - see Note 14I.
PC guarantees fulfillment of its Project Companies' obligations
under certain loan agreements, up to an aggregate amount of
E63.9 million (NIS 348.0 million; $75.6 million).
PC and/or EUN undertook in the context of various loan agreements
to supplement shareholders' equity (including shareholder loans)
of the Project Companies, in accordance with the financing
agreements or alternatively provide additional financing in the
event of a budget overrun or should same be required for
operation or maintenance of the respective project.
C. As to bank deposits made to secure loans and guarantees received
therefrom, by the Group Companies - see Notes 4 and 8 above.
(4) SC BUCURESTI TOURISM SA ("BUCURESTI")
In order to secure a bank loan in the amount of NIS 119.6 million
($26.0 million) received by the controlling shareholder in Domino
("BHEE"), for the financing of investment in Bucuresti, Elscint
granted a first ranking pledge on a bank deposit of NIS 64.4 million
($14.0 million) and on all rights and income deriving therefrom. In
addition, BHEE granted a fixed pledge on its Domino shares and a
floating charge on all Domino's assets as well as a lien on the
Bucuresti shares. Elscint pledged its BHEE shares and also granted a
floating charge on BHEE's assets. An undertaking was granted in favor
of the financing bank, not to allow for any change in the ownership
and control structure of BHEE throughout the duration of the credit.
Elscint furthermore provided a guarantee, unlimited in amount, to
secure BHEE's undertakings to the bank. The bank restricted its right
to realize this guarantee, by linking it to the realization terms of
the Bucuresti shares owned by Domino (except for certain instances as
stipulated in the agreement).
(5) Within the framework of an investment, in which Insightec has raised
from existing shareholders through the issuance of convertible notes,
$21.0 million (NIS 96.6 million), Insightec undertook that, so long as
any note remains outstanding and until a qualified IPO of at least 25%
of Insightec's shares or a financing of at least $50.0 million
($230.2 million) at a price per share not lower than $14.0, it will
comply with certain limitations regarding dividend distributions,
merger and/or asset acquisition transactions totaling $5.0 million per
annum, and the like. Similarly, Insightec is obliged to meet certain
financial covenants regarding a level of liquidity of at least $ 5.0
million (NIS 23.0 million) and to maintain a ratio between
consolidated EBITDA (as defined in the agreement) and interest
payments of not less than 1:1 for 2006, 1.5:1 for 2007 and 2:1 for
2008 and thereafter. Should Insightec does not maintain the above
covenants it will be considered as default.
Insightec further undertook with respect to the convertible notes, not
to repay part of a bank loan in the amount of $5.0 million (NIS 23.0
million) until December 31, 2007. Concurrently, the Company undertook
to extend the term of its guarantee through March 31, 2007 (see (6)
below).
(6) In order to secure a bank loan granted to Insightec, the Company
provided a bank guarantee (inter-branch) at the amount of NIS 22.9
million ($5.0 million), valid until March 2007.
(7) Insightec's technology developed with OCS funding is subject to
transfer restrictions, which may impair its ability to sell its
technology assets or to outsource manufacturing. The restrictions
continue to apply even after Insightec has paid the full amount of
royalties' payable for the
-85-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
grants. In addition, the restriction may impair Insightec's ability to
consummate a merger or similar transaction in which the surviving
entity is not an Israeli company.
-86-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 18 - SHARE CAPITAL
A. COMPOSITION:
ORDINARY SHARES
OF NIS 1.00 PAR VALUE EACH
DECEMBER 31
-------------------------------
2005 2004
-------------- --------------
Authorized share capital 50,000,000 50,000,000
Issued and outstanding 28,226,298(*) 24,397,082(*)
(*) Including 2,842,400 shares "dormant" shares (see Note 2Q, above and section
B.(iv), below) and 524,187 shares held by Elscint Ltd. (see B.(iii) below).
B. FURTHER INFORMATION REGARDING THE SHARE CAPITAL AND DISPOSITIONS THEREIN
(i) As of December 31, 2005, the balance of the shares includes 562,130
shares (including 276,925 shares issued by the Company to Elscint's
employees and directors in the framework of the merger with Elscint
-(see Note. 9B.(1) above) in exchange for unexercised 522,500 shares
issued by Elscint within the framework of Elscint's employee and
officers incentive plan) held by the Group's employees and directors,
issued thereto, within the framework of employees and officers
incentive plan ("Employees" and "2001 Plan"). The acquisition of the
shares by the Employees was financed by a loan provided for such
purpose by the Company, to be repaid at the end of a five-year period.
The loan bears an annual interest of 6%. Any tax to which Employees
may be subject as a result of the said interest shall be borne by the
Company. However, the Company will not assume any liability for the
payment of tax imposed, if so, in respect of the allotment of the
shares and their subsequent sale. The shares are held in escrow, and
will be used as sole security for repayment of the said loan. In the
event an Employee elects to transfer its vested shares, whether to
himself or to any other third party, then he shall be obliged to
deposit an amount equal to the balance of the loan as security for its
repayment.
Should the Company distribute any dividends, with a "record" date
occurring at any date during the escrow period, then the Company shall
transfer to the escrow agent such dividends corresponding to the
number of shares held on behalf of Employees by the escrow agent, who
in turn will transfer such dividends to the respective Employees.
On January 2006, the Company issued 42,400 ordinary shares to
Employees within the framework of the 2001 Plan, out of its "dormant"
shares.
All shares held by the Employees, as of December 31, 2005, are free of
any restriction ("Vested"). Following the balance sheet date, shares
were exercised by Employees such that the balance thereof, as of the
date immediately preceding the date of approving the financial
statements ; is 375,640 shares.
(ii) In 2001, an agreement was signed between the Company, PC and EUN as
one party, and Triple-S Holdings NV ("Triple-S") as another party,
under which the latter transferred to PC its rights (existing and
future) to acquire shares in the commercial centers project companies.
The Company issued to Triple-S, as consideration thereof, 250,000
ordinary shares. In accordance with the terms of the agreement, a
valuation was carried out, on January 15, 2004, as to the market value
on such date, of the issued shares (calculated based on the average
price of the Company's shares on the NASDAQ during the 30 trading days
prior to said date). As the market value of the shares on that date
was lower than $6.0 million, the Company issued 623,362 additional
ordinary shares to Triple-S (according to a resolution of the Board of
Directors adopted in January 2004), such that the total value of
shares issued to Triple-S would equal $6.0 million, based on the
average price per share, as indicated above. An amount of NIS 18.9
million that previously recorded as a long-term liability, was charged
upon the issuance of shares, to share capital and to premium on
shares, respectively.
-87-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 18 - SHARE CAPITAL (CONT.)
B. FURTHER INFORMATION REGARDING THE SHARE CAPITAL AND DISPOSITIONS THEREIN
(CONT.)
(iii) In November 2004, a transaction was consummated in terms of which
Elscint transferred to an institutional investor ("the Investor")
357,953 shares of the Company in consideration for 576,923 Elscint
shares held by the Investor. The ratio of the share transfer was
determined based on the closing price of the Company's shares on the
stock exchange as at the date of the transaction ($8.4 per share). The
price of Elscint's share on the NYSE as at such date was $4.3 per
share. This transaction was recorded, in the Company's financial
statements, as an investment in the shares of Elscint in exchange for
the issuance of shares at their fair value as at the date of the
transaction.
(iv) On December 27, 2004, the Company executed a tender offer, in the
framework of which it purchased 2,800,000 of its ordinary shares from
its shareholders (approximately 11.5% of the Company's issued share
capital), for cash consideration of $11.4 per share.
(v) As for issuance of shares to the minority shareholders of Elscint
within the framwork of a merger - see Note 9B.(1) above.
(vi) As for issuance of shares to the Chairman of the Board of Directors as
a result of exercise of warrants - see Note 20A.(4) below.
(vii) As for sale of dormant shares by Elscint in May 2006 - See Note 24C.
below,
(viii) As for additional options plan to the Company's directors and
employees, and options issued to the Executive Chairman of the Board
which were approved by the Company Shareholders meeting on May 31,
2006 - See Note 20E. (i) and (ii).
C. OUTSTANDING WARRANTS
26,500 options which were issued to directors and officers of Elscint,
against options granted to them by Elscint (see Note 9B.(1) above). The
options are exercisable to 26,500 ordinary shares of the Company in
consideration of NIS 38.7 per share ($8.4 per share). As of December 31,
2005 the options are fully vested. On March 2006, the options were
exercised into 27,964 ordinary shares of the company (the additional 1,464
shares deriving from an adjustment in connection with the distribution of a
dividend on January 17, 2006 - see note 18D below).
D. DIVIDEND DECLARED
(i) On March 17, 2005, the Company distributed to its shareholders a
dividend in the amount of NIS 159.5 million (which represents NIS 7.28
per share; $1.69 per share). Out of the said amount: (i) NIS 3.2
million ($0.7 million) was paid to employees and is recorded as salary
in these financial statements; and (ii) NIS 3.8 million ($0.9 million)
was paid to Elscint in respect of its shareholding in the Company's
stock.
(ii) On January 17, 2006, the Company distributed to its shareholders a
dividend in the amount of NIS 130.0 million ($28.2 million) which
represents NIS 5.1 ($1.1) per share. Out of that amount: (i) NIS 3.1
million ($0.7 million) was paid to employees and will be recorded as
salary in the financial statements of the first quarter of 2006; and
(ii) NIS 2.7 million ($0.6 million) was paid to Elscint in respect of
its shareholding in the Company's stock.
-88-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 19 - ADDITIONAL DETAILS CONCERNING STATEMENT OF OPERATIONS ITEMS
A. REVENUES FROM SALE OF REAL ESTATE ASSETS, NET AND INVESTMENTS
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Sales of commercial centers (i) 223,280 131,921 -- 48,508
Sales of hotels (ii) 58,381 -- -- 12,683
------- ------- --- ------
281,661 131,921 -- 61,191
======= ======= === ======
(i) As for information as to the transactions for the sale of the
commercial centers - see Note 9B.(3)a., b. & d.
The gain generated from the transactions of 2005 include loss from
realization of capital reserves from foreign currency translation
adjustments in respect of realized investments (shares and
shareholders' loans) amounted to NIS 39.7 million ($8.6 million). 2004
include gain from such realization amount to NIS 153.3 million.
(ii) Within the framework of an agreement, executed on December 19, 2005,
for the sale of the entire (100%) equity and voting rights in a
company ("Shaw") which owns a hotel located in London, that is subject
to a long-term lease agreement concluded in 2003 for a period of 25
years ("the sold hotel"), B.H. has sold all the shares and rights held
by it in Shaw (30%) to an unrelated third party. The transaction
reflects an asset value of L74.9 million (NIS 594.5 million;
$129.2 million) in which the Company's share is L22.5 million
(NIS 178.3 million; $38.8 million). Consequently, the Company recorded
a gain (before tax) of NIS 58.3 million ($12.7 million) in the fourth
quarter of 2005. The gain includes NIS 14.2 million ($3.1 million)
from realization of capital reserves from foreign currency translation
adjustments in respect of realized investments (shares and
shareholders' loans).
The book value of Shaw's assets, and the revenues and operating
profits thereof, as recorded in the consolidated financial statements
as of December 31, 2004 and for the year then ended, totals
L15.9 million (NIS 126.2 million), L1.6 million (NIS 12.7
million) and L1.3 million (NIS 10.8 million), respectively.
As part of the Company's real estate assets' liquidation process, as
detailed in Note 2c. above, the Company currently examines the optimal
methods for realizing its assets, considering the business
opportunities currently available to it as well as certain financial
conditions and other parameters (e.g. location of property, the
Company's capital yield, cost of external credit, market yields, cash
flow timeline, etc.)
Accordingly, the Company executed, (or contemplated) confrom time to
time, variable liquidation or deemed liquidation transaction, which
differ by nature each one from the other, such as, long term lease
transactions, refinance of loans attributed to specific assets,
absolute sales of real estate assets, and the like.
Although that the sold hotel constitutes a Reportable Segment, the
Company's management does not consider the result of its sale as well
as the results of its current operations, as "discontinuing
operations", since the Company intends to continue to take steps in
the future in order to liquid its real estate assets, from time to
time, through means such as long term lease transactions.
-89-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 19 - ADDITIONAL DETAILS CONCERNING STATEMENT OF OPERATIONS ITEMS (CONT.)
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
B. REVENUES FROM HOTEL OPERATIONS AND MANAGEMENT
Rooms 165,225 135,208 123,640 35,895
Food, beverage and other services 92,447 74,793 56,144 20,084
Rental of commercial space 12,385 8,364 9,421 2,691
------- ------- ------- ------
270,057 218,365 189,205 58,670
======= ======= ======= ======
C. REVENUES FROM REALIZATION OF INVESTMENTS
Decrease in shareholding of Insightec (i) -- 13,003 20,417 --
Realization of investment in Algotec (ii) 1,958 3,412 24,712 425
------- ------- ------- ------
1,958 16,415 45,129 425
======= ======= ======= ======
(i) Derives from recording in the statement of operations, deferred income in
respect of a decrease in the shareholding in Insightec (see Note 2H.
above).
(ii) In November 2003 a transaction was completed within the framework of which
Elscint sold to a third party its entire holding (16% fully diluted) in
Algotech Systems Ltd., in consideration for an estimated total of NIS 33.7
million (following adjustments). Elscint generated NIS 30.0 million as gain
from such transaction, which was recorded in the years 2003 to 2005 (see,
in addition, Note 17B.(6) above).
-90-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 19 - ADDITIONAL DETAILS CONCERNING STATEMENT OF OPERATIONS ITEMS (CONT.)
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
D. OTHER OPERATIONAL INCOME
Sales of goods 31,790 -- -- 6,906
Lease of assets 12,619 13,238 13,495 2,742
------- ------- ------- ------
44,409 13,238 13,495 9,648
------- ------- ------- ------
E. COST OF COMMERCIAL CENTERS OPERATIONS
DIRECT EXPENSES:
Wages and fringe benefits 13,083 18,411 13,139 2,842
Energy costs 15,439 40,744 40,616 3,354
Taxes and insurance 4,070 10,501 13,992 884
Maintenance of property and other
expenses 27,564 44,902 40,843 5,989
------- ------- ------- ------
60,156 114,558 108,590 13,069
------- ------- ------- ------
OTHER OPERATING EXPENSES:
Wages and fringe benefits 15,882 14,929 11,473 3,450
Advertising 6,292 17,820 15,275 1,367
Doubtful debts 1,540 9,511 6,432 335
Other expenses 27,190 25,713 24,781 5,908
------- ------- ------- ------
50,904 67,973 57,961 11,060
------- ------- ------- ------
DEPRECIATION OF BUILDING AND
EQUIPMENT 46,580 88,861 91,362 10,119
------- ------- ------- ------
157,640 271,392 257,913 34,248
======= ======= ======= ======
F. COST OF HOTEL OPERATIONS AND MANAGMENT
DIRECT EXPENSES:
Wages and fringe benefits 89,118 69,194 65,033 19,361
Food and beverages 17,656 12,652 12,516 3,836
Other 67,544 55,776 50,752 14,674
------- ------- ------- ------
174,318 137,622 128,301 37,871
OTHER OPERATING EXPENSES 42,386 31,899 29,400 9,208
DEPRECIATION AND AMORTIZATION 42,589 37,631 30,971 9,252
------- ------- ------- ------
259,293 207,152 188,672 56,331
======= ======= ======= ======
-91-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 19 - ADDITIONAL DETAILS CONCERNING STATEMENT OF OPERATIONS ITEMS (CONT.)
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
G. COSTS AND EXPENSES OF MEDICAL SYSTEMS OPERATION
COST OF SALES:
Wages and fringe benefits 4,384 1,093 -- 952
Materials and subcontractors 9,524 7,352 -- 2,069
Royalties to OCS (Note 17A.(5)) 2,271 1,317 -- 493
Others 3,149 1,058 -- 684
------ ------ ----- ------
19,328 10,820 -- 4,198
Changes in work in process and finished goods -- (986) -- --
------ ------ ----- ------
19,328 9,834 -- 4,198
------ ------ ----- ------
MARKETING AND SELLING EXPENSES:
Wages and fringe benefits 10,231 3,283 -- 2,223
Advertising 4,976 4,033 902 1,081
Others 2,471 1,950 -- 537
------ ------ ----- ------
17,678 9,266 902 3,841
------ ------ ----- ------
GENERAL AND ADMINISTRATIVE EXPENSES:
Wages and fringe benefits 4,943 3,237 2,191 1,074
Depreciation and amortization 302 360 376 66
Others 7,326 3,342 5,251 1,592
------ ------ ----- ------
12,571 6,939 7,818 2,732
------ ------ ----- ------
49,577 26,039 8,720 10,771
====== ====== ===== ======
H. OTHER OPERATIONAL EXPENSES
COST OF LEASE OF ASSETS 2,802 3,175 3,510 609
------ ------ ----- ------
COST OF SALE OF GOODS:
Inventories - Opening balance 3,426 -- -- 744
Purchases 18,051 -- -- 3,922
Less - Inventories closing balance 8,034 -- -- 1,745
------ ------ ----- ------
13,443 -- -- 2,921
Marketing and selling expenses 19,361 -- -- 4,206
General and administrative expenses 3,426 -- -- 744
------ ------ ----- ------
36,230 -- -- 7,871
------ ------ ----- ------
PROJECT INITIATION EXPENSES (*) 7,761 480 -- 1,686
------ ------ ----- ------
46,793 3,655 3,510 10,166
====== ====== ===== ======
(*) On April 2005, the Second Television and Radio Authority informed the
joint-venture (50%), established for the purpose of submitting A bid for
participating in a tender published by the Second Television and Radio
Authority, that is not included among the winning groups in the tender. As
a result, the Company has recorded in these financial statements a total
initiation expense of approximately NIS 5.0 million ($1.1million).
-92-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 19 - ADDITIONAL DETAILS CONCERNING STATEMENT OF OPERATIONS ITEMS (CONT.)
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
I. RESEARCH AND DEVELOPMENT EXPENSES, NET:
Wages and fringe benefits 26,180 20,572 17,796 5,687
Materials and subcontractors 20,859 16,369 25,875 4,532
Depreciation and amortization 5,945 5,849 4,508 1,292
Others 9,841 3,052 3,008 2,138
-------- ------- -------- -------
62,825 45,842 51,187 13,649
Less - participation of the OCS 3,926 7,684 7,468 853
-------- ------- -------- -------
58,899 38,158 43,719 12,796
======== ======= ======== =======
J. GENERAL AND ADMINISTRATIVE EXPENSES
Wages and fringe benefits 20,436 22,873 21,794 5,041
Depreciation and amortization 976 968 928 212
Others 15,527 19,786 19,422 2,772
-------- ------- -------- -------
36,939 43,627 42,144 8,025
======== ======= ======== =======
K. FINANCIAL INCOME (EXPENSES), NET
In respect of:
Bank loans (186,264) (68,088) (161,215) (40,466)
Deposits, debentures and long- term receivables 22,356 2,082 (42,178) 4,857
Gains (losses) from currency Transactions 14,658 (14,880) (12,451) 3,184
Gains (losses) on securities 656 2,496 4,567 143
Others (including erosion of monetary items and
other, net) 2,501 (19,115) (16,443) 543
-------- ------- -------- -------
(146,093) (97,505) (227,720) (31,739)
Financial expenses (income), net capitalized to
buildings under construction (*) 34,861 13,808 (9,857) 7,574
Financial costs (income) credited to capital
reserves from translation differences (11,089) 30,128 25,756 (2,409)
-------- ------- -------- -------
(122,321) (53,569) (211,821) (26,574)
======== ======= ======== =======
(*) The discount rate applicable to non-specific
credit (see Note 2U. above) 11.1% 3.7% (4.0%) 11.1%
======== ======= ======== =======
-93-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 19 - ADDITIONAL DETAILS CONCERNING STATEMENT OF OPERATIONS ITEMS (CONT.)
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
L. OTHER EXPENSES, NET
Gain from realization (repayment) of investment-type
monetary balances in Investees (1) -- 12,378 32,253 --
Loss from disposition of assets and liabilities (2) (21,836) (12,201) (7,808) (4,744)
Provision for impairment of investments and assets (2) (24,617) (52,620) (30,252) (5,348)
Others, net (3) (10,653) 1,015 (4,670) (2,314)
------- ------- ------- -------
(57,106) (51,428) (10,477) (12,406)
======= ======= ======= =======
(1) Throughout 2003 to 2004, certain subsidiaries have entered into agreements
with foreign banks and other financial institutions for the refinancing of
several real estate assets located in Europe. The borrowing companies have
transferred, to their respective shareholders certain financing surplus of
the credits received, as repayment of shareholders' loans. As a result,
capital reserves from foreign currency translation adjustments attributed
to the said shareholders' loans, were realized.
(2) See, in addition, Notes 9A.3 and 10A -10C, above.
(3) Including a provision, at the amount of NIS 9.5 million ($2.0 million),
recorded before consummation of the merger (see Note 9B.(1) above), for a
loss that may result from a decrease in the Company's shareholding in
Elscint, assuming realization of Elscint's employees rights to shares. The
provision was recorded in accordance with Israeli GAAP, as is in effect
through the end of 2005 (see Note 2d.2. above, regarding the accounting
method that will be in effect as from January 1, 2006).
M. EARNINGS PER SHARE
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
1. BASIC EARNINGS PER SHARE
Earnings (loss) from continuing operations 81,648 36,537 (124,154) 17,738
====== ====== ======== ======
Earnings from discontinuing operations 5,917 6,810 12,073 1,285
====== ====== ======== ======
Weighted average number of shares
(in thousands) 22,282 23,025 22,337 22,282
====== ====== ======== ======
2. DILUTED EARNINGS PER SHARE
Net income (loss) 86,943 43,347 (112,081) 18,888
====== ====== ======== ======
Weighted average number of shares
(in thousands) 22,282 23,925 22,337 22,282
====== ====== ======== ======
-94-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 20 - RELATED PARTIES
A. TRANSACTIONS
(1) COMPONENTS:
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
General and administrative expenses (I) 8,810 7,570 10,161 1,914
Project expenses (coordination, supervision
and aviation services) - charged, mainly
to cost of the fixed assets (II) 18,486 25,045 7,730 4,016
Cost of construction of the Arena - charged
to the cost of the fixed assets -- 7,800 154,039 --
(I) INCLUDES:
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
A. BENEFITS GRANTED TO RELATED PARTIES,
AS FOLLOWS:
PAYMENTS TO DIRECTORS:
Non-employee -
Cost 352 386 316 76
===== ===== ===== =====
Number of recipients 4 5 5
===== ===== =====
Employed -
Cost 7,444 6,375 6,926 1,674
===== ===== ===== =====
Number of recipients 3 3 3
===== ===== =====
B. PARTICIPATION IN JOINT EXPENSES (*) 792 471 1,946 172
===== ===== ===== =====
(*) based on an agreement for the cost allocation between the group companies,
which was in force through December 31, 2005.
(II) See Note 17A(3), above and item (8), below.
-95-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 20 - RELATED PARTIES (CONT.)
A. TRANSACTIONS (CONT.)
(2) On March 2005 an amendment in the Chairman's monthly cost of
employment to NIS 220,000 ($47,820), was approved at the Company's
general shareholders' meeting, with effect as from January 1, 2005. As
for aprroval of services agreement with a company controlled by the
Chairman commencing retroctively on August 1, 2005 - See Note 20 F.
(iii).
(3) Shares and warrants issued to related parties - see Notes 9B.(2)
above.
(4) In September 2004, Company's shareholders' meeting approved a 1-year
extension to the exercise period of the options issued to the Chairman
of the Board of Directors (through September 8, 2005). The exercise
price was determined to NIS 45.7 per warrant (instead of NIS 44.0).
Other conditions of the options remain unchanged. The computed
theoretical economic value of the options, based on the
"Black-Scholes" model, totaled as of June 22, 2004 (the Board of
Directors' resolution in respect of the change in exercise terms) NIS
1.5 million (calculated on the basis of a 37% annual standard
deviation and 6% annual capitalization rate). The closing price of the
Company's share on the Tel Aviv Stock Exchange and on the NASDAQ,
immediately prior to the Board of Directors' resolution as to the
change was NIS 37.3 and $8.4, respectively. In February 2005, the
options were exercised into 350,000 ordinary shares of the Company, in
consideration of $3.5 million.
(5) The directors and officers of the Company, of EIL and its Group
companies and of companies in which directors serve on behalf of the
Company, are covered through October 2006 by insurance of up to $40.0
million (per event and for the period) in respect of their liability
(the coverage amount for EIL amounts up to $10.0 million). The
coverage is within the framework of a joint insurance policy for the
EIL Group companies. The allocation of the insurance costs between the
Company and its subsidiaries (92%) and EIL (8%) was approved by the
Audit Committee of the Company as a reasonable allocation in this
specific circumstances.
On December 2005 the audit committee and the Board of Directors of the
Company resolved to approve the coverage of liability of the Chairman
of the Company's Board of Directors under the above insurance policy,
in terms of a framework resolution of the Company's general meeting
effective through December 31, 2008.
(6) As for directors' indemnification - see Note 17C.(1) and (2) above.
(7) EIL acquired a "Run off" insurance policy covering itself, the Company
and Elscint, up to $20.0 million over the coverage of $40.0 million
included in the additional policies, and all through September 2006.
Premium for said insurance totals $810,000 for the entire six year
duration of coverage (33% for each company). The insurance covers
officers who served in the companies through May 1999 and in respect
of events occurring prior thereto subject to same neither being
reported nor known in May 1999.
(8) Subsidiaries receive, from time to time, aviation services from Jet
Link Ltd. - a company controlled by Control Centers - for purposes of
their activities and operations, in exchange for a payment based on
Jet Link's price list, net of a discount of at least 5%. Due to our
increasing business needs, the Company purchased during 2005 and 2004
additional approximately 200 and 70 flight hours from Jet Link,
respectively under the same terms. The purchase of the additional
flight hours was approved by the Audit Committee and the Board of
Directors as a non-extraordinary transaction within the meaning of the
Israeli Companies Law.
(9) The Company and Elscint lease office space from Control Centers at
customary commercial terms.
-96-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 20 - RELATED PARTIES (CONT.)
B. BALANCES
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
ASSETS:
Receivables and other debit accounts 3,186 521 1,649
LIABILITIES:
Payables and other credit accounts 3,153 830 1,644
C. COMMITMENTS - see Note 17A, above.
D. LIENS AND GUARANTEES - see Note 17D, above.
E. The Group companies conduct business (the receipt of credit, deposits and
management of security portfolio transactions) with a banking corporation,
being a related party of the Company. As these transactions are executed in
the ordinary course of business and under customary market terms and
conditions, no segregation has been made in respect thereof and no
disclosure has been provided thereto in the financial statements.
F. On March 29, 2006 the Company's Audit Committee and its Board of Directors
approved the following decisions:
(i) The grant of up to 1,000,000 non-marketable options to the employees,
directors and officers of the Company and companies under its control,
directly or indirectly. In accordance with the terms of the plan
353,500 options were approved for grant to all the Company's directors
except the Executive Chairman, and the remaining shall be granted to
the Company's employees and officers ("the Offerees")
The Options will be granted to the Offerees for no consideration. The
exercise price per Option will be the lower of: (i) NIS 83.71, which
constitutes the average closing price of the Shares on the Tel Aviv
Stock Exchange ("TASE") during the 30-trading day period preceding
March 29, 2006; or (ii) the average closing price of the Shares on the
TASE during the 30-trading day period preceding the date of grant of
the Options. (The "Exercise Price")
The Options may be exercised into shares of the Company in such manner
that the on the exercise date the Company will issue to each Offerees
shares equivalent to the gain from the realization of the options
(i.e.: the difference between the opening price of the shares on the
TASE on the exercise date, provided however, that such price will not
exceeds 166% of the Exercise Price ("Share price"), less the Exercise
Price) divided by the Share Price. Accordingly, the maximum number of
shares issuable upon exercise of all of the options that may be
granted under the Plan is 397,590.
The vesting period of the options will occur ratably over a three
years period (33.33% of the Options shall vest on each of the first
three anniversaries of the date of grant (the "Vesting Periods"). The
options will expired after five years from the date of grant.
The issuance of options under the plan is subject to the fulfillment
of certain conditions, including the approval of the Israeli tax
authority to the plan. As of the date hereof, no options have been
issued under the Plan.
-97-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 20 - RELATED PARTIES (CONT.)
F. (CONT.)
(ii) The Grant of 350,000 non-marketable options to the Company's Executive
Chairman of the Board who is also considered the indirect controlling
shareholder of the Company, exercisable into 350,000 shares. The
exercise price of each option shall equal 125% of the average closing
price in NIS of the Company's shares on the TASE during the 30-trading
day period preceding the date of grant of the options (the "Exercise
Price") which is equal to NIS 137.4 per share. The Options will become
exercisable immediately upon their grant and will remain exercisable
for a period of three years thereafter (the "Exercise Term").
(iii) The approval of a service agreement with a company controlled
(directly or indirectly) by its Executive Chairman of the Board (the
"Management Company" and the "Chairman" respectively) according to
which, the Management Company will provide the Company with Executive
Chairman services (the "Services"). The Management Company may
provide the Services to private subsidiaries and/or affiliates of the
Company. In accordance with the term of the agreement, the Services
will be provided by the Chairman only, as an employee of the
Management Company and the Chairman will devote at least 80% of his
time, skills and efforts to his position as Executive Chairman of the
Company. The control over the Management Company will not be changed
during the term of the Service Agreement.
In consideration for the Chairman services the Company will pay the
Management Company a monthly amount of U.S.$50 thousand (NIS 230.0
thousands) as well as reimbursement of direct expenses incurred with
the provision of the Services.
In accordance with the terms of the service agreement, the Management
Company will be the sole employer of Chairman and no employer-employee
relationship will exist between the Chairman and the Company. The
Management Company has agreed to indemnify the Company with respect to
any amount, rights or benefits the Company would be required to pay
the Chairman including legal fees, in connection with any
determination by the labor court and/or any other competent authority
that the Chairman was or is an employee of the Company during the term
of the Service Agreement. The Service Agreement is for a five-year
term commencing retroactively on August 1, 2005.
The Chairman has guaranteed all of the Management Company's
obligations as far as they relate to it and has further guaranteed the
Management Company's indemnification undertakings and responsibility
for damages.
(iv) Approval of bonus payments for the fiscal years commencing January
1,2006 to the Chairman which will be paid following the approval of
the Company's annual audited consolidated financial statements and
will be calculated, as follows: (i) 0% of the first NIS 100 million of
the annual consolidated pre- tax profits of the Company ("Profits");
(ii) 3% of Profits between NIS 100 million and NIS 125 million; (iii)
3.5% of Profits between NIS 125 million and NIS 150 million; and (iv)
4% of Profits exceeding NIS 150 million.
(v) Approval of bonus payments for the fiscal years commencing January
1,2006 to two of the Company's employed directors which will be paid
following the approval of the Company's annual audited consolidated
financial statements and will be calculated, as follows: (i) 0.75% of
the first NIS 125 million of the annual consolidated pre-tax profits
of the Company ("Profits"); (ii) 0.875% of Profits between NIS 125
million and NIS 150 million; and (iii) 1% of Profits exceeding NIS 150
million.
-98-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 20 - RELATED PARTIES (CONT.)
F. (CONT.)
(vi) Approval of an agreement with Control Centers according to which the
Company will receive from Control Centers (either directly or through
its subsidiaries or affiliates) coordination, planning, execution and
supervision services (the "Services") over real estate projects of the
Company and/or its subsidiaries and/or affiliates in consideration for
a fee equal to 5% of the actual execution costs (excluding land
acquisition costs, financing cost and the consideration for Control
Centers under the agreement)of each such project ("Supervision Fees").
The agreement will apply to real estate projects whose initiation will
begin following the approval of the agreement by the Company's
shareholders and to three other real estate projects which are
currently under early stage of development. ("Real Estate Projects")
Supervision Fees will be paid in installments upon the meeting of
milestones as stipulated in the agreement. In addition, the Company
will reimburse Control Centers for all reasonable costs incurred in
connection with the services rendered thereby, not to exceed a total
of E75 thousand (NIS 408.0 thousands) per Real Estate Project.
If the purpose of a Real Estate Project is changed for any reason
prior to the completion of the project or if the development of the
Real Estate Project is terminated for any reason (including the sale
of the Real Estate Project), the payment to Control Centers will be
calculated as a percentage of the budget for the project and provided
that such percentage shall not exceed the percentage determined for
the next milestone of the project had it had continued as planned. The
calculation of such payments to Control Centers will be subject to the
approval of an external accountant and the approval of the Audit
Committee and Board of Directors.
In addition, the Company and/or its subsidiaries and/or affiliates may
also purchase from Control Centers through Jet Link Ltd. up to 125
flight hours per calendar year in consideration for payments to Jet
Link in accordance with its price list deducted by a 5% discount. This
Agreement does not derogate from a previous agreement entered into
between the Company and Jet Link Ltd. for the purchase by the Company
of aviation services. See Note 17A.(3)b.
-99-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 21 - BUSINESS AND GEOGRAPHIC SEGMENTS
DATA REGARDING BUSINESS SEGMENTS
A. PRIMARY REPORTING -
YEAR ENDED DECEMBER 31, 2005
COMMERCIAL
AND
ENTERTAIN- IMAGE LEASE
MENT GUIDED OF OTHER
CENTERS HOTELS TREATMENT ASSETS ACTIVITIES TOTAL
---------- --------- --------- ------ ---------- ---------
REPORTED
(IN THOUSAND NIS)
YEAR ENDED DECEMBER 31 2005:
REVENUES 366,237 270,057 75,713 71,000 33,748 816,755
========= ========= ======= ====== ======= =========
OPERATING INCOME (LOSS) BY SEGMENT 189,093 (156) (34,950) 68,199 (34,739) 187,447
========= ========= ======= ====== =======
Share in associates' results 220 (12,248) (12,028)
========= =======
Less - unallocated general and administrative
expenses (36,939)
Financial expenses, net (122,321)
---------
INCOME BEFORE TAXES ON INCOME 16,159
Taxes on income 7,798
---------
INCOME AFTER TAXES ON INCOME 8,361
Minority interest in results of subsidiaries,
net 73,287
---------
INCOME FROM CONTINUING OPERATION 81,648
INCOME FROM DISCONTINUING OPERATION 5,917
CUMMULATIVE EFFECT OF ACCOUNTING CHANGE AT THE
BEGINNING OF THE YEAR (622)
---------
NET INCOME 86,943
=========
PURCHASE COST OF SEGMENT FIXED (TANGIBLE AND
INTANGIBLE) ASSETS (*) 507,248 128,639 11,121 46,269
========= ========= ======= =======
DEPRECIATION AND AMORTIZATION OF SEGMENT ASSETS 58,082 42,589 9,945 2,636 2,263
========= ========= ======= ====== =======
PROVISION FOR IMPAIRMENT OF INVESTMENTS AND
ASSETS 4,128 5,617 13,883
========= ========= =======
DECEMBER 31 2005:
TOTAL SEGMENT ASSETS (*) 1,375,577 1,485,138 56,942 -- 26,752 2,944,409
========= ========= ======= ====== =======
INVESTMENT ON THE EQUITY BASIS 16,515 40,280 56,795
========= =======
UNALLOCATED ASSETS 784,913
---------
3,786,117
=========
SEGMENT LIABILITIES 111,179 60,273 40,666 -- 8,275 220,393
========= ========= ======= ====== =======
UNALLOCATED LIABILITIES 2,498,865
---------
2,719,258
=========
(*) As for the balance of assets under construction and changes therein, during
the reporting year - see Note 10A., above.
-100-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 21 - BUSINESS AND GEOGRAPHIC SEGMENTS (CONT.)
DATA REGARDING BUSINESS SEGMENTS (CONT.)
A. PRIMARY REPORTING (CONT.) -
YEAR ENDED DECEMBER 31, 2005 (CONT.)
CONVENIENCE TRANSLATION
--------------------------------------------------------------------
COMMERCIAL
AND
ENTERTAIN- IMAGE LEASE
MENT GUIDED OF OTHER
CENTERS HOTELS TREATMENT ASSETS ACTIVITIES TOTAL
---------- --------- --------- ------ ---------- ---------
REPORTED
(US$'000)
YEAR ENDED DECEMBER 31 2005:
REVENUES 79,565 58,670 16,449 15,425 7,331 177,440
======= ======= ====== ====== ======
OPERATING INCOME (LOSS) BY SEGMENT 41,080 (34) (7,593) 14,816 (7,547) 40,722
======= ======= ====== ====== ======
Share in associates' results 48 (2,661) (2,613)
======= ======
Less - unallocated general and administrative
expenses (8,025)
Financial expenses, net (26,574)
-------
INCOME BEFORE TAXES ON INCOME 3,510
Taxes on income 1,694
-------
INCOME AFTER TAXES ON INCOME 1,816
Minority interest in results of subsidiaries,
net 15,922
-------
INCOME FROM CONTINUING OPERATION 17,738
INCOME FROM DISCONTINUING OPERATION 1,285
CUMMULATIVE EFFECT OF ACCOUNTING CHANGE AT THE
BEGINNING OF THE YEAR (135)
-------
NET INCOME 18,888
=======
PURCHASE COST OF SEGMENT FIXED (TANGIBLE AND
INTANGIBLE) ASSETS (*) 110,200 27,947 2,416 10,052
======= ======= ====== ======
DEPRECIATION AND AMORTIZATION OF SEGMENT ASSETS 12,618 9,252 2,160 573 492
======= ======= ====== ====== ======
PROVISION FOR IMPAIRMENT OF INVESTMENTS AND
ASSETS 897 1,220 3,016
======= ======= ======
DECEMBER 31 2005:
TOTAL SEGMENT ASSETS (*) 298,844 322,646 12,371 -- 5,810 639,671
======= ======= ====== ====== ======
INVESTMENT ON THE EQUITY BASIS 3,588 8,751 12,339
======= ======
UNALLOCATED ASSETS 170,522
-------
822,532
=======
SEGMENT LIABILITIES 24,154 13,094 8,835 -- 1,798 47,881
======= ======= ====== ====== ======
UNALLOCATED LIABILITIES 542,877
-------
590,758
=======
(*) As for the balance of assets under construction and changes therein, during
the reporting year - see Note 10A., above.
-101-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 21 - BUSINESS AND GEOGRAPHIC SEGMENTS (CONT.)
DATA REGARDING BUSINESS SEGMENTS (CONT.)
A. PRIMARY REPORTING (CONT.)
- YEAR ENDED DECEMBER 31, 2004
COMMERCIAL AND IMAGE LEASE
ENTERTAINMENT GUIDED OF OTHER
CENTERS HOTELS TREATMENT ASSETS ACTIVITIES TOTAL
-------------- --------- --------- ------- ---------- ---------
REPORTED
(IN THOUSAND NIS)
YEAR ENDED DECEMBER 31 2004:
REVENUES 443,814 218,365 57,052 13,238 3,412 735,881
========= ========= ====== ======= ======= =========
OPERATING INCOME (LOSS) BY SEGMENT 124,703 11,513 (7,099) 10,063 (1,123) 138,057
========= ========= ====== ======= =======
Share in associates' results 2,890 (18,858) (15,968)
========= =======
Less - unallocated general and administrative
expenses (43,627)
Financial expenses, net (53,569)
---------
INCOME BEFORE TAXES ON INCOME 24,893
Taxes on income 15,804
---------
INCOME AFTER TAXES ON INCOME 9,089
Minority interest in results of subsidiaries,
net 27,448
---------
INCOME FROM CONTINUING OPERATION 36,537
INCOME FROM DISCONTINUING OPERATION 6,810
---------
NET INCOME 43,347
=========
PURCHASE COST OF SEGMENT FIXED (TANGIBLE AND
INTANGIBLE) ASSETS (*) 199,369 161,361 511
========= ========= =======
DEPRECIATION AND AMORTIZATION OF SEGMENT ASSETS 94,257 37,631 6,069 2,895
========= ========= ======= =======
PROVISION FOR IMPAIRMENT OF INVESTMENTS AND
ASSETS 36,668 10,025 3,876
========= ========= =======
DECEMBER 31 2004:
TOTAL SEGMENT ASSETS (*) 2,028,028 1,522,842 51,198 129,914 14,678 3,746,660
========= ========= ====== ======= =======
INVESTMENT ON THE EQUITY BASIS 16,685 40,245 56,930
========= =======
UNALLOCATED ASSETS 716,689
---------
4,520,279
=========
SEGMENT LIABILITIES 165,638 45,352 27,432 8,311 246,733
========= ========= ====== =======
UNALLOCATED LIABILITIES 3,038,891
---------
3,285,624
=========
(*) As for the balance of assets under construction and changes therein, during
the reporting year - see Note 10A., above.
-102-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 21 - BUSINESS AND GEOGRAPHIC SEGMENTS (CONT.)
DATA REGARDING BUSINESS SEGMENTS (CONT.)
A. PRIMARY REPORTING (CONT.)
- YEAR ENDED DECEMBER 31, 2003
COMMERCIAL AND IMAGE LEASE
ENTERTAINMENT GUIDED OF OTHER
CENTERS HOTELS TREATMENT ASSETS ACTIVITIES TOTAL
-------------- --------- --------- ------- ---------- ---------
ADJUSTED
(IN THOUSAND NIS)
YEAR ENDED DECEMBER 31 2003:
REVENUES 347,056 189,205 20,412 13,495 24,717 594,885
========= ========= ======= ======= ======= =========
OPERATING INCOME (LOSS) BY SEGMENT 96,134 (10,943) (32,016) 9,985 18,714 81,874
========= ========= ======= ======= =======
Share in associates' losses (20,951) (20,951)
=======
Less - unallocated general and administrative
expenses (42,144)
Financial expenses, net (211,821)
---------
LOSS BEFORE INCOME TAXES (193,042)
Tax benefit (20,217)
---------
LOSS AFTER TAXES ON INCOME (172,825)
Minority interest in results of subsidiaries,
net 48,671
---------
LOSS FROM CONTINUING OPERATION (124,154)
INCOME FROM DISCONTINUING OPERATION 12,073
---------
LOSS FOR THE YEAR (112,081)
=========
PURCHASE COST OF SEGMENT FIXED (TANGIBLE AND
INTANGIBLE) ASSETS(*) 348,413 176,960 1,593 2,186 --
========= ========= ======= ======= =======
DEPRECIATION AND AMORTIZATION OF SEGMENT ASSETS 104,471 34,619 5,304 2,994 --
========= ========= ======= ======= =======
PROVISION FOR IMPAIRMENT OF INVESTMENTS AND
ASSETS 12,215 15,597 -- -- 1,155
========= ========= ======= ======= =======
DECEMBER 31 2003:
TOTAL SEGMENT ASSETS (*) 3,401,171 1,270,257 48,465 119,979 21,936 4,861,808
========= ========= ======= ======= =======
EQUITY METHOD INVESTMENT 27,321 58,305 85,626
========= =======
UNALLOCATED ASSETS 580,141
---------
5,527,575
=========
SEGMENT LIABILITIES 81,875 53,147 20,487 7,718 431 163,658
========= ========= ======= ======= =======
UNALLOCATED LIABILITIES 3,938,665
---------
4,102,323
=========
(*) As for the balance of assets under construction and changes therein, during
the reporting year - see Note 10A, above.
-103-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 21 - BUSINESS AND GEOGRAPHIC SEGMENTS (CONT.)
DATA REGARDING BUSINESS SEGMENTS (CONT.)
B. SECONDARY REPORTING
REVENUES BY GEOGRAPHICAL MARKETS
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Israel 92,226 71,678 65,235 20,036
West Europe 304,731 203,615 181,668 66,203
East and central Europe 359,420 414,457 346,200 78,084
Others 60,378 46,131 1,782 13,117
------- ------- ------- -------
816,755 735,881 594,885 177,440
======= ======= ======= =======
PURCHASE COST OF SEGMENT
FIXED (TANGIBLE AND INTANGIBLE) ASSETS
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Israel 24,780 25,353 188,954 5,383
West Europe 73,952 143,904 171,570 16,066
East and central Europe 594,543 191,984 168,628 129,165
------- ------- ------- -------
693,275 361,241 529,152 150,614
======= ======= ======= =======
SEGMENT ASSETS
YEAR ENDED DECEMBER 31
-----------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
--------- --------- -----------
(IN THOUSAND NIS) US$'000
Israel 648,441 702,659 140,874
West Europe 1,252,253 1,437,807 272,051
East and central Europe 1,070,260 1,637,524 232,514
Others 30,050 25,600 6,528
--------- --------- -------
3,001,004 3,803,590 651,967
========= ========= =======
-104-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 22 - DISCONTINUING OPERATIONS
A. Following the sale of the diagnostic ultrasound activity, previously
conducted by subsidiaries and the sale of Nuclear Medicine (NM), Magnetic
Resonance Imaging (MRI) and Computerized Tomography (CT) activities by
Elscint, the Group's core activity in these areas was, during 1998,
terminated. The results from same have therefore been presented in the
statements of operations, as discontinuing operation. Balances included in
the statement of operations and/or dispositions in balance sheet items
through the reported years, reflect primarily settlements or resolution of
disputes and/or lawsuits and/or certain claims relating to the ultrasound,
CT and MRI businesses and the ultimate sale thereof by Elscint.
B. The following table states composition of assets, liabilities, income and
expenses relating to the discontinuing operations in previous years:
DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
CURRENT ASSETS
Receivable and other debit accounts 2,276 2,577 494
LONG-TERM INVESTMENTS AND RECEIVABLES 10,331 12,123 2,245
------ ------ ------
12,607 14,700 2,739
====== ====== ======
CURRENT LIABILITIES
Payables and other credit accounts 62,430 71,986 13,563
====== ====== ======
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Financial income (expenses), net (5,236) 2,512 6,463 (1,138)
Other income, net 14,266 8,555 10,600 3,099
------ ------ ------ ------
9,030 11,067 17,063 1,961
Minority interest (3,113) (4,257) (4,990) (676)
------ ------ ------ ------
NET INCOME FROM DISCONTINUING OPERATION 5,917 6,810 12,073 1,285
====== ====== ====== ======
-105-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 23 - FINANCIAL INSTRUMENTS
A. CURRENCY TRANSACTIONS AT DECEMBER 31, 2005
SWAP TRANSACTIONS
Two companies within the B.H. Group have entered into a Swap transaction
with a foreign financial institution (which granted thereto a
variable-interest bearing loan), with respect to the interest rate on the
loan principal, namely the determination thereof at a fixed 5.1% interest
rate through 2009. The Company's share in the principal amount of the loan
and in the fair value of the transaction (liability) as of December 31,
2005, based on the market valuation of transactions similar thereto
(considering all terms and conditions thereof), totals E35.6 million (NIS
193.9 million; $42.1 million) and E0.5 million (NIS 2.7 million; $0.6
million), respectively.
B. FAIR VALUE OF FINANCIAL INSTRUMENTS
The Group's financial instruments include monetary assets - cash and cash
equivalents, short and long-term deposits, trade accounts receivable,
marketable securities as well as other receivables and current accounts,
and these monetary liabilities - short-term credits and long-term
liabilities, trade accounts payable as well as payables and other credit
balances. Due to the nature of the financial instruments included in
working capital, their fair values approximate those presented in the
balance sheet.
The fair value of long-term trade accounts receivable, deposits and
long-term liabilities is ordinarily based on the present value of future
receipts and payments, discounted by the interest rate applicable to the
Company's lending or borrowing activities under similar terms as of the
balance sheet date, and it is not materially different from the value
thereof as stated in the financial statements.
As for the presentation of long-term balances not under market conditions -
see Note 2K.
Derivative financial instruments having an active market, were evaluated
based on market value.
C. CONCENTRATION OF CREDIT RISKS
Israeli and foreign cash and deposits are placed in banks.
Investments in marketable securities - as for composition of the short and
long-term investment portfolio- see Note 4 and Note 9 above.
Investments in marketable securities are exposed to market-price
fluctuations. Capital markets are also subject to fluctuations in respect
of events over which the Group has no control. Such changes may have an
impact on the value of these investments upon realization.
Due to the nature of their activity, the Group companies are not materially
exposed to credit risks stemming from dependence on a given customer. The
Group companies examine on an ongoing basis the credit amounts extended to
their customers and, accordingly, record a provision for doubtful debts
based on those factors they consider having an effect on specific
customers.
As for transaction for the sale of commercial centers to Klepierre in 2004
and in 2005 - See Note 9B(3) a. and d.Debts included in the framework of
long-term receivables - see Note 8A above.
D. INTEREST-RATE RISKS
As for interest rates - see Notes 3, 4, 8, 9, 12 and 14 above.
-106-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 24 - MATERIAL SUBSEQUENT EVENTS (UNAUDITED)
A. On April 11, 2006, third party shareholder of Domino (see Note 9B.(4))
filed a claim against Elscint, the Chairman of the Board of Directors of
Elscint, Elscint's office holders and against companies controlled by
Elscint.
In the framework of this claim, the court has been asked to declare that
the third party shareholder is the legal owner of 20% of Domino's shares,
to enforce the MOU signed by the parties and to order the defendants to pay
damages in the amount of NIS 25 million ($5.5 million).A statement of
defense has not yet been filed.
Management of the Company believes - based, inter alia, on legal opinion
that chances are good that the claim would be dismissed either partially or
in its entirety.
B. In May 25, 2006, the Plaintiff filed an additional lawsuit to the law suits
described in Note 17B.(7) in the District Court in Tel-Aviv-Jaffa against
the Company, Mr. Zisser and/or Control Centers and/or the Company's board
members and/or the management companies related to Mr. Zisser and Control
Centers, requesting the court to state the annulment of any decision made
by the Company for granting of any benefits to Mr. Zisser and/or Control
Centers using shares the subject of Plaintiff's claimed.
Alternatively, the Plaintiff requested the court to determine that the
Plaintiff's claimed rights to the Company's shares will be taken into
account as an opposing side to any decision made in any general meetings of
the Company, while reserving the Plaintiff's rights to take legal
proceedings to prevent infringement of his rights as a minority shareholder
in the company. Alternatively, the Plaintiff requested the court to
determine that in every general meeting that convenes for determining the
above stated decisions, the Plaintiff's claimed rights to the Company's
shares will not be considered as taking any side in the decisions, while
reserving his above legal rights.
Management, based on a legal advice received, is of the opinion that it is
not possible at this early stage to estimate the outcome of the claim.
C. On May 17, 2006, Elscint sold 524,187 dormant shares of the Company in
consideration for NIS 115 for each share, through a private transaction.
Accordingly, the Company's shareholders' equity will increase in the amount
of NIS 60 million.
Prior to the reported transaction, these shares did not have voting rights
inasmuch as they were held by a subsidiary of the Company. However,
following the transaction the shares sold will enjoy full equity and voting
rights.
D. As for non-convertible debentures issuance in March 2006 - see Note 14H.
E. On April 11, 2006 the Company was informed that on April 5, 2006 the
Company and PC were served with a summary procedure claim before the
District Court of Tel-Aviv by third party in term of which, the Court was
requested to order the Company and PC to pay the plaintiff an amount of NIS
10.8 million ($2.3 million) as an intermediary fee for the sale by PC to
Klepierre of commercial centers in Poland and Czech Republic.(See Note9B.
(3)d.)
An application for leave to defend has not yet been filed. The Company and
PC filed a motion to strike out this claim in limine or alternatively to
strike out the title "summary procedure".
Management of the Company believes - based, inter alia, on legal opinion -
that chances are good that the claim would be dismissed either partially or
in its entirety.
F. As for refinance loan agreement signed on March 2, 2006 - see Note 14I.
-107-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 24 - MATERIAL SUBSEQUENT EVENTS (UNAUDITED) (CONT.)
G. As for related party transactions approved by the Company's Audit Committee
and its Board of Directors in March and April 2006 - see Note 20F. On May
31, 2006 the Company's shareholders meeting approved the audit committee
and the Board resolution described in Note 20F save that the Exercise Price
of the options granted to the Company's employees, directors and officers
(See Note 20 F (i)) will be NIS 100.0.
H. In May 2006, the Budapest General Assembly approved the amendment to the
local town-planning scheme ("KSZT"), which approves the construction plans
for the Obuda island (see Note 9B.(3)f.). Formal regulatory approvals of
the KSZT modification contained in the Budapest General Assembly resolution
are currently pending. As part of the above approval provided, the target
Company has undertaken to ensure the traffic connections to, from and
within the island and to develop details landscape works. The additional
investment required in consideration of the aforementioned projects is
estimated in approximately E55 million.
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS
The consolidated financial statements of the Company are prepared in accordance
with accounting principles generally accepted in Israel ("Israeli GAAP"), which
differ, in certain significant respects, from those generally accepted in the
United States ("U.S. GAAP"), as follows:
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
1. EFFECT OF INFLATION
In accordance with Israeli GAAP. Through December 31, 2003, the
Company's financial statements were prepared in adjusted values (in
NIS of constant purchase power), on the basis of changes in the
consumer price index ("Inflation" and "CPI"), in accordance with
Opinions No. 36 and 50 of the ICPAI ("Opinion 36" and "Opinion 50").
On January 1, 2004, Accounting Standard No. 12 of the IASB came into
effect ("Standard 12"). In accordance with the provisions of Standard
12, adjustment of financial statements to the inflation shall cease
commencing January 1, 2004. Adjusted amounts of non-monetary items
which were included in the balance sheet of December 31, 2003, are to
be used as the basis for the nominal financial reporting as of and
from January 1, 2004. Amounts presented in the financial statements
for periods commencing January 1, 2004 were, therefore, included in
values to be hereinafter referred to as "Reported amounts". For the
basis of presentation and principles of the adjustment - see Note 2A.,
above.
In accordance with U.S. GAAP. The financial statements should be
expressed in nominal historical terms.
As permitted by the United States Securities and Exchange Commission
rules for foreign private issuers whose financial statements
comprehensively include the effects of inflation, price level
adjustments have not been reversed in the reconciliation of Israeli
GAAP to the U.S. GAAP financial statements.
-108-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
2. JOINTLY CONTROLLED COMPANIES
In accordance with Israeli GAAP. The financial statements of jointly
controlled companies are included in the consolidated financial
statements in accordance with the "proportionate consolidation
method".
In accordance with U.S. GAAP. Investments in jointly controlled
companies are accounted for by the equity method. However, use of the
proportionate consolidation method is permitted by Securities and
Exchange Commission rules for a foreign issuer. Use of proportionate
consolidation does not have any effect on the income (loss) and/or
shareholders' equity. Differences in classifications or display of
items in the balance sheet, in the statement of operations and in the
statement of cash flows, that result from using proportionate
consolidation, are not required to be included in the reconciliation
to the U.S. GAAP financial statements. However, summarized data on a
pro forma basis, regarding reporting differences between the
proportionate consolidation method and the equity method, is provided
in B.3 below.
3. DEFERRED TAX
A. DEFERRED TAXES IN RESPECT OF INFLATION ADJUSTMENT
In accordance with Israeli GAAP. Through December 31, 2004
deferred taxes in respect of inflation adjustments of fixed
assets are provided only to the extent that such fixed assets are
depreciated over a period not exceeding 20 years.
In July 2004, Accounting Standard No. 19 - Income Taxes
("Standard 19") published by the IASB, went into effect. Standard
19 sets forth principles for recognition, measurement,
presentation and disclosure of income taxes in financial
statements. Standard 19 applies to financial statements for
periods commencing on or after January 1, 2005. Initial
implementation of Standard 19, mainly for the initial inclusion
of deferred taxes in respect of adjustment component for land and
buildings, is included as "cumulative effect for the beginning of
the year due to a change in accounting method" in the statement
of operations and in the statement of changes of shareholders'
equity for the current period.
Thus, as from January 1, 2005 no difference between Israeli GAAP
and US GAAP regarding this issue, exists.
In respect of inflation-adjustment component for land and
buildings- see Note 2W., above.
In accordance with U.S. GAAP. Deferred taxes are provided on all
such inflation-adjustments, to the extent that they are temporary
differences, regardless of the period through which they will be
depreciated or when they will be deductible for tax purposes.
-109-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
3. DEFERRED TAX (CONT.)
B. DEFERRED TAXES IN RESPECT OF BUSINESS COMBINATION
In accordance with Israeli GAAP. Through December 31, 2004,
deferred taxes are recorded for differences between the assigned
value, at the acquisition date, and the book value for tax
purposes, of identifiable assets and liabilities of subsidiaries,
upon acquisition of the investment therein, except for assets for
which depreciation is not allowable for tax purposes (e.g. land
and similar assets). As from January 1, 2005 deferred taxes are
recorded for such differences which were out of the scope of the
accounting principles which were in effect through December 31,
2004, as mentioned above (including land and the same) as long as
such differences relate to transactions occurring as of that date
and thereafter.
In accordance with U.S. GAAP. Deferred taxes are recorded for
temporary differences mentioned in the preceding paragraph, in
respect of assets whether or not their depreciation is allowed
for tax purposes.
C. TAX EFFECT ON ITEMS INITIALLY CHARGED OR CREDITED TO
SHAREHOLDERS' EQUITY
Any related tax effects in respect of items charged or credited
directly to shareholders' equity during the current year, should
also be included directly in equity.
In accordance with Israeli GAAP. Current-year deferred taxes
related to prior-years equity items (arising from (i) changes in
assessments of recovery of deferred tax assets; or (ii) changes
in tax rates, tax laws, or other measurement factors), should be
included directly in shareholders' equity.
In accordance with U.S. GAAP. SFAS No. 109 prohibits the
inclusion of such tax effects directly in shareholders' equity.
The taxed effect must be reflected in the statement of operations
of the current reporting year.
D. INITIAL RECOGNITION OF AN ASSET OR A LIABILITY
Temporary differences which arise on initial recognition of an
asset or a liability, such as an event that part of the cost of
an asset is not deductible for tax purposes.
In accordance with Israeli GAAP. It is not allowed to recognize
deferred tax asset or liability on initial recognition, when
temporary differences generated upon initial recognition of
goodwill or upon transaction not in respect with a business
combination, and that which at the initial recognition thereof
had no effect on the accounting or tax net income.
In accordance with U.S. GAAP. EITF 98-11 addresses recognition of
deferred taxes resulting from purchases of assets which are not
business combination. Thus, even if the transaction is not a
business combination, and affects neither accounting income nor
taxable income, an enterprise would recognize the resulting
deferred tax liability or asset and adjust the carrying amount of
the asset by the same amount.
-110-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
4. STOCK-BASED COMPENSATION
In accordance with Israeli GAAP. Through December 31, 2005 the
Intrinsic value within an equity-settled share based payment
transaction (including shares granted to employees against loans which
constitute the sole security for the loans repayment, that are treated
as options), granted by companies to their employees and/or directors,
is not charged as compensation expenses in the statement of
operations. As for accounting standard No. 24 (share-based payments),
which is effective from January 1, 2006 - see Note 2X(iii).
In accordance with U.S. GAAP. The Company applies the intrinsic value
method for employee stock-based compensation in accordance with
Accounting Principles Board Opinion No. 25, "Accounting for Stock
Issued to Employees" ("APB 25"), and in accordance with FASB
Interpretation No. 44. Pursuant to these accounting pronouncements,
the Company records compensation for stock options in respect of fixed
awards (i.e., award in which the number of shares granted and their
exercise price is fixed and known at the grant date), granted to
employees and/or directors over the vesting period of the options,
based on the difference, if any, between the exercise price of the
options and the fair value of the underlying shares at that date of
grant. With respect to variable awards, changes in the market price of
the underlying shares at each balance sheet date, may affect the
aggregate amount of compensation recorded. Accordingly, in some of the
Company's and its subsidiaries' stock option plans, no compensation
expenses has been recognized for options granted, as grants were made
at the quoted market value of the underlying shares. However, in stock
option plans, adopted by one of the Company's subsidiaries, a
privately held company (see Note 9B(2)d. above), its Board of
Directors determined that, at the various times of issuance of its
stock options under two Stock Option Plans, the fair value of the
shares underlying the stock options exceeded the stock option exercise
prices by an accumulated amount of approximately $7.7 million.
Deferred compensation is amortized to compensation expenses over the
vesting period of the options and is included as salary, as part of
the cost of revenues, research and development costs, selling and
marketing expenses and general and administrative expenses, as the
case may be.
Grants to other-than employees/directors are accounted for at fair
value as of the date of grant, in accordance with SFAS No. 123,
"Accounting for Stock-based Compensation" ("SFAS No. 123"), as amended
by SFAS 148 and related interpretations and in accordance with EITF
96-18.
Regarding the pro forma effect, according to SFAS No. 123, see
B.5A.(4) below.
As of SFAS 123-R, which is effective from January 1, 2006 - see item
18b. below.
5. ISSUANCE OF SHARES BY A DEVELOPMENT STAGE INVESTEE
In accordance with Israeli GAAP. The increase in the Company's share
of the net asset value of such an investee, as a result of an issuance
of shares by the investee to third parties, is recorded as deferred
income, which is charged to the statement of operations over a three
year period or up to the Company's share in investee's losses during
the relevant period, whichever is higher, on an cumulative basis.
In accordance with U.S. GAAP. The increase in the Company's share in
the investee's net asset value, is included directly in shareholders'
equity.
The accumulated losses of Insightec during its development stage
period, amounts to
-111-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
approximately $63.9 million.
-112-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
6. IMPLEMENTATION OF THE EQUITY METHOD
A. Investment previously accounted for on the cost basis which
becomes qualified for use of the equity method, due to an
increase in the level of ownership as a result of acquisition by
the Company of additional voting stock of the investee or due to
a change in the investor's status because of no longer meeting
the applicable Venture Capital Investment Fund conditions, is
treated as follows:
In accordance with Israeli GAAP.
(i) The company (the Investor) should implement the equity
method only from the date the investment become qualified
for use of the equity method (i.e. from the date the change
has occurred) and thereafter. Restatement of previous years'
data, presented within the financial statements, is not
required or permitted.
(ii) Through December 31, 2005, goodwill is amortized - as part
of the investment as a whole - periodically over its
respective estimated useful life, and is reviewed
periodically, for impairment. In accordance with the
provisions of Standard No.20 - which applies to financial
statements covering periods beginning January 1, 2006 -
goodwill in respect of associated companies will no longer
be amortized but rather examined for impairment - see Note
2X(v). Thus, as from January 1, 2006 no difference between
Israeli GAAP and US GAAP regarding this issue, exists.
In accordance with U.S. GAAP.
(i) The investment, results of operations (current and prior
periods presented) and retained earnings of the company,
should be adjusted, retroactively, by applying the
accounting of step-by-step acquisition of the investee's
stock.
(ii) Goodwill related to equity method investees is not amortized
(as from January 1, 2002 and thereafter) but is tested for
impairment under the provisions of APB 18.
B. In circumstances where the Company's ownership in an investee
company (mainly, venture capital investments) is in the form of
preferred securities or other senior securities, the Company
records equity losses based on the ownership level of the
particular investee securities or loans extended by the Company
to which the equity method losses are being applied.
In accordance with Israeli GAAP. If the investor is able to
exercise significant influence over the investee's operational
and financial policies, the equity method of accounting shall be
applied.
In accordance with U.S. GAAP. Effective for reporting periods
beginning after September 15, 2004, the equity method of
accounting is no longer to be applied in respect of investments
that are not common stock (or in-substance common stock),
regardless of the Company's ability to carry out through such
securities significant influence over the investee's operational
and financial policies.
-113-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
7. CAPITALIZATION OF FINANCIAL EXPENSES DURING THE CONSTRUCTION PERIOD
In accordance with Israeli GAAP. The amount of financial expenses to
be capitalized for qualifying assets is that portion of the financial
expenses in real terms, including exchange rate differences, incurred
during the assets' construction period.
In accordance with U.S. GAAP. Financial expenses eligible for
capitalization for qualifying assets include only interest costs, and
do not include exchange rate gains and losses.
8. IMPAIRMENT OF LONG-LIVED ASSETS AND INVESTMENTS
Throughout the process of assessing the need for recording an
impairment loss, the Company considers certain indicators, so as to
trigger an impairment review, that include, among other things, the
following: (i) a material adverse industry or economic trend; (ii)
significant under-performance relative to historical or projected and
expected operating results; (iii) a significant change in the manner
in which an asset is used, or is supposed to or intended to be used;
(iv) significant changes, with an adverse effect, in the market,
economic or legal environment in which each asset is operating and/or
in which we own or lease real estate; (v) an accumulation of costs
significantly in excess of the amount originally expected to be used
for the construction, operation and/or holding of an asset; and (vi)
various other indications as to the fair value of assets in their
respective active markets.
In accordance with Israeli GAAP. As from January 1, 2003, the
impairment review for such assets is based on the assets' estimated
net selling price or the estimated value-in-use, based on discounted
cash flows expected to be generated by those assets, whichever is
higher (see also Note 2N. above).
According to the provisions set forth in opinion No. 68 of the ICPAI
(which were in effect through December 31, 2002), in case of a decline
in value (other than of a temporary nature) that causes the fair value
of an investment in an autonomous foreign investee company (including,
subsidiaries) to be less than its carrying amount, a provision for the
decline in fair value was provided.
Through December 31, 2005, goodwill is amortized over its estimated
useful life, and is reviewed periodically, for impairment. In
accordance with the provisions of Standard No.20 - which applies to
financial statements covering periods beginning January 1, 2006 -
positive goodwill presented in the balance sheet on December 31, 2005
will no longer be amortized but rather examined for impairment - see
Note 2X(v). Thus, as from January 1, 2006 no difference between
Israeli GAAP and US GAAP regarding this issue, exists.
In accordance with U.S. GAAP. The impairment review for such assets
that are held for use is based on undiscounted future cash flows
expected from the holding and use of these assets in accordance with
SFAS 144 ("Accounting for the Impairment or Disposal of Long-Lived
Assets"). The principles set forth in APB 18, in respect of fair value
measurement and loss recognition for a decline in an investment's
value, refers to investments in associated companies only. Tests and
measurements for impairment of the company's share in subsidiary's
equity are performed on a consolidated basis and is covered by
provisions, included in other statements for measuring assets and/or
liabilities.
Goodwill, arising from business combination, determined to have an
indefinite useful life and is not amortized, but is tested for
impairment, at least annually, together with the entire investment, as
a whole.
-114-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
9. REALIZATION OF CAPITAL RESERVE FROM TRANSLATION ADJUSTMENT
A. As a result of impairment loss recognition:
In accordance with Israeli GAAP. Through December 31, 2002, such
an impairment loss was charged directly against any credit
balance in the capital reserves for translation adjustments,
previously recorded in respect of this investment. Commencing
January 1, 2003, (the date a new accounting standard regarding
impairment of assets became effective in Israel) such a decline
in value is charged directly to the statement of operations.
Thus, as from that date no difference between Israeli GAAP and
U.S. GAAP regarding this issue, exists.
In accordance with U.S. GAAP. Capital reserves for translation
adjustments are realized only upon sale or upon complete (or
substantially complete) liquidation of the investment in the
foreign entity. Realization of such capital reserve as a result
of recording a provision for impairment loss, is prohibited.
B. As a result of a repayment of a monetary balance of a capital
nature:
In accordance with Israeli GAAP. The accumulated translation
adjustment relating to such monetary balance, is released to the
statement of operations.
In accordance with U.S. GAAP. Capital reserves for translation
adjustments are realized only upon sale or upon complete (or
substantially complete) liquidation of the investment in the
foreign entity. Realization of such capital reserve, as a result
of a repayment of a monetary balance of a capital nature, is
prohibited.
-115-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
10. DERIVATIVE FINANCIAL INSTRUMENTS
A. The Company leases its commercial centers under long-term
contracts. The leases are denominated, generally, in Euro (some
are denominated in dollars), most of which are linked to the Euro
Index.
In accordance with Israeli GAAP. Derivatives embedded within
non-derivative instruments, should not be bifurcated from the
host instruments and are treated for accounting purposes together
with the host instrument.
In accordance with U.S. GAAP. According to Statement of Financial
Accounting Standards No. 133, "Accounting for Derivative
Instruments and Hedging Activities" ("SFAS 133"), a "derivative"
is typically defined as an instrument whose value is derived from
an underlying instrument, index or rate, has a notional amount,
requires no or little initial investment and can be net settled.
Derivatives include, but are not limited to, the following types
of investments: interest rate swaps, interest rate caps and
floors, put and call options, warrants, futures, forwards and
commitments to purchase securities and combinations of the
foregoing.
Derivatives embedded within non-derivative instruments, must be
bifurcated from the host instrument and accounted for in
accordance with SFAS 133, when the embedded derivative is not
clearly and closely related to the host instrument. Rental for
the use of leased assets and adjustments for inflation on similar
property are considered to be clearly and closely related. Thus,
the inflation-related derivative embedded in an inflation-indexed
lease contract is not bifurcated from the host contract.
In conformity with SFAS 133, foreign currency forward contracts
that are embedded within such lease contract ("the host
contract") should be bifurcated and accounted for separately. The
bifurcated forward contracts are recorded at their fair value
while changes in their fair values are charged to the statement
of operations and classified under financial income, (expenses)
net.
An embedded foreign currency instrument is not bifurcated from
the host contract, if (i) contracts in which specified volumes of
sales of one of the parties to the contract serve as the basis
for settlement ("underlying"); (ii) the host contract is not a
financial instrument and it requires payments denominated in the
functional currency of any substantial party to that contract,
determined based on the conditions exists at the inception of the
lease agreement.
B. In order to partially hedge the risk of variable interest rate on
long term loans, the Company fixed certain variable interest
rates by swap transactions.
In accordance with Israeli GAAP. Derivative financial instruments
that are designated for hedging cash flows are not presented as
assets or liabilities.
In accordance with U.S. GAAP. Derivative financial instruments
that are designated for hedging cash flows, are stated, according
to FAS No. 133, at their estimated fair value. Changes in their
fair value during the reporting period are charged, when
occurred, as capital reserve, under other comprehensive income,
in shareholders' equity.
-116-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
11. DISCONTINUED OPERATIONS
A. DETERMINATION OF A "COMPONENT OF AN ENTITY":
Upon realization of a "component of an entity" the results
thereof should be accounted for as discontinued operations.
In accordance with Israeli GAAP. A "component of an entity"
comprises operations that (i) can be distinguished operationally
and for financial reporting purposes, from the rest of the
entity; and (ii) represent a separate major line of business or
geographical area of operations. The applicable Israeli
principles do not address a "reporting unit" (as defined in
standard No. 15 of the IASB) to be considered "a component of an
entity" for discontinued operation purposes.
In accordance with U.S. GAAP. A "component of an entity"
comprises operations and cash flows that can be clearly
distinguished, operationally and for financial reporting
purposes, from the rest of the entity. A "component of an entity"
may be a "reportable segment" or an "operating segment" (as those
terms are defined in SFAS No. 131), a "reporting unit" (as that
term is defined in SFAS No. 142), a subsidiary, or an "asset
group" (as that term is defined in SFAS No. 144). The results of
operations of a "component of an entity" that either has been
disposed of or is classified as held-for-sale, shall be reported
as discontinued operations, if both of the following conditions
are met: (i) the operations and cash flows of the component have
been (or will be) eliminated from the ongoing operations of the
entity as a result of the disposal transaction; and (ii) the
entity will not have any significant continuing involvement in
the operations of the component after the disposal transaction.
Each hotel or commercial center is, as of the date of the
financial statements, the lowest level at which the operations
and cash flows can be clearly distinguished, operationally and
for financial reporting purposes, from the rest of the entity.
Therefore, each hotel and/or commercial center which were
disposed of is considered for discontinued operations purpose, as
a "component of the entity".
B. GAIN RECOGNITION:
In accordance with Israeli GAAP. A gain from a sale transaction
is recognized only after providing an acceptable level of
assurance of the existence and the amount of the gain. Gain
generation process is deemed to be culminated when: (i) realized
(assets are exchanged for cash or claim to cash) or realizable;
and (ii) the seller has substantially accomplished what it must
do in order to be entitled to the benefits represented by the
gain. The gain from the sale of a business should be recognized,
generally, when the following conditions have been satisfied: (i)
the seller has transferred to the buyer the significant risks and
rewards of ownership; (ii) the seller retains neither continuing
managerial involvement to the degree usually associated with
ownership nor effective control over the assets/business sold;
(iii) any major uncertainties as to ultimate realization of
profit have been removed and the amount of the gain can be
measured reliably; and (iv) it is probable that the economic
benefits associated with the transaction will flow to the seller
and the collection of the sale price is reasonably assured. In
light of the above mentioned, the gain from the sale of Elscint's
Plant in Ma'a lot was recognized in the Company's 2002 financial
statements.
-117-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
11. DISCONTINUED OPERATIONS (CONT.)
B. GAIN RECOGNITION (CONT.):
In accordance with U.S. GAAP. Gain from such sale of business
should not be recognized unless all consideration was in the hand
of the seller at the balance sheet date. Since in the Ma'alot
transaction, a significant portion of the cash consideration was,
according to the buyer's request, deposited in escrow, for future
release, in order to secure the potential purchase price
adjustments, that may be required (if any), the gain on the sale
was recognized, for U.S. GAAP purposes, in the Company's 2003
financial statements.
12. SUBSEQUENT EVENTS - DIVIDEND
If a dividend is declared subsequent to the balance sheet date but
before the financial statements are issued, the dividend is not
recognized as a liability at the balance sheet date.
In accordance with Israeli GAAP. Such dividend is to be recorded as a
separate item in the shareholders' equity, named "declared dividend
after the balance sheet date".
In accordance with U.S. GAAP. Such dividend is not recorded as a
separate item in the shareholders' equity.
13. CONVERTIBLE DEBENTURE
In accordance with Israeli GAAP.
A. Through December 31, 2005, convertible debentures are included,
in each reporting period, on the basis of the probability of
their conversion as at the date of the end of each respective
reporting period. If conversion is not probable they are recorded
as liabilities at their monetary value; if conversion is probable
they are presented as a separate caption between liabilities and
shareholders' equity, at the higher of their monetary or
non-monetary value.
B. The "beneficial conversion feature" component is not recognized
in the financial statements, separately, within the shareholders'
equity.
In accordance with the provisions of Standard No.22 - which
applies to financial statements covering periods beginning
January 1, 2006 - an entity should evaluate, as from January 1,
2006, the terms of each financial instrument in order to
determine whether it contains both a liability and an equity
component. Such components shall be classified separately as
financial liabilities, financial assets or equity instruments, in
accordance with the substance of the contractual arrangement and
the definitions of a financial liability, a financial asset and
an equity instrument - see Note 2X(i).
-118-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
13. CONVERTIBLE DEBENTURE (CONT.)
In accordance with U.S. GAAP.
A. Convertible debentures are recorded as liabilities at their
monetary value.
B. In accordance with EITF No. 98-5, "Accounting for Convertible
Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios" and EITF No. 00-27, "Application of
Issue No. 98-5 to Certain Convertible Instruments", embedded
"beneficial conversion features" included in convertible
securities, should be valued separately at issuance. The embedded
"beneficial conversion feature" should be recognized and measured
by allocating a portion of the proceeds equal to the intrinsic
value of that feature to additional paid-in capital. That amount
should be calculated at the commitment date as the difference
between the conversion price and the fair value of the common
stock or other securities into which the security is convertible,
multiplied by the number of shares into which the security is
convertible (intrinsic value).
14. PRINCIPLES OF CONSOLIDATION IN RESPECT OF "VARIABLE INTEREST ENTITIES"
("VIE")
In accordance with Israeli GAAP. Statement of Opinion No. 57 of the
ICPAI, which constitutes the sole prevailing pronouncement for
consolidation principles in Israel, does not deal with control
achieved through means other than voting rights.
In accordance with U.S. GAAP. Interpretation No. 46 ("FIN 46"),
"Consolidation of Variable Interest Entities, an interpretation of ARB
51", provides a new framework for identifying variable interest
entities ("VIE") and determining when a company should include the
assets, liabilities and results of operations of a VIE in its
consolidated financial statements. In December 2003, the FASB issued
FIN 46 (revised December 2003), "Consolidation of Variable Interest
Entities" ("FIN 46-R") to address certain FIN 46 implementation
issues.
An entity is considered as a VIE when (i) the equity investment at
risk is not sufficient to permit the entity from financing its
activities without additional subordinated financial support from
other parties; or (ii) equity holders either: (a) lack direct or
indirect ability to make decisions about the entity; (b) are not
obligated to absorb expected losses of the entity; or (c) do not have
the right to receive expected residual returns of the entity if they
occur. If an entity or investment is deemed to be a VIE, an enterprise
that absorbs a majority of the expected losses of the VIE or receives
a majority of the residual returns (if no other variable interests
absorb majority of the VIE's losses), or both, is considered the
"primary beneficiary" and must consolidate the VIE.
FIN 46 was effective immediately for VIEs created after January 31,
2003. For VIEs created before January 31, 2003, the provisions of FIN
46, as revised, were adopted as of December 31, 2004. The Company
evaluated its investee companies in respect of the need for adoption
of FIN 46-R and it was determined that one of its investee companies
(which, in accordance with the Israeli GAAP, is consolidated on the
basis of the proportionate-consolidation method), should be fully
consolidated in the Company financial statements, in accordance with
U.S. GAAP.
-119-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
15. CONVERTIBLE SECURITIES OF INVESTEES
In accordance with Israeli GAAP. A company is required to record a
provision for losses which may incur as a result of the dilution of
its shareholdings in investees upon exercise of vested share options,
when it is probable that they will be exercised. . The provisions of
Opinion No. 48 were terminated by Standard No. 22 - which is effective
as from January 1, 2006 - Thus as from that date no difference between
Israeli GAAP and U.S. GAAP regarding this issue, exits.
In accordance with U.S. GAAP. A loss resulting from the dilution of a
Company's shareholdings, in the event the share options are exercised,
is recorded in its financial statements only at the time of exercise.
16. EXCESS OF FAIR VALUE OF AQUIRED NET ASSETS OVER COST
In accordance with Israeli GAAP. The excess of fair value of net
assets acquired in a business combination or in acquisition of some or
all of the non-controlling equity interest in a subsidiary over cost,
should be allocated as a pro rata reduction to the amount that
otherwise would have been assigned to all of the acquired non-monetary
assets.
In accordance with U.S. GAAP. In accordance with the provision of SFAS
No. 141 such allocation is not permitted to assets of the acquired
entity to be disposed of by sale.
17. GUARANTEES PROVIDED IN FAVOR OF THIRD PARTIES
In accordance with Israeli GAAP. A guarantor is not required to
recognize a liability for the fair value of the obligation undertaken
in issuing the guarantee that is the obligation to stand ready to
perform in the event that specified triggering events or conditions
occur.
In accordance with U.S. GAAP. In November 2002, FASB Interpretation
No. 45 ("FIN 45"), "Guarantor's Accounting and Disclosure Requirements
for Guarantees, Including Indirect Guarantees of Indebtedness of
Others" was issued. FIN 45 requires elaborating on the disclosures
that must be made by a guarantor in its financial statements about its
obligations under certain guarantees that it has issued. It also
clarifies that a guarantor is required to recognize, at the inception
of a guarantee, a liability for the fair value of the obligation
undertaken in issuing the guarantee. The Interpretation requires the
guarantor to recognize a liability for the non-contingent component of
the guarantee, that is the obligation to stand ready to perform in the
event that specified triggering events or conditions occur. The
initial measurement of this liability is the fair value of the
guarantee at inception. The recognition of the liability is required
even if it is not probable that payments will be required under the
guarantee or if the guarantee was issued with a premium payment or as
part of a transaction with multiple elements. The management of the
Company is of the opinion that FIN 45 does not have a material impact
on its financial statements.
-120-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
18. OTHER DIFFERENCES
a. Translation of profit and loss items:
In accordance with Israeli GAAP. As from January 1, 2004 revenues
and expenses of foreign operations constituting "autonomous
foreign entities", are translated based on the exchange rate as
at the date of transaction or cash flow, as the case may be, or
for sake of practicality, using the average exchange rate for the
period; thus, as from that date, no differences between Israeli
GAAP and U.S. GAAP, exists. Principles used through Decembers 31,
2003 provided for translation of all items of the "autonomous
foreign entities" financial statements (including those of the
statements of operations and cash flows), based on "closing
rates".
In accordance with U.S. GAAP. In accordance with SFAS No. 52, the
transactions included in the statements of operations and cash
flows of an "autonomous foreign entity," are translated at the
actual transaction rates or the average rate for the period, for
all reporting years included in these financial statements.
b. Start-up costs:
In accordance with Israeli GAAP.
(i) Pre-operating costs in respect of hotels and/or commercial
centers operations are stated at cost and amortized over a
three-year period from commencement of full scale
operations.
(ii) Initiation costs of projects which do not meet
capitalization criteria (see Note 2I. above) are included as
operating expenses.
In accordance with U.S. GAAP. In accordance with the Statement of
Position ("SOP") 98-5 "Reporting on the Costs of Start-up
Activities", all costs of start-up activities (pre-opening,
pre-operating and organizational costs) are expensed, within
operating expenses, as incurred.
c. Marketable Securities:
In accordance with Israeli GAAP. Investments in marketable
securities, designated by management for sale in the short term,
are included in current assets at their market value at the
balance-sheet date. Changes in value are charged to the statement
of operations, as incurred.
In accordance with U.S. GAAP. In accordance with SFAS No. 115,
marketable securities that are acquired and held principally for
the purpose of selling them within the near future, are
classified as trading securities and are reported at their fair
value. Unrealized gains and losses in respect of such securities,
are included in the statement of operations. Marketable
securities not classified as trading securities, are classified
as available-for-sale securities and are reported at their fair
value. Unrealized gains and losses in respect of such securities,
are included in a separate item within the shareholders' equity
and reported as other comprehensive income. Held-to-maturity
securities are debt securities for which the Company has the
intent and ability to hold to maturity. Losses resulting from
other-than-temporary impairment, are included in the statement of
operations, as
-121-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
incurred.
-122-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
18. OTHER DIFFERENCES (CONT.)
d. Capitalization of rent costs:
In accordance with Israeli GAAP. Rent costs incurred during the
construction period have been capitalized to the cost of the
assets.
In accordance with U.S. GAAP. There are two acceptable methods to
account for rent costs incurred during the construction period as
follows: (i) to expense these costs as incurred in the period
they are recognized (the "Expense Method"); or (ii) to capitalize
these costs to the cost of the assets (the "Capitalization
Method"). The Company applies for U.S. GAAP purposes the Expense
Method.
e. Contingent consideration based on security price:
Consideration for a business combination may be contingent on the
change in the market price of the shares issued by the acquirer.
Under such an agreement, unless the price of the shares issued
equals, at least, an agreed amount ("Specified Amount") on the
date such contingency have been resolved ("Specified date") the
acquiring corporation is required to issue additional shares or
to transfer cash (at the acquirer's sole discretion) in order to
make the current value of the total consideration equal to the
Specified Amount. The Company in such a transaction elected at
the settlement (specified) date to issue additional shares (see
Note 18B.(ii), above).
In accordance with Israeli GAAP. The shares, which are issued
unconditionally at the date the transaction is consummated,
should be recorded at their market price at such date. The
difference between the market price of such shares upon issuance,
and the Specified Amount, is recorded as a monetary liability.
Changes in the value of the liability (since the shares issuance
through the specified date), are recorded in the statement of
operations for each reporting period. On the specified date, by
way of issuance of additional shares, such liability is to be
charged to share capital and to premium on shares.
In accordance with U.S. GAAP. The shares issued unconditionally
at the date the transaction is consummated, should be recorded at
the Specified Amount, discounted to its present value. No
adjustments on the shareholders' equity and on other balance
sheet items are required until and after the contingency is
resolved by way of issuance of additional shares.
f. Costs incurred in connection with an exchange or modification of
a debt instrument between an existing borrower and lender:
In accordance with Israeli GAAP. Fees paid by the debtor to the
creditor ("fees") or costs incurred with third parties ("Costs")
directly related to the exchange or modification of a debt
instrument, which is not accounted for as a debt extinguishment,
should be accounted as an adjustment to the carrying amount of
the new debt, due to the fact that the terms of the old debt and
the new debt are not considered substantially different, and are
amortized over the remaining term of the replacement or modified
debt.
In accordance with U.S. GAAP. Such expenses are distinguished
into two categories: (i) Fees paid as part of an exchange or
modification, which is not accounted for as a debt
extinguishment, should be accounted as an adjustment of interest
expense and amortized over the remaining term of the replacement
or modified debt instrument; (ii) Costs incurred with third
parties, should be expensed, as incurred.
-123-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
18. OTHER DIFFERENCES (CONT.)
g. Classification of certain expenses:
In accordance with Israeli GAAP. Certain expenses (mainly,
impairment of long-lived assets and investments which are
included on cost basis) are presented as "other expenses".
In accordance with U.S. GAAP. These expenses are included within
operating expenses.
h. Cost relating to written options:
In accordance with Israeli GAAP. Written options, which permit
the option holder to buy or sale shares of investees, should not
be recorded in the financial statements.
In accordance with U.S. GAAP. SEC long standing position is that
written options, which permit the option holder to buy or sale
shares of investees, should be reported at their fair value
thought the statement of operations.
19. EARNINGS PER SHARE ("EPS")
In accordance with Israeli GAAP.
a. Share options and shares issued to employees for consideration of
loans for which the sole security for their repayment is the
shares granted (that are treated as options) are included in the
computation of basic earnings per share only when vested and if
their exercise is considered to be probable. In such case, basic
earnings are adjusted for "notional interest" resulting from such
securities. Calculation of the probability is based on the ratio
between the market price of the shares and the present value of
the exercise price of the options or the present value of the
repayment amount of the loans granted for the purchase of such
shares, as applicable.
b. Shares whose issuance is contingent on the Company's future share
price ("Contingently issuable shares"), are not included in the
weighted average number of issued shares for the purpose of both
calculating the basic EPS and the diluted EPS.
c. Share options (including shares for consideration of loans for
which the sole security for repayment is the shares granted),
which are unvested and/or whose exercise is not probable, are
nevertheless considered as exercised, for the purpose of
calculating the diluted earnings per share, in addition to the
outstanding and issued shares, whereas the basic earnings are
adjusted for "notional interest" resulting out of such option
exercised if their effect is dilutive.
d. In addition to the above, and for the purpose of calculating the
diluted earnings per share, the net income of the Company is
adjusted for the provision for losses, if any, as a result of a
dilution of its shareholding in investees, assuming that all of
the investees' convertible securities (including those whose
exercise is not probable) are considered as exercised. In
computing, basic EPS, the Company's share in investees' results
of operations is taken into account in accordance with the
amount, which is included in the financial statements.
As for Accounting Standard No, 21 - See Note 2X (iv).
-124-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
19. EARNINGS PER SHARE ("EPS") (CONT.)
In accordance with U.S. GAAP.
a. In accordance with SFAS 128, basic earnings per share is computed
on the basis of the weighted average number of shares outstanding
during the year, without taking into consideration any
convertible securities other than participating convertible
securities.
b. If all necessary conditions have not been satisfied by the end of
the year, the number of contingently issuable shares included in
diluted EPS shall be based on the number of shares, if any, that
would be issuable if the end of the reporting year were the end
of the contingency year and if the result would be dilutive.
c. Diluted earnings per share is computed on the basis of the
weighted average number of shares outstanding during the year,
with the addition of the potential dilution of the options
exercisable into shares outstanding during the year (including
shares issued for consideration of loans which the sole security
for their repayment is the shares granted), applying the
"treasury stock method".
d. The Company's share in the investees' results of operations is
computed by multiplying the number of the investee's shares or
convertible securities held by the Company, by the investee's EPS
(basic or diluted).
20. RECENTLY ISSUED ACCOUNTING STANDARDS UNDER U.S. GAAP
a. In November 2004, the FASB issued FAS 151, "Inventory Costs--an
amendment of Accounting Research Bulletin, ARB 43, Chapter 4".
This statement is effective for inventory costs incurred
beginning January 1, 2006. This statement amends current guidance
to clarify the accounting for abnormal amounts of idle facility
expense, freight, handling costs, and wasted material. This
statement requires that those items be recognized as
current-period charges. In addition, this statement requires that
allocation of fixed production overheads to the costs of
conversion be based on the normal capacity of the production
facilities. The Company does not expect this statement to have a
material effect on the Company's financial statements or its
results of operations.
b. In December 2004, the FASB issued a revision to SFAS No. 123
(revised 2004), Share-Based Payment ("SFAS No. 123R"). In March
2005 the SEC staff issued Staff Accounting Bulletin No. 107 ("SAB
107"), providing guidance on SFAS No. 123R. SFAS No. 123R
supercedes APB Opinion No. 25, Accounting for Stock Issued to
Employees, and amends SFAS No. 95, Statement of Cash Flows.
Generally, the approach in SFAS No. 123R is similar to the
approach described in SFAS No. 123.
SFAS 123R establishes standards for the accounting for
transactions in which an entity exchanges its equity instruments
for goods or services; focuses primarily on accounting for
transactions in which an entity obtains employee and directors
services in share-based payment transactions; and does not change
the accounting guidance for share-based payment transactions with
parties other than employees.
-125-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
20. RECENTLY ISSUED ACCOUNTING STANDARDS (CONT.)
b. (Cont.)
SFAS 123R eliminates the alternative to use APB 25's intrinsic
value method of accounting that was provided in SFAS 123 as
originally issued and requires to measure the cost of employee
services received in exchange for an award of equity instruments
based on the grant-date fair value of the award. The
fair-value-based method in this Statement is similar to the
fair-value-based method in SFAS 123 in most respects. The costs
associated with the awards will be recognized over the period
during which an employee is required to provide service in
exchange for the award - the requisite service period (usually
the vesting period).
The grant-date fair value of employee share options and similar
instruments will be estimated using option-pricing models
adjusted for the unique characteristics of those instruments
(unless observable market prices for the same or similar
instruments are available). If an equity award is modified after
the grant date, incremental compensation cost will be recognized
in an amount equal to the excess of the fair value of the
modified award over the fair value of the original award
immediately before the modification.
The provisions of SFAS 123R apply to all awards to be granted by
the Company after January 1, 2006 and to awards modified,
repurchased, or cancelled after that date. When initially
applying the provisions of SFAS 123R, the Company will be
required to elect between using either the "modified prospective
method" or the "modified retrospective method". Under the
modified prospective method, the Company is required to recognize
compensation cost for all awards granted after the adoption of
SFAS 123R and for the unvested portion of previously granted
awards that are outstanding on that date. Under the modified
retrospective method, the Company is required to restate its
previously issued financial statements to recognize the amounts
previously calculated and reported on a pro forma basis, as if
the original provisions of SFAS 123 had been adopted. Under both
methods, it is permitted to use either a straight line or an
accelerated method to amortize the cost as an expense for awards
with graded vesting.
The Company has elected to apply the modified prospective
transition method to all past awards outstanding and unvested as
of the date of adoption. The estimated impact of adopting SFAS
123R for 2006, relating to prior year unvested stock option
grants only, will be approximately NIS 4.7million.
c. In June 2005, the FASB issued FAS 154, "Accounting Changes and
Error Corrections--a replacement of APB No. 20 "Accounting
Changes" and FAS No. 3 "Reporting Changes in Interim Financial
Statements". This statement provides guidance on the accounting
and reporting of accounting changes and error corrections, and
guidance in the determination of retrospective application of
changes in accounting principals. As applicable to the Company,
the provisions of FAS 154 are effective as for year beginning
January 1, 2006.
-126-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
A. DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP (CONT.)
20. RECENTLY ISSUED ACCOUNTING STANDARDS (CONT.)
d. In February 2006, the FASB issued FAS 155, accounting for certain
Hybrid Financial Instruments, an amendment of FASB statements No.
133 and 140. This statement permits fair value measurement for
any hybrid financial instrument that contains an embedded
derivative that otherwise would require bifurcation. This
statement is effective for all financial instruments acquired or
issued after the beginning of an entity's first fiscal year that
begins after September 15, 2006. Earlier adoption is permitted as
of the beginning of an entity's fiscal year, provided that no
interim period financial statements have been issued for that
financial year. Management is currently evaluating the impact of
this statement, if any, on the Company's financial statements or
its results of operations.
e. In March 2005, the FASB issued FASB Interpretation (FIN) No. 47,
Accounting for Conditional Asset Retirement Obligations, an
Interpretation of FASB Statement No. 143, which requires an
entity to recognize a liability for the fair value of a
conditional asset retirement obligation when incurred, if the
liability's fair value can be reasonably estimated. The
Interpretation is effective no later than the end of fiscal years
ending after December 15, 2005. The adoption of the provisions of
FIN 47 did not have an effect on the Company's consolidated
financial position, results of operations or cash flows.
f. In June 2005, the FASB ratified the consensus reached by the EITF
regarding EITF No. 05-06, Determining the Amortization period of
Leasehold Improvements. The guidance requires that leasehold
improvements acquired in a business combination, or purchased
subsequent to the inception of a lease, be amortized over the
lesser of the useful life of the assets or term that includes
renewals that have been reasonably assured at the date or the
business combination of purchase. The guidance is effective for
periods beginning after June 29, 2005. EITF 05-06 did not impact
the Company's, financial position, results of operations, or cash
flows.
-127-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS
1. STATEMENTS OF OPERATIONS:
A. THE STATEMENT OF OPERATIONS IN ACCORDANCE WITH ISRAELI GAAP IS
RECONCILED TO U.S. GAAP AS FOLLOWS:
YEAR ENDED DECEMBER 31, 2005
REPORTED
----------------------------------------------------------------
ISRAELI U.S. GAAP
GAAP --------------------------------------------------
AS REPORTED
IN THESE DIS- CON-
FINANCIAL RE- CONTINUED VENIENCE
STATEMENTS CONCILIATIONS OPERATION TOTAL TRANSLATION
----------- ------------- --------- -------- -----------
IN THOUSAND NIS US$'000
REVENUES
Sale of real estate assets and investments, net 281,661 15,773 (297,434) -- --
Commercial center operations 142,957 -- (58,156) 84,801 18,423
Hotels operations and management 270,057 -- -- 270,057 58,670
Sale of medical systems 75,713 -- -- 75,713 16,449
Realization of investments 1,958 -- -- 1,958 425
Other operational income 44,409 -- (12,619) 31,790 6,906
------- ------ -------- -------- -------
816,755 15,773 (368,209) 464,319 100,873
------- ------ -------- -------- -------
COSTS AND EXPENSES
Commercial center operations 157,640 -- (36,934) 120,706 26,223
Hotels operations and management 259,293 244 -- 259,537 56,384
Cost and expenses of medical systems operation 49,577 4,083 -- 53,660 11,658
Other operational expenses 46,793 (1,700) (2,802) 42,291 9,188
Research and development expenses, net 58,899 4,598 -- 63,497 13,795
General and administrative expenses 36,939 -- -- 36,939 8,025
Share in results of associated companies, net 12,028 (4,223) -- 7,805 1,696
Financial expenses, net 122,321 9,295 (24,899) 106,717 23,184
Other expenses 57,106 828 -- 57,934 12,585
------- ------ -------- -------- -------
800,596 13,125 (64,635) 749,086 162,738
------- ------ -------- -------- -------
PROFIT (LOSS) BEFORE INCOME TAXES 16,159 2,648 (303,574) (284,767) (61,865)
Income taxes (tax benefits) 7,798 (5,752) 1,866 3,912 850
------- ------ -------- -------- -------
PROFIT (LOSS) AFTER INCOME TAXES 8,361 8,400 (305,440) (288,679) (62,715)
Minority interest in results of subsidiaries, net 73,287 4,379 -- 77,666 16,873
------- ------ -------- -------- -------
PROFIT (LOSS) FROM CONTINUING OPERATION 81,648 12,779 (305,440) (211,013) (45,842)
Profit from discontinued operation, net of taxes:
Profit from the ordinary activities of the
operation 5,917 -- 7,917 13,834 3,005
Gain on discontinuance -- -- 297,523 297,523 64,637
------- ------ -------- -------- -------
5,917 -- 305,440 311,357 67,642
------- ------ -------- -------- -------
Cumulative effect of accounting change at the
beginning of the year (622) 622 -- -- --
------- ------ -------- -------- -------
NET INCOME (LOSS) 86,943 13,401 -- 100,344 21,800
======= ====== ======== ======== =======
EARNING (LOSS) PER SHARE:
BASIC:
Continuing operations 3.66 (9.52) (2.07)
Discontinued operations 0.27 14.05 3.05
Cumulative effect for the beginning of the year
due to a change in accounting method (0.03) -- --
------- -------- -------
3.90 4.53 0.98
======= ======== =======
DILUTED:
Continuing operations 3.66 (9.52) (2.07)
Discontinued operations 0.27 14.05 3.05
Cumulative effect for the beginning of the year
due to a change in accounting method (0.03) -- --
------- -------- -------
-128-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
3.90 4.53 0.98
======= ======== =======
-129-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
1. STATEMENTS OF OPERATIONS (CONT.):
A. THE STATEMENT OF OPERATIONS IN ACCORDANCE WITH ISRAELI GAAP IS
RECONCILED TO U.S. GAAP AS FOLLOWS (CONT.):
YEAR ENDED DECEMBER 31, 2004
REPORTED
--------------------------------------------------
ISRAELI U.S. GAAP
GAAP ------------------------------------
AS REPORTED
IN THESE DIS-
FINANCIAL RE- CONTINUED
STATEMENTS CONCILIATIONS OPERATION TOTAL
----------- ------------- --------- --------
IN THOUSAND NIS
REVENUES
Sale of real estate assets and investments, net 131,921 (116,210) (15,711) --
Commercial center operations 311,893 -- (243,919) 67,974
Hotels operations and management 218,365 -- -- 218,365
Sale of medical systems 44,049 -- -- 44,049
Realization of investments 16,415 (13,003) -- 3,412
Other operational income 13,238 -- (13,238) --
------- -------- -------- -------
735,881 (129,213) (272,868) 333,800
------- -------- -------- -------
COSTS AND EXPENSES
Commercial center operations 271,392 1,914 (160,828) 112,478
Hotels operations and management 207,152 1,507 -- 208,659
Cost and expenses of medical systems operation 26,039 3,830 -- 29,869
Other operational expenses 3,655 1,699 (3,175) 2,179
Research and development expenses, net 38,158 3,412 -- 41,570
General and administrative expenses 43,627 -- -- 43,627
Share in results of associated companies, net 15,968 (4,368) -- 11,600
Financial expenses, net 53,569 9,030 9,227 71,826
Other expenses 51,428 6,848 (25,274) 33,002
------- -------- -------- -------
710,988 23,872 (180,050) 554,809
------- -------- -------- -------
PROFIT (LOSS) BEFORE INCOME TAXES 24,893 (153,085) (92,818) (221,810)
Income taxes (tax benefits) 15,804 (19,641) (16,863) (20,700)
------- -------- -------- -------
PROFIT (LOSS) AFTER INCOME TAXES 9,089 (133,444) (75,955) (200,310)
Minority interest in results of subsidiaries, net 27,448 (2,349) -- 25,099
------- -------- -------- -------
PROFIT (LOSS) FROM CONTINUING OPERATION 36,537 (135,793) (75,955) (175,211)
Profit from discontinued operation, net of taxes:
Profit from the ordinary activities of the
operation 6,810 -- 60,242 67,052
Gain on discontinuance -- -- 15,713 15,713
------- -------- -------- -------
6,810 -- 75,955 82,765
------- -------- -------- -------
NET INCOME (LOSS) 43,347 (135,793) -- (92,446)
======= ======== ======== =======
EARNING (LOSS) PER SHARE:
BASIC:
Continuing operations 1.59 (7.61)
Discontinued operations 0.30 3.59
------- -------
1.89 (4.02)
======= =======
DILUTED:
Continuing operations 1.56 (7.61)
Discontinued operations 0.28 3.59
------- -------
1.84 (4.02)
======= =======
-130-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
1. STATEMENTS OF OPERATIONS (CONT.):
A. THE STATEMENT OF OPERATIONS IN ACCORDANCE WITH ISRAELI GAAP IS
RECONCILED TO U.S. GAAP AS FOLLOWS (CONT.):
YEAR ENDED DECEMBER 31, 2003
ADJUSTED
---------------------------------------------------
ISRAELI GAAP U.S. GAAP
AS REPORTED ------------------------------------
IN THESE DIS-
FINANCIAL RE- CONTINUED
STATEMENTS CONCILIATIONS OPERATION TOTAL
------------ ------------- --------- --------
IN THOUSAND NIS
REVENUES
Commercial center operations 347,056 (12,673) (324,116) 10,267
Hotels operations and management 189,205 3,748 -- 192,953
Realization of investments 45,129 (20,417) -- 24,712
Other operational income 13,495 -- (13,495) --
-------- -------- -------- --------
594,885 (29,342) (337,611) 227,932
-------- -------- -------- --------
COSTS AND EXPENSES
Commercial center operations 257,913 (5,695) (201,763) 50,455
Hotels operations and management 188,672 1,504 -- 190,176
Cost and expenses of medical systems operation 8,720 5,100 -- 13,820
Other operational expenses 3,510 -- (3,510) --
Research and development expenses, net 43,719 9,920 -- 53,639
General and administrative expenses 42,144 -- -- 42,144
Share in results of associated companies, net 20,951 (5,167) -- 15,784
Financial expenses, net 211,821 (170,465) (30,222) 11,134
Other expenses 10,477 19,682 (6,408) 23,751
-------- -------- -------- --------
787,927 (145,121) (241,903) 400,903
-------- -------- -------- --------
PROFIT (LOSS) BEFORE INCOME TAXES (193,042) 115,779 (95,708) (172,971)
Income taxes (tax benefits) (20,217) 27,011 (11,522) (4,728)
-------- -------- -------- --------
PROFIT (LOSS) AFTER INCOME TAXES (172,825) 88,768 (84,186) (168,243)
Minority interest in results of subsidiaries, net 48,671 (18,796) -- 29,875
-------- -------- -------- --------
LOSS FROM CONTINUING OPERATION (124,154) 69,972 (84,186) (138,368)
Profit from the ordinary activities of the
discontinued operation, net of taxes 12,073 22,858 84,186 119,117
-------- -------- -------- --------
LOSS (112,081) 92,830 -- (19,251)
======== ======== ======== ========
EARNING (LOSS) PER SHARE:
BASIC:
Continuing operations (5.56) (6.20)
Discontinued operations 0.54 5.33
-------- --------
(5.02) (0.87)
======== ========
DILUTED:
Continuing operations (5.56) (6.20)
Discontinued operations 0.54 5.33
-------- --------
(5.02) (0.87)
======== ========
-131-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
1. STATEMENTS OF OPERATIONS (CONT.):
B. THE RECONCILIATION OF NET INCOME (LOSS) IN ACCORDANCE WITH
ISRAELI GAAP TO THE LOSS IN ACCORDANCE WITH U.S. GAAP, IS AS
FOLLOWS (RECONCILING ITEMS ARE SHOWN NET OF TAXES):
YEAR ENDED DECEMBER 31
----------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Net income (loss) according to Israeli GAAP 86,943 43,347 (112,081) 18,888
Less - profit from discontinuing
operation, net (5,917) (6,810) (12,073) (1,285)
Less - cumulative effect of accounting
change 622 -- -- 135
-------- -------- -------- -------
Net income (loss) from continuing
operations according to Israeli GAAP 81,648 36,537 (124,154) 17,738
Deferred taxes A3 (2,363) 38,190 (4,700) (513)
Stock based compensation A4 (8,681) (7,268) (14,473) (1,886)
Issuance of shares by a development stage
investee A5 -- (13,003) (20,417) --
Implementation of the equity method A6 4,223 4,368 5,167 917
Capitalization of financial expenses
during the construction period A7 (9,823) (6,093) 33,265 (2,134)
Provision for impairment loss of long
lived assets and investments A8 158 7,279 13,849 34
Realization of capital reserve from
translation adjustments A9 (2,727) (99,066) (32,253) (592)
Derivative financial instruments A10 24,805 (61,120) 115,982 5,389
Discontinued operations A11 (305,440) (75,955) (84186) (66,357)
Convertible securities of investees A15 6,182 -- -- 1,343
Excess of fair value of aquired net assets
over cost A16 (14,225) -- -- (3,090)
Other differences A18 10,850(1) 3,270 (8,852) 2,358
Minority interest in the abovementioned
reconciliations 4,380 (2,350) (17,596) 951
-------- -------- -------- -------
Loss from continuing operations according
to U.S. GAAP (211,013) (175,211) (138,368) (45,842)
Income from discontinued operations, net
of taxes according to U.S. GAAP A11 311,357 82,765 119,117 67,642
-------- -------- -------- -------
Net (income) loss according to U.S. GAAP 100,344 (92,446) (19,251) 21,800
======== ======== ======== =======
(1) Mainly in respect of realization of capital reserve from translation of
profit and loss items in the amount of NIS 8.7 million (see item 18a.) and
an amount of NIS 6.1 million in respect of cost of raising loans (see item
18 f.).
-132-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
2. THE RECONCILIATION OF THE BALANCE SHEETS PREPARED IN ACCORDANCE WITH
ISRAELI GAAP TO U.S. GAAP, IS AS FOLLOWS:
RECONCILIATION AS OF DECEMBER 31, 2005 - REPORTED
ISRAELI GAAP AS
REPORTED IN
THESE FINANCIAL
Item\Subsection STATEMENTS (1) A3 A4 A5 A6 A7 A8 A9 A10
- --------------- --------------- ------ ------- ------- ------- ------ ------ -------- -------
IN THOUSAND NIS
Short term deposits and
investment 240,072 -- -- -- -- -- -- -- --
Receivables and other debit
balances 76,680 -- -- -- -- -- -- -- --
Long-term deposits,
debentures, loans and other
long-term balances 62,139 -- -- -- -- -- -- -- --
Investments in investees and
other companies 56,798 -- -- -- (16,695) -- -- -- --
Fixed assets, net 2,508,726 25,508 -- -- 1,643 (2,742) 21,907 -- 998
Real estate subject to a sale
contract 249,739 -- -- -- -- -- -- -- --
Other assets and deferred
expenses 30,476 28,527 -- -- -- -- -- -- --
Total assets 3,786,117 54,035 -- -- (15,052) (2,742) 21,907 -- 998
Suppliers and service providers 82,013 -- -- -- -- -- -- -- --
Non-current deferred income
tax liabilty, net 39,928 48,042 -- -- -- -- -- -- --
Currency transaction -- -- -- -- -- -- -- -- 2,696
Convertible debentures 62,159 -- -- -- -- -- -- -- --
Long term liabilities 1,902,391 -- -- -- -- -- -- -- --
Capital reserves 789,165 -- 31,104 48,645 1,831 -- -- -- (1,988)
Deferred stock based
compensation -- -- (3,658) -- -- -- -- -- --
Cumulative foreign currency
translation adjustments 67,872 1,095 (674) 9,598 (2,933) 2,145 (492) 168,914 (23,053)
Dividend declared after
balance sheet date 126,839 -- -- -- -- -- -- -- --
Retained earnings 215,472 4,897 (26,772) (58,243) (13,950) (4,886) 22,399 (168,914) 23,343
Total shareholders' equity 1,055,410 5,993 -- -- (15,052) (2,742) 21,907 -- (1,698)
TOTAL TOTAL CON-
RE- U.S. VENIENCE
Item\Subsection A12 A13 A14 A15 A16 A18 CONCILIATION GAAP TRANSLATION
- --------------- -------- ------- ------- ----- ------- ------- ------------ --------- -----------
IN
THOUSAND
U.S.
IN THOUSAND NIS DOLLAR
Short term deposits and
investment -- -- 657 -- -- -- 657 240,729 52,298
Receivables and other debit
balances -- -- 1,624 -- -- -- 1,624 78,304 17,012
Long-term deposits,
debentures, loans and other
long-term balances -- -- (19,134) -- -- -- (19,134) 43,005 9,343
Investments in investees and
other companies -- -- -- -- -- -- (16,695) 40,103 8,712
Fixed assets, net -- -- -- 6,182 (14,225) (666) 38,605 2,547,331 553,407
Real estate subject to a sale
contract -- -- 29,900 -- -- -- 29,900 279,639 60,751
Other assets and deferred
expenses -- -- -- -- -- (3,176) 25,351 55,827 12,128
Total assets -- -- 13,047 6,182 (14,225) (3,842) 60,308 3,846,426 835,635
Suppliers and service providers -- -- 3,757 -- -- 5,500 9,257 91,270 19,828
Non-current deferred income
tax liabilty, net -- -- -- -- -- 1,539 49,581 89,509 19,446
Currency transaction -- -- -- -- -- -- 2,696 2,696 586
Convertible debentures -- (62,159) -- -- -- -- (62,159) -- --
Long term liabilities -- 62,159 9,291 -- -- -- 71,450 1,973,841 428,816
Capital reserves -- -- -- -- -- 347 79,939 869,104 188,813
Deferred stock based
compensation -- -- -- -- -- -- (3,658) (3,658) (795)
Cumulative foreign currency
translation adjustments -- -- -- -- -- (12,883) 141,717 209,589 45,533
Dividend declared after
balance sheet date (126,839) -- -- -- -- -- (126,839) -- --
Retained earnings 126,839 -- -- 6,182 (14,225) 1,655 (101,675) 113,797 24,722
Total shareholders' equity -- -- -- 6,182 (14,225) (5,381) (10,516) 1,044,894 227,002
(1) Reclassified, in order for balance sheet items to conform with U.S. GAAP
presentation requirements.
-133-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
2. THE RECONCILIATION OF THE BALANCE SHEETS PREPARED IN ACCORDANCE WITH
ISRAELI GAAP TO U.S. GAAP, IS AS FOLLOWS (CONT.):
RECONCILIATION AS OF DECEMBER 31, 2004 - REPORTED
ISRAELI GAAP
AS REPORTED
IN THESE
FINANCIAL
STATEMENTS
ITEM\SUBSECTION (1) A3 A4 A5 A6 A7 A8 A9
- --------------- ------------ ------- ------- ------- ------- ------ ------ --------
IN THOUSAND NIS
Long-term deposits,
debentures,
loans and other
long-term balances 113,785
Investments in
investees and
other companies 71,608 (20,199)
Fixed assets, net 3,225,885 68,102 14,760 52,268
Real estate subject
to a sale contract 302,103
Other assets and
deferred expenses 45,110 43,217
Acquired patent
rights, technical
know-how and other
intellectual
property 10,749
Total assets 4,520,279 111,319 (20,199) 14,760 52,268
Long-term
liabilities -
Deferred income
taxes 31,552 107,982 971
Currency transaction
on long term
agreements --
Minority interest 430,687 1,486 (1,915) 5,692 20,025
Capital reserves 484,218 34,193 48,645 3,398
Deferred stock based
compensation -- (6,402)
Cumulative foreign
currency
translation
adjustments 50,618 (1,657) 1,162 9,598 (1,801) 3,087 4,755 166,188
Dividend declared
after balance
sheet date 153,938
Retained earnings 259,056 3,508 (28,953) (58,243) (19,881) 5,010 27,488 (166,188)
Total shareholders'
equity 803,968 1,851 -- -- (18,284) 8,097 32,243 --
TOTAL
RE- TOTAL
ITEM\SUBSECTION A10 A12 A18 CONCILIATION U.S. GAAP
- --------------- ------- -------- -------- ------------ -----------
In Thousand
IN THOUSAND NIS U.S. Dollar
Long-term deposits,
debentures,
loans and other
long-term balances 1,372 1,372 115,157
Investments in
investees and
other companies (20,199) 51,409
Fixed assets, net 11,754 (3,657) 143,227 3,369,112
Real estate subject
to a sale contract 302,103
Other assets and
deferred expenses (11,888) 31,329 76,439
Acquired patent
rights, technical
know-how and other
intellectual
property 10,749
Total assets 13,126 (15,545) 155,729 4,676,008
Long-term
liabilities -
Deferred income
taxes 1,420 110,373 141,925
Currency transaction
on long term
agreements 57,957 57,957 57,957
Minority interest (841) (3,415) 21,032 451,719
Capital reserves (1,646) (1,764) 82,826 567,044
Deferred stock based
compensation (6,402) (6,402)
Cumulative foreign
currency
translation
adjustments (40,883) (4,924) 135,525 186,143
Dividend declared
after balance
sheet date (153,938) (153,938) --
Retained earnings (1,461) 153,938 (6,862) (91,644) 167,412
Total shareholders'
equity (43,990) -- (13,550) (33,633) 770,335
-134-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
(1) Reclassified, in order for balance sheet items to conform with U.S. GAAP
presentation requirements.
-135-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
3. PROPORTIONATE CONSOLIDATION:
Summarized data regarding the differences between the proportionate
consolidation method and the equity method:
DECEMBER 31, 2005
---------------------------------------
AS REPORTED
IN THESE EFFECT OF
FINANCIAL PROPORTIONATE EQUITY
STATEMENTS CONSOLIDATION METHOD
----------- ------------- ---------
IN THOUSAND NIS
BALANCE SHEET:
Current assets 865,632 (44,903) 820,729
Non-current assets 2,920,485 (641,312) 2,279,173
Current liabilities 692,278 (61,525) 630,753
Non-current liabilities 1,964,821 (666,712) 1,298,109
STATEMENT OF OPERATIONS:
Revenues 816,755 (209,580) 607,175
Profit (loss) before income taxes 16,159 47,439 63,598
STATEMENT OF CASH FLOWS:
Net cash used in operating activities (99,108) 197 (98,911)
Net cash provided by investing activities 5,496 39,266 44,762
Net cash provided by financing activities 243,727 (49,059) 194,668
DECEMBER 31, 2004
---------------------------------------
AS REPORTED
IN THESE EFFECT OF
FINANCIAL PROPORTIONATE EQUITY
STATEMENTS CONSOLIDATION METHOD
----------- ------------- ---------
IN THOUSAND NIS
BALANCE SHEET:
Current assets 736,339 (67,035) 669,304
Non-current assets 3,783,940 (829,476) 2,954,464
Current liabilities 794,741 (263,711) 531,030
Non-current liabilities 2,490,883 (632,800) 1,858,083
STATEMENT OF OPERATIONS:
Revenues 735,881 (186,624) 549,257
Profit (loss) before income taxes 24,893 (3,210) 21,683
STATEMENT OF CASH FLOWS:
Net cash used in operating activities (21,562) (33,247) (54,809)
Net cash provided by investing activities 128,481 206,586 335,067
Net cash provided by financing activities 75,872 (171,680) (95,808)
-136-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
3. PROPORTIONATE CONSOLIDATION (CONT.):
Summarized data regarding the differences between the proportionate
consolidation method and the equity method:
DECEMBER 31, 2003
---------------------------------------
AS REPORTED
IN THESE EFFECT OF
FINANCIAL PROPORTIONATE EQUITY
STATEMENTS CONSOLIDATION METHOD
----------- ------------- ---------
IN THOUSAND NIS
BALANCE SHEET:
Current assets 577,467 (42,942) 534,525
Non- current assets 4,950,108 (636,878) 4,313,230
Current liabilities 1,178,415 (271,398) 907,017
Non- current liabilities 2,923,908 (408,422) 2,515,486
STATEMENT OF OPERATIONS:
Revenues 594,885 (153,991) 440,894
Profit (loss) before income taxes (193,042) (5,602) (198,644)
STATEMENT OF CASH FLOWS:
Net cash used in operating activities (8,333) (19,452) (27,785)
Net cash provided by investing activities 131,443 167,855 299,298
Net cash used in financing activities (174,995) (155,820) (330,815)
4. COMPREHENSIVE INCOME (LOSS)
"Comprehensive income" consists of the change, during the current
period, in the Company's shareholders' equity not derived from
shareholders' investments or from the distribution of earnings to
shareholders (including capital reserve from transaction with
controlling shareholders).
YEAR ENDED DECEMBER 31
-------------------------------------------
2005
2004 2003 REPORTED
2005 -------- ------- CONVENIENCE
REPORTED ADJUSTED TRANSLATION
-------- ------------------ -----------
(IN THOUSAND NIS) US$'000
Net loss in accordance with U.S. GAAP 100,344 (92,446) (19,251) 21,800
Other comprehensive income (loss),
after tax:
Foreign currency translation
adjustments 23,446 (53,239) 49,098 5,094
Unrealized gain (losses) from derivative
instruments (361) (4,230) 2,584 (78)
Unrealized gains (losses) from
securities -- -- 3,114 --
------- -------- ------- ------
Total comprehensive income (loss) 123,429 (149,915) 35,545 26,816
======= ======== ======= ======
-137-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
5. ADDITIONAL INFORMATION AS REQUIRED BY U.S. GAAP
A. THE EFFECT ON PRO FORMA DATA CALCULATED ACCORDING TO SFAS NO. 123
IS AS FOLLOWS:
(1) Under the provisions of SFAS No. 123, all option plans and
share incentive plan in the Company and in Elscint are
recorded in the statement of operations, based on the fair
value of the shares or options granted, at the grant date.
As of December 31, 2005 all options plans and share
incentive plan are fully vested.
(2) The Black - Scholes model is used for estimating fair value
of such securities (at each applicable measurement date),
utilizing the following assumptions:
ELBIT INSIGHTEC
----- ---------
a. Dividend yield (%) -- --
b. Risk free interest rate (%) 6 1.5-4
c. Expected lives from the date of grant (years) 5 7
d. Expected volatility (%) 24 --
For pro forma disclosure, the compensation expense for the
shares and the share options, granted, as estimated, is
amortized over the period of the benefit ("vesting period").
(1) See Note 18C.
(3) Information relating to shares (in consideration of loans
which the sole security for their repayment is the shares
granted) and options granted to employees and directors:
SHARE INCENTIVE
OPTION PLAN ELBIT INSIGHTEC
--------------- ------ ---------
Authorized 1,077,400 26,500 3,594,000
========= ====== =========
Granted 1,009,295 26,500 3,165,000
========= ====== =========
Vested 1,009,295 26,500 2,707,000
========= ====== =========
-138-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
5. ADDITIONAL INFORMATION AS REQUIRED BY U.S. GAAP (CONT.)
A. THE EFFECT ON PRO FORMA DATA CALCULATED ACCORDING TO SFAS NO. 123
IS AS FOLLOWS (CONT.):
(4) If the cost of the benefit in respect of shares or share
options issued to employees under this plan had been
computed on the basis of their fair value, in accordance
with SFAS No. 123, the effect on net income and earnings per
share in accordance with U.S. GAAP would have been as
follows:
YEAR ENDED DECEMBER 31,
---------------------------
2005 2004 2003
------- ------- -------
IN THOUSAND NIS
Profit (loss) according to U.S. GAAP 100,344 (92,446) (19,251)
Add - stock based compensation determined under APB 25
- see Note 25A.(4) 8,681 6,742 5,202
Deduct - stock based compensation determined under FAS 123 (11,788) (9,568) (5,818)
------- ------- -------
Pro forma net profit (loss) 97,237 (95,272) (19,867)
======= ======= =======
Pro forma basic earnings (loss) per share (in NIS) 4.43 (4.14) (0.89)
======= ======= =======
Pro forma diluted earnings (loss) per share (in NIS) 4.39 (4.14) (0.89)
======= ======= =======
B. VALUATION ALLOWANCE OF DEFERRED TAX ASSETS ACCORDING TO FAS NO.
109:
The differences between Israeli GAAP and U.S GAAP as described in
paragraph A changed the balance of the valuation allowance as
follows:
YEAR ENDED DECEMBER 31
---------------------------------
2005
REPORTED
2005 2004 CONVENIENCE
REPORTED REPORTED TRANSLATION
-------- -------- -----------
(IN THOUSAND NIS) US$'000
As reported, according to Israeli GAAP 216,786 384,528 47,097
Reconciliation as per U.S. GAAP (23,903) (24,624) (5,193)
------- ------- ------
According to U.S GAAP 192,883 359,904 41,904
======= ======= ======
-139-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
5. ADDITIONAL INFORMATION AS REQUIRED BY U.S. GAAP (CONT.)
C. BUSINESS SEGMENTS (BASED ON ISRAELI GAAP FINANCIAL STATEMENTS)
Supplementary segment information requires according to U.S. GAAP
(SFAS131):
COMMERCIAL
AND IMAGE LEASE
ENTERTAINMENT GUIDED OF OTHER
CENTERS HOTELS TREATMENT ASSETS ACTIVITIES TOTAL
------------- ------- --------- ------ ---------- --------
IN THOUSAND NIS
YEAR ENDED
DECEMBER 31, 2005:
Financial income (expenses),
net (1) (42,058) (50,664) -- (8,035) (21,564) (122,321)
Income taxes (tax benefits) 1,005 1,442 -- -- 5,351 7,798
YEAR ENDED
DECEMBER 31, 2004:
Financial income (expenses),
net (1) 10,423 (9,904) (3,298) (8,367) (42,423) (53,569)
Income taxes (tax benefits) 18,295 (647) -- -- (1,844) 15,804
YEAR ENDED
DECEMBER 31, 2003:
Financial income (expenses),
net (1) (190,756) 2,564 (3,137) (20,492) (211,821)
Income taxes (tax benefits) (22,070) (6,583) -- 8,436 (20,217)
(1) Excluding financial results in respect of inter-company balances and
transactions.
-140-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
5. ADDITIONAL INFORMATION AS REQUIRED BY U.S. GAAP (CONT.)
D. STATEMENT OF CASH FLOWS
1) SUPPLEMENTAL INFORMATION REQUIRED ACCORDING TO U.S. GAAP:
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Interest paid 139,554 143,068 140,918 30,318
------- ------- ------- ------
Income tax paid 11,431 2,695 4,751 2,483
======= ======= ======= ======
2) EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH
EQUIVALENTS:
IN ACCORDANCE WITH ISRAELI GAAP:
The statement shall report the effect of exchange rate
changes on cash balances held in foreign currencies, only in
"autonomous foreign entities", in a separate part of the
reconciliation of the change in cash and cash equivalents
during the period.
IN ACCORDANCE WITH U.S. GAAP:
The statement shall report the effect of exchange rate
changes on all cash balances held in foreign currencies in
all foreign entities as a separate part of the
reconciliation of the change in cash and cash equivalents
during the period.
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
As reported, according to Israeli GAAP (6,516) (522) 3,959 (1,416)
Reconciliation as per U.S. GAAP 1,332 3,362 (1,113) 289
------ ----- ------ ------
According to U.S. GAAP (5,184) 2,840 2,846 (1,127)
====== ===== ====== ======
-141-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
5. ADDITIONAL INFORMATION AS REQUIRED BY U.S. GAAP (CONT.)
D. STATEMENT OF CASH FLOWS (CONT.)
3) CASH FLOW CLASSIFICATION:
IN ACCORDANCE WITH ISRAELI GAAP
a. Proceeds from sale or purchase of marketable securities
are presented in cash flows from investing activities
in the statement of cash flows.
b. In accordance with standard No. 8 of the IASB an entity
should provide segregation of cash flows from
continuing and discontinuing operation for each of the
categories of cash flows (i.e.: operating, investing
and financing cash flow).
IN ACCORDANCE WITH U.S. GAAP
a. Proceeds from sale or purchase of marketable
securities, which are classified by the Company as held
for trading are included in cash flows from operating
activities.
b. In accordance with SFAS 95 segregation of cash flows
from continuing and discontinuing operation is not
required.
YEAR ENDED DECEMBER 31
--------------------------------------------
2005
REPORTED
2005 2004 2003 CONVENIENCE
REPORTED REPORTED ADJUSTED TRANSLATION
-------- -------- -------- -----------
(IN THOUSAND NIS) US$'000
Cash flows from operating activities:
As reported, according to Israeli GAAP (99,108) (21,562) (8,333) (21,531)
Reconciliation as per U.S. GAAP 2,724 (1,951) 2,413 592
------- ------- ------- ------
According to U.S. GAAP (96,384) (23,513) 5,920 20,939
======= ======= ======= ======
Cash flows from investing activities:
As reported, according to Israeli GAAP 5,496 128,481 131,443 1,194
Reconciliation as per U.S. GAAP (2,724) 1,951 (2,413) (592)
------- ------- ------- ------
According to U.S. GAAP 2,772 130,432 129,030 602
======= ======= ======= ======
-142-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
NOTE 25 - MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP AND THEIR
EFFECT ON THE CONSOLIDATED FINANCIAL STATEMENTS (CONT.)
B. THE EFFECT OF THE MATERIAL DIFFERENCES BETWEEN ISRAELI GAAP AND U.S. GAAP
ON THE FINANCIAL STATEMENTS (CONT.)
5. ADDITIONAL INFORMATION AS REQUIRED BY U.S. GAAP (CONT.)
E. EARNING PER SHARE
YEAR ENDED DECEMBER 31
------------------------
2005 2004 2003
------ ------ ------
NUMBER OF SHARES
(THOUSAND)
Number of shares used in basic and
diluted earning (loss) per share 22,154 23,025 22,337
====== ====== ======
-143-
ELBIT MEDICAL IMAGING LTD.
NOTES TO THE FINANCIAL STATEMENTS
LIST OF MAJOR INVESTEE COMPANIES - DECEMBER 31, 2005
RATE OF
(DIRECT AS
WELL AS
INDIRECT) COUNTRY
OWNERSHIP OF
NAME OF COMPANY NATURE OF ACTIVITY AND CONTROL RESIDENCE
- --------------- ------------------ ----------- -----------
%
ELSCINT LTD. (*) ("Elscint") Management and operation of
Arena; investment in companies 100.0 Israel
Bea Hotels N.V. ("B.H.") A holding company in the hotel The
segment, mainly in Europe 100.0 Netherlands
SLS Sails Ltd. ("SLS") Ownership of a commercial and
entertainment center ("Arena") 100.0 Israel
Mango Israel Clothing and ("Mango") A distributor and retailer of
Footwear Ltd. the retail brand name MANGO -
MNG(TM) 100.0 Israel
ELBIT ULTRASOUND NETHERLANDS B.V. ("EUN") A holding company 100.0 The
Netherlands
Plaza Centers (Europe) B.V. ("PC") Investment in the commercial 100.0 The
centers in Central and Eastern Netherlands
Europe
Insightec - Image Guided ("Insightec) Development manufacturing and 57.3(**) Israel
Treatment Ltd. marketing of means of
imaging-guided treatment
(*) See Note 9B.(1), above.
(**) Including exercise of options which were granted for par value (NIS 0.01)
consideration - See Note 9B. (2).
-144-
(ERNST & YOUNG LOGO)
- KOST FORER GABBAY & KASIERER
3 Aminadav St. - Phone: 972-3-6232525
Tel-Aviv 67067, Israel Fax: 972-3-5622555
REPORT OF INDEPENDENT AUDITORS
TO THE SHAREHOLDERS OF
GAMIDA CELL LTD.
(A DEVELOPMENT STAGE COMPANY)
We have audited the accompanying consolidated balance sheets of Gamida Cell
Ltd. (a development stage company) ("the Company") and its subsidiary as of
December 31, 2004 and 2005, and the related consolidated statements of
operations, changes in shareholders' equity and cash flows for each of the three
years in the period ended December 31, 2005 and for the period from February 17,
1998 (date of inception) to December 31, 2005. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
consideration of internal control over financial reporting as a basis for
designing audit procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial report. Accordingly, we express no such opinion.
An audit also includes examining, on a test basis, evidence supporting the
amounts and disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, and evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above,
present fairly, in all material respects, the consolidated financial position of
the Company and its subsidiary as of December 31, 2004 and 2005, and the
consolidated results of their operations and cash flows for each of the three
years in the period ended December 31, 2005 and for the period from February 17,
1998 (date of inception) to December 31, 2005, in conformity with accounting
principles generally accepted in the United States.
Tel-Aviv, Israel KOST FORER GABBAY & KASIERER
March 20, 2006 A Member of Ernst & Young Global
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
TO THE BOARD OF DIRECTORS AND SHAREHOLDERS OF
PLAZA CENTERS (EUROPE) B.V.
We have audited the accompanying consolidated balance sheet of Plaza Centers
(Europe) B.V. ("the Company") and its subsidiaries as at December 31, 2005 and
2004 and the related consolidated statements of income, changes in shareholders'
equity and cash flows for each of the three years in the period ended December
31, 2005. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by the management, as well as evaluating the overall
financial statement presentation. We believe that our audit provide a reasonable
basis for our opinion.
In our opinion, based on our audit, the consolidated financial statements
referred to above present fairly, in all material respects, the consolidated
financial position of the Company and its subsidiaries as at December 31, 2005
and 2004 and the consolidated results of their operations, the changes in
shareholders' equity and their cash flows for each of the three years in the
period ended December 31, 2005, in conformity with generally accepted accounting
principles in Israel.
As explained in Note 2, the financial statements for dates and reporting periods
subsequent to December 31, 2003 are stated in reported amounts, in accordance
with the accounting standards of the Israel Accounting Standards Board. The
financial statements for dates and reporting periods that ended up to the
aforementioned date are stated in values that were adjusted to that date
according to the changes in the general purchasing power of the local currency,
in accordance with opinions of the Institute of Certified Public Accountants in
Israel
Budapest, Hungary
April 5, 2006
KPMG Hungaria Kft.
REPORT OF INDEPENDENT AUDITORS
TO THE SHAREHOLDERS OF
B.E.A. HOTELS N.V.
INTRODUCTION
We have audited the accompanying balance sheets of B.E.A. Hotels N.V. ("the
Company") as of December 31, 2005 and 2004 and the statements of income and the
statements of changes in shareholders' equity of the company for each of the two
years in the period ended December 31, 2005. These financial statements are the
responsibility of the Company's Board of Directors and management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
SCOPE
We conducted our audit in accordance with International Standards of Auditing
and in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the
audit in order to obtain reasonable assurance that the financial statements are
free of material misstatement. An audit includes examining on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by the Board of Directors and management of the company, as well
as evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion.
MATTERS AFFECTING OPINION
The financial statements do not contain a statement of cash flows as required by
International Accounting Standard No. 7. In our opinion, information about the
company's cash flows is necessary for a proper understanding of the company's
state of affairs and result.
OPINION
In our opinion (except for the failure to provide information about the
company's cash flows) the financial statements referred to above present fairly,
in all material respects, the financial position of the Company as of December
31, 2005 and 2004 and the results of its operations for each of the two years in
the period ended December 31, 2005, in accordance with International Financial
Reporting Standards.
Amsterdam, April 6, 2006
MAZARS PAARDEKOOPER HOFFMAN N.V.
F.D.N. Walta RA
MAZARS PAARDEKOOPER HOFFMAN N.V.
Mazars Tower, Delflandlaan 1 - P.O. box 7266 - 1007 JG Amsterdam -
amsterdam.audit@mazars.nl
Tel: +31 (0)20-2060500 - Fax: +31 (0)20-6448051
ACCOUNTANTS - Tax advisers - Management consultants
Mazars Paardekooper Hoffman N.V., with its registered office in Rotterdam (Trade
register Rotterdam nr. 24389296).
Independent Member Of (MN LOGO)
ITEM 19. EXHIBITS
Exhibits.
---------
1.1(1) Memorandum of Association of the Company.
1.2(1) Articles of Association of the Company.
1.3(2)@ Notice dated March 4, 2001, sent by the Registrant to the Israeli
Companies Registrar with respect to an amendment to the Articles of
Association.
4.2(3) Loan facility agreement dated January 22, 2002 between OVAG, MKB and
OPT banks, Amanati Ltd., Duna Plaza Kft. Sopron Plaza Kft. and Plaza
Centers Europe BV with respect to a credit facility in the amount of
Euro 82.9 million.
4.3(2)@ Loan facility agreement dated September 27, 2000, between the
Registrant and Bank Hapoalim BM with respect to a $150 million line
of credit.
4.4(2) Loan Agreement dated March 1, 2001, between Krakow Plaza Sp.z.o.o.
and OVAG with respect to a credit facility in the amount of $35
million.
4.5(4) Loan agreement among, inter alia, Depfa Bank AG, Victoria Hotel C.V.
and Utrecht Victoria Hotel B.V. dated March 24, 1999.
4.6(4) Hotel management agreement between Euston Road Hotel Operators Ltd.
and Park Plaza Europe Ltd. dated December 1997.
4.7(4) Management agreement between Victoria Hotel C.V. and Park Plaza Hotel
Europe, Ltd. (previously Prestige Hotels International Ltd.) dated
October 4, 1993.
4.8(4) Management support and sub-license agreement between Astrid Park
Plaza N.V. and Park Plaza Hotels Europe Ltd. dated April 15, 1997.
4.9(5) Loan agreement dated December 21, 2000 with Bank Hapoalim B.M. with
respect to the financing of the Victoria Park Plaza Hotel.
4.10(5)@ Loan facility agreement dated October 23, 2000 between Elscint and
Bank Hapoalim BM with respect to a $110 million line of credit.
4.11(5)@ Development agreement dated December 17, 2000 between Elscint and the
Israeli Land Administration with respect to the Monfort Project.
4.12(6)@ Agreement dated April 14, 2002 between SLS Sails Ltd. and C.D.P.M.
Kft. for the completion of the construction works of Elscint's
commercial and entertainment center in Herzliya.
4.13(8) Framework Transaction Agreement, dated as of July 30, 2004, by and
among Klepierre S.A., Klepierre Hongrie S.A.S., LP7 S.A.S. and
Segece, as Buyers, and Plaza Centers (Europe) B.V., Elbit Ultrasound
Netherlands B.V., Szeged 2002 Kft., and Plaza Centers Management
B.V., as Vendors.
4.14(8) Transaction Agreement, dated January 31, 2005, Plantridge Limited, as
Purchaser, Plaza Centers (Europe) B.V., Elbit Ultrasound Netherlands
B.V., and Amanati Limited, as Vendors.
4.15* Framework Transaction Agreement, dated as of July 29, 2005, by and
among Klepierre S.A., Klepierre Sadyba Sp.z.o.o. Klepierre Krakow
Sp.z.o.o., Klepierre Poznan Sp.z.o.o, LP7 S.A.S. and Segece S.C.S, as
Buyers, and Plaza Centers (Europe) B.V. as Vendor.
4.16* Share Sale And Purchase Agreement relating to the shares in Shaw
Hotel Holding B.V. dated 19 December 2005 by and between Euro Sea
Hotel N.V., B.E.A. Hotels N.V.and Shawpark Investments B.V. as
Sellers and WG Mitchell (Scotland) Ltd as Purchaser
4.17* Deed of Trust entered into between the Company and Orora Fidelity
Trust Company Ltd. dated 21.2.2006 for the issuance of series A
debentures.
4.18* Deed of Trust entered into between the Company and Orora Fidelity
Trust Company Ltd. dated 21.2.2006 for the issuance of series A
debentures.
4.19(9) Agreement and Plan of Merger dated August 21, 2005 between the
Company and Elscint.
4.20* Amended and Restated Loan Agreement, Multicurrency Term Credit
Facility, dated December 5, 2005, between Elscint and Bank Hapoalim
B.M.
4.21* Lease Agreement dated January 6, 2003 between Euston Road Hotel
Limited and Accor SA for a long term lease of the hotel property
located on Euston Road in London, England (previously Bernard Shaw
Park Plaza) for a period of 25 years.
4.22* A form of Hotel Management Agreement entered into with Park Plaza.
4.23* Amended and Restated Loan Agreement dated July 9, 2003 between
Elscint and Bank of Hapoalim B.M.
4.24* Amended and Restated Loan Agreement dated July 9, 2003 between Elbit
Ultrasound (Netherlands) B.V. and Bank of Hapoalim B.M.
8.1* List of subsidiaries. (Incorporated by reference to "Item 4 -
Information on the Company - Organizational Structure)
10.1* Consent of Brightman Almagor & Co.
10.2* Consent of KPMG Hungaria Kft.
10.3* Consent of Mazars Paardekooper Hoffman N.V.
10.4* Consent of Kost, Forer Gabbay & Kasierer.
11.1* Code of Ethics and Business Conduct for Directors, Officers and Other
Employees
12.1* Certification of the Principal Executive Officer and Principal
Accounting Officer pursuant to Section 302 of the Sarbanes Oxley Act
of 2002
13.1* Certification of the Principal Executive Officer and Principal
Accounting Officer pursuant to Section 906 of the Sarbanes Oxley Act
of 2002
- ----------
(1) Previously filed as an Exhibit to EMI's Annual Report on Form 20-F, File
No. 0-28996, filed with the Securities and Exchange Commission on November
22, 1996 and incorporated by reference herein.
(2) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2000, File No. 0-28996, filed with the Securities
and Exchange Commission on July 16, 2001 and incorporated by reference
herein.
(3) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2001, File No. 0-28996, filed with the Securities
and Exchange Commission on July 1, 2002 and incorporated by reference
herein.
(4) Previously filed as an Exhibit to Elscint's Annual Report on Form 20-F for
the year ended December 31, 1999, File No. 2-44872, filed with the
Securities and Exchange Commission on June 2, 2000, and incorporated by
reference herein.
(5) Previously filed as an Exhibit to Elscint's Annual Report on Form 20-F for
the year ended December 31, 2000, File No. 2-44872, filed with the
Securities and Exchange Commission on July 10, 2001 and incorporated by
reference herein.
(6) Previously filed as an exhibit to Elscint's Annual Report on Form 20-F for
the year ended December 31, 2001, File No. 2-44872, filed with the
Securities and Exchange Commission on June 28, 2002 and incorporated by
reference herein.
(7) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2003, File No. 0-28996, filed with the Securities
and Exchange Commission on June 30, 2004 and incorporated by reference
herein.
(8) Previously filed as an exhibit to EMI's Annual Report on Form 20-F for the
year ended December 31, 2004, File No. 0-28996, filed with the Securities
and Exchange Commission on June 30, 2005 and incorporated by reference
herein.
(9) Previously filed as an exhibit to Joint Proxy Statement/Prospectus filed
with the Securities and Exchange Commission on September 21, 2005 and
incorporated by reference herein.
* Filed herewith.
@ Translation from Hebrew.